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Abstract 
Human African trypanosomiasis (HAT) is a disease that is in desperate need of 
new pharmacological agents active against the causative parasite, the 
flagellated protozoan Trypanosoma brucei.  
In this thesis, new metabolomics techniques have been developed to study 
pathways in response to drug action with the aim of defining the mode of action 
of current and future drugs. Eflornithine, a polyamine pathway inhibitor, was 
used as a proof of principle, revealing both expected changes that correlate well 
with the literature and unexpected changes that lead to pathways and 
metabolites not previously described in bloodstream form trypanosomes. One 
metabolite not previously described in trypanosomes is acetylornithine, whose 
levels correlate well with ornithine and whose production comes directly from 
ornithine transported from the medium. Nifurtimox and the nifurtimox-
eflornithine combination therapy were assayed for changes to their 
metabolomes revealing changes in nifurtimox treatment that included 
alterations to sugar and purine levels. The combination therapy had reduced 
changes to some metabolites compared to each drug in isolation suggesting 
reasons for the combination‟s lack of synergy. Isotopically labelled metabolites 
were also of use in determining flux through the pathways identified as being 
affected by drug perturbation. These techniques, along with other biochemical 
techniques, were used to show arginase activity is absent in bloodstream form 
trypanosomes and that ornithine is not made from arginine when ornithine is 
present in the medium. Arginine can, however, be used to produce ornithine 
through an arginase-independent mechanism when exogenous ornithine is 
lacking. Evidence is also provided that parts of the pentose phosphate pathway, 
not thought to be active in bloodstream form trypanosomes, may still be active 
in in vitro grown cells. 
A mechanism of resistance to eflornithine involving the deletion of an amino 
acid transporter that is able to transport eflornithine is also described. It is 
hoped that simple PCR-based tests for this resistance mechanism will be of use 
in resistant foci in prescribing appropriate drugs to HAT patients. iii 
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1. Introduction 
Human African trypanosomiasis is a neglected disease with a paucity of useful 
drugs and resistance evident to many of those in use. For the drugs in use, the 
modes of action are largely unknown. This project was conceived with the aim of 
developing metabolomic technologies to analyse the mode of action and 
mechanism of resistance to trypanocidal chemotherapeutic agents.  
1.1  Protozoan parasites 
Protozoan parasites are responsible for many lethal and debilitating diseases 
worldwide. In the West, toxoplasmosis is the cause of around 40 % of first 
trimester miscarriages (Abdel-Hameed and Hassanein, 2004). Trypanosoma cruzi, 
the causative agent of Chagas disease, currently affects 10 million people in the 
Americas (Barfield et al., 2011). In South America, the Middle East and India 
Leishmaniasis affects 13 million people at any one time (Kato et al., 2010). 
Malaria is infamously linked with the statistic of “one child dies every 30 
seconds” and the fight against malaria is one of the top priorities of the WHO 
and the Bill and Melinda Gates Foundation. These parasites are all protozoa 
(single-celled eukaryotes) and, with the exception of toxoplasma, are all 
transmitted by biting insects. 
Trypanosomes are single-celled flagellated extracellular protozoa that reside in 
the nutrient-rich fluids of their host and can be found on all continents 
(Hamilton et al., 2007). Plants, animals and humans can all be infected with 
trypanosomes, with biting insects acting as a vector for transmission between 
hosts. Mechanical transfer may also occur through sexual intercourse (Rocha et 
al., 2004) or through blood sucking bats and insects (Vincent Alibu, University of 
Aberdeen,  personal communication), but such cases are rare and species 
dependent. 2 
 
1.2 Human African Trypanosomiasis 
1.2.1 Causative species 
Human African trypanosomiasis (HAT), also known as sleeping sickness, a name 
too benign for the disease it causes, is caused by a single species of protozoan 
parasite - Trypanosoma brucei. Disease progression can vary dramatically 
depending on the geographical location, leading Hoare (1973) to postulate that 
there were two human-infective sub-species of Trypanosoma brucei parasite: T. 
b. rhodesiense and T. b. gambiense. More recent genetic analyses have shown 
that taxonomy of T. brucei is actually much more complicated than Hoare‟s 
model suggested : T. b. rhodesiense is now regarded as a host-range variant of 
T. b. brucei (a sub-species not able to infect humans) (Gibson, 2002;Balmer et 
al., 2011), with the added presence of a serum resistance protein, which allows 
T. b. rhodesiense to survive in human serum where T. b. brucei cannot. 
T. b. gambiense variants are now classed into two groups. Group one is less 
diverse and displays low virulence in rodents (Inoue et al., 1998) and group two 
is more genetically diverse, able to infect rodents and shows biological and 
genetic similarities to T. b. brucei (MacLeod et al., 2001).  
T. b. gambiense causes 90 % of all infections and is found in West and Central 
sub-Saharan Africa. T. b. rhodesiense causes the remaining 10 % of infections in 
East sub-Saharan Africa (Simarro et al., 2008). The tsetse fly (Glossina spp.) 
vectors for these two sub-species of T. brucei are physically separated by the 
mountains along the Rift Valley, which cause lower temperatures not conducive 
to insect survival and therefore prevent the two sub-species from mixing. The 
only country where the two sub-species of T. brucei co-exist is Uganda, where 
there still remains a spatial separation between the sub-species (Fig 1-1), mainly 
due to the different climatic and vegetative conditions required by the two 
species (Berrang-Ford et al., 2010). 3 
 
 
Figure 1-1. The distribution of human African trypanosomiasis. Red spots show the location 
of T. b. gambiense, blue spots show T. b. rhodesiense. From (Berrang-Ford et al., 2010). 
 
In 2006 it was estimated that 50,000-70,000 people were infected with HAT 
(World Health Organisation, 2006), although true figures are often difficult to 
come by due to under-reporting. For example, during an epidemic of T. b. 
rhodesiense sleeping sickness in Uganda between 1988 and 1990, it was 
estimated that with every death from HAT, twelve cases went undetected (Odiit 
et al., 2005). The most up to date figures from the World Heath Organisation put 
the number of people infected at fewer than 10, 000. 4 
 
1.2.2 Stages of HAT 
There are two stages of HAT, defined by the location of the parasites within the 
host. The first stage is characterised by parasite presence in the blood and 
lymph, but not the cerebral spinal fluid (CSF) of the host. Symptoms of the first 
stage of HAT can include swelling of the face, fever, loss of appetite, chancre, 
headaches and rashes, but not all of these symptoms need be present.  
The second stage of HAT occurs when parasites enter the CSF and then the brain 
and is when patients will usually present at a clinic. The symptoms of this more 
serious stage are confusion, personality changes, altered sleep-wake patterns, 
difficulty in walking and coma. If untreated, HAT is 100 % fatal. It is difficult to 
design new compounds to counter this most commonly presenting stage mainly 
because the blood-brain barrier evolved as a very tight border control between 
the body and the delicate tissue of the brain. It is notoriously difficult to design 
trypanocides (or indeed any compounds) that can cross the blood-brain barrier 
and as a result there are only two licensed compounds active in the latter stages 
of the disease; melarsoprol and eflornithine. 
1.2.3 History of control 
During the mid 20
th century there was a huge effort to eradicate HAT and the 
disease was largely brought under control (Barrett, 2006). Unfortunately, due to 
huge political restructuring over much of sub-Saharan Africa, successful control 
programmes broke down and HAT saw a re-emergence (Barrett, 1999). At the 
end of colonial rule the feeling was that HAT had been all but eradicated and a 
culture of complacency was born. After a massive resurgence in the late 1990s 
(Barrett, 1999) control efforts were again stepped up and the situation is again 
coming under control (Simarro et al., 2011). The risk now is that control 
programmes will lose funding as governments see the disease as no longer posing 
an immediate critical problem. HAT is becoming closer to elimination and with a 
concerted effort could still be eradicated if regular screening is maintained, 
drugs are made available, drug resistance is combated and vector control 
programmes are not de-prioritised. 5 
 
1.3 The T. brucei life cycle 
Compared to many parasites, trypanosomes have a relatively simple life cycle. 
They must, however, be able to survive in several vastly differing environments 
from the blood, lymph and cerebrospinal fluid of the mammalian host to the gut 
and salivary glands of the tsetse fly vectors (Fig 1-2). 
 
Figure 1-2. The Lifecycle of Trypanosoma brucei. The parasites develop through two 
mammalian stages and three insect stages in the tsetse fly vector. ST: stumpy form, SL: 
slender form, SIF: stumpy induction factor, PC: procyclic form, Epi: epimastigote form, 
Meta: metacyclic form, CCA: cisaconitate, GPEET: a type of procyclin, EP: a type of 
procyclin, PV: proventricular forms, BARP: brucei alanine rich protein, VSG: variable 
surface glycoprotein. From Fenn and Matthews (2007). 
Starting with the bite of an infected mammal by a tsetse fly, stumpy forms of 
the parasite are taken up with the vector‟s blood meal. Differentiation from 
variable surface glycoprotein (VSG)-expressing bloodstream forms to procyclin-
expressing insect forms, known as procyclic stages, takes place after pH and 
temperature triggers are activated. Citrate or cisaconitate (CCA) in the tsetse 6 
 
midgut also appears to act as a trigger for stumpy to procyclic differentiation 
(Brun and Schonenberger, 1981;Czichos et al., 1986). Upon reaching the tsetse 
gut, parasite development and maturation takes 20-30 days (Aksoy et al., 2003). 
Procyclic stages can be cultured in rich medium in the laboratory and so are well 
studied in comparison to the later epimastigote and metacyclic insect stages. 
Procyclic trypanosomes express a surface coat of GPEET and EP procyclin, with 
GPEET down regulated in later stages of development (Vassella et al., 2004). 
After multiplication in the midgut of the tsetse fly, the cells migrate towards the 
salivary glands dividing asymmetrically on the way to produce the long, slender 
and the short epimastigote forms (Van Den et al., 1999). Short epimastigotes 
attach to the salivary gland and are thought to undergo sexual genetic exchange. 
A new surface coat of brucei alanine rich protein (BARP) is expressed here 
(Urwyler et al., 2007) and differentiation to the infective metacyclic forms takes 
place along with the acquisition of the VSG coat for evasion of the mammalian 
immune system. 
Within the bloodstream of the mammalian host there are two distinct stages: 
slender and stumpy. Differentiation from the long, slender, rapidly dividing 
bloodstream forms to less active, stumpy forms appears to work via a quorum-
sensing type mechanism where a soluble factor released by the slender 
trypanosomes builds up and promotes cell cycle arrest (Vassella et al., 
1997;Reuner et al., 1997). This soluble factor has been named stumpy induction 
factor (SIF) although it has, as yet, eluded numerous efforts at identification. 
There is some evidence from factors that mimic SIF‟s action that the cAMP 
pathway is involved in SIF induction of differentiation (Vassella et al., 1997; 
Laxman et al., 2006), but this will not be conclusive until SIF is identified. A 
collaboration between the Barrett group at the University of Glasgow and the 
Matthews group at the University of Edinburgh is attempting to characterise the 
metabolome of trypanosomes throughout the lifecycle, which may identify this 
elusive factor. 
Stumpy, bloodstream forms of T. brucei do not divide, which is a crucial 
characteristic for limiting parasitaemia within the host. Cell cycle arrest also 
seems to be important for the subsequent differentiation to procyclic forms 
when taken into a tsetse vector. Slender and intermediate forms cannot proceed 
to procyclic forms within the mammalian host, probably because they are 7 
 
outwith the G1/G0 stage of growth (Matthews and Gull, 1994;Ziegelbauer et al., 
1990). Stumpy forms are primed to differentiate to procyclic forms upon uptake 
into the insect vector. This priming appears to involve production of a group of 
carboxylate transporters deemed PADs (Proteins Associated with Differentiation) 
(Dean et al., 2009). These transporters are sequestered in the flagellar pocket of 
the trypanosome ready for transfer to the surface when citrate and CCA promote 
differentiation to procyclic forms (Dean et al., 2009). 8 
 
1.4 Trypanosome biology 
Trypanosomes are model organisms, in which many novel processes have first 
been discovered, including RNA (ribonucleic acid) editing, trans-splicing, 
glycosylphosphatidylinositol membrane anchoring and polycistronic transcription 
of protein-coding eukaryotic genes (Field and Carrington, 2009). RNA 
interference is possible in trypanosomes, allowing the analysis of the effects of 
reduced or elimated expression of individual genes in an inducible system. 
Trypanosomes can also be cloned in vitro making them a popular choice for 
genetic and metabolic studies too. 
African trypanosomes have a number of unusual features, which can make 
chemotherapy difficult and are described in detail below. 
1.4.1 Gene expression regulation 
Eukaryotic gene expression is usually controlled at the transcript level, 
producing less mRNA for a particular gene leading to reduced protein 
production. In trypanosomes, this method is not possible because genes are 
transcribed as multi-gene cistrons into pre-mRNA. These cistrons are often tens 
of genes long (Imboden et al., 1987;Daniels et al., 2010) meaning that the genes 
cannot be individually regulated at this level. Further evidence that expression 
is not regulated at the transcriptional level comes from an analysis of the level 
of the polycistronic transcript produced, which shows very little variation across 
the genome (Daniels et al., 2010).  
Gene regulation may occur when the cistrons are cut into individual genes or 
when the monocistronic pre-mRNAs are capped with a spliced leader sequence 
and polyadenylated to produce the final, functional mRNA (Huang and van der 
Ploeg, 1991). Another level of regulation may occur through mRNA degradation, 
which, contrary to most eukaryotes, occurs via two pathways attacking different 
ends of the transcript (Schwede et al., 2009). 9 
 
1.4.2 Variable surface glycoproteins 
One of the most interesting aspects of the trypanosome is how they manage to 
survive extracellularly while avoiding clearance by the host immune system. The 
main reason trypanosomes are able to stay one step ahead of their host‟s 
defences lies in the fact that trypanosomes are covered in a thick VSG coat that 
they are able to shed and swap between generations. The coat is made of 
around 10
7 identical molecules with a conserved core structure of 
glycosylphosphatidylinositol anchored in the cell membrane and an exposed 
proteinacious antigen (Cross, 1975) (Fig 1-3). Only the exposed antigen of the 
VSG is capable of change and is able to do so via a repertoire of thousands of 
silent VSG genes and gene fragments that can be moved to one of several 
telomeric expression sites (Horn and Barry, 2005). There may be several million 
trypanosomes within a host at one time, all of which will be expressing the same 
VSG copy. The immune system will recognise this VSG and will launch an 
adaptive immune attack. Trypanosomes do not appear to recognise when they 
are under attack from the immune system (trypanosomes in the absence of an 
immune system act in the same way (Doyle et al., 1980)), but a number of 
trypanosomes within the several million will exchange their expressed VSGs and 
as the trypanosomes with the first copy are killed, those with the second copies 
are able to clonally expand. This leads to a characteristic cyclic parasitaemia 
with an associated periodic fever and is useful in the diagnosis of HAT. 10 
 
 
Figure 1-3. The structure of variable surface glycoprotein. A: the superimposed structures 
of the N-terminal domains of two VSGs (MITat1.2 and ILTat1.24 ) to show the highly 
conserved structure. B: The dimeric structure of a VSG. One monomer is depicted in grey, 
the other in colours that correspond to regions of the primary structure below. From 
Schwede and Carrington (2010). 
The shedding of VSG is also problematic as it means that when antibodies are 
produced and adhere to the trypanosome‟s coat the molecule can be shed and 
the trypanosome can avoid destruction. Shedding affects the innate immune 
system in a similar way when complement binds in an attempt to construct its 
lysis machinery that would normally bind and make holes in the trypanosomes‟ 
cell membranes. The thickness of the coat and the presence of proteases is also 
problematic to complement-mediated lysis (Jokiranta et al., 1995). The 
thickness of the coat prevents access to the membrane and the proteases 
degrade proteinaceous immune machinery. 
1.4.3 Organelles 
T. brucei have many peculiarities in their organelles, which has led them to be 
considered as a very old species and are evident in the eukaryotic lineage (as 
Trypanosoma gray in the blood of crocodiles) from around 480 million years ago 11 
 
(Teixeira et al., 2009). Whereas most eukaryotic cells have many small 
mitochondria, trypanosomes contain one large, spindle-shaped mitochondrion 
that spans the entire length of the cell joining the flagellum via the basal body. 
This mitochondrion contains its own DNA (deoxyribonucleic acid), as do other 
eukaryotic mitochondria, but unlike other eukaryotes the mitochondrial DNA is 
in a large complex with many copies of the same genome. This DNA complex is 
termed the kinetoplast.  The kinetoplastid DNA is organised into around 5, 000 
interlinking minicircles and around 25 maxicircles (Chen et al., 1995). The 
maxicircles have been known to encode the usual mitochondrial and ribosomal 
proteins for many years, but the minicircles eluded explanation for a long time. 
Now we know that the maxicircles‟ RNA transcripts are extensively edited before 
becoming functional and the minicircles provide guide RNAs to allow the editing 
(a series of uridine additions and deletions) to proceed (Benne et al., 
1986;Feagin et al., 1988;Blum et al., 1990; van der et al., 1991).  
There is an extensive electron transport chain in the procyclic trypanosome‟s 
mitochondrion, which is essential to provide the majority of energy production 
(Bochud-Allemann and Schneider, 2002;Coustou et al., 2003). Conversely, 
bloodstream form trypanosomes do not express cytochromes and lack many of 
the tri-carboxylic acid cycle intermediates required for oxidative 
phosphorylation (Clayton and Michels, 1996;Tielens and van Hellemond, 1998) 
and therefore require glycolysis to produce ATP (adenosine triphosphate).  
Glycolysis within the kinetoplastida occurs within a specialised organelle termed 
the glycosome. Bearing many similarities in structure, origin and replication to 
peroxisomes, glycosomes encompass the first seven enzymes of the glycolytic 
pathway bound by a single phospholipid bilayer (Opperdoesand Borst, 1977) (Fig 
1-4). In fact, 90 % of all the protein content of a glycosome comprises glycolytic 
enzymes (Michels et al., 2006). 12 
 
 
Figure 1-4. Energy generation in procyclic form trypanosomes. Light grey arrows highlight 
the pathways utilised when glucose is the energy source, dark grey when proline or 
threonine are used. Excreted end products are represented with white text on a black 
background. Abbreviations: AA, amino acid; 1,3BPGA, 1,3-bisphosphoglycerate; C, 
cytochrome c; CoASH, coenzyme A; DHAP, dihydroxyacetone phosphate; F-6-P, fructose 6-
phosphate; FBP, fructose 1,6-bisphosphate; G-3-P, glyceraldehyde 3-phosphate; G-6-P, 
glucose 6-phosphate; Gly-3-P, glycerol 3-phosphate; OA, 2-oxoacid; PEP, 
phosphoenolpyruvate; 3-PGA, 3-phosphoglycerate; Pi, inorganic phosphate; PPi, inorganic 
pyrophosphate; SucCoA, succinyl-CoA; UQ, ubiquinone pool. Enzymes are: 1, hexokinase: 
2, glucose-6-phosphate isomerase; 3, phosphofructokinase; 4, aldolase; 5, triosephosphate 
isomerase; 6, glycerol-3-phosphate dehydrogenase; 7, glycerol kinase; 8, glyceraldehyde-3-
phosphate dehydrogenase; 9, glycosomal phosphoglycerate kinase; 10, cytosolic 
phosphoglycerate kinase; 11, phosphoglycerate mutase; 12, enolase; 13, pyruvate kinase; 
14, phosphoenolpyruvate carboxykinase; 15, pyruvate phosphate dikinase; 16, glycosomal 
malate dehydrogenase; 17, cytosolic (and glycosomal) fumarase (FHc); 18, glycosomal 
NADH-dependent fumarate reductase; 19, mitochondrial fumarase (FHm); 20, mitochondrial 
NADH-dependent fumarate reductase; 21, glycosomal adenylate kinase; 22, malic enzyme; 
23, unknown enzyme; 24, alanine aminotransferase; 25, pyruvate dehydrogenase complex; 
26, acetate:succinate CoA-transferase; 27, unknown enzyme; 28, succinyl-CoA synthetase; 
29, FAD-dependent glycerol-3-phosphate dehydrogenase; 30, rotenone-insensitive NADH 
dehydrogenase; 31, alternative oxidase; 32, F0F1-ATP synthase; I, II, III and IV, complexes of 
the respiratory chain. (Bringaud et al., 2006). 13 
 
The net production of ATP within the bloodstream form T. brucei glycosome is 
zero. All usable ATP from glycolysis is therefore produced by pyruvate kinase 
(enzyme 13 in Fig 1-4) in the cytosol.  Sequestration of the glycolytic enzymes 
within the glycosome has been shown to be essential (Bakker et al., 
2000;Guerra-Giraldez et al., 2002;Furuya et al., 2002). Glycolysis in other 
organisms has negative feedback loops from glucose 6-phosphate or trehalose 6-
phosphate on hexokinase and phosphofructokinase to prevent the autocatalytic 
pathway from losing control (Haanstra et al., 2008). T. brucei has no such 
feedback and glycolysis is instead regulated by compartmentalisation allowing 
ATP levels to be controlled (Haanstra et al., 2008). Without this 
compartmentalisation, ATP produced by the latter stages of the pathway would 
be accessible to the early stages causing a turbo explosion within the pathway 
leading to death by accumulation of toxic intermediates (Haanstra et al., 2008). 
Flux balance analysis of glycolysis within the trypanosome highlights the rate of 
glucose transport to be the main regulator of glycolysis, and blocking glucose 
transport invokes an anti-homeostatic response, increasing the effects of the 
inhibition (Haanstra et al., 2011). Both of these studies used computer models of 
glycolysis to build hypotheses with regards to regulation and control, which can 
then be tested biochemically. They highlight the use of modelling within drug 
discovery and in gaining a greater overall understanding of metabolism.    
1.4.4 Biochemistry 
Biochemically, trypanosomes evolved to maximise host energy exploitation and 
therefore rely on their insect and vertebrate hosts for the biosynthetic 
metabolic components such as purines, fatty acids, and sterols (Fairlamb, 1989). 
The parasites retain the capacity to induce many pathways but maintain a 
stream-lined metabolism in periods of nutritional abundance (Fig 1-5), utilising 
an extensive transporter repertoire over the entire trypanosome surface and 
endocytosis in the flagellar pocket to salvage nutrients. When the T. b. brucei 
genome was published there were estimated to be nearly 400 transporters, 38 of 
which were apparent amino acid transporters (although these figures are refined 
as more information is garnered about the transporter repertoire) (Berriman et 
al., 2005). This is a significant proportion (more than 4 %) of the 9, 000 14 
 
predicted genes, demonstrating how important salvage is to these parasites 
(Berriman et al., 2005).  
 
Figure 1-5. Metabolism within the trypanosome (right panel) is streamlined compared to a 
typical mammalian cell (left panel). Dots represent metabolites and lines represent 
biochemical transformations. From (Fairlamb, 1989) 
Figure 1-5 depicts the greatly increased complexity and number of metabolites 
in the generalised mammalian metabolome as compared to the trypanosome 
metabolome (Fairlamb, 1989;Nerima et al., 2010). 
The flagellar pocket is a small invagination in the plasma membrane of the 
trypanosome, at the root of the flagellum. The flagellar pocket serves as the 
only site of exocytosis and endocytosis (Field and Carrington, 2009) and is the 
origin of cell division in the parasite (Hammarton, 2007). 
The bloodstream is very rich in glucose as well as amino acids and other small 
molecules, allowing the trypanosome to use glucose as its main energy source. 
When the trypanosome is within the tsetse fly vector, however, glucose is scarce 
and proline (and to a lesser extent threonine) is used as a source of energy 
(Bringaud et al., 2006). This clearly requires extensive re-modelling of the 
trypanosome metabolome upon differentiation from bloodstream to insect 15 
 
stages of the parasite, which in turn means that many genes and proteins will 
not be in use in some stages of the parasite‟s lifecycle.   
Another interesting aspect of trypanosome biochemistry is the production of 
trypanothione, a thiol unique to trypanosomatids. Trypanothione is produced 
upon the conjugation of two glutathione molecules with a spermidine group (Fig 
1-6). This thiol is more efficient than glutathione as it can form intramolecular 
disulphide bonds more rapidly than glutathione (Olin-Sandoval et al., 2010). 
Trypanothione has been the subject of much research in the hope that its 
essentiality (Li et al., 1996; Huynh et al., 2003;Comini et al., 2004) will allow 
selective drugs to be designed that abrogate its production. Indeed, the only 
trypanocide in use with a known mode of action is thought to abrogate the 
production of this unique thiol (Fairlamb et al.,1987). 16 
 
 
 
Figure 1-6. The polyamine pathway. L-arginine and L-methionine are transported across the 
plasma membrane (represented by double line) into the cell. Metabolites are in boxes. 
Enzymes are in italics. ROS; Reactive oxygen species. 
It should be noted that although the arginase enzyme (EC: 3.5.3.1) has been 
annotated in many of the trypanosome databases, the identification is not 
robust and the possibility has been raised (Bakker et al., 2010) that the 
annotated gene does not encode arginase in trypanosomes.  17 
 
1.5 Control strategies 
A multifaceted control strategy is possible in the fight against HAT. As T. b. 
rhodesiense (and possibly T. b. gambiense (Ezeani et al., 2008)) is zoonotic, 
animal reservoirs must be reduced where possible. Livestock may be treated 
with trypanocides and infected wild animals may be slaughtered. Financial 
problems, however, in many of the affected countries limit the drugs available 
to treat infected animals. The availability of new compounds to treat animals is 
also a limiting factor. Human trypanocides are not used in animals (with the 
exception of suramin in T. evansi (Muhammad et al., 2007)) to reduce the risk of 
resistance building through over-use. 
1.5.1 Tsetse control  
During the 1980s the future of the tsetse fly looked uncertain. It was 
internationally recognised that reduction in tsetse numbers would have a hugely 
positive impact in reducing the number of infected individuals, and as a result, a 
large control programme was initiated across a 330, 000 km
2 area of Malawi, 
Mozambique, Zambia, Zimbabwe and Somalia (Jordan, 1985). Various strategies 
including aerial spraying, ground spraying, odour-baited traps and pyrethroid-
treated cattle were used with much celebrated success. In the 1990s, however, 
European spending priorities changed and the onus fell on the local farmers to 
treat their cattle and to communities to maintain traps. This led to the 
development of smaller treatment foci, which are far less effective due to the 
mobile nature of tsetse populations (Torr et al., 2005). The main problems 
associated with tsetse control are therefore political, although there is some 
work that can be done by the scientific community.  
The sterile insect technique (SIT) has been the focus of much research of late 
due to its potential in the control of plasmodium carrying mosquitoes. SIT has 
been used successfully to eliminate Glossina austeni in Zanzibar (Vreysen et al., 
2000), but was very costly and the longer-term benefits are unclear as the 
vector moves back into the treated area. Methods used to produce sterile insects 
include irradiating them before release (Franz and Robinson, 2011). Cheaper, 18 
 
and more effective SITs may be developed, such as the use of viruses specific to 
the tsetse fly (Lietze et al., 2011), but are not available at present.  
1.5.2 Vaccines  
When variable surface glycoproteins (VSGs) were discovered in 1969 (Vickerman 
and Luckins, 1969) to be the trypanosome‟s main protection against the host 
immune system, researchers were excited to finally have an exposed epitope 
that they could purify and use to develop a vaccine. Indeed, early research 
suggested that the VSG repertoire was limited to no more than a dozen VSGs (Le 
Ray et al., 1978;Barry et al., 1979;Esser et al., 1982;Crowe et al., 1983). 
Attempts were made to vaccinate using irradiated metacyclic trypanosomes, 
which resulted in promising early results (Esser et al., 1982). However, when it 
was subsequently discovered that the mosaic nature of expressed VSGs means 
that the repertoire is virtually limitless (McCulloch and Horn, 2009), exposed 
antigen vaccination programmes fell out of favour.  
Trypanosomes require a highly developed cytoskeleton, integral to motility, 
flexibility and mechanical stability. As a consequence, β-tubulin and actin are 
highly expressed and have been used as vaccine candidates, producing some 
positive results (Lubega et al., 2002;Li et al., 2007;Li et al., 2009), although 
negative controls also offered some protection suggesting that the initially 
positive results are actually a result of a general immune system boost at a non-
specific level.  
Transmission blocking vaccines have been used successfully in experimental tests 
for malaria (Outchkourov et al., 2008), leishmania (Saraiva et al., 2006) and 
babesiosis(Willadsen et al., 1995;de la Fuente et al., 1998) and may be possible 
in trypanosomiasis too. Transmission blocking vaccines can follow a number of 
strategies. Interruption of the development of the parasites to the insect 
infective stage within the human body is one target. Similarly, development of 
the parasite within the midgut of the insect vector can be abrogated (as is the 
case with malaria and leishmania vaccine trials). Insect fecundity is also a 
target, taking advantage of the tsetse fly‟s requirement for albumin to provide 
osmoregulation during storage of the blood meal (Nogge and Giannetti, 1980). 
Antibodies against the insect mid-gut can also have devastating effects on the 19 
 
vector population as was shown with babesiosis (Willadsen et al., 1995;de la 
Fuente et al., 1998). These methods hold their own controversies as they are 
often unspecific to the disease the arthropod vector is carrying. 
In different cattle species, infected with T. congolense, there is a significant 
disparity in the disease progression, enabling animals to be labelled as 
trypanosusceptible and trypanotolerant. It appears that the main difference 
between the trypanosusceptble and the trypanotolerant cattle is that the latter 
are able to mount an anti-congopain IgG, an immunoglobulin produced by white 
blood cells of the adaptive immune response. Congopain is a cathepsin-L like 
cysteine protease in T. congolense trypanosomes and is under investigation as a 
vaccine candidate for cattle (Boulange et al., 2011). Humans however, do not 
show the same spectrum of disease susceptibility as cattle and some researchers 
defined the cause of this discrepancy to be due to suppression of the immune 
system during human trypanosome infection (Murray et al., 1974;Murray et al., 
1974;Askonas et al., 1979;Clayton et al., 1979). More recently, it has been 
reported that in addition to immune suppression there is a significant reduction 
in several B cell responses (Radwanska et al., 2008). This destruction appears to 
be very rapid and permanent, explaining why the large majority of vaccines 
trialed up until now have shown promising initial results, but no long-term 
memory. This is a worry, not just for the future of trypanosome vaccination 
research, but also for vaccination programmes against the many other infections 
in the trypanosome-exposed population. A permanent destruction of B-cells, 
leading to a lack of herd immunity can vitiate a whole vaccination programme 
(e.g. for human immunodeficiency virus, schistosomiasis or malaria) so it may be 
beneficial to these programmes to invest in anti-trypanosome therapies before 
commencing vaccine trials. 
1.5.3 Chemotherapy 
There are only four drugs licensed for the treatment of HAT: pentamidine, 
suramin, melarsoprol and eflornithine (Fig 1-7). Although many of the drugs have 
been around for decades, we only know how one of these compounds, 
eflornithine, exerts its actions. 20 
 
 
Figure 1-7. The four drugs licensed for use against HAT. Suramin and pentamidine are used 
in the early stages of infection. Melarsoprol and eflornithine in stage two of the disease 
when the CSF has been invaded. 
1.5.3.1  Pentamidine 
Pentamidine is a diamidine effective against stage one T. b. gambiense 
infections. It has been available since the early 1940s and has previously been 
heavily used as a prophylactic as well as a curative agent (Bacchi, 1993). The 
action of pentamidine appears to be multifactorial possibly due to the drug 
binding to DNA in regions of the minor groove rich in adenine and thymine 
(Moreno et al., 2010). Pentamidine isethionate is currently given for free by 
Sanofi-Aventis to the WHO and distributed by Médecins Sans Frontières. Four 
milligrams per kilogram are given daily or on alternate days by intramuscular 
injection for 7-10 days (Sands et al., 1985). Pentamidine is concentrated within 
trypanosomes principally via the P2 aminopurine permease (Lanteri et al., 
2004). High affinity and low affinity pentamidine transporters (HAPT and LAPT) 
also contribute to uptake (De Koning, 2001).  
An analogue of pentamidine containing a furan ring has been developed and was, 
until recently, in clinical trials for use against Pneumocystis jiroveci carinii 
pneumonia, advanced immunodeficiency syndrome and malaria in addition to 
HAT (Lanteri et al., 2004). It is administered as a pro-drug, DB289, and can be 
given orally, which is a major advantage for use in less developmentally 
advanced countries. The active compound of DB289, DB75 (2,5-bis-4-21 
 
amidinophenylfuran), is also fluorescent due to its furan and benzene ring 
conjugation systems and has been seen to localise to the mitochondrion in yeast 
cells (Lanteri et al., 2004) along with other DNA containing organelles in the 
trypanosome (Mathis et al., 2006). The usability of DB75 on trypanosomes may 
be limited however, as the mechanism of uptake is via the P2 transporter 
(Lanteri et al., 2006) and so it is likely that the resistance mechanism will be the 
same as that for pentamidine (see section 1.6). DB289 was shown to be 
successful in phase III clinical trials as an oral drug against stage one HAT. During 
extended phase I trials, however, using a 14 day instead of the 10 day dose used 
in the phase III trials, serious toxic side effects were exposed and the drug has 
now been removed from clinical consideration (Paine et al., 2010).  
1.5.3.2  Suramin  
Suramin is a polysulphonated naphthalene derivative (Barrett et al., 2007) 
discovered by Oskar Dressel and Richard Kothe at Bayer in 1916 (Haberkorn et 
al., 2001) and has been used to treat “surra”, caused by T. evansi, in camels for 
many years (Zhou et al., 2004). The large, negatively-charged polyanion appears 
to inhibit many positively-charged enzymes unspecifically, so it is difficult to 
conclude which may be the determinant of drug action (Pepin and Milord, 
1994;Wang, 1995). Suramin (along with other naphthalene dyes) is selectively 
concentrated by trypanosomes through either receptor-mediated endocytosis 
when conjugated with low-density lipoproteins (Vansterkenburg et al., 1993) or 
some other mechanism (Pal et al., 2002). Suramin can be administered in stage 
one cases of T. b. gambiense and rhodesiense infection by five slow intravenous 
injections every 3-7 days for 28 days (Barrett et al., 2007). There has, however, 
been some treatment failure in T. b. gambiense, so suramin has been reserved 
for preferential use against T. b. rhodesiense, where pentamidine is ineffective. 
1.5.3.3  Melarsoprol 
Only melarsoprol and eflornithine are effective in the latter stages of the 
disease when the parasites have invaded the brain and CSF due to difficulties in 
other compounds in crossing the blood-brain barrier. Melarsoprol, a 
melaminophenyl arsenical, was first synthesised in 1949 and its action is based 
on the severely toxic arsenic moiety. The severely toxic nature of this drug 22 
 
results in the death of around 5 % of recipients treated (in HAT (Blum et al., 
2001) and leukaemia patients (Soignet et al., 1999)), via a reactive arsenical 
encephalopathy.  It is not known how melarsoprol kills trypanosomes, but it is 
known to form stable adducts with thiols, particularly with dihydrotrypanothione 
to form MelT (Fairlamb et al., 1989). MelT then acts as a competitive inhibitor 
of trypanothione reductase, an essential enzyme that protects from oxidative 
stress (Bacchi, 1993). Adducts are also formed with lipoic acid (Barrett et al., 
2007) and glycolysis is targeted via fructose 6-phosphate 2-kinase (Bacchi, 1993). 
Actions on glycolysis do not appear to be the main mode of action of melarsoprol 
however, and the effects on this pathway are minimal (Bacchi, 1993). It is likely 
that there are more modes of action for melarsoprol. 
 Melarsoprol is distributed in glass vials and usually administered intravenously in 
glass syringes as the solvent (ethylene glycol) is known to dissolve plastic-ware. 
The recommended course is 10 days long with daily injections of 2.2 mg/kg 
(Brun et al., 2010). Melarsoprol is the only drug effective against late stage T. b. 
rhodesiense infections. 
1.5.3.4  Eflornithine 
Due to the unacceptable toxicity of melarsoprol, eflornithine (DL-α-
Difluoromethylornithine; DFMO) has been recommended by the WHO as the first 
line treatment in areas where T. b. gambiense is prevalent (Chappuis et al., 
2005;Balasegaram et al., 2006;Priotto et al., 2008). Eflornithine, manufactured 
by Sanofi-Aventis, is the only drug with a well understood mode of action. It was 
originally developed in the 1970s as an antineoplastic agent (Janne et al., 
1981;Heby et al., 2007) and is a suicide inhibitor of ornithine decarboxylase 
(ODC) in the polyamine pathway (Fig 1-5). ODC exists in trypanosomes as a 
homodimer and is dependent of pyridoxal 5‟-phosphate for its structural 
integrity (Grishin et al.,1999). ODC is irreversibly inhibited by the formation of 
adducts with eflornithine in the active site of the enzyme (Poulin et al., 1992). 
In mice these adducts form at residues lysine 69 and cysteine 360, forming a 
Schiff base to pyridoxal 5‟-phosphate (Poulin et al., 1992).   In the trypanosome 
enzyme, eflornithine also forms a schiff base with pyridoxal 5‟-phosphate and 
covalently binds to cysteine 360 (Grishin et al.,1999).  23 
 
Eflornithine is only active against T. b. gambiense forms of HAT possibly due to a 
reduced rate of ODC turnover in this sub-species (Iten et al., 1997). The rate of 
turnover of ODC may be influenced by differences in the C-terminal peptides of 
the enzymes, as T. b. gambiense has been shown to lack a 36 amino acid region 
rich in proline, glutamate, aspartate, serine and threonine (PEST) when 
compared to the mouse orthologue (Phillips et al., 1987), which has a much 
faster turnover rate. These PEST regions appear to be indicators of enzyme 
instability (Ghoda et al., 1992). 
Eflornithine treatment is difficult to administer in the field as it has poor bio-
availability when given orally and therefore must be administered by intravenous 
infusion. Eflornithine‟s high IC50 (inhibitory concentration for 50 % growth 
reduction) (225 µM (Phillips and Wang, 1987) or 100 µM (Bellofatto et al., 1987) 
in vitro for procyclic stages) and low half life of around three hours, also dictate 
that large quantities of the drug are required (nearly 4 kg for a 50 kg patient 
(Brun et al., 2010)) for the treatment regime of 56 infusions over 14 days. It is 
logistically difficult to deliver and to administer the large quantities of drug 
required to the rural areas where patients are often diagnosed leading to a 
continued reliance on melarsoprol in some places. This problem is also driving 
research into combination therapies that might reduce the amount of drug 
required. 
ODC inhibition by eflornithine leads to an increase in levels of ornithine, S-
adenosyl methionine and decarboxylated S-adenosyl methionine, and a decrease 
in putrescine, spermidine and trypanothione after 48 hours (Fairlamb et al., 
1987). Bacchi et al. (1983) also recorded a decrease in putrescine and 
spermidine and an increase in dc-SAM, but also noted an increase in spermine. 
This is interesting as spermine is not thought to be synthesised or utilised in T. 
brucei and may even be toxic to the cells (Merkel et al., 2007). Margaret 
Phillips‟s lab in Texas recorded polyamine levels by high performance liquid 
chromatography after the addition of eflornithine to bloodstream form cells in 
vitro. The group reported a depletion of putrescine and decreases (to 20-40 % of 
untreated levels) of spermidine, glutathionyl-spermidine, glutathione and 
trypanothione after three days, in agreement with the other studies (Xiao et al., 
2009). Decarboxylated S-adenosyl methionine levels increased around 40 % after 24 
 
treatment with eflornithine as the previous studies showed, but S-adenosyl 
methionine levels were unchanged (Xiao et al., 2009).  
Bacchi et al. (1995) found that trypanosomes rapidly incorporate heavy 
methionine into S-adenosyl methionine, methylthioadenosine, S-
adenosylhomocysteine, homocysteine, csytathione, cysteine and glutathione. 
When treated with eflornithine, these cells rapidly (within 30 minutes) 
accumulate S-adenosyl methionine but also accrue decarboxylated S-adenosyl 
methionine (Bacchi et al., 1995), albeit at a slower rate. 
Roles of spermidine include the formation of complexes with polynucleotides to 
alter their stability and transcription, the binding to membranes influencing 
stability and the enhancement of some enzyme catalysis (Li et al., 1996). 
Spermidine conjugates with two molecules of glutathione to form trypanothione, 
a thiol unique to trypanosomatids (Heby et al., 2007). The synthesis of 
polyamines is essential to parasite survival, since polyamines are important for 
G-S phase transition (Li et al., 1996) and protection against oxidative stress 
(Steenkamp, 2002). The increase in S-adenosylmethionine levels causes aberrant 
methylation of proteins (Yarlett and Bacchi, 1988). Levels of all proteins 
including VSG decrease with eflornithine addition (Bitonti et al., 1988;Heby et 
al., 2007). The reduction in VSG exchange associated with the decrease in VSG 
expression may allow easier recognition by the host immune system (Bitonti et 
al., 1988). Parasites treated with eflornithine are not actually killed by the drug 
directly, but are forced to differentiate to the non-replicative stumpy forms 
(Barrett et al., 2007). These stumpy forms of the parasite are auxotrophic for 
polyamines (Barrett et al., 2007) and are killed by the host immune system.  
1.5.3.5  Nifurtimox-eflornithine combination therapy 
Nifurtimox is a 5-nitrofuran pro-drug that has been used for more than 40 years 
to treat Chagas disease (American trypanosomiasis). To be active, the drug must 
undergo nitroreduction. In trypanosomes this nitroreduction is undertaken by 
NADH-dependent type I nitroreductases that are rare in eukaryotic cells 
(Wilkinson et al., 2008). 25 
 
An eflornithine-nifurtimox combination therapy (NECT) has been gaining 
momentum as an alternative to eflornithine monotherapy in recent years 
(Priotto et al., 2009;Opigo and Woodrow, 2009). It has been suggested that 
eflornithine and nifurtimox work in synergy with one another, thus allowing 
lower doses of each drug to be prescribed. This postulated synergy is thought to 
be due to the reduction in polyamine levels (and consequently reduced 
trypanothione) during eflornithine treatment being insufficient to deal with the 
oxidative stress attributed to nifurtimox. That oxidative stress may be caused by 
nifurtimox is a matter of debate. It was observed that trypanosome extracts 
produced superoxide anions and nitro anion free radicals upon treatment with 
nifurtimox (Docampo and Stoppani, 1979;Docampo et al., 1981), but there is 
little evidence that the same results occur in vivo. N-acetylcysteine can 
antagonise oxidative stress via interactions with free radicals produced by 
nifurtimox (Enanga et al., 2003). When administered at 0.5 mM with nifurtimox 
on in vitro bloodstream form cells, N-acetylcysteine provided a mild protective 
effect (IC50 of 12.72 µM, compared to 3.37 µM without N-acetylcysteine) (Enanga 
et al., 2003). However, the over-expression of trypanothione reductase (which 
would be expected to counteract any induced oxidative stress) confers no 
difference in susceptibility to nifurtimox over wildtype controls (Kelly et al., 
1993). Given the current evidence, no conclusions can be made on the mode of 
action of nifurtimox although recent evidence implicates an open chain nitrile 
that attcks macromolecules such as DNA and protein (Hall et al., 2011). 
The administration of the combination therapy compared to eflornithine 
monotherapy is much easier to implement. Nifurtimox can be given orally (three 
times a day for 10 days) and the eflornithine infusions are reduced in frequency 
to 14 over seven days. Logistically, drugs are easier to transport due to the 
lower quantities required and the reduction in refrigeration costs (the cost is 
reduced from €107 to €39 per patient (Yun et al., 2010)). There are fewer 
infections at the site of infusion due to the reduced frequency of infusion and 
fewer side effects overall (Priotto et al., 2009). It will be interesting to 
determine how this combination works biochemically after noting its 
effectiveness in the field. 26 
 
1.6 Drug resistance 
As with all monotherapies, resistance to each of the drugs used in isolation is a 
growing worry. A treatment failure has been defined as a resurgence of 
parasitaemia within 18 months (or 24 months in some studies) post treatment. It 
is difficult to note treatment failures due to the difficulties patients face in 
travelling to treatment centres, in most cases making patient monitoring very 
hard to implement. Treatment failures have been noted to all the drugs in the 
field (Barrett et al., 2011), but determination as to the cause of the treatment 
failure is difficult and could be due to a number of factors including re-infection 
and non-compliance with the treatment regimes.  Resistance to all the drugs in 
use has, however, been selected in the laboratory (Phillips and Wang, 1987;Scott 
et al., 1996;Scott et al., 1997; Bridges et al., 2007) allowing the study of the 
potential mechanisms of resistance, although these may not hold relevance in 
the field as life cycles are not completed and culture conditions are optimised in 
vitro. 
Resistance to stage one drugs is unlikely to be detected in the field as it will be 
assumed that treatment failures at stage one will have resulted from a mis-
diagnosis of a stage two infection and will therefore be re-treated as stage two. 
There are multiple ways to confer resistance to a drug including a reduction in 
drug uptake, an increase in drug efflux, the loss of pro-drug activation, an 
increased production of the target enzyme, metabolism of drug, alterations to 
the drug target and increased ability to bypass the inhibited drug target (Borst 
and Ouellette, 1995). Two of these resistance mechanisms are transporter-based 
and transporters have been implicated in resistance to two of the drugs in use 
against HAT as discussed below.  
Resistance to melarsoprol is a worry as it is the only drug available against late 
stage T. b. rhodesiense infections and treatment failures in some T. b. 
gambiense areas have already reached levels of 30 % (Legros et al., 1999;Brun et 
al., 2001;Stanghellini and Josenando, 2001). Parasites selected for resistance in 
the laboratory (Carter and Fairlamb, 1993;Barrett and Fairlamb, 1999;Maser et 
al., 1999;Stewart et al., 2005) have lost the P2 transporter, and several relapse 27 
 
patients yielded parasite isolates deficient in P2 transport (Maser et al., 
1999;Matovu et al., 2001;Stewart et al., 2005). This is in contrast to the 
perceived fitness cost of losing the P2 transporter (Berger et al., 1995;Bray et 
al., 2003). 
Loss of transporters can confer some resistance, but the gain or increased 
expression of a transporter that serves as an efflux mechanism for a drug can 
also lead to resistance, as has been seen in the case of Multidrug Resistance 
Protein A (MRPA). A homologue of this transporter protein (PGPA) was originally 
identified in leishmania as being responsible for resistance to arsenite or 
antimony drugs. PGPA and MRPA transport metal-thiol conjugates out of the cell 
and overexpression of MRPA can lead to 10 fold resistance of T. b. brucei to 
melarsoprol in vitro (Shahi et al., 2002). Conversely, RNAi of MRPA in resistant 
isolates can increase sensitivity to melarsoprol (Alibu et al., 2006). 
During selection of pentamidine resistance in vitro the P2 and HAPT (and 
possibly LAPT) (Fig 1-8) transporters are usually lost in order, conferring 
increasing levels of resistance. Development of high levels of resistance appears 
to come with severe cost to parasite fitness (Berger et al., 1995;Bridges et al., 
2007), which appears to be linked to loss of HAPT (Bridges et al., 2007), thus 
restricting the chances of resistance developing in the field. Increased 
expression of MRPA does not provide a decreased sensitivity to pentamidine 
(Shahi et al., 2002).  
Visceral and cutaneous leishmaniasis is also occasionally treated with 
pentamidine and some resistance to this drug is emerging in Leishmania 
donovani (Sundar, 2001) and L. mexicana (Basselin et al., 2002). These 
resistance mechanisms have been studied and in L. mexicana appear to involve 
diminished uptake of the drug into the mitochondrion associated with decreased 
mitochondrial membrane potential (Basselin et al., 2002) and are not the same 
as the resistance mechanisms studied in trypanosomes so far. 28 
 
 
Figure 1-8. Routes of uptake for each of the currently used trypanocidal drugs. P (orange) = 
pentamidine, M (green) = melarsoprol, N (purple) = nifurtimox, E (red) = eflornithine, S 
(magenta) = suramin.  Also, where known, cellular targets are marked, including ornithine 
decarboxylase (ODC) for eflornithine and the nitroreductase (NTR) that metabolises 
nifurtimox into its active form (N*).  Pentamidine binds to kinetoplast DNA (K). Resistance to 
eflornithine relates to loss of TbAAT6. Resistance to melarsoprol (or its active metabolite 
melarsen oxide) relates to loss of the TbAT1 (P2) and HAPT1 transporters.  Alternatively up-
regulation of TbMRPA and can cause resistance when melarsen oxide-trypanothione 
conjugates are pumped from the cell.  Pentamidine resistance also relates to loss of TbAT1 
and HAPT1 transporters. Suramin enters by receptor mediated endocytosis at the flagellar 
pocket and resistance may relate to changes in the endocytic pathway. Nifurtimox 
resistance can come around when the nitroreductase activity involved in its activation is 
diminished.  
 
Resistance to suramin was reported in the 1950s and resulted in its replacement 
with pentamidine as the recommended drug for early stage T. b. gambiense 
trypanosomiasis, although suramin is still used for T. b. rhodesiense HAT (Barrett 
et al., 2007). The mechanisms for suramin resistance may involve changes to 
receptor-mediated endocytosis of the drug (David Horn, unpublished 
observations). 29 
 
Resistance to eflornithine has not been officially reported in the field to date, 
although numerous anecdotal reports from physicians in the field suggest that 
treatment failures are a real and increasing threat to eflornithine‟s use (Matovu, 
2011).  30 
 
1.7 Transporters 
1.7.1 Roles for membrane transporters 
The lipid bilayer surrounding the trypanosome is permeable only to small 
lipophilic compounds. Larger compounds or lipophobic compounds must 
therefore gain entry via endocytosis or through transporter proteins. As noted 
earlier, trypanosomes have a high rate of endo and exocytosis within their 
flagellar pockets. The flagellar pocket also contains an aggregation of 
transporters, required for the uptake of many essential nutrients (Field and 
Carrington, 2009). 
Trypanosomes are exposed to ever-changing environments during their life cycle 
through insect and vertebrate hosts and as such have a varying repertoire of 
transporters on their surfaces (Besteiro et al., 2005;Berriman et al., 2005). 
These can serve both as a means to pick up essential nutrients and as 
environmental sensors (Holsbeeks et al., 2004). Putative transporters in 
trypanosomes can be identified by sequence or structural similarity with known 
transporters in other organisms. In addition, some genes encoding transporters in 
Leishmania spp. have been shown to have a conserved location (synteny) in 
trypanosomes (Jackson, 2007).  
As trypanosomes have such a reliance on nutrient uptake, much effort has been 
invested into transport research in the hope that essential transporters can be 
discovered and chemically blocked leading to new chemotherapies.  
Purine transport in particular has received much attention as one of the purine 
transporters (P2) carries melarsoprol and diamidines as well as purines (De 
Koning et al., 2004). A recognition motif that allows compounds to enter the 
transporter has been identified and it was hoped that this motif may be grafted 
onto other compounds to target drugs to the trypanosome‟s interior (Barrett and 
Fairlamb, 1999;De Koning and Jarvis, 1999).  
Glucose transport has also been a topic of trypanosomatid research as glycolysis 
is essential for bloodstream form trypanosomes. T. brucei express two glucose 
transporters, one, low affinity transporter in the bloodstream stage and one, 31 
 
higher affinity transporter in the insect stages (Hasne and Barrett, 2000). A 
problem that arises when attempting to block glucose uptakes in bloodstream 
form is that blood glucose levels are in the milimolar range meaning that 
competitive inhibitors would be extremely difficult to administer (Hasne and 
Barrett, 2000).  
The transport of many amino acids has also been studied. L-proline transport in 
procyclic forms was found to be inhibited by L-alanine and L-cysteine (L'Hostis et 
al., 1993), L-methionine uptake was inhibited by D/L-homocysteine, L-leucine, 
L-phenylalanine and L-tryptophan (Hasne and Barrett, 2000) and L-glutamine and 
L-cysteine were shown to share a transporter (Marciano et al., 2009). The 
apparent high level of redundancy in amino acid transporters suggests that 
blocking these would not cause detriment to the cells. 
1.7.2 Transporter-mediated drug uptake 
The transport mechanisms have been putatively identified for suramin 
(Vansterkenburg et al., 1993), although these mechanisms have been much 
debated and it is now widely believed that suramin gains trypanosome entry via 
endocytosis (Barrett and Gilbert, 2006). Robust evidence exists for the role of 
the P2 transporter in pentamidine and melarsoprol uptake and HAPT and LAPT in 
pentamidine uptake (De Koning, 2001). HAPT may also play a role in melarsoprol 
uptake as has been eluded to in cross resistance studies where selection of high 
levels of pentamidine resistance due to loss of HAPT are also more resistant to 
cymelarsen (a melaminophenyl arsenical similar to melarsoprol) than loss of P2 
alone (Teka et al., 2011). 
 Eflornithine has been shown to be accumulated in Neurospora crassa by a 
permease for basic amino acids encoded by the pmb gene (Davis et al., 1994), 
and in procyclic form trypanosomes transport of eflornithine is saturable (Phillips 
and Wang, 1987) apparently following Michaelis-Menten kinetics. However, 
Bitonti et al. (1986) claimed that eflornithine transport is unsaturated at 10 mM 
in bloodstream form T. b. brucei and concluded that the drug enters by passive 
diffusion. This study did however, reveal a temperature sensitivity of 
eflornithine uptake in T. b. brucei and mammalian cells and a partial uptake 32 
 
inhibition by salicylhydroxamic acid, both of which suggest an active transport 
mechanism (Bitonti et al., 1986).  
Since eflornithine is an amino acid, structurally similar to the basic amino acids 
arginine and lysine (Fig 1-9), it is possible that there is a shared uptake 
mechanism.  
 
Figure 1-9. Eflornithine (left), a basic amino acid, is a modification of ornithine (right).  
Using Andrew Jackson‟s classification system (Jackson, 2007), there are 48 
predicted amino transporters in T. b. brucei. This differs from the genome 
project prediction of 38 (Berriman et al., 2005), due to different prediction 
methods. These 48 transporters are divided into 17 groups based on sequence 
similarity, evolutionary relationships and synteny (Fig 1-10) (Jackson, 2007). 
None of these 17 groups contain a transporter annotated as being a transporter 
for basic amino acids, indeed the amino acid transporters are poorly annotated 
in general and most have not been functionally studied.  33 
 
 
Figure 1-10. Amino acid transporters in T. brucei. There are 17 groups of amino acid 
transporters depicted here on the 11 chromosomes. There is a high concentration of 
transporters on chromosomes 4, 8, 10 and 11. AAT: amino acid transporter. From Jackson 
(2007). 34 
 
1.8 Metabolomics 
Defined as the analysis of all the small molecules (Mr<1200) within a cell, 
metabolomics is a rapidly growing branch of the –omic technologies (Griffin, 
2006;Oldiges et al., 2007). Measurements of the levels of substrates, products 
and cofactors of enzymatic reactions can be used as indicators of deeper-lying 
biological alterations at the genomic, transcriptomic or proteomic level.  
There are a number of methods one can utilise to obtain information about 
metabolites within a cell. Nuclear magnetic resonance (NMR) can be used for 
targeted analyses as it is much more facile to quantify metabolites using a single 
internal standard, requires minimal separation and is non-destructive (Beckonert 
et al., 2007). It is, however, far less sensitive than other techniques and 
provides a much reduced coverage of the metabolome. Raman spectroscopy 
detects vibrations or rotations in metabolites as they are excited by a laser, but 
as with NMR spectroscopy, Ramen spectroscopy does not provide a large 
coverage of the metabolome. The alternative to NMR and Ramen spectroscopies 
lies in mass spectrometry.  
1.8.1 Mass spectrometry  
Mass spectrometry is a method that measures the mass of a metabolite by 
creating charged species at the ion source, which are separated on mass and 
detected by the completion of an electronic circuit that produces a signal in the 
detector (Fig 1-11).  35 
 
 
Figure 1-11. A generalised mass spectrometer from Dunn (2008). The sample is usually 
introduced in solvent from a chromatographic column into the ESI source. It is then ionised 
and the mass is analysed by filtering or by time of movement along a plane or around a 
pole. The detected masses are recorded in mass spectra files, usually with the time 
dimension from the chromatography column mapped for each mass detected against the 
intensity of the signal. 
 
1.8.1.1  Chromatography 
When analysing a complex metabolite sample it is usual to conduct some 
separation of the metabolites using chromatography columns reducing the 
complexity of the sample and reducing ion suppression effects. Metabolites 
travel along a column as either a gas (gas chromatography, GC) or a liquid (liquid 
chromatography, LC) phase. GC-MS is frequently used for volatile substances 
such as explosives, flavours and fragrances, although other, less volatile 
compounds may have to be derivatised before they can be run as a gas (Dorman 
et al., 2010). The GC columns use phase partitioning to separate the mobile gas 
phase from a liquid phase on the inner surface of the column (Dorman et al., 
2010). Liquid chromatography is used for less volatile metabolites and is often 
considered more useful for metabolomics as metabolites have no requirement 
for derivatisation and sampling can therefore be more high-throughput.  
There are several LC-MS columns used to separate metabolite samples. 
Lipophilic metabolites can be separated well by reverse-phase LC, but polar 
metabolites are not retained on these columns. HILIC (hydrophilic interaction 
chromatography) columns are therefore more frequently used for separating 
metabolite samples (Cubbon et al., 2010). These columns use a stationary 
aqueous layer (such as water) and a mobile phase (such as acetonitrile) to 
separate metabolites based on both their polarity (more polar metabolites will 36 
 
be retained for longer on the aqueous layer) and degree of salvation (Cubbon et 
al., 2010).  
1.8.1.2  Ionisation 
There are many types of ionisation used in mass spectrometry, with electrospray 
ionisation (ESI) being most commonly coupled to LC-MS. ESI works via the 
production of a large voltage potential that creates a charge on the metabolites 
in solvent pushed through an ultra fine needle (Careri and Mangia, 2011). 
Charged solvent droplets exit the needle and, as solvent evaporates, the charge 
density in the droplet increases until the electrostatic repulsion between ions 
overcomes surface tension, and the droplet breaks up. Ultimately, charged 
solute ions are transferred to the gas phase and enter the ion path of the mass 
spectrometer, where they can be manipulated by electrodes for mass analysis 
and detection.  
ESI can operate in two polarities (or modes), which means that a greater range 
of metabolites can be detected compared to techniques that operate in just one 
polarity. For example, some metabolites, such as amines are more stable in a 
protonated state and are therefore more easily detected by positive ionisation, 
whereas very acidic ions such as phosphates are more stable in a deprotonated 
form so are detected in negative mode (Watson, 2010).  
ESI has a tendency to create multiply-charged ions (Careri and Mangia, 2011), 
which must be dealt with in the data processing stages of analysis. ESI also has a 
capability to fragment metabolites, which can be cumbersome during data 
analysis, but can also be very useful when providing structural information that 
can aid metabolite identification. 
1.8.1.3  Mass analysers 
Mass analysers measure the mass of a metabolite by detecting the time the 
metabolite takes to travel a certain distance (time of flight spectroscopy), how 
the metabolite oscillates in a magnetic field (Fourier transform ion cyclotron 
resonance mass spectroscopy (FT-ICR)), how the metabolite travels around a 37 
 
central electropole in an orbit (Orbitrap), or sieves metabolites based on their 
charge and mass (Quadrupole) (Dunn, 2008). 
1.8.1.4  Species detection 
The detector in the mass spectrometer creates an electronic signal when a 
charge or an electrical current is detected as a charged species hits or passes by. 
This signal is often very small so signal amplification is common in detectors.  
1.8.2 Applications 
As metabolomic techniques develop the number of studies that involve an 
element of mass spectrometry or aim to improve methods and data processing 
are also increasing at a profound rate. Researchers will use the parts of the 
technologies that are useful to them allowing different areas of metabolomics to 
evolve independently of one another. For this reason, different areas have their 
own softwares that are more frequently in use. The terms in use can also differ 
between different niches of research. Some of the terms are described below 
(Dunn, 2008). 38 
 
1.8.2.1  Metabolic fingerprinting – a snapshot of a metabolome aimed at sorting 
samples into groups rather than gaining high resolution metabolic data. 
1.8.2.2  Metabolic Footprinting – the extracellular metabolome of an organism. 
(also known as the secretome) can be taken non-invasively. 
1.8.2.3  Metabolomic Profiling - an untargeted look at as many metabolites 
within the organism of interest as possible. Multiple extraction methods will 
be used to gain as global an overview as possible. Relative intensities of 
each of the metabolite will be measured, but no real quantification is 
attempted. 
1.8.2.4  Metabolite flux analysis – the rate at which carbon flows though a 
pathway. This can be measured using radio-labelled metabolites in a time 
course assay and can be useful in determining choke points within a 
pathway. 
1.8.2.5  Choke points – a critical enzyme in a pathway where metabolites do not 
have an alternative route to synthesise the products of the reaction. 
1.8.2.6  Metabonomics – a term that was at first used synonymously with 
metabolomics, but now refers to quantitative changes to a metabolome in 
response to pathophysiological or genetic stimuli. 
1.8.2.7  Biomarker studies - much effort is currently being invested into 
technologies aimed at the detection of biomarkers of disease in blood or 
urine of diseased humans or animal models. If biomarkers are discovered, 
these could potentially have a huge impact in the development of new 
diagnostic tests for diseases such as cancer, diabetes or heart disease.  
A major advantage of metabolomics over the other –omics technologies is that 
there are far fewer metabolites (around 3, 000 in the human metabolome (Kell, 
2006)) than genes (around 32, 000 in the human genome) or proteins (at least 
one per gene) and so the data set is often much more manageable (provided 
only the cell metabolites are detected with minimal contaminants and 
background ions). Metabolomics can also be a much cheaper method of analysis 39 
 
because sample preparation is not as difficult and labour intensive as in 
proteomics, as gel separations and trypsin digests are not required. 
Transcriptomics requires the use of costly chips specific to the organism under 
investigation, which are not required in metabolomics. Variability in metabolite 
signal intensities does, however, often necessitate additional machine runs. 
High-throughput analyses can be performed with metabolomic technologies 
because metabolites are much more generic between organisms than proteins, 
RNA transcripts or genes (Kell et al., 2005). For example, the metabolite glucose 
has the same structure in every organism, whereas the gene coding for 
hexokinase may have subtle sequence differences even within a species, and the 
protein may have additional post translational modifications even within a clonal 
population of cells. 
1.8.2.8  Mode of action studies 
Drug discovery is a very expensive process and the licensing of a drug is much 
easier if more is known about the compound‟s mode of action. Whereas drug 
discovery used to be led by the active compound, with definition of the mode of 
action coming later, new research is much more often drawn from the discovery 
of a good metabolic target.  
Metabolomics can be an extremely useful technique when looking at a drug‟s 
effect on the small metabolites within a cell population. From a complex 
metabolome, a drug‟s mode of action may be inferred, allowing easier licensing 
and bringing down the cost of drug discovery. 
There are two approaches that metabolomic-based mode of action studies 
generally take. In the first, a metabolic fingerprint of the changes the drug 
induces in the metabolome is taken and compared using multivariate statistical 
analysis to drugs with known modes of action (Yi et al., 2007). The second takes 
a more detailed look at the individual metabolite abundance changes after drug 
introduction (Le Roch et al., 2008). This approach provides much more 
information on the mode of action of a drug, allows new modes of action to be 
defined and allows the prediction of off-target effects. In addition to 
determining the modes of action of drugs on pathogens, it would be possible to 40 
 
predict any side effects on human cells and tissues. This would be hugely 
beneficial to reduce the amount of animal testing required for new compounds if 
side effects can be recognised before animal trials begin. It would also 
potentially reduce the cost of developing new compounds and speed up the time 
it takes for a compound to reach the market.  
If the pathways that a drug acts upon are known, then synergistic compounds 
can be sought and resistance mechanisms might be predicted. 
Once a potential target has been identified, then further analyses can be 
undertaken to dissect the exact mode of action. For example, if the potential 
target is an enzyme, then the enzyme may be knocked down by RNA 
interference and the phenotype, drug IC50 and metabolomes of the drug treated 
and the knocked down target cells can be compared.  
Jess Allen and colleagues at the University of Wales took metabolic fingerprints 
of Saccharomyces cerevisiae in response to antifungal drugs and analysed them 
by discriminant function and hierarchical cluster analyses (Allen et al., 2004). 
When compared to drugs of known action, new compounds could be 
discriminated into classes of predicted mode of action (Allen et al., 2004). 
Principal component analysis was used in a similar way to evaluate the mode of 
action of berberine on Staphylococcus aureus (Fig 1-12) (Yi et al., 2007).   41 
 
 
 
Figure 1-12. A principal components analysis of modes of action in anti-Staphylococcus 
aureus drugs. A mathematical transformation produces a single point on the graph for each 
mass spectrum. The different symbols indicate mass spectra for different pharmacological 
compounds. Clustering of different symbols is an indication of a similar metabolic profile 
between those compounds and therefore a similar mode of action. Taken from Yi et al. 
(2007). 
 
These methods could have some use in putative drug classification if large 
comparison sets are available. However, many of the clusters are close together 
and would be largely influenced by small deviations in the data due to 
experimental error for example. These methods are also unable to determine 
the targets of the drugs, so target identification would always need to be 
undertaken alongside multivariate data analyses. Another drawback with the 
two approaches using pattern recognition is that drugs with novel modes of 
action cannot be classified.  
A more sensitive method of pattern recognition has been developed using 
artificial neural network analysis with NMR (Aranibar et al., 2001). This machine 
learning-based method uses a training set of metabolite profiles from herbicide-
treated Zea mays to build a decision tree that can classify the profiles of other 
herbicide-treated Z. mays plants (Aranibar et al., 2001). This method is similar 
to the previous two methods in that it is based on classification with spectra 42 
 
from treatments with compounds with known modes of action, but machine 
learning can often reveal the individual metabolites responsible for 
classification. Aranibar‟s method used NMR spectra however, and was not of high 
enough sensitivity to define the metabolites important in the decision tree 
(Aranibar et al., 2001). The authors also point out the sampling procedures need 
to be highly reproducible for this method to be of use (Aranibar et al., 2001). 
Untargeted metabolome studies to look at the mode of action of a drug are very 
rare although some targeted analyses have started to emerge. In 2008 Karine Le 
Roch and colleagues used heavy labelled phoshphocholine precursors to look at 
the effects of a bisthiazolium compound, T4, on phosphocholine biosynthesis in 
Plasmodium falciparum (Le Roch et al., 2008). The group found a decrease in 
phosphocholine synthesis from choline and ethanolamine after treatment with 
T4 (Le Roch et al., 2008).  
In one untargeted metabolomics approach, FT-ICR-MS was used to analyse the 
modes of action of four toxins on the daphnid metabolome (Taylor et al., 2010). 
The number of features in this study is large and the results very clearly 
highlight relevant pathways (such as effects on fatty acid metabolism after 
treatment with propranolol (a beta blocker) and disruption of amino sugar 
metabolism with fenvalerate (a pyrethroid insecticide) treatment (Taylor et al., 
2010) affected by the toxins. Data reduction has, however, been inefficient 
leading to an increased potential for false positive metabolite identifications. 
Data reduction is major part of analysing metabolomics data and is something 
that the metabolomics community are focussing resources on at present. 
Where the genomics and proteomics communities have repositories that collect 
experimental data from the community (e.g. GenBank for genomics and UniProt 
for proteomics), the metabolomics community have been a step behind in the 
production of similar database. Since the release of the Human Metabolome 
Database (HMDB) however, researchers are beginning to appreciate the benefits 
of having a large, pooled reference dataset. There are difficulties in producing 
repositories  based on experimental data for metabolomics as techniques are so 
widely variable: column retention times will differ depending on the column and 
the solvents used and ionisation and fragmentation techniques will change the 
mass and the mass:charge ratio of the metabolite. The Wishart group at the 43 
 
University of Alberta have gone to extensive lengths to produce reference 
metabolomes for human cerebrospinal fluid (Wishart et al., 2008) and human 
serum (Psychogios et al., 2011), running multiple metabolomics platforms on 
clinical samples and conducting thorough literature searches to produce a 
searchable metabolite databank that includes quantitation of metabolites across 
various disease states. Another notable advancement in recent years is the 
improvement in compound databases such as KEGG, PubChem, ChemSpider, 
MassBank and Metlin. These databases are extremely useful in the identification 
of metabolites as well as raising awareness of the number of isomers a particular 
metabolite may have.  
1.8.2.9  Biomarker discovery 
There has been a recent surge in metabolomics papers attempting the discovery 
of biomarkers to various diseases and toxicities. In general, these studies 
endeavour to compare the metabolites of a sample of disease tissue or the 
biofluid of an infected patient to healthy controls (Mamas et al., 2011).  
Biomarkers are already routinely used to diagnose non-infectious diseases such 
as neuroblastoma (catecholamines (Monsaingeon et al., 2003)), diabetes (insulin) 
and prostate cancer (sarcosine (Sreekumar et al., 2009)) and there have been 
recent attempts to diagnose infectious diseases as well. One group analysed the 
serum and plasma of people in an Onchocerca volvulus endemic foci and 
discovered 14 biomarkers that were able to distinguish between infected and 
non-infected individuals (Denery et al., 2010). This experiment was flawed, 
however in that there was not enough power behind many of the analyses and 
training sets used for the machine learning were also part of the test sample set, 
which forces the fit of the data to the model. The metabolic responses of mice 
to T. b. brucei infections have also been elucidated (Wang et al., 2008) using 
NMR. This study pin-pointed many changes in the blood and urine of the infected 
mice as compared to the same mice pre-infection, including an increase in 
lactate, which may be due to an upregulation of glycolysis (Wang et al., 2008).  
This increase in lactate was confirmed by another study that analysed the 
effects of co-infections of two T. b. brucei strains (Li et al., 2011).  44 
 
1.8.2.10  Computational models 
As more and more quantitative metabolite information is created, efforts are 
increasingly being made to mathematically model the data to understand 
metabolism at a system-based level. It is the eventual aim to integrate genomic, 
transcriptomic and proteomic data with metabolomic information to form a 
“silicon cell”, which can be virtually perturbed generating an output that would 
be similar to a live cell‟s response. The rates of enzyme activity are key to these 
models and have already been used to build models of parts of trypanosome 
metabolism. A kinetic model of glycolysis uses ordinary differential equations to 
describe glucose uptake and metabolism to pyruvate and highlights the 
importance of compartmentation within these systems (Bakker et al., 
1997;Bakker et al., 2000). This model has helped to identify which enzymes 
within the pathway, would, when blocked, induce the greatest effects on 
glycolysis and would therefore be the most effective drugs. Enzymes within a 
pathway that consume just one substrate or produce just one product are known 
as choke points and these enzymes have been shown in P. falciparum to be 
better drug targets than other enzymes (Yeh et al., 2004). MetExplore, a web 
server designed to automatically build connections between metabolites 
creating an ab initio network reconstruction, has been developed by Cottret et 
al. at the Institut National de Recherche Agronomique (Cottret et al., 2010). 
Experimental data may be uploaded into MetExplore and information, such as 
how the relative levels of metabolites change after perturbation with a drug, 
can be mapped in the context of the whole metabolic network for the organism 
in question (Cottret et al., 2010). 
Ab initio models such as MetExplore are very useful, but could be even more 
useful once the community is able to record more quantitative measurements of 
the metabolites in the system. This would bolster the models and make more 
accurate predictions possible. 
1.8.2.11  Quantitative metabolomics 
A true quantification of metabolites is only really possible in a targeted analysis. 
Researchers have been developing methods to attempt a global quantification 
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al., 2011;Wu et al., 2005;Kiefer et al., 2008). The ion suppression effects in 
these samples can be normalised by comparison to standards, but the data 
processing involved to deconvolute these data will be immense leading most 
people to pursue targeted analyses for quantification. 
Once a target has been identified, a heavy-labelled version of the metabolite of 
interest can be spiked into the samples over a range of concentrations, creating 
a calibration curve against which the metabolite of interest can be measured.   
1.8.2.12  Heavy metabolite tracking 
Another use of heavy metabolites is to measure the flux of metabolites through 
pathways of interest. A metabolite with one or more heavy atoms is added to a 
population of cells, tissue or whole organism, samples are taken over a range of 
time points and the heavy atom or atoms are traced through the pathways, cells 
or tissues. This technique has been used to compare the metabolome of 
cancerous and non-cancerous human lung tissue (Fan et al., 2009), finding a 
higher rate of glucose metabolism and anaplerotic pyruvate carboxylation in 
cancerous tissues.  
In P. falciparum, Olszewski et al. used 
13C and/or 
15N-labelled glucose, aspartate 
and glutamine to analyse the tricarboxylic acid cycle and found that, contrary to 
biochemical textbooks, a branched structure was found, meaning that several 
enzymes must operate in the reverse direction (Olszewski et al., 2010) within 
these parasites. This discovery was very surprising and has yet to be 
independently confirmed, but reveals the power of fluxomics in the 
metabolomic field.  
1.8.3 Sample preparation 
Sample preparation methods can vary enormously depending on the metabolites 
one is interested in detecting and the organisms under examination. Generally, a 
cellular sample for metabolic analysis is quenched in a solvent at extreme 
temperature (either hot or cold) to prevent further enzymatic processes. Cells 
are often washed and then lysed before cell debris is removed. Shin et al. (2010) 
evaluated sample preparation methods in the Gram negative bacterium 46 
 
Saccharophagus degradans. They compared pure methanol, acetonitrile:water 
(1:1, v/v), acetonitrile:methanol:water (2:2:1) and water:isopropanol:methanol 
(2:2:5) for the metabolite intensity, total number of metabolites detected and 
the reproducibility of detected metabolites. They found that both 
acetonitrile:methanol:water and water:isopropanol:methanol performed well, 
but covered different ranges of metabolites. Similar studies have produced 
optimised extraction solvents for almost all cell populations and tissues including 
liver (Masson et al., 2010), erythrocytes (Darghouth et al., 2010), leishmania 
(t'Kindt et al., 2010;Saunders et al., 2010), adherent cell cultures (Danielsson et 
al., 2010) and plants (Kim and Verpoorte, 2010). The literature on the extraction 
of the trypanosome metabolome is lacking so optimisation of extraction methods 
is a priority. 
There have been efforts to standardise the techniques used for sample 
extraction and analysis within the metabolomics community (Jenkins et al., 
2004;Sansone et al., 2007), but as each organism requires different treatment 
during the extraction method, and methods will vary depending on what 
metabolites a researcher is interested in and what mass spectrometry 
instrument is in use, these efforts have not yet proven successful and are often 
abandoned.  
1.8.4 Computation in metabolomics 
Perhaps the main reason that metabolomics is not as widely used as the other –
omic technologies lies in the lack of reliable computational solutions for the 
deconvolution of the highly complex data. There are many programmes 
available, but of the ones that are freely available there is not one that 
accomplishes all the needs of the biologist without extensive training in 
computer languages. One of the biggest hurdles in deconvoluting the raw files 
from the mass spectrometer is in finding a way for the computer to recognise a 
peak relating to one mass eluting from the chromatography apparatus. Simple 
programmes can choose peaks that are of a certain abundance (such as the 
Xcalibur software), but these will miss the more subtle peaks that are robust but 
small. Other, more sophisticated programmes are able to recognise the shape of 
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enabling a more robust mass identification and comparison between samples 
(Smith et al., 2006). 
Other issues in the software are in comparing samples and performing statistical 
analyses. If the programmes are too generous in their parameters then huge lists 
of metabolites are generated with a large proportion being false positives. 
Conversely, if the parameters are too strict then many of the smaller or more 
variable peaks will be lost. This is an issue that cannot be resolved without 
having an understanding of how reliable an individual user‟s data is and 
therefore cannot be automated and parameters must be user-defined. 
Another big issue in the simplification of metabolomics data is the number of 
related peaks that are generated from one metabolite. Masses may be multiply-
charged or fragmented or have isomers, isotopes or adducts, which all produce 
extra peaks relating to a parent metabolite. Reducing the data based on these 
features will be vital in producing a dataset that is able to be interpreted in a 
biological context. MzMatch is a new software that resolves many of these 
issues, by identifying and combining related peaks, but is also modular so that 
users can decide how robust they would like the filtering of their data to be 
(Scheltema et al., 2011). 
1.8.5 Trypanosome metabolism 
There have been notably few metabolomics studies in trypanosomes so far. 
Studies have focussed on glycolysis(Visser and Opperdoes, 1980; Mackenzie et 
al., 1983; Albert et al., 2005;Haanstra et al., 2008) and trypanothione synthesis 
(Fairlamb et al., 1987;Shim and Fairlamb, 1988;Xiao et al., 2009). These 
metabolites were recorded using either HPLC, NMR or classical biochemistry 
techniques. NMR has been used to quantify phosphorylated compounds in 
bloodstream and procyclic T. brucei (Moreno et al., 2000) and to analyse the 
effects of enzyme deletions in procyclic T. brucei (Coustou et al., 2005;Coustou 
et al., 2008). These studies are, however, all targeted to the pathways of 
interest and so could miss many interesting metabolite changes. 
The HILIC-Orbitrap mass spectrometry platform was previously used to analyse 
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untargeted way when they switch from a glucose (the carbon source in the in 
vitro growth medium SDM-79) to a proline (the carbon source available in the 
tsetse midgut) carbon source (Kamleh et al., 2008). This study revealed a shift in 
proline metabolism resulting in many changes including higher levels of 
glutamate, glutathione and carboxypyrroline in the proline-grown cells (Kamleh 
et al., 2008). 
Trypanosomes may be the ideal organisms to study the applications of 
metabolomics as they have a minimal set of metabolites (Fairlamb, 
2002;Breitling et al., 2006)  due to the parasitic nature of the organism‟s 
lifestyle i.e. they salvage many more metabolites from their host than other 
organisms. The bloodstream form of the parasite, for example, appears not to 
have a fully functional TCA cycle, whereas the insect stages do(Fairlamb, 
2002;van Weelden et al., 2005). This would suggest that some of the citric acid 
cycle intermediates are salvaged from the mammalian host, but are not salvaged 
in the insect vector. The bloodstream forms of the parasite therefore have to 
rely on substrate level phosphorylation (from glycolysis) for ATP production 
(Carter and Fairlamb, 1993;Besteiro et al., 2005). 
Trypanosomes are also relatively easy to grow in vitro in large numbers creating 
a large, clonal population on which metabolite extractions can be performed. 
1.9 Metabolomics at the University of Glasgow 
The Orbitrap mass spectrometer is a type of Fourier transform mass 
spectrometer that was developed by Alexander Makarov. The Orbitrap is much 
smaller than fourier transform ion cyclotron resonance (FT-ICR) mass 
spectrometers as it does not use electromagnets whereas FT-ICRs do. Instead, 
the Orbitrap uses an electric field to trap ions in separate kinetic energies 
orbiting around a central electrode (Makarov et al., 2006). This mass 
spectrometer achieves an ultra high mass accuracy of two parts per million 
(ppm) using ubiquitous plasticising agents as internal calibrant masses. A 
resolution of over 100, 000 fwhm (full width at half maximum, a measurement of 
pulse duration) is achieved allowing spectra to be generated in the order of up 
to three per second (Makarov et al., 2006). A high resolution mass spectrometer 49 
 
permits non-isobaric metabolites to be distinguished between much more easily, 
allowing separation steps to be removed or reduced (Breitling et al., 2006). 
Scheltema et al. (2008) showed that the advertised mass accuracy of the 
Orbitrap (2 ppm) can be improved to 0.21 ppm using internal background ions 
for additional calibration. 
Generally it is thought that the use of buffers to help prevent cell damage needs 
to be limited as excess salt can clog the skimmer in the mass spectrometer 
(Mashego et al., 2007) causing inefficient ionisation. Ion suppression can also 
occur, whereby molecules with a stronger potential to catch the charge (e.g. 
salts) are preferentially ionised, abrogating the potential for other molecules to 
become charged. Salt accumulation can also limit the amount of sample that can 
be analysed by HPLC (high performance liquid chromatography) (Theobald et al., 
1997) as can high protein concentrations. 
To improve the confidence of identification of a metabolite, separation 
apparatus is often coupled to the mass spectrometer, which also has the 
advantage of minimising suppression effects by keeping metabolites separate as 
they enter the ionisation source. Chromatography columns are used that can 
separate on mass, charge or polarity. The ZIC-HILIC (hydrophilic interaction 
chromatography) uses acetonitrile and water to separate metabolites on the 
basis of their polarity. Less polar metabolites are washed through the column 
with the solvent phase, while more polar metabolites are retained for longer, so 
two masses with different hydrophobicities should be distinguishable by their 
retention time on the column. 
MzMatch is a modular programme developed by Richard Scheltema and Andris 
Jankeviks. The pipeline used in this project (IDEOM) was automated and given a 
graphical user interface (GUI) by Darren Creek. The components of the software 
used in our analyses are summarised in figure 1-13.  50 
 
 
Figure 1-13. The metabolomics pipeline used at the University of Glasgow (Sheltema et al., 
2011). MzXML files are obtained by simple processing of the raw MS data. Peaks of 
metabolites eluting from the chromatography apparatus are the isolated and compared 
across replicates and samples. These are then filtered according to their relative standard 
deviation (rsd) and combined into one data set, which can be used to search metabolite 
databases allowing putative metabolite names to be assigned. 51 
 
The accuracy of identification was improved by the development of a retention 
time predictor by Darren Creek. This algorithm predicts the time that a 
metabolite will exit our chromatography apparatus (the ZIC-HILIC column) for 
the metabolites which we do not have a standard for. Having retention times 
predicted aids enormously in the identification stage of the analysis and helps 
the computer distinguish between isomers more easily. 
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1.10 Aims 
Human African trypanosomiasis is a disease that has neared elimination in the 
past. There is a paucity of drugs that are effective against either early or late 
stages of the disease. Those that are available are often dangerously toxic and 
are difficult to transport to and store in places of need. Resistance to the drugs 
in use also poses a problem for the future of the available compounds. The 
mechanisms of resistance to many of the drugs have been investigated, but the 
drug that is increasing in use most rapidly, eflornithine, has no predicted 
mechanism of resistance. 
Metabolomics is a relatively new set of technologies that measure the presence 
and levels of small molecules within tissues or cell populations. There is a huge 
scope for useful applications of these new technologies.  
The aims of this project were to: 
1, Investigate the mechanism of resistance to eflornithine in order to combat it 
before it occurs in the field. A combination of classic biochemical and molecular 
techniques were used in addition to newer metabolomic techniques. 
2, Analyse the mode of action of drugs on trypanosomes using eflornithine as a 
proof of principle. 
3, Develop new metabolomic methodologies for the analysis of pathways in T. 
brucei. Quantification of specific metabolites and heavy metabolite tracking 
were used to analyse the flux of nitrogen through the bloodstream form 
polyamine pathway. 53 
 
  2. Methods 
2.1 Trypanosome growth and resistance selection 
2.1.1 Culturing cells 
Bloodstream form trypanosomes were grown in HMI-9 (Biosera) (Hirumi et al., 
1977) supplemented with 10 % foetal calf serum (FCS, Biosera), incubated at 
37˚C, 5 % CO2. Procyclic form trypanosomes were grown in SDM-79 (Biosera) with 
10 % FCS at 28˚C. Generally, growth was in 10 ml medium in 25 cm
2 Corning 
vented culture flasks (unvented for procyclic forms). A typical starting density of 
10
4 cells per ml was used (counted by haemocytometer), and cells reached 
stationary phase after 2-3 days for bloodstream form or 5 days for procyclic 
forms. Cells were bulked up for metabolomics and uptake assays in 175 ml 
medium in 500 cm
2 Corning vented culture flasks. 
Leishmania mexicana were cultured in Homem medium (Biosera) with 10 % FCS. 
Conditions were the same as for procyclic trypanosomes. 
2.1.2 Selection of eflornithine resistance 
Wildtype bloodstream form 427 cells were grown in 5 ml cultures in 25 cm
2 flasks 
as described above. The first drug concentration used on the wildtype cells was 
10 µM. At each passage, three flasks were created; 1, drug-free. 2, drug 
concentration equal to previous passage. 3, two times the drug concentration 
from the previous passage. Cells were cloned out and stabilated at various 
stages of the selection process for later analyses. 
2.1.3 Microscopy 
Trypanosomes were centrifuged at 1, 250 RCF and resuspended at a high density 
before smearing onto a glass slide. Smears were air dried and stained in 10 % 
Giemsa (v/v in water) for 24 hours and destained for several washes in water. 
Cells were observed with 100 x magnification under oil immersion with a Zeiss 
Axioplan 2 microscope and Velocity software. 54 
 
2.1.4 Cloning of trypanosomes 
Clonal populations of cells were diluted to one parasite per ml medium and 200 
µL medium was added to each well of a 96 well plate. If fewer than 30 % 
(calculated for a 96 well plate using a poisson distribution) of the wells 
contained live cells after 14 days then the populations were considered to be 
clonal. 
2.1.5 Creating stabilates 
Stabilates were created from clonal populations of cells by adding 15 % glycerol 
to confluent cells at approximately 5 x 10
5 cells/ml. These were then wrapped in 
cotton wool and frozen at -80ºC before transferring to liquid nitrogen for long-
term storage. 
2.1.6 Alamar Blue assay  
The alamar Blue assay developed by Raz et al. (1997) for bloodstream form 
trypanosomes was used. Bloodstream form parasites were diluted to a 
concentration of 4 x 10
4 cells per ml. The drug under test was diluted in medium 
to twice the maximum desired concentration. 200 µL of drug in medium was 
added to the first two wells in the first column of a 96 well plate. 100 µL of 
medium was added to the remaining wells on the plate in the top four rows. The 
drug was serially diluted from left to right and top to bottom along the 96 well 
plate, leaving the last two wells drug free. 100 µL of 4 x 10
4 cells per ml 
parasites were added to each well. 
Plates were incubated for 48 hours at 37˚C, 5 % CO2 then 20 µL Resazurin dye 
(Sigma) at 0.49 µM was added to each well. Plates were incubated for a further 
24 hours then read on a fluorimeter (emission 530, excitation 595) (FLUOstar 
Optima, BMG Labtech).  
For isobologram analyses, alamar Blue assays were conducted for one drug in the 
presence of three different concentrations (IC50, 2 x IC50 and 0.5 x IC50) of 
another drug.  55 
 
2.1.7 Mouse work 
All mouse work was conducted by Dr. Pui Ee Wong, University of Glasgow. 
Cells from culture were prepared for inoculation into adult female ICR (Institute 
of Cancer Research) mice by washing twice in CBSS (Carter‟s Buffered Salt 
Solution). They were re-suspended to a density of 5 x 10
5/ml and 0.2 ml (1 x 10
5) 
cells were injected intraperitontoneally into the mouse. 
Blood straws were defrosted into 0.2 ml CBSS and 0.2 ml of the resulting 
suspension was injected into the peritoneum.   
Mice were exsanguinated with 100 international units of heparin sodium per 1 ml 
of blood. Trypanosomes were purified on a PSG (Na2HPO4 (57 mM), NaH2PO4 (3.9 
mM), NaCl (44 mM), glucose (61 mM)) resin column. 
2.2 Metabolomics 
2.2.1 Metabolite extraction  
Mass spectrometry was undertaken by Darren Creek (University of Glasgow) or 
Muhammed Anas Kamleh (University of Strathclyde). Metabolite extraction 
methods were adapted from Leishmania spp extraction techniques developed by 
groups in Melbourne, Australia (Saunders et al., 2010) and Antwerp, Belgium 
(t‟Kindt et al., 2010). 
Cells were grown in 500 ml Corning flasks to a maximum volume of 175 ml in 
HMI-9. Cultures were kept in log phase growth (below 1 x 10
6/ml). At the time of 
harvest, 4 x 10
7 cells were rapidly cooled to 4 ˚C by submersion of the flask in a 
dry ice-ethanol bath, and kept at 4 ˚C for all subsequent steps. The cold cell 
culture was centrifuged at 1, 250 RCF for 10 minutes and the supernatant 
completely removed. Cell lysis and protein denaturation was achieved by 
addition of 200 µL of 4 ºC chloroform:methanol:water (ratio 1:3:1) plus internal 
standards (theophylline, 5-fluorouridine, Cl-phenyl cAMP, N-methyl glucamine, 
canavanine and piperazine, all at 1 µM), followed by vigorous mixing for 1 hour 
at 4 ºC.  56 
 
Extract mixtures were centrifuged for two minutes at 16, 000 RCF, 4˚C. The 
supernatant was collected, frozen and stored at -80˚C until further analysis. 
2.2.2 Mass Spectrometry 
Samples were analysed on an Exactive Orbitrap mass spectrometer (Thermo 
Fisher) in both positive and negative modes (rapid switching), coupled to HPLC 
with a ZIC-HILIC column. The apparatus was operated by either Muhammed Anas 
Kamleh (University of Strathclyde) or Darren Creek (University of Glasgow). 
Exactive data was acquired at 25,000 resolution, with spray voltages +4.5kV and 
-2.6kV, capillary temperature 275 ˚C, sheath gas 20 units, auxillary gas 15 units 
and sweep gas 1 unit. Minor adjustments were made to the published (Kamleh et 
al., 2008) HPLC mobile phase gradient as follows: Solvent A is 0.1 % formic acid 
in water, and solvent B is 0.1 % formic acid in acetonitrile, 80 % B (0 min),  50 % 
B (12 min), 50 % B (26 min), 20 % B (28 min), 20 % B (36 min), 80 % B (37 min), 80 
% B (47 min).  
2.2.3 Metabolomics data processing 
2.2.3.1  Untargeted metabolomics 
Peaks of metabolite signals eluting from the chromatography apparatus were 
identified and relative quantitation was undertaken using mzMatch software 
developed by Richard Scheltema (University of Groningen) and Andris Jankevics 
(University of Glasgow) (Scheltema et al., 2011). An Excel-based macro system 
(IDEOM – IDEntification Of Metabolites) developed by Darren Creek (University of 
Glasgow, in press) was used to identify metabolites, merge related peaks and 
compare relative intensities of metabolites between sample sets. A retention 
time error of 5 % was allowed for retention times for which standards have been 
run and 35 % was allowed for calculated retention times. 
Raw files from the Orbitrap mass spectrometer were converted to mzXML using 
msconvert and metabolite peaks were picked using xcms (Smith et al., 2006). 
Data was filtered and reduced using mzMatch (Scheltema et al., 2011) with a rsd 
filter of one, an intensity filter of 10, 000 and a minimum number of detections 
of two. 57 
 
2.2.3.2  Targeted metabolomics 
To analyse specific pathways, Xcalibur software (Thermo Scientific) was used to 
create a processing file with user-specified masses and retention times and run 
it through a sample list picking out all the metabolite relative intensities, using 
the Quan Browser, within a set of samples.  
Accuracy of metabolite identification was improved for targeted and untargeted 
analyses using retention times. These were either identified using standards and 
calibrated using an internal standard mix or calculated using an algorithm 
developed by Darren Creek.  
2.2.4 Radiolabel tracking 
Amino acids were obtained with 
15N incorporation from Cambridge Isotope 
Laboratories (L-threonine (98 % enrichment, one incorporation, alpha-N, 
cat:NLM-742-0), L-glutamine (98 % enrichment, one incorporation, alpha-N, cat: 
NLM-1016-0), L-aspartic acid (98 % enrichment, one incorporation, alpha-N, NLM-
718-0), L-arginine (98 % enrichment, four incorporations, allo-N, cat: NLM-396-
0), L-ornithine (98 % enrichment, two incorporations, allo-N, cat: NLM-3610-0), 
L-lysine (95 - 99% enrichment, one incorporation, alpha-N, cat: NLM-143-0)) or 
Sigma Aldrich (L-proline (98 % enrichment, one incorporation, alpha-N, cat: 
608998), L-glutamate (98 % enrichment, one incorporation, alpha-N, cat: 
332143)).  
Cells were grown in 500 ml Corning flasks to a maximum volume of 175 ml in 
HMI-9. Cultures were kept in log phase growth (below 2 x 10
6/ml). At the time of 
harvest, cells were centrifuged at 1, 250 RCF for 10 minutes and the supernatant 
completely removed and resuspended in CBSS. Cells were split into aliquots of 4 
x 10
7 cells. Labelled and unlabelled amino acid was added at 1 mM. Cell extracts 
were prepared as method 2.2.1. 58 
 
2.3 Molecular Biology 
2.3.1 Gene searches 
Nucleotide sequences for genes were located either via text searches for the 
gene names in GeneDB (www.genedb.org) or TriTrypDB (tritrypdb.org). For 
proteins that were not annotated, amino acid sequences for bacterial or 
protozoan microorganisms were taken from NCBI databases 
(www.ncbi.nlm.nih.gov ) and a BLAST (Basic Local Alignment Search Tool) search 
of these against the parasite genomes was performed in GeneDB or TriTrypDB. 
2.3.2 PCR 
Generally, genomic DNA was denatured at 94˚C for two minutes, followed by 30 
cycles of 94˚C for 15 seconds, annealing for 15 seconds (variable annealing 
temperatures between 50 and 65˚C) and extension at 72˚C for 30 seconds/500 
bases. A final elongation of 7 minutes was used. GoTaq polymerase (Promega) 
was used for low fidelity PCRs and KOD Hot Start polymerase (Novagen) for high 
fidelity reactions according to manufacturer‟s instructions. Mg
2+ was used at 1.5 
mM and dNTPs at 200 µM. 
Approximately 10 ng of DNA in water was used in each reaction along with 100 
ng of each primer (Table 2-1). 
For PCR from blood cultures of trypanosomes, blood was spotted on to FTA® 
cards (Whatman) and washed four times with FTA® purification reagent (200 µL 
for five 2 mm discs, cut with a hole punch), then three times with TE buffer (10 
mM Tris-Cl, pH 7.5. 1 mM EDTA) (200 µL). Generally, one disc was used in each 
PCR reaction.  
Primer  Sequence  Gene 
AAT1 forward  ATATGGATCCGCGATTTCTCACGAGCCTACG  Tb927.4.3930 
AAT1 reverse  ACATCTCGAGTACGACACCTCACCACCAAAA  Tb927.4.3930 
AAT2 forward  ATATGGATCCACATTCTTTACGAAGGTGAGT  Tb927.4.3990 
AAT2 reverse  ACATCTCGAGGATCACAATGACAAAATACAC  Tb927.4.3990 
AAT3 forward  GGAGAAGCACAAAAGCCCGA  Tb927.4.4730 
AAT3 reverse  GATGAAGAGTGCGGGGAATA  Tb927.4.4730 59 
 
AAT4 forward  ATATGGATCCGCTAATGAGGGAGAAGGGGAA  Tb927.4.4840/4820/4860
/4830 
AAT4 reverse  ACATCTCGAGGTGCCGAAGAGGTGAATGCCC  Tb927.4.4840/4820/4860
/4830 
AAT5 forward  ATATGGATCCACCGCGCGGTGGTGCCCTTCC  Tb927.8.4710 
AAT5 reverse  ACATCTCGAGTTCACATGACAAAGATAAGCG  Tb927.8.4710 
AAT6 forward  CCAATCGCGTGTTGATACGT  Tb927.8.5450 
AAT6 reverse  GCGGCACACCACAGCTCGGA  Tb927.8.5450 
AAT7 forward  ATATGGATCCGTGAGTCTATTTATGGCAACT  Tb927.8.7600/7680 
AAT7 reverse  ACATCTCGAGGCATGAGTGCACTACAATGGC  Tb927.8.7600/7680 
AAT8 forward  ACGGGTGAACCGTTCGTTAG  Tb927.8.7740/Tb927.4.4
730 
AAT8 reverse  GATTTGCGTAGGGGTCGTAA  Tb927.8.7740/Tb927.4.4
730 
AAT9 forward  ATATGGATCCTGATGTGGTAAAGGAAGTGAA  Tb927.8.8220 
AAT9 reverse  ACATCTCGAGATAGCCAAGATAATCACCAAC  Tb927.8.8220 
AAT10 forward  ATATGGATCCTCGTGTCTAAATGGGCTTCCG  Tb927.8.8290/8300 
AAT10 reverse  ACATCTCGAGCTTTGGGATGAAGAGACCCAA  Tb927.8.8290/8300 
AAT11 forward  ATATGGATCCTGCATGCATTAGTGGTGGTTA  Tb09.211.1760 
AAT11 reverse  ACATCTCGAGCCTCCAGGGATCTGGATGAAG  Tb09.211.1760 
AAT12 forward  AAGGGGAACGCTTTAGTGGT  Tb10.70.1170 
AAT12 reverse  TCTGCAAACAGTGATGAGGC  Tb10.70.1170 
AAT13 forward  ATATGGATCCAAACAGATCAATTCCCTGCGC  Tb10.70.0300 
AAT13 reverse  ACATCTCGAGACATAATTTGGCAACGAGCCC  Tb10.70.0300 
AAT14 forward  ATATGGATCCGTAAACGTCGGGCTGTGATTG  Tb10.6k15.0450 
AAT14 reverse  ACATCTCGAGAATTTCGCACAATGTCACCAC  Tb10.6k15.0450 
AAT15 forward  TCGAACGCTGCCTTCTTAAT  Tb11.02.4520 
AAT15 reverse  CCTTCTCGTATGCTTGCTCC  Tb11.02.4520 
AAT16 forward  ATATAAGCTTCCTCACTTACTGCGCATATTG  Tb11.01.7500/7520 
AAT16 reverse  ACATGGATCCGAGGGTATACTTCAATTAGGT  Tb11.01.7500/7520 
AAT17 forward  ATATGGATCCTTTTCCCTGCATATCCTGTCA  Tb11.01.7590 
AAT17 reverse  ACATCTCGAGGAACCTGGCACAGCTGCGCTT  Tb11.01.7590 
ODC forward  ATGACCACCAAATCAACCCC  Tb11.01.5300 
ODC reverse  TTATGATTTTTGACTTTTCAACTC  Tb11.01.5300 
Tb-44_forwards  CCTATGCTATGTTCACGCTG  Tb927.8.5460 
Tb-44_reverse  GCAGAACCCATCAGTAATGC  Tb927.8.5460 
Tb927.8.5410_F  TGGACAGCTGAGGCACATAG  Tb927.8.5410 
Tb927.8.5410_R  ACGCCTTAGTTCCTTGAGCA  Tb927.8.5410 
Tb927.8.5420_F  TCCTCGGTATAAGCCGATTG  Tb927.8.5420 
Tb927.8.5420_R  TCAACTGTTGGGTTTCCACA  Tb927.8.5420 
Tb927.8.5430_F  ATGGGCAACAACGGAAGTAG  Tb927.8.5430 
Tb927.8.5430_R  GTTGTGATACCGGGACAACC  Tb927.8.5430 
Tb927.8.5480_F  CAGCAACTGAGATGAAGGCA  Tb927.8.5480 
Tb927.8.5480_R  CGCGTCAAACTTCTTGAACA  Tb927.8.5480 
Tb927.8.5490_R  AAAACGAGAGCCAACTCGAA  Tb927.8.5490 
Tb927.8.5490_R  GTCAGCAAGCGCAGTGATTA  Tb927.8.5490 
TbAAT6 RNAi 
forward 
GATCGGGCCCGGTACCAAATTTATTTTCGGGCC
ACC  Tb927.8.5450 
TbAAT6 RNAi  GATCTCTAGAGGATCCGTCTTCTGATTGCATCC Tb927.8.5450 60 
 
reverse  GGT 
Table 2-1. Primers used for PCRs and for the production of expression and RNA 
interference constructs. 
 
2.3.3 Constructs for RNAi, gene knock outs and overexpression 
The pRPa
iSL (RNAi (Alsford and Horn, 2008)), pGL1688 (knock out, a gift from 
Jeremy Mottram) and pHD676 (overexpression (Biebinger et al., 1997)) 
constructs were created by PCR of a gene fragment (400 bases chosen using 
RNAit (http://trypanofan.path.cam.ac.uk/software/RNAit.html) for RNAi, gene 
flanking regions for knock out vectors and the whole gene for overexpression 
vectors). PCR products were created using the KOD high fidelity polymerase and 
treated with Taq polymerase to create a T overhang. These DNA fragments were 
ligated into the pGEM-T vector (Promega) using the instructions included in the 
kit. 2 µl of plasmid was added to 50 µl chemically competent DH5α Escherichia 
coli cells and left for 30 minutes on ice. Cells were heat shocked for 45 seconds 
at 42˚C then put on ice for two minutes. 1 ml of Luria broth was added and the 
cells were left to recover for one hour at 37˚C. 200 µl of cells were plated out 
onto an Luria broth agar plate with 50 µg/ml ampicillin. Colonies positive for the 
plasmid (by PCR) extracted from overnight cultures in Luria broth using a 
miniprep kit (Qiagen) and digested for ligation to the final construct using one 
unit of the digestion enzyme as specified in the literature (Biebinger et al., 
1997;Alsford and Horn, 2008;). 
2.3.4 Southern blot and hybridisation 
Southern blots were performed according to standard procedures (Sambrook and 
Russell, 2001). 
5-10 µg DNA was digested with Eco RI (Promega) and ran on a 0.7 % agarose gel 
with 8 µL SYBR Safe stain (10,000 x Invitrogen) in 100 ml. The gel was blotted 
using a hybond-N membrane (Amersham) and probed with Easytides 
32P-ATP 
(Perkin Elmer) incorporated into the gene of interest using the Stratagene 
Prime-it kit with random primers used on β-actin, ornithine decarboxylase and 
TbAAT6 containing DNA fragments extracted from plasmids. 61 
 
2.3.5 Transfection of Trypanosomes 
2 x 10
7 of bloodstream form cells (LaCount et al., 2000) were attained from 
cultures of no more than 1 x 10
6 cells/ml. These cells were centrifuged at 2,500 
RCF for 10 minutes and re-suspended in 100 µl T cell buffer (Lonza). 10 µg of 
linearised plasmid was added and cells were transferred to 0.4 cm gap 
transfection cuvettes. Cells were electroporated using programme X-001 on an 
Lonza Nucleofector II and then added to HMI-9 with 10 % FCS. After a recovery 
period of 24 hours, appropriate selection drugs were added (hygromycin (15 
µg/ml), neomycin (15 µg/ml), phleomycin (0.5 µg/ml) or puromycin (0.2 
µg/ml)). These cells were cloned out and stabilated. 
The same protocol was used for 29-13 procyclic trypanosomes, but with 5 x 10
7 
of no more than 5 x 10
6/ml cells. 
2.3.6 RNAi in trypanosomes 
2Ti bloodstream form cells (Alsford and Horn, 2008) were used to create the 
RNAi cell line with the pRPa
iSL construct. Cells were grown in tetracycline-free 
medium and induced with 1 µg/ml tetracycline. The pRPa
iSL plasmid (Alsford and 
Horn, 2008) (modified for use in 29-13 cells by Dr. Jane Munday, University of 
Glasgow) was also used to transfect 29-13 procyclic trypanosomes, which were 
inducible in the same way as the bloodstream form cells. 
2.3.7 Northern blot 
Northern blots were performed according to standard procedures (Sambrook and 
Russell, 2001). Certified RNA-free equipment was used and equipment was 
sprayed with RNaseZap (Ambion) or treated with DEPC water. 
20 µg RNA was extracted using Trizol reagent (Invitrogen), run on a 
formaldehyde (16 %), Na2HPO4 (18 mM), NaH2PO4 (2 mM), agarose (1 %)  gel, 
blotted using a hybond-N membrane (Amersham) and probed with Easytides 
32P-
ATP (Perkin Elmer) incorporated into the gene of interest using the Stratagene 
Prime-it kit. 62 
 
2.3.8 Tritiated amino acid uptake – cell preparation 
Radiolabelled amino acids were obtained from Sigma Aldrich (L-arginine (2,3-
3H, 
specific activity: 60 Ci/mmol, concentration: 0.95 mCi/mL)), Moravec 
Biochemicals (L-proline (2,3,4,5-
3H, specific activity: 71.3 Ci/mmol, 
concentration: 5.0 mCi/ml), L-eflornithine (specific activity: 1.6 Ci/mmol 
concentration: 1 mCi/ml), D-ribose (1-
3H, specific activity: 14.3Ci/mmol, 
concentration: 1 mCi/ ml)) or American Radiolabeled Chemicals L-ornithine (4,5-
3H, specific activity: 40 Ci/ mmol, concentration: 1 mCi/ ml).  
2.3.8.1  Trypanosoma brucei brucei 
Mid-log phase cells were cultured to attain sufficient cell densities to permit use 
of more than 2 x 10
7 cells per reaction. Cells were centrifuged at 1, 250 RCF for 
10 minutes and re-suspended in CBSS buffer. Cells were centrifuged again at 1, 
250 RCF and re-suspended to approximately 2 x 10
8/ml in CBSS buffer. Cells 
were counted, using a haemocytometer, and stored on ice until ready to use. 
2.3.8.2  Leishmania mexicana 
Leishmania mexicana were harvested at logarithmic stage of growth (between 5 
x 10
5 and 2 x 10
7 cells per ml) and treated in the same way as T. b. brucei. 
2.3.9 Tritiated amino acid uptake – rapid oil/stop protocol 
A rapid oil/stop spin protocol, previously described by Carter & Fairlamb (1993), 
was used to determine uptake of radiolabelled compounds. 100 µl of oil (1-
Bromodo-decane, density: 1.066 g/cm
3 (50 % mineral oil was used for 
Leishmania)) (Aldrich) and 100 µl radiolabelled compound in CBSS buffer was 
added to 0.5 ml Eppendorf tubes. These were centrifuged briefly to remove 
bubbles.  
Cells were added to the tubes at room temperature and centrifuged through the 
oil at 16, 000 RCF for one minute to stop the reaction after a specified length of 
time. 63 
 
Cells were centrifuged for one minute at 16, 000 RCF in a centrifuge (Biofuge). 
The resulting cell pellet was flash frozen in liquid nitrogen and the base of the 
tube containing the pellet was cut into 200 µl of 2 % SDS in scintillation vials and 
left for 30 minutes. Three ml of scintillation fluid was added to each vial and 
these were left overnight at room temperature. A control with 200 µl SDS, 10 µl 
radiolabelled compound and three ml scintillation fluid (Optiphase „hisafe‟ 2; 
PerkinElmer) was included to work out the counts per minute of the radiolabel. 
Counts per minute were read on a 1450 microbeta liquid scintillation counter 
(Perkin Elmer) and normalised between samples for the cell density. This was 
then converted to moles of compound uptake per 10
7 cells. Michaelis-Menton 
kinetic analyses were performed using Graphpad Prism 5. 
2.3.10  Arginase assay 
A QuantiChrom Arginase assay kit (BioAssay Systems) was used to 
spectrophotometrically measure the amount of urea produced in the conversion 
of arginine to ornithine. L. mexicana and T. brucei cells were used at 1 x 10
8 per 
sample. Controls with no arginine and with no cells and a standard with 1 mM 
urea were used to calculate final urea production values. Urea levels were read 
on a spectrophotometer (Dynex) at a wavelength of 450 nM.   
2.4 Computational Analyses 
2.4.1 Heat maps  
Heat maps were created in Microsoft Excel. Using conditional formatting on a 
three colour scale with a minimum of blue set at 0.2 (ratio of 0 time point 
divided by comparison time point), yellow set at 1 and the maximal red set at a 
five.  
2.4.2 Metabolite identification 
Metabolites were identified from the mass and retention time information 
output of mzMatch using IDEOM, a software developed by Darren Creek at the 64 
 
University of Glasgow (unpublished). Pathways were compared to the Metacyc 
and KEGG trypanosome metabolite databases. 
2.4.3 Statistics 
Graphs and Student‟s t-test values were created in Microsoft Excel. ANOVAs 
were performed in Graphpad Prism 5. 
2.4.4 Cladogram construction 
Cladograms were constructed using the CLC genomics workbench software 
alignment and tree building tools. A neighbour joining algorithm was used and 
the tree was bootstrapped 1, 000 times. 
2.4.5 Sequence Alignments 
Sequence alignments were created from amino acid sequences sourced through 
the NCBI database (www.ncbi.nlm.nih.gov ) in CLC workbench. A gap open cost 
of 10 and a gap extension cost of one were used. 65 
 
  3. Resistance to eflornithine 
3.1 Introduction 
There are numerous drawbacks with the drugs currently available for the 
treatment of HAT. Side effects such as rashes (melarsoprol, suramin, 
eflornithine and pentamidine), renal problems (melarsoprol, eflornithine and 
pentamidine), encephalopathy (melarsoprol) and pain (melarsoprol, eflornithine 
and suramin) are often severe and can cause patients to deviate from 
recommended treatment regimes. Failure to complete the full treatment course 
can result in treatment failure and can expose parasites to sub-lethal levels of 
drug, that may result in the selection of drug resistance. Drug resistant parasites 
can also be selected through prophylactic use or from using sub-lethal levels of 
drug (which may be a problem if drugs are shared amongst communities with 
inadequate funding – a less prominent problem for HAT where drugs are 
distributed through dedicated health centres). 
Resistance can be difficult to detect. Currently relapse rates in the field are not 
systematically recorded. If a patient does relapse, it may not be clear whether 
they were re-infected or if the treatment failed for some reason. It has been 
shown that eflornithine in mice is not efficient at crossing the blood-brain 
barrier (Levin et al., 1983) and so levels of the drug may be sub-lethal in the 
brain and may therefore help to select resistant parasites (Sanderson et al., 
2008). In humans, however, there seems to be more uptake into the brain (Burri 
and Brun, 2003) and suramin has been shown to increase the concentration of 
eflornithine crossing the barrier in mice (Jennings, 1993;Sanderson et al., 2008). 
In humans it has been suggested that a transporter carriers eflornithine over the 
blood-brain barrier (O'Kane et al., 2006) creating CSF:plasma ratios of between 
0.1 and 0.9 (Barrett et al., 2007). 
Eflornithine is administered intravenously as a racemate in saline solution 
(Barrett et al., 2007). Patients must spend at least 14 days in hospital to receive 
a total of 56 infusions (Barrett et al., 2007). This extended hospital stay is 
clearly very costly to the family of the patient and the large drug volumes are 
difficult to transport to the places where they are required. These two big issues 66 
 
with eflornithine treatment mean that many people with the disease die 
unnecessarily either because they cannot travel to a clinic and spend large 
amounts of time away from their families and livelihoods or because the drugs 
cannot be transported close enough to them. Efforts to reduce the amount of 
drug required (and therefore reduce transport issues) have resulted in 
nifurtimox-eflornithine combination therapy (NECT). However, this therapy does 
still require a 10 day stay in hospital. Greater efforts to reduce the quantities of 
drugs required would be beneficial. 
Eflornithine targets ornithine decarboxylase (ODC) in trypanosomes (Bacchi et 
al., 1983;Phillips et al., 1987), and this was shown to cause diminished 
polyamine biosynthesis (Bacchi et al., 1983) and reduced production of the 
trypanosome-specific redox-active metabolite trypanothione (Fairlamb et al., 
1987).  Accumulation of S-adenosyl methionine, measured by HPLC, has been 
reported in eflornithine-treated cells, which might perturb cellular methylation 
reactions (Yarlett and Bacchi, 1988) although more recent data, obtained 
through the use of RNA interference to reduce expression of ODC, increased 
levels of decarboxylated S-adenosyl methionine, but not of its precursor, S-
adenosyl methionine (Xiao et al., 2009).  
How eflornithine enters trypanosomes is a subject of debate.  An early report 
measuring the uptake of 
14C-eflornithine in bloodstream form trypanosomes and 
in hepatoma human cells showed that eflornithine uptake was not saturable, 
generating the hypothesis that eflornithine enters trypanosomes by passive 
diffusion (Bitonti et al., 1986). However, studies on eflornithine resistant 
procyclic trypanosomes showed reduced accumulation of 
14C-eflornithine  
(Phillips and Wang, 1987) and uptake of eflornithine was saturable (at 0.01 nmol 
per 10
7 cells) in the resistant line, which is typical of a transporter. Bellofatto et 
al (1987) also found uptake of eflornithine in procyclic cells to be temperature 
dependent and thus likely to be transporter mediated.  Indeed as a zwitterionic, 
charged amino acid, eflornithine would not be expected to diffuse across 
membranes and transport-mediated uptake is a more likely route of entry, 
perhaps via one of the numerous amino acid transporters that are encoded in the 
trypanosome genome.   67 
 
In T. brucei, loss of transport has been shown to be a key determinant in 
resistance to melaminophenylarsenicals (Carter and Fairlamb, 1993) and 
diamidine drugs (Barrett and Fairlamb, 1999; Matovu et al., 2001;Stewart et al., 
2005). It would be interesting to determine whether loss of transport is also a 
factor in resistance to eflornithine. 
The mechanisms of drug resistance are often discovered after resistance has 
been detected in the field. It is an arms race where biologists are often caught 
on the back foot. Given the increased use of eflornithine, alone or in 
combination with nifurtimox, a better understanding of the risk of resistance is 
critical. Such an understanding may help limit its spread and allow the 
development of diagnostic tools. Fluorescence-based tests are available to 
predict the loss of the P2 transporter and therefore resistance to melarsoprol 
(Stewart et al., 2005). Genetic tests would be of less use to determine the 
status of the P2 transporter as different, often complex, genetic mutations are 
seen in different isolates (Stewart et al., 2010). 
As described above, eflornithine is now preferentially used in combination with 
nifurtimox. It was predicted that nifurtimox and eflornithine would work 
synergistically with one another as nifurtimox was shown to induce oxidative 
stress in cell extracts (Docampo and Stoppani, 1979;Docampo and Moreno, 
1984;Viode et al., 1999) and eflornithine reduces the thiol pool which would 
otherwise deal with this stress (Fairlamb et al., 1987). This synergism has not, 
however, been formally shown. If resistance to eflornithine is easily selected 
then it may be that the use of the combination therapy is under threat. In this 
chapter, I describe work revealing a molecular mechanism for resistance to 
eflornithine.  68 
 
3.2 Results 
3.2.1 Selection of eflornithine resistant bloodstream form T. b. 
brucei.   
Although there has been anecdotal evidence of eflornithine treatment failures in 
the field (Enock Matovu, unpublished data), resistant samples have not, as yet, 
been isolated. To investigate mechanisms of eflornithine resistance, parasites 
were selected in vitro from a wildtype bloodstream form T. b. brucei strain 427 
by growth in increasing concentrations of eflornithine. T. b. brucei was used as 
it is a tractable, non-human infective sub-species, which has a much better 
annotated genome sequence than T. b. gambiense (although there is some 
concern that T. b. brucei is genetically more similar to T. b. rhodesiense (see 
section 1.2 of this thesis), and T. b. rhodesiense is insensitive to eflornithine).  
It took two months (24 passages) to attain a line demonstrating forty fold less 
sensitivity to drug, based on the IC50 value of eflornithine in the drug sensitive 
parent strain (Fig 3-1A). No altered growth phenotype was observed (data not 
shown). Two independent cell lines (DFMOR1 and DFMOR2) were generated in 
this way. The IC50 levels were also recorded by alamar Blue assay at various 
stages during the selection process to measure the levels of resistance. This is 
also shown in figure 3-1. It should be noted that eflornithine is thought to act in 
a cytostatic way (Bitonti et al., 1986), so IC50 levels should be taken as a relative 
measure of the resistance, rather than the absolute amount of drug required to 
kill the cells. In an in vivo assay, where there is a healthy immune system, it is 
likely that the IC50 will be lower. 
The resistant lines also grew in female ICR mice and exhibited resistance to both 
the minimum curative dose of 2 % w/v and a higher dose of 5 % w/v eflornithine 
whilst mice infected with wildtype cells were cured with the lower 2 % w/v 
dose.  Resistant cells remained susceptible to pentamidine (4 mg/kg, four daily 
doses) (Fig 3-1B), as was also seen in vitro (Table 3-1). This demonstrates that 
the in vitro selected mechanism for resistance is also operative in vivo.    69 
 
 
Figure 3-1 Eflornithine resistance in T. b. brucei. (A), Selection of eflornithine resistance in 
T. b. brucei. Black triangles and left hand y-axis show the eflornithine concentration in 
which the parasites grew. Bars and the right hand y-axis show milimolar IC50 values at 
various stages of the selection process. One clone out of two is shown.  (B), Treatment of 
mice infected with wildtype or eflornithine resistant (DFMOR1) parasites. Closed circles; 
untreated, open diamonds; 2 % eflornithine, open squares; 5 % eflornithine, closed 
triangles; pentamidine (4 mg/kg).  
 
An alamar blue assay was used on the wildtype and DFMOR1 lines to determine 
whether there was cross-resistance with other trypanocides (Table 3-1). This 
would indicate a shared mode of entry, mode of action or drug efflux 
mechanism. There was no cross-resistance with other currently used 
trypanocides, although there was a significant increase in sensitivity to 
pentamidine. 70 
 
 
Trypanocide  Wildtype IC50 (nM)  Resistant IC50 (nM)  Average R:WT 
Suramin (n = 3)  4.6 ± 0.7  4.4 ± 0.4  0.99 
Melarsen Oxide (n = 2)  4.3  2.4  0.67 
Cymelarsan (n = 2)  6.3  3.7  0.73 
Nifurtimox (n = 5)  2, 940 ± 600  2, 880 ± 300  1.09 
Pentamidine (n = 5)  0.43 ± 0.1  0.1 ± 0.04  0.27* 
Eflornithine (n = 5)  22, 000 ± 3, 000  906, 000 ± 192, 000  41.46* 
Table 3-1 IC50 values for known trypanocides on wildtype and eflornithine resistant cell 
lines. Number of replicates are in parentheses, numbers represent mean ± s.e.m where 
appropriate. * indicates significance at a p = 0.05 level from a paired t-test. 
 
3.2.2 Analysis of resistant lines 
Initial metabolomics experiments were undertaken before a full protocol 
optimisation was completed. As a result, the intensities of some of the 
metabolites (notably the more water-soluble metabolites) may be reduced, but 
the relative intensities between the two groups remain valid. Briefly, the 
wildtype and DFMOR1 cells were grown to a density of 1-2 x 10
6/ml. These cells 
were concentrated by centrifugation (1, 250 RCF) to 1 x 10
9/ml. 2 x 10
8 cells 
suspended in HMI-9 were quenched in 800 µl 80ºC ethanol and the supernatant 
after centrifugation (at 16, 000 RCF) was flash frozen in liquid nitrogen.  
Samples were run on the Orbitrap at the University of Strathclyde, Glasgow by 
Dr. Muhammed Anas Kamleh.  
Significant differences between the untargeted metabolite profiles of wildtype 
and resistant cells were not apparent using multivariate statistical analysis 
(Appendix 8.1), nor were changes seen in any of the identified polyamine 
pathway metabolites. It was previously shown in eflornithine resistant procyclic 
stages of the parasite that an increased uptake of putrescine can relieve the 
blockage of ODC caused by eflornithine (Bacchi et al., 1993). An increase in 
putrescine was not observed in our analyses, however, so it seems that increased 
putrescine uptake is not required for resistance in bloodstream forms of the 71 
 
parasite. There was a slight, although not significant, decrease in ornithine 
levels in the resistant cell line (Fig 3-2).  
 
Figure 3-2 Metabolomic analysis of eflornithine resistance.  Relative abundance of 
polyamine metabolites in wildtype (WT) and eflornithine resistant (R) cell extracts. Error 
bars show standard deviation. 
 
This reduction in ornithine in the resistant cell line could be explained by 
reduced ornithine uptake. This was investigated with tritiated ornithine at a 
concentration of 10 µM over a 30 minute time period using ribose uptake as a 
control (Fig 3-3). 72 
 
 
Figure 3-3. The uptake of ornithine into wildtype and DFMOR1 cell lines. Tritiated ornithine 
was used to determine whether ornithine uptake was lost in the resistant cell line. Ribose 
uptake (inset) was monitored as a control (30 minute time point shown). Data shown is one 
of four replicates. P = 0.318 from a 2 tailed t-test comparing 0 and 30 minute time points. 
 
The reduced levels of ornithine in the resistant cells do not appear to be a 
consequence of reduced uptake (the difference in uptake seen in figure 3-3 is 
not reproducible or significant, especially when normalised to the difference in 
ribose uptake). It is therefore likely that the reduction in ornithine is due to a 
metabolic mechanism such as increased flux through ornithine decarboxylase. 
This could be analysed further by tracking the metabolism of isotopically-
labelled ornithine through wildtype and the resistant cell lines, but was not 
followed up as part of this work. This was because in a targeted analysis of 
eflornithine (m/z = 183.0940, RT = 19.72 minutes) accumulation using mass 
spectrometry, it was evident that eflornithine levels were greatly reduced in 
resistant cells compared to wildtype (Fig 3-4). This result indicated that 
exclusion of drug from the resistant line (DFMOR1) rather than changes to 
metabolism were responsible for loss of sensitivity.  73 
 
 
Figure 3-4, The uptake of eflornithine (m/z = 183.0940, RT = 19.72) into wildtype and 
DFMOR1 cell lines. Wildtype (filled bars) show an increased accumulation of eflornithine 
compared to resistant cells (hatched bars) over one hour. Stars indicate a significant 
difference at a p=0.01 level between WT at time 0 and WT after 60 minutes. A hash indicates 
that R at time 0 and R after 60 minutes show no significant difference at a p=0.05 level. 
 
There are no known isomers of eflornithine and since the retention time 
detected is very similar to the predicted retention time from the empirical 
formula of eflornithine (-0.2 % error) we can be extremely confident that the 
detected peak represents eflornithine. 
The slight change in sensitivity to pentamidine observed in DFMOR1 was also 
investigated using metabolomics. A time course experiment (0, 1 and 2 hours) 
with 40 nM (ten times the IC50) pentamidine was conducted, but no significant 
differences in levels of any metabolites were observed apart from reduced 
ornithine levels in all resistant samples (data not shown) as seen in the 
comparison of wildtype and resistant cell lines. This indicates that visible 
changes to the metabolome are not seen within two hours of pentamidine 
treatment in wildtype or in resistant cells. 
Eflornithine targets the enzyme ornithine decarboxylase. Alterations to the 
amino acid composition of proteins is often responsible for drug resistance as 74 
 
variants with diminished ability to bind drug are selected (Farooq and Mahajan, 
2004). To rule this out we amplified the ODC gene from the wildtype and the 
resistant cell line (DFMOR1 and DFMOR2) and found no differences in the 
sequence (Appendix 8.2). 
3.2.3 Loss of eflornithine accumulation into resistant cells.  
To determine quantitatively the relative transport rates of the drug in wildtype 
and resistant cells, 
3H-eflornithine was used to measure accumulation in each 
cell type. Eflornithine was used at a concentration of 20 µM. Threonine uptake 
was assayed as a control (as threonine is another amino acid, but is uncharged 
and likely therefore to use alternative transport mechanisms). A greater rate of 
eflornithine uptake was observed in the wildtype cell line compared to the 
resistant line (DFMOR1), with around five fold more drug taken into wildtype 
cells after 30 minutes (Fig 3-5). Levels of threonine uptake were the same in 
both cell lines. 75 
 
 
Figure 3-5. Quantitative uptake of eflornithine in wildtype and DFMOR1 cell lines. 
3H-
eflornithine transported into wildtype (triangles) and resistant (circles) cells was measured 
over 30 minutes. Measurements are an average of four separate experiments, each with 
three internal replicates. Error bars are the standard error of the mean. Inset graph shows 
threonine uptake in the same cell lines. The y-axis shows nmol of threonine per 10
7 cells. 
The x-axis shows the time in minutes.  
 
The transporter appears to be concentrative, as an internal concentration of 344 
µM is measured (assuming a trypanosome cell volume of 0.58 µL per 10
7 cells 
(Opperdoes et al., 1984)) compared to the external concentration of 20 µM. In 
procyclic cells the internal concentration measured by Bellofatto et al. was 47 
µM after 70 minutes in 100 µM tritiated eflornithine (1987), which led them to 
conclude that eflornithine is not transported. Phillips and Wang measured 180 
µM after 60 minutes in 54 µM (1987), also in procyclic cells, which led them to 
conclude that eflornithine is transported. Whether the transporter is active and 
concentrative within procyclic forms of the trypanosome is therefore 
inconclusive.  
It might have been expected that ornithine and eflornithine share an uptake 
mechanism. In fact, we found no appreciable difference in ornithine uptake 
between the wildtype and the resistant cell lines (Fig 3-3) but we saw much 76 
 
reduced eflornithine uptake in the resistant line (Fig 3-5). These observations 
lead to three possible hypotheses: 1, Eflornithine and ornithine do not share an 
uptake mechanism, 2, an eflornithine efflux mechanism has no effect on 
ornithine or 3, ornithine is able to use a wider variety or transporters than 
eflornithine and loss of one does not prevent ornithine entry into the cell.  
To determine whether ornithine and eflornithine share an uptake mechanism 
ornithine uptake assays were performed in increasing competition with cold 
eflornithine (Fig 3-6) and cold ornithine as a control. 
 
Figure 3-6. Eflornithine inhibition of ornithine uptake in wildype 427 bloodstream form cells. 
Increasing concentrations of cold eflornithine (x-axis) do not significantly inhibit the uptake 
of tritiated ornithine (y-axis). Inset: tritiated ornithine uptake (y-axis) can be inhibited by cold 
ornithine (x-axis).  
 
Reciprocal experiments with ornithine inhibition of eflornithine uptake 
confirmed a lack of uptake cross inhibition (data not shown). Increasing 
concentrations of cold eflornithine have no effect on ornithine uptake suggesting 
either that ornithine is accumulated via multiple transporters, which can 
compensate for the inhibition of one transporter, or that the two amino acids do 
not share a transport mechanism.   77 
 
Whether ornithine and eflornithine share a transporter or not remains to be 
concluded, but the data indicate a transporter phenotype for eflornithine 
resistance, as seen previously in selection of resistance to melamine-based 
arsenicals (Carter and Fairlamb, 1993) and diamidines (Barrett and Fairlamb, 
1999; Stewart et al., 2005; Lanteri et al., 2006;Bridges et al., 2007). As 
eflornithine is an amino acid analogue (Fig 1-9), we hypothesised loss of an 
amino acid transporter. Several members of this amino acid transporter family 
were characterised by Charles Ebikeme (University of Glasgow). The TbAAT7 
locus (which encodes at least nine amino acid transporters) was shown to 
transport threonine, glycine, cysteine, asparagine, alanine and serine, but none 
of the other 13 essential amino acids assayed (tyrosine was not assayed) 
(Ebikeme, 2008). With the exception of asparagine, which is a relatively poor 
substrate at this locus, all of these amino acids are neutral and have a small side 
chain of fewer than two carbon unit. The TbAAT5 locus was also investigated by 
RNAi and was shown not to transport proline (Ebikeme, 2008). It is not known 
which members of the amino acid permease superfamily transport lysine, 
arginine or ornithine, the closest amino acids to eflornithine based on structure 
and charge.  
To test the theory that eflornithine resistance occurs due to loss of an amino 
acid permease, all members of the amino acid permease gene family (Fig 3-7) in 
the T. brucei genome (Jackson, 2007) were systematically amplified from both 
wildtype and each of the two independently selected resistant lines. 78 
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In each of the independently selected lines only one single copy amino acid 
transporter gene, TbAAT6 (Tb927.8.5450), was shown to be absent (Fig 3-7). 
Southern blot analysis confirmed this and also demonstrated that there were no 
alterations in ODC copy number. 
TbAAT6 appears to be an orphan within the amino acid transporter family; it has 
no homologue in leishmania or T. cruzi and where other amino acid transporters 
appear in clusters on their chromosomes, many with tandem repeats, TbAAT6 
stands alone (Jackson, 2007). This is an advantage for molecular characterisation 
as it means that expression can be inhibited by RNA interference with less risk of 
unintentional knockdown of other genes with similar sequences. The 
identification of TbAAT6 also provides the possibility of expression in a 
heterologous system for further analysis of function. 
PCR analysis indicated a deletion of TbAAT6, and surrounding genes, from both 
resistant lines (DFMOR1 and DFMOR2) (Fig 3-8a). This result indicated the 
possibility that the TbAAT6 gene could play a role in eflornithine‟s entry into T. 
brucei and that its loss was responsible for drug resistance. The gene was 
amplifiable at day 34 of the selection process, but by day 50 was no longer 
amplifiable (Fig 3-8b), this correlates with the loss of sensitivity to eflornithine 
between days 34 and 50.  80 
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As eflornithine is less effective in T. b. rhodesiense parasites, the status of the 
rhodesiense gene was checked by PCR on DNA isolated from the field (a kind gift 
of Craig Duffy, University of Glasgow) and the gene was found to be present and 
of a similar size to the T. b. brucei gene. The sequence of this gene was not 
analysed, however, as the genome of T. b. rhodesiense is not published.  
Patients from the field who have been shown to be refractory to eflornithine 
treatment, or who have shown a resurgence of parasitaemia after eflornithine 
treatment, may routinely have a blood sample spotted on to an FTA® card. 
FTA® cards lyse cells, denature proteins and protect nucleic acids. Cards are 
washed to remove contaminating red blood cells and any parasite DNA can be 
amplified. Blood spots from eflornithine-relapse and eflornithine-cured patients 
were obtained from Omugo, Uganda courtesy of Enock Matovu, (Makerere 
University). Several attempts to amplify TbAAT6 or phospholipase C (as a 
positive control) were made using PCR and nested PCR without success. The 
parasitaemia within the samples was not recorded, but was thought to be very 
low, which may explain why parasites could not be detected even with the 
positive control. 
3.2.4 Functional confirmation of a role for TbAAT6 in eflornithine 
resistance.  
To confirm a role for TbAAT6 in eflornithine resistance we used RNA interference 
(Alsford and Horn, 2008) to ablate its expression in T. b. brucei. The pRPa
iSL 
vector was used which integrates into a ribosomal spacer locus of the 
trypanosome DNA in the 2Ti cell line, completing a hygromycin resistance 
marker to achieve efficient integration rates and reproducible siRNA transcript 
levels. The vector contains a stem-loop system to create the double stranded 
RNA. This is thought to be more efficient than using opposing T7 promoters as 
intermolecular RNA interactions are more likely than intramolecular interactions 
(Alsford and Horn, 2008). 
The gene sequence to be used in the vector was chosen using the RNAit 
programme (http://trypanofan.path.cam.ac.uk/software/RNAit.html) using the 82 
 
same 400 bases for each section of the stem-loop vector. Positive transfections 
were selected using hygromycin.   
Five cloned lines were selected and were induced with tetracycline for six days 
before commencing the alamar blue assay to determine the IC50 for eflornithine. 
The induced lines showed no growth defect over seven days (data not shown). 
All five of the TbAAT6
RNAi mutants became resistant to eflornithine to an extent 
similar to the lines selected for resistance to the drug (40 x resistance factor) 
(Fig 3-9A). These cells did not become resistant to DB75, used as a control (data 
not shown).  Attempts to confirm knock down of TbAAT6 by northern analysis 
were unsuccessful, even with β-actin controls. 
Attempts were made to create a TbAAT6 null mutant line, but removal of the 
second allele of the gene was not achieved. This is unexpected as selection of 
resistance was very fast, implying that the gene would not be difficult to 
remove. It is therefore likely that other changes are required to enable the loss 
of TbAAT6. The line with just one allele of TbAAT6 was analysed in an alamar 
blue assay and was surprisingly found to be more sensitive to eflornithine than 
the wildtype parent line (IC50 10.7 ± 3.2 µM c.f. 47.5 ± 6.5 µM for wildtype 
(results are mean ± s.e.m, n = 4)). This may be due to a compensatory 
mechanism within the heterozygote line such as increased expression of the one 
allele, but has not been confirmed.  
A procyclic RNAi line for TbAAT6 was also created using the same construct as 
the bloodstream form, with a slight modification to remove the partial 
hygromycin resistance marker and replacing it with a full hygromycin resistance 
gene. This 29-13 derived line (Jane Munday, University of Glasgow) showed no 
growth defect over nine days when induced with tetracycline, but as neither 
induced or non-induced cells were sensitive to eflornithine (in an alamar blue 
assay with eflornithine concentrations up to 20 mM, data not shown), a 
resistance phenotype could not be determined. It is of note that the Horn group 
at the London School of Hygiene and Tropical Medicine reported a growth defect 
in RNAi ablation of TbAAT6 expression in procyclic cells during a large scale RNAi 
library screen, but that this defect was not reproduced in a targeted RNAi assay 
for TbAAT6 (David Horn, personal communication). 83 
 
Next, we expressed the TbAAT6 gene in the eflornithine resistant trypanosomes 
using vector pHD676 (Biebinger et al., 1997).  This vector also integrates into 
the ribosomal spacer regions of the trypanosome DNA and constitutively 
expresses TbAAT6 using a PRRN promoter (a ribosomal RNA promoter) (Biebinger 
et al., 1997). Cloned cells in which the gene was re-expressed re-gained levels 
of eflornithine sensitivity similar to wildtype (Fig 3-9B).   
 
Figure 3-9 RNAi and re-expression of TbAAT6. (A) RNAi was induced for 12 days and the 
IC50 value to eflornithine measured. Stars indicate significant difference at a p = 0.05 level 
compared to wildtype, whereas a hash indicates that RNAi (773 ± 53 µM) and resistant lines 
(886 ± 200 µM) show no significant difference. (B) Re-expression of TbAAT6, IC50 values for 
eflornithine of the wildtype parent line (24.6 ± 5.8 µM), the resistant line (886 ± 200 µM) and 
the resistant line constitutively re-expressing TbAAT6 (111 ± 18 µM). Stars indicate a 
significant difference at a p = 0.05 level compared to resistant, whereas a hash indicates 
that wildtype and re-expressor show no significant difference. IC50 measurements were at 
least n = 5.   
 
Loss of expression of TbAAT6 is therefore both necessary and sufficient to confer 
resistance to eflornithine and its re-expression in defective lines is capable of 
restoring sensitivity, regardless of other changes to the cell. 
To analyse further the natural substrate of TbAAT6, a heterologous expression 
system without endogenous eflornithine uptake was sought. Leishmania were 84 
 
found to transport eflornithine (Fig 3-10), so were eliminated as a potential 
expression system.  
 
Figure 3-10. Eflornithine uptake in L. mexicana. The increase in eflornithine signal from 1.25 
to 3 pmol per minute is indicative of uptake in Leishmania spp. Proline uptake (inset) was 
used as a control. 
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3.2.5 Further studies of TbAAT6 
Eflornithine is a chiral amino acid with L- and D- enantiomers. In the field, 
eflornithine is administered as a racemate and we know that both the L- and D- 
enantiomers are able to interact with trypanosome ornithine decarboxylase 
(Margaret Phillips, personal communication). The L-enantiomer does, however 
exhibit 20 fold more potency on the human ODC (Qu et al., 2003). We do not 
know, however, whether both enantiomers of eflornithine are able to enter the 
trypanosomes and knowing whether this is the case or not could have 
implications for drug formulations in the field. 
To determine the stereospecificity of TbAAT6, alamar blue assays were used to 
establish the IC50 values of each enantiomer of eflornithine (Fig 3-11).  86 
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Figure 3-11. Alamar blue assays on different enantiomers of eflornithine. The IC50 values for 
wildtype cells (top graph) were; L-eflornithine (42 µM), D-eflornithine (1277 µM), D/L-
eflornithine (23 µM). The IC50 values for resistant cells (bottom graph) were; L-eflornithine 
(2400 µM), D-eflornithine (3600 µM), D/L-eflornithine (800 µM). Points from an average of two 
experiments is shown with line of best fit. 
 
The L-enantiomer of eflornithine has a similar IC50 value to the L/D mixture used 
as the final drug in wildtype cells. The D-enantiomer has an IC50 value more 
similar to the resistant cell lines where uptake of the drug is not observed. As 
both isoforms are able to bind to ornithine decarboxylase, this suggests that D-
eflornithine is not internalised by TbAAT6. The L-enantiomer of eflornithine was 
not more efficacious than the D/L racemate of eflornithine. It is not known what 
the ratio of L to D eflornithine is in the racemate. It is possible that there is a 
high ratio of L-eflornithine already within the racemic eflornithine. 87 
 
3.3  Discussion 
Note; parts of the work in this chapter have now been published (Vincent et al., 
2010) (Appendix 8-3). 
3.3.1 Selection of resistance 
In the absence of useful eflornithine refractory field isolates of trypanosomes, 
resistance was selected by increasing concentrations of drug. Resistance was fast 
to select for and the resistance gene, TbAAT6 appeared to be lost at a selection 
pressure of 200 µM eflornithine, after 40 days of selection. 
There was no cross-resistance with other known trypanocides, not unexpected 
now we know that the resistance is due to loss of an eflornithine transporter. 
The structures of the other trypanocides are very dissimilar to eflornithine and 
are therefore unlikely to share a transport mechanism. 
There was an increased sensitivity to pentamidine upon selection of eflornithine 
resistance. This is unlikely to be related to a transport mechanism for 
pentamidine as pentamidine uptake is well characterised and a role for TbAAT6 
in uptake is highly unlikely. It is therefore likely that there are other changes in 
the resistant cells apart from the loss of the transporter and the surrounding 
genes. This theory is supported by the slight increase in resistance seen when 
cells are grown in 64 µM eflornithine (Fig 3-1).  
The metabolomes of the resistant and wildtype cells were compared and the 
only difference was in ornithine levels, with around 40 % less in the resistant 
cells. Not all metabolites within the cells are detectable, however, in the 
metabolomic methods used, so changes may still occur in levels of metabolites 
that weren‟t detected. Other changes that could have occurred include greater 
expression of ornithine decarboxylase or another enzyme or post-translational 
modifications that alter the function of ODC or of other proteins. 88 
 
3.3.2 Uptake of eflornithine 
Selection of eflornithine resistance results in reduced eflornithine uptake into 
the trypanosome. The loss of TbAAT6 either by gene deletion as observed in the 
selected drug resistance lines, or by RNAi is sufficient to render trypanosomes 
over 40 fold less sensitive to eflornithine than wildtype cells.   Furthermore, 
ectopic expression of TbAAT6 in trypanosomes that have deleted the gene is 
sufficient to restore wildtype levels of eflornithine sensitivity confirming that 
loss of TbAAT6 alone is necessary and sufficient to generate resistance. 
The fact that TbAAT6 was lost so easily is very interesting. In Leishmania, genes 
can be amplified easily by the creation of a circular amplicon. These are created 
by homologous recombination at tandem repeats around the area of interest 
(Grondin et al., 1996;Leprohon et al., 2009).  It is not known, however, if 
trypanosomes are able to amplify genes in the same way or if genes can be 
deleted by homologous recombination in this way. It is notable, however, that 
the amplification of circular replicons is frequently seen in Leishmania, but not 
T. brucei selected for drug resistance. As there is a high degree of repetition 
around TbAAT6, it is possible that this will aid recombination to remove the 
transporter, but this is yet to be proven as a mechanism of gene deletion. It is 
interesting that the entire TbAAT6 gene has been deleted, whereas smaller 
mutations may also result in loss of function. Both point mutations and whole 
genes losses have been seen in TbAT1 (Stewart et al., 2010).  
It has been shown that there is redundancy in the trypanosome amino acid 
transporter repertoire. This redundancy allows amino acid transporters to be lost 
without affecting the nutrients available to the cell and loss of transporters is 
not uncommon (e.g. (Lanteri et al., 2006)). It is still unclear, however, why the 
trypanosome would delete TbAAT6 at the genomic level rather than reduce its 
expression. It may be a function of the transcription of trypanosome mRNA being 
polycistronic, meaning that regulation at the transcriptional level is not possible. 
However the transporter regulation occurs, its plasticity allows quick adaptation 
to different environments. 
We have, as yet, been unable to assign a physiological function to TbAAT6 in 
African trypanosomes. Ornithine transport, which would be expected to share a 89 
 
route of entry with its difluormethylated derivative, was not reduced 
significantly in the eflornithine resistant line. Ornithine was not able to inhibit 
uptake of eflornithine, providing further evidence that the two amino acids do 
not share a mechanism of uptake.  
TbAAT6 is one of a large family of related genes described in the kinetoplastida 
belong to the amino acid transporter 1 superfamily. Only a few other members 
of the family have been functionally characterised. These include an arginine 
transporter in Leishmania donovani (Shaked-Mishan et al., 2006), an arginine 
transporter in T. cruzi (Canepa et al., 2004) and polyamine transporters in L. 
major (Hasne and Ullman, 2005) and T. cruzi (Hasne et al., 2010). The TbAAT6 
gene is not syntenic with genes in Leishmania spp. or T. cruzi. Furthermore, the 
evolution of the AAT family (Jackson, 2007) makes it impossible, currently, to 
define specific functionality to any of these transporters, based on homology 
alone.   
 We also provide evidence that L, but not D-eflornithine enters the trypanosome 
via TbAAT6. As both enantiomers are known to inhibit ODC in humans (Qu et al., 
2003) and trypanosomes (Margaret Phillips, personal communication) and 
eflornithine is not thought to need any processing or activation then the higher 
IC50 value for D-eflornithine compared to L-eflornithine suggests that D-
eflornithine cannot be taken into the cell through TbAAT6.  It is possible to 
separate the enantiomers of eflornithine (Jansson-Lofmark et al., 2010), but the 
process of separation is very costly and inefficient. If the costs and efficiency 
can be optimised, however, then the cost at the field level would be very 
significantly reduced. The transportation, saline and administration costs would 
be significantly depreciated, which may make research into enantiomer 
separation a very worthwhile research avenue to pursue. However, in our in 
vitro assay racemic eflornithine is as effective as L-eflornithine, suggesting that 
the ratio of D to L is already low. 
3.3.3 Implications for the field 
Since eflornithine has only recently been implemented as first line treatment for 
stage two HAT, formal published reports of clinical resistance have not yet 
appeared, although unpublished data (Enock Matovu (Makerere University), 90 
 
personal communication) points to a substantial increase in eflornithine 
treatment failures in Northern Uganda. Nifurtimox resistance has been selected 
in vitro and has been shown to be cross resistant with another emerging 
trypanocide, fexinidazole, currently in clinical trials (Torrelle et al., 2010). 
Given nifurtimox‟s lack of efficiency (Janssens and De Muynck, 1977), 
eflornithine resistance alone is likely to lead to large numbers of treatment 
failures from the combination.  If the loss of TbAAT6 is involved in resistance in 
the field, then it will be possible to implement a simple PCR-based test for 
resistance, allowing for more suitable treatments to be administered. Tests 
conducted so far with blood samples on FTA® cards were not successful. It is 
thought that this is due to very low levels of parasitaemia on the cards, so 
efficient methods of extracting DNA from the field samples will be required. 
Methods of concentrating trypanosomes in blood are continually improving to aid 
in HAT diagnosis (Buscher et al., 2009) and can also be used to detect resistance 
phenotypes by PCR.  Fluorescence-based tests are unlikely to be developed for 
use in the same way as for melarsoprol resistance (Stewart et al., 2005), as an 
amino acid transporter would be unlikely to import a large, charged fluorophore. 
It will be interesting to see if, now that the data on TbAAT6 is published, 
scientists in the field will start to report finding resistant parasites missing 
TbAAT6. 
Given the ease with which trypanosomes become resistant, it is perhaps 
surprising that resistance has not been seen in the field more often. It is of 
course possible that the loss of TbAAT6 would be detrimental to the survival of 
the parasites within the insect vector and therefore the mechanism of resistance 
would not be transmissible through the parasite‟s life cycle. Preliminary results 
with RNAi in procyclic forms do not show a growth defect or resistance to 
eflornithine, but without confirmation of knockdown by northern blot or reverse 
transcriptase real time PCR, conclusions on the function of TbAAT6 in procyclic 
cells cannot be drawn. David Horn‟s group developed a high throughput RNAi 
screen for trypanosomes and indicated that TbAAT6 is essential in procyclic form 
trypanosomes, but not bloodstream forms (Alsford et al., 2011). However, more 
targeted analyses of TbAAT6 counteract this data with evidence that TbAAT6 is 
not essential in procyclic forms (David Horn, personal communication). 91 
 
Resistance to nifurtimox has been selected in vitro and cell lines were found to 
be cross resistant with other nitro-drugs including fexinidazole, a clinical trial 
candidate retaining their virulence and resistance in mice (Sokolova et al., 
2010). This highlights the need for combination therapies, and in particular, the 
need to provide combination therapies with drugs that work on different 
pathways. This also therefore highlights the need to understand the modes of 
action of all the drugs in use against HAT in order to design these combination 
therapies. Care must be taken, however, as resistance to one of the drugs within 
a combination therapy could mean that sub-lethal doses of monotherapy are 
inadvertently administered leading to the likely selection of multidrug resistant 
strains. Tests for the presence of resistant strains are therefore of paramount 
importance. 
The evidence presented in this chapter conclusively demonstrates that TbAAT6, 
an L-eflornithine transporter from the amino acid permease family, is lost in in 
vitro derived, eflornithine resistant, cell lines. This has since been 
independently corroborated in two high-throughput RNAi screens (Baker et al., 
2011;Burkard et al., 2010). 
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  4. Determining Drug mode of action by 
metabolomics 
4.1 Introduction 
It is very rare for a new chemotherapeutic agent to be licensed without prior 
knowledge of its mode of action (MOA). In 2009, 19 drugs were approved by the 
FDA‟s centre for drug evaluation and Research in the US, only one of which had a 
wholly unknown MOA (Hughes, 2010). A knowledge of the MOA reduces the risk 
of toxicity and allows synergism and resistance to be predicted. Currently, the 
MOA of a drug is predicted using expensive and time-consuming enzyme-based 
assays. 
Mode of action studies using metabolomic techniques are only just starting to be 
used (Aranibar et al., 2001; Allen et al., 2004;Bando et al., 2010;Sun et al., 2011  
and often involve clustering metabolic profiles from compounds with known 
MOAs without analysing the individual metabolites involved. This means that 
drugs with novel MOAs would not be detected, so new, unique compounds need 
another method for determining their MOA. 
There have been a limited number of studies that look at the individual 
metabolites within an organism and the changes that are induced in these 
metabolites in response to drugs. One such study used a systems biology 
approach to combine proteomic, transcriptomic and metabolomic data in the 
analysis of methamphetamine-induced perturbations to Drosophila homeostasis 
(Sun et al., 2011). Using GC-MS they observed decreased trehalose, a major 
blood sugar and antioxidant in insects, and using transcriptomics they also saw 
decreased aconitase (a regulator of antioxidant production and cell death) and 
alcohol dehydrogenase expression, which they attributed to increased oxidative 
stress caused by the drug (Sun et al., 2011). Unfortunately, the metabolomics 
branch of this study focussed on sugars, so levels of glutathione and other 
metabolites known to be important in oxidative stress were not analysed. 93 
 
Another study looked at the toxicity of hydrazine, a metabolite of many drugs 
including the antihypertensive agent, hydralyzine (Bando et al., 2010). GC-MS 
was used to analyse the plasma and urine of rats treated with hydrazine, 
followed by principle components analysis (PCA) of the spectra. The loadings 
plots of the PCAs revealed the masses that were responsible for causing the 
highest degrees of separation between treated and untreated groups. Gas 
chromatography provides a highly reproducible separation, allowing masses to be 
matched to library entries for mass spectra of standards, providing an 
identification of the metabolites altered during hydrazine toxicity. The group 
recorded an increase in cysteine, glutamate, glycine (all glutathione precursors), 
ascorbate and oxoproline, due to the increase in oxidative stress as well as 
changes to the urea and tricarboxylic acid cycles (Bando et al., 2010). 
New lead compounds against HAT are rare and not seen as financially beneficial 
for most drugs companies. Knowing the MOA and potential side effects of a 
compound could bring down the cost of research by predicting side effects and 
toxicity before drugs reach clinical trials. If the cost of research can be brought 
down, then it is possible that the pharmaceutical industry will be persuaded to 
invest more in compound validation for this, and other deadly diseases. As 
trypanosomes are considered model organisms and have a relatively simple 
metabolome they could also be very useful for more general metabolomic MOA 
studies. This is especially true as trypanosome populations can be clonally 
expanded and can be grown to relatively large quantities. 
There are five drugs in use against HAT (see section 1.5.3 of this thesis). Of 
these five, only eflornithine has a known MOA (Fig 4-1). Eflornithine inhibits 
ornithine decarboxylase only (Poulin et al., 1992;Grishin et al., 1999), making it 
ideal for use as a proof of principle for MOA action studies using metabolomics. 
In addition to the four licensed drugs, nifurtimox has been recommended by the 
World Health Organisation for use against late-stage disease in combination with 
eflornithine (Priotto et al., 2009). The MOA for nifurtimox has, however, yet to 
be fully elucidated. 94 
 
 
Figure 4-1. Eflornithine is an inhibitor of ornithine decarboxylase in the polyamine pathway. 
Enzymes are shown in italics, metabolites in boxes. The cell membrane is depicted by a 
double line and transporters as cylinders. The probable absence of arginase is discussed in 
chapter 5 of this thesis, although included here, representative of the classical pathway.  
 
ODC inhibition (Fig 4-1) by eflornithine has been studied in vivo and was shown 
to lead to an increase in levels of ornithine, S-adenosyl methionine and 
decarboxylated S-adenosyl methionine, and a decrease in putrescine, spermidine 
and trypanothione after 48 hours (Bacchi et al., 1983; Fairlamb et al., 1987). In 
vitro studies by Margaret Phillips‟s lab in Texas used HPLC after the addition of 
eflornithine to bloodstream form cells to measure polyamine levels. The group 
reported a complete depletion of putrescine and decreases in spermidine, 
glutathionyl-spermidine, glutathione and trypanothione levels after three days, 
in agreement with the in vivo studies (Xiao et al., 2009). The depletion in 
glutathione levels suggests that there is a feedback mechanism that controls the 
levels of glutathione when the polyamine levels are depleted as glutathione is 
not produced from ornithine. Decarboxylated S-adenosyl methionine levels 95 
 
increased around 40 % after treatment with eflornithine as the previous studies 
showed, but S-adenosyl methionine levels were unchanged (Xiao et al., 2009). 
These targeted studies all focussed on metabolite levels in the polyamine 
pathway and therefore it would be interesting to conduct an untargeted assay on 
the alterations to the whole trypanosome metabolome on eflornithine addition. 
The Bacchi study administered eflornithine in drinking water (after dehydration 
for 12 hours) with rats consuming an average of at 1.7 g/kg/12 hours and 
recorded serum levels of 10-70 µM (Bacchi et al., 1983). The Fairlamb group also 
administered eflornithine in drinking water (after 12 hours of dehydration) and 
recorded an average of 560 µM after 12 hours, 400 µM after 36 hours and 1,340 
µM eflornithine in rat blood plasma after 48 hours (Fairlamb et al., 1987). The 
amount of eflornithine water consumed by the rats was not reported in the 
Fairlamb study so if higher levels were used then this would account for the 
difference in serum levels. Levels within the trypanosome did not appear to be 
higher than those in plasma (Fairlamb et al., 1987). The in vitro study (Xiao et 
al., 2009) administered eflornithine in medium at 12.5 µM (half the calculated 
IC50). 
It has been proposed in T. cruzi that nifurtimox induces oxidative stress (Maya et 
al., 1997) and this may be a reason why the nifurtimox-eflornithine combination 
is thought to be synergistic. Recently, however, Boiani et al. (2010) have 
presented evidence against the oxidative stress theory in T. cruzi. The team 
used Ellman‟s method (Ellman (1959)) to measure the thiol content of the cells 
after nifurtimox treatment and found that thiols (all sulfhydryl groups) decrease 
significantly, but reactive oxygen species are not produced and redox cycling is 
not upregulated except at very high doses (Boiani et al., 2010). The Wilkinson 
lab subsequently showed  that nifurtimox is metabolised to an open chain 
metabolite firstly through reduction by a type 1 (oxygen insensitive) 
nitroreductase before dehydration of the furyl hydroxylamine and furan ring 
opening (Hall et al., 2011). The group were only able to detect nifurtimox and 
the unsaturated open chain nitrile in their HPLC assay, suggesting that the 
intermediate, necessary steps are rapid. The open chain nitrile was saturated 
slowly at more than 24 hours. The open chain nitrile is likely to exert its effects 96 
 
by binding to macromolecules rather than causing oxidative stress (Hall et al., 
2011).  
In this study we aimed to go beyond clustering techniques and look at how the 
metabolism of the trypanosome is altered in real time in response to drugs. An 
untargeted approach was taken, allowing an unbiased analysis of perturbations. 
Cell lysates were separated on a ZIC-HILIC column coupled to an Orbitrap mass 
spectrometer and MS data was deconvoluted using mzMatch (Scheltema et al., 
2011) and IDEOM (Darren Creek, University of Glasgow) softwares for automated 
processing. Metabolites of interest were selected on the basis of altered 
abundance and were verified and compared using Thermo Xcalibur software. 97 
 
4.2 Results 
4.2.1 Eflornithine MOA 
4.2.1.1  Experimental design 
It has been reported that eflornithine is a cytostatic drug and a healthy immune 
system is required for cell clearance (Bitonti et al., 1986). Rats treated with 
dexamethasone, an antibody production inhibitor, at the same time as 
eflornithine were less able to clear trypanosome infections than controls not 
treated with dexamethasone (Bitonti et al., 1986). Nude (athymic) mice are 
cured of trypanosomes, but eventually succumb to relapse (Bitonti et al., 1986). 
The MOA in vitro may therefore differ from the MOA in vivo. The IC50 is likely to 
be higher as the cells will not die at the concentrations required to turn them 
into stumpy forms and may still metabolise the resazurin dye used in the alamar 
blue assay. The T. b. brucei 427 bloodstream form line used in these assays is 
monomorphic, however, and is therefore unable to transform into stumpy forms 
of the parasite. 
Eflornithine levels in blood reach 49.2 µM in children and 87.5 µM in adults (68.9 
µM in CSF) (Milord et al., 1993) during the standard treatment regime of 14 
days, which is higher, although not much higher, than the IC50 in vitro of 35 µM 
(Fig 4-2). This is in line with the Bacchi level recorded in mice of between 10 
and 70 µM, but not with the Fairlamb levels of 560 µM (Bacchi et al., 1983; 
Fairlamb et al., 1987). 
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Figure 4-2. The IC50 value of eflornithine in vitro is 35 µM. An average of five experiments is 
shown. Error bars depict standard error of the mean. 
 
Upon inspection of the cells in the alamar blue assay, it was found that the cells 
were still alive in many of the wells where the resazurin dye was not 
metabolised, although were dead at higher doses of the drug. Eflornithine was 
therefore acting cytostatically at 35 µM, and prevented the metabolism of the 
dye, but did not kill the cells at the IC50 dose. 
Although the Fairlamb study found that eflornithine was not concentrated within 
the trypanosome (Fairlamb et al., 1987), data from the previous chapter of this 
thesis clearly shows that eflornithine is transported into the trypanosome (Fig 3-
5). 
To determine the levels at which eflornithine is cytostatic and cytotoxic, time 
course assays were conducted with drug at various concentrations (Fig 4-3).  
Eflornithine was found to be cytostatic (cells remained at the same density 
before dying) even at 500 µM until around 55 hours in drug. There was no sign of 
stumpy formation, but as the 427 strain is monomorphic, this would not be 
expected. 99 
 
 
Figure 4-3. Eflornithine time course. A time course was conducted with various 
concentrations of eflornithine.  Cells in 500 µM eflornithine do not die, until between 52 and 
69 hours, but do not increase in number. 
 
It was decided to conduct two experiments to determine eflornithine‟s MOA. In 
order to be able to detect the molecular target of the drug, levels below the IC50 
(20 µM) were used so that the metabolites changing in direct response to the 
target inhibition could be assayed without the risk of masking with general 
toxicity-related effects. To detect how the cell died from the drug, higher levels 
of drug were also used at 500 µM (14 times the IC50 value).  
Drug was added to the 427 bloodstream form wildtype cell line in growth 
medium so that cells were metabolising as normal apart from the perturbation 
by the drug.  
For the sub-IC50 experiments early time points (0 and one hour) were taken to 
determine the target of eflornithine. Later time points were also taken (24, 48 
and 72 hours) to determine later effects of the inhibition and to detect any off-
target effects.  
For the measurements of metabolites in dying cells more early time points were 
taken (at 0, 0.5, 1, 2 and 5 hours) to determine how quickly this higher dose of 
drug disseminates its effects through the metabolome. Later time points (24 and 100 
 
48 hours) were taken as the cells were dying. Cells generally died at 
approximately 55 hours at this drug dose of 500 µM. 
Cells were quenched in chloroform:methanol:water (1:3:1), run on the Orbitrap 
mass spectrometer and changes in metabolite abundance were analysed using 
our in-house software, mzMatch (Scheltema et al., 2011) and IDEOM (Creek et 
al. in preparation for publication) (see method 2.2 of this thesis). Where there 
was more than one possible isomer for a metabolite mass the most likely 
metabolite (predicted from retention time on the column) is displayed. 
4.2.1.2  Sub IC50 metabolome 
The stringent filtering systems in the mzMatch and IDEOM software reduced the 
number of peaks in the spectra from several hundred thousand to 127 robust 
masses. The flexible parameters in IDEOM were standardised. A relative standard 
deviation allowance of one and an intensity filter of 10, 000 were chosen as 
filters to remove less robust peaks. The minimum number of detections across 
the replicates was set at two out of three replicates. 
The majority of metabolite levels were unaltered over the time points taken 
indicating a high state of robustness within the trypanosome metabolome. Only 
ornithine (M+H: 133.0971, RT: 27.9 minutes) from the polyamine pathway 
metabolites (Table 4-1) was found to be highly increased over the time course 
(Fig 4-4). Putrescine (M+H: 89.1073, RT: 36.91 minutes) was the only metabolite 
to significantly decrease over time. Acetylated versions of ornithine and 
putrescine were also identified and these correlated highly with their non-
acetylated counterparts. N-acetyl ornithine (M+H: 175.1077, RT: 15.3 minutes) 
showed the most striking correlation as shown in figure 4-4. Acetyl-putrescine 
(M+H: 131.1178, RT: 15.5 minutes) was seen in early samples (detected from 
more targeted analyses), but levels rapidly (after the 0 hour time point) fell 
below the level of detection (1, 000) from an average intensity of 41, 000 (peak 
height) before drug addition, correlating with the decrease in putrescine.  101 
 
 
M/Z 
Retention 
Time 
Formula  Isomers  Name 
Ratio compared to 0 hour 
time point 
1  24  48  72 
297.0898  9.5  C11H15N5O3S  2 
Methylthio -
adenosine 
1.64  1.41  1.16  1.46 
174.1117  26.9  C6H14N4O2  1  Arginine  1.02  0.91  1.02  0.98 
130.1106  15.5  C6H14N2O  2  Acetylputrescine  0  0  0  0 
307.0841  14.5  C10H17N3O6S  3  Glutathione  2.20  2.69  1.48  1.00 
132.0899  27.9  C5H12N2O2  3  Ornithine  1.97  5.04  6.31  4.89 
149.0511  13.1  C5H11NO2S  4  Methionine  1.01  0.90  1.02  0.99 
174.1005  15.3  C7H14N2O3  4  Acetylornithine  2.59  6.22  7.53  5.01 
88.09997  36.8  C4H12N2  1  Putrescine  0.81  0.41  0.30  0.23 
398.1376  34.1  C15H23N6O5S  1 
S-Adenosyl-L-
methionine 
1.12  0.87  1.42  1.18 
360.6447  29.8 
C27H47N9O10S
2  1 
Trypanothione 
disulfide 
1.29  1.16  1.24  0.98 
187.1686  35.2  C9H21N3O  2  Acetylspermidine  0.75  0.57  1.20  0.62 
182.0868  23.1  C6H12F2N2O2  1  Eflornithine  3824  3928  4691  5563 
Table 4-1. The metabolite levels of the polyamine pathway after treatment with eflornithine 
(peak height). Glutathionylspermidine, dc-S-adenosylmethionine, methylthioribose 1-
phosphate, methylthioribulose 1-phosphate and methylthio 2-oxobutanoate could not be 
detected. The isomers column states how many metabolites the mass could represent 
predicted from database searches. Spermidine was not identified in this analysis as it eluted 
from the column very late (42 minutes) and as such the whole peak was not detected. „M/Z‟ 
relates to the detected mass charge ratio (peak height) corrected for positive or negative 
ionisation. 
 
Yarlett and Bacchi have previously shown that adenosylmethionine and 
decarboxylated adenosyl methionine levels are greatly increased (48 fold and 
390 fold respectively over 36 hours) after eflornithine treatment (Yarlett and 
Bacchi, 1988). This increases the methylation index nearly 20 fold, causing 
aberrant methylation of proteins within the trypanosomes. Adenosylmethionine 
was not increased in our experiment and decarboxylated adenosylmethionine 
was not detected. The Yarlett experiment treated trypanosomes in rats with 4 % 
eflornithine in drinking water, but didn‟t record how much water the rats drank, 
so it is unknown whether the cells were exposed to a higher drug dose. 
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Figure 4-4. Ornithine, N-acetylornithine, putrescine and N-acetylputrescine levels upon the 
addition of eflornithine to wildtype cells in culture. Intensities (peak heights) are shown 
relative to the 0 hour time point level on the y-axis. A representative of three separate 
experiments is shown. 
 
It is interesting to see a recovery in affected metabolite levels at the 72 hour 
time point (e.g. glutathione, ornithine, acetylornithine and trypanothione 
disulphide (Table 4-1)). The cells appear to be adapting to the non-lethal dose of 
drug, perhaps through increased expression of ODC or reduced transport of 
eflornithine through TbAAT6. Levels of eflornithine stay high at 72 hours (Fig 4-
5), but this may be exogenous eflornithine that is carried over when the cells are 
quenched. The turnover rate of ODC is 18 hours in T. b. gambiense (Iten et al., 
1997). It therefore seems feasible that T. b. brucei are able to upregulate ODC 103 
 
production within a 72 hour time scale. Ornithine decarboxylase protein 
regulation is noted for being complicated and levels are controlled at the level 
of transcription, translation, post translationally and through an inhibitor termed 
antizyme (Xiao et al., 2009). Antizyme binds to the ODC monomer preventing 
homodimerisation of the ODC subunits (Pegg, 2006). The inhibitor is produced by 
a +1 frame shift during ODC translation. The mistranslated enzyme bound to ODC 
is degraded by the 26 S proteosome, but binds an antizyme inhibitor with a 
higher affinity. Transcription of the antizyme inhibitor is stimulated during cell 
growth, freeing antizyme from ODC. Antizyme translation is upregulated by 
polyamines (Pegg, 2006). 
Isomers for each metabolite were identified using the IDEOM database, which 
incorporates information from KEGG, Lipidmaps, HMDB and Metacyc as well as 
metabolites manually added by our laboratory. There are three isomers for 
acetylornithine (Val-Gly, L-prolinylglycine, theanine), two for ornithine 
(diaminopentanoate and N4-acetyl-N4-hydroxy-1-aminopropane) and none for 
putrescine. Acetylputrescine had one isomer (aminocaproamide). Validation of 
the acetylornithine identification was conducted using isotopically labelled 
ornithine and is discussed further in section 5.3.3.5. 
Standards were run for ornithine, putrescine, methylthioadenosine, glutathione, 
S-adenosyl methionine and trypanothione disulphide to verify the identification 
of the masses in our assay by retention time. These standards were run for each 
metabolomics assay conducted and identifications were made when the 
retention times were within 5 % of the standard.  
The increase of ornithine and the decrease of putrescine after treatment of 
trypanosomes with eflornithine are in line with the published literature and 
predicted mode of action (Bacchi et al., 1983;Fairlamb et al., 1987;Xiao et al., 
2009) . Fairlamb et al. and Bacchi et al. also noted increases in S-adenosyl 
methionine, which are not replicated in our assay, and decarboxylated S-
adenosyl methionine, which was also not detected in our assay. The decreases in 
spermidine and trypanothione observed by Fairlamb and Bacchi were also not 
seen in our data. The Phillips group reported decreases in glutathionyl-
spermidine (a metabolite not detectable in our data) and glutathione and an 
increase in decarboxylated S-adenosyl methionine (in direct opposition to the 104 
 
Fairlamb and Bacchi results) (Xiao et al., 2009) there may be differences 
between the in vitro and in vivo data if there is a carry over of some metabolites 
from the rat blood or from the medium. HMI-9 used in our experiments and the 
Phillips experiment contains some blood serum, but at 10 %, carry-over of 
polyamine metabolites from this would be less than with rat blood. HMI-9 is not 
expected to contain any of the polyamine pathway metabolites except for the 
amino acids. The decrease in glutathione observed by Phillips was not seen in 
our data. Xiao et al. used a similar drug concentration (12.5 µM) as our 
experiment (20 µM) and was in the same in vitro medium, so it might have been 
expected that results would have been similar.  
Glutathione would not be expected to be affected by an inhibition of ODC as its 
synthesis occurs in a different branch of the polyamine pathway (Fig 4-1). It 
may, however, be regulated via levels of another metabolite such as  
spermidine, which was decreased in the Phillips assay (Xiao et al., 2009), but not 
in ours. 
The Fairlamb group reported eflornithine serum levels of between 560 and 1,340 
µM (Fairlamb et al., 1987), which is much higher than the levels used in our 
assays so may be expected to exhibit more changes. The Bacchi group reported 
serum levels of 10 - 70 µM, which is in the same order of magnitude as our 
experiments. As these assays were both conducted in vivo however, any 
differences between the profiles may be due to the different growth conditions 
(Fairlamb et al., 1987). 
N-acetylornithine has not been seen in trypanosomes before. Differences in the 
retention times between ornithine (RT = 27.9 minutes) and acetylornithine (RT = 
15.3 minutes) suggest that ornithine has not been acetylated in the ionisation 
process during mass spectrometry as the ionisation occurs after chromatographic 
separation. Also, we have shown in subsequent experiments that ornithine in 
CBSS buffer solution or in medium does not spontaneously convert to 
acetylornithine (see chapter 5, particularly figure 5-13). N-acetylornithine is 
highly correlated with ornithine implying that it is closely linked in the 
metabolic network, which indicates a direct metabolic link between the two 
metabolites. There is a metabolic pathway in some bacteria that is able to 105 
 
convert glutamate to ornithine via acetylornithine. This is discussed further in 
chapter 5. 
Acetylputrescine also appears to be a biologically relevant metabolite as it too 
has a significantly different retention time to putrescine. The metabolite has 
just one isomer, aminocaproamide, not thought to be a naturally occurring 
metabolite in trypanosomes. Acetylputrescine is used in the conversion of 
putrescine to aminobutanoate. There is no specific putrescine acetylase, but 
promiscuous acetyltransferases may be able to acetylate putrescine. There are 
at least 10 putative acetyltransferases annotated in TritrypDB (Tb427.01.4490, 
Tb427.05.2280, Tb427.07.2360, Tb427.07.2530, Tb427.08.3310, 
Tb427tmp.160.2010, Tb427.10.3150, Tb427.10.8310, Tb427.10.12830 and 
Tb427tmp.01.2886). 
Other metabolites that exhibited large fold changes over the 72 hours are shown 
in figure 4-5. 106 
 
 
 
Figure 4-5. Heat map showing that the majority of metabolites are unchanged with the 
addition of low level eflornithine to wildtype cells. Yellow boxes show levels remaining the 
same. Red shows an increase and blue shows a decrease. Metabolites are classified down 
the left hand side. Red arrows highlight metabolites that consistently increase, blue 
highlights those consistently decreased over the time course. 
 
The metabolites highlighted with blue and red arrows indicate those masses with 
small, but consistent increases or decreases respectively. Ectoine is a pyrimidine 
breakdown product and its reduced levels may relate to the reduced levels of 
thymidine and thymine seen. Why this group of metabolites, normally involved 
in DNA synthesis, should be reduced, however, is unclear, but it could be that 
trypanosomes are stopping DNA synthesis as the trypanostatic drug takes effect. 
Urocanate (m/z: 139.0502, RT: 10.9 minutes) results from the loss of ammonia 
from histidine (m/z: 156.0767, RT: 25.0 minutes). As the retention times are not 107 
 
similar, this loss is not thought to be a mass spectrometry artefact and may 
result from an enzymatic conversion through histidine-ammonia lyase. Levels of 
histidine are not significantly altered, but due to the high levels of amino acids 
in the medium (from 78 µM (tryptophan) to 4 mM (glutamine), histidine is at 271 
µM), changes in levels of these metabolites can be masked. Urocanate can be 
used to create more glutamate or oxoglutarate. All but one of the enzymes for 
this pathway are present in T. cruzi (histidine ammonia lyase 
(Tc00.1047053506247.220), urocanate hydratase (Tc00.1047053504047.5) and 
imidazolone propionase (Tc00.1047053509137.30)), but absent in T. brucei. An 
increase in glutamate may be required to keep glutathione levels stable. 
The phosphocholine-containing lipid shows reduced levels over the 72 hours (Fig 
4-5), as do phenolsulfan phthalein (phenol red – a pH indicator in the medium) 
and pyridoxal (vitamin B6). These three changes appear to hold no obvious 
connections either to the polyamine pathway or to one another, so their 
alterations may be explained by biological variation and perhaps, were the 
experiment to be repeated, these changes would not persist. 
Ornithine decarboxylase requires pyridoxal 5‟-phosphate as a cofactor in the 
conversion of ornithine to putrescine (Jackson et al., 2004). Pyridoxal 5‟ 
phosphate can be detected from the standard mix used to calibrate the masses 
from the Orbitrap mass spectrometer around six minutes after pyridoxal elutes. 
This standard mixture contains 1 µM pyridoxal 5‟-phosphate, but the intensity 
detected is relatively low, suggesting that it is either not well ionised or not well 
detected. The pyridoxal seen (m/z: 168.0655, RT: 14.0 minutes) (Fig 4-5) may 
be due to an increased phosphorylation of pyridoxal to provide more pyridoxal 
5‟-phosphate for ornithine decarboxylase. It would be interesting to see how 
levels of pyridoxal kinase (Tb927.6.2740) are affected by incubation with 
eflornithine or to see if kinase inhibitors are synergistic with eflornithine. 
4.2.1.3  The eflornithine toxicity metabolome 
At 500 µM eflornithine, bloodstream form trypanosomes stop dividing over 48 
hours in drug. This is reflected by many more changes to the metabolome 
(Appendix 8.4 and on included compact disc).  108 
 
A targeted analysis of the polyamine pathway metabolites was undertaken using 
the Xcalibur Quan Browser from Thermo Scientific (Fig 4-6). Putrescine and 
spermidine decreased over the 48 hours in drug whereas ornithine and 
acetylornithine were seen to increase. Methythioadenosine increased over the 
first five hours in drug and then remained relatively level. This was not reported 
in previous studies. Trypanothione disulphide stayed level over the first five 
hours before decreasing slightly, but not significantly. The reported decrease in 
S-adenosylmethionine seen by Bacchi et al., (1983) and Fairlamb et al. (1987) 
and or the increase as seen by Xiao et al. (2009) was not observed, with levels 
staying relatively stable. In the sub IC50 experiment only ornithine, putrescine 
and their acetylated counterparts were altered. Higher doses therefore show a 
greater cascade effect through the metabolome after ODC inhibition. 
 
Figure 4-6. Polyamine metabolite changes in 500 µM eflornithine. X-axes indicate the time in 
hours since drug addition. Y-axes indicate the relative intensity (area under the curve) of 
each metabolite. ND: not detected. Methionine (M+H: 150.0581, RT: 11.9 minutes), S-
adenosylmethionine (M+H: 399.1444, RT: 22.7 minutes), methylthioadenosine (M+H: 
298.0968, RT: 7.82 minutes), arginine (M+H: 175.1190, RT: 25.3 minutes), ornithine (M+H: 
133.0971, RT: 21.9 minutes), acetylornithine (M+H: 175.1077, RT: 17.12 minutes), putrescine 
(M+H: 89.1072, RT: 23.9 minutes), spermidine (M+H: 146.1652, RT: 41.8 minutes), glutathione 
(M+H: 308.0910, RT: 15.3 minutes) and trypanothione disulphide (M+H: 722.2960, RT: 22.7 
minutes). * indicates a p-value less than 0.05 in a Student‟s paired t-test to the 0 time point, 
** indicates a p-value less than 0.001. N = 3. 109 
 
 
It was hypothesised that the first few hours in drug would show eflornithine-
specific effects and the last two time points (24 and 48 hours) would show 
changes related to cell death, unspecific to eflornithine. 
Five hundred and seventy masses were putatively identified using the mzMatch 
and IDEOM softwares. This is much more than the number detected in the sub 
IC50 experiments as the samples were all run at the same time in this 
experiment, whereas in the previous experiment they were not, producing 
differences in machine efficiency. Table 4-2 shows all of the metabolites that 
change significantly over three replicate experiments for the first five hours 
(from paired t-tests comparing 0 and five hours, p<0.05).  
S-adenosylmethionine decarboxylase is thought to be stimulated by putrescine in 
humans and T. cruzi (Clyne et al., 2002) and weakly stimulated in T. brucei 
(Bitonti et al., 1986) meaning the decrease in putrescine caused by the blockage 
of ornithine decarboxylase activity would be expected to cause an increase in S-
adenosylmethionine and a decrease in decarboxylated-S-adenosylmethionine. As 
decarboxylated S-adenosylmethionine was not observed and S-
adenosylmethionine levels were not significantly altered, conclusions on this 
theory could not be drawn. 110 
 
 
M/Z  RT  Formula  Isomers  Name 
Fold 
Change 
p-
value 
416.2325  7.6  C21H37O6P  1 
1-octadecanoyl-sn-glycero-2,3-
cyclic phosphate 
3.20  0.011 
222.0674  21.2  C7H14N2O4S  4  Cystathionine  2.75  0.011 
297.0896  7.8  C11H15N5O3S  2  Methylthioadenosine  2.23  0.013 
130.1107  13.3  C6H14N2O  2  Acetylputrescine  0.37  0.017 
568.2426  19.7  C23H36N8O7S  1  Arg-Cys-Gln-Tyr  4.31  0.017 
801.5525  7.8  C43H80NO10P  1  Phospho glycerol (17:0/20:4)  1.25  0.027 
114.0793  13.9  C5H10N2O  2  proline amide  1.61  0.029 
402.0227  19.7  C10H16N2O11P2  1  dTDP  1.30  0.030 
163.0666  8.6  C6H13NO2S  6  Methylmethionine  1.66  0.030 
182.0867  19.7  C6H12F2N2O2  1  Eflornithine  1.98  0.034 
101.0476  22.7  C4H7NO2  5  Azetidine 2-carboxylic acid  2.11  0.035 
133.0739  11.6  C5H11NO3  4  Hydroxyvaline  2.54  0.036 
174.1004  16.2  C7H14N2O3  5  Acetylornithine  3.03  0.036 
96.0209  15.5  C5H4O2  3  Furfural  1.47  0.038 
202.1317  8.3  C9H18N2O3  3  Leu-Ala  1.40  0.042 
 
Table 4-2. Metabolites changing significantly over the first five hours in 500 µM eflornithine. 
Peptides are shaded blue and lipids yellow. „M/Z‟ relates to the detected mass charge ratio 
(peak height) corrected for positive or negative ionisation. Fold change relates to the ratio 
of the five hour sample intensity compared to 0 hour intensity. P-values were calculated 
using a Student‟s t-test. 
 
The important thiols within the trypanosome are thought to include 
trypanothione, cysteine, methionine, glutathionylspermidine, 
methylthioadenosine and ovothiol A (Steenkamp, 2002) (Fig 4-7). The precise 
role of ovothiol A as an antioxidant is not well understood, but is thought to be 
absent in bloodstream form trypanosomes (Ariyanayagam and Fairlamb, 2001). 111 
 
 
Figure 4-7. Thiols in T. brucei. Thiols are in shaded boxes. From KEGG and Vogt et al. 
(2001). 
 
There is a general increase in thiols (cystathionine, methylthioadenosine and 
methyl-methionine) seen over the first five hours in toxic doses of eflornithine 
(ovothiol A could not be measured as several peaks with the same mass were 
seen and the one corresponding to ovothiol A could not be determined). This 
may be due to an attempt by the cells to combat the oxidative stress caused by 
a reduction in trypanothione and spermidine levels. Cystathionine is a 
stereoisomer of a threonine-cysteine dipeptide, but the retention time matches 
that of the cystathionine standard (0.1 % error) so the identification of 
cystathionine can be made with a high degree of confidence. Levels of cysteine 
decrease (although not significantly) over the five hours suggesting that cysteine 
may combine with ketobutyrate to form cystathionine, which may, in turn, be 
used to produce homocysteine and methionine. The enzymes in this pathway, 
cystathione gamma lyase (Tb427tmp.211.3330) and homocysteine S-
methyltransferase (Tb927.1.1270), are present in T. b. brucei. Methionine levels 
do not increase, however, this may be due to high levels in the medium (200 µM) 
masking any changes within the cells. Homocysteine levels fall below the 
minimum peak intensity so cannot be analysed. S-adenosyl methionine and 112 
 
methylthioadenosine were increased also, increasing the general thiol pool to 
counter any increased oxidative stress. 
Ornithine, putrescine and spermidine were not picked out in this automatic 
processing either because the peak picking software (XCMS) missed a peak or 
because the relative standard deviation was higher than the filter allowed. 
These metabolites were therefore analysed manually (Fig 4-6). 
The increases in hydroxyvaline, proline amide and the peptide levels may be 
indications of protein break down as cells die. 
The lipids, shaded in yellow in table 4-2, both increase with eflornithine 
addition. Trypanosomes are able to synthesise all major phospholipids 
(Serricchio and Butikofer, 2011), unlike most other eukaryotes. Trypanosomes do 
also take up a lot of lipids from the host serum (Voorheis, 1980;Bowes et al., 
1993) and it is unclear whether the increase in these lipids is due to enhanced 
synthesis, uptake or indeed from the breakdown of trypanosome membranes. 
Furfural is a sugar fragment and shares a retention time with glucose suggesting 
it is an ionisation artefact of glucose. Azetidine 2- carboxylic acid is also likely to 
be a fragment as it has no reported biological role except as a proline analogue 
in plants. It shares a retention time with adenosylmethionine and also shows the 
same pattern of perturbation (fold changes for one hour, two hours, five hours, 
24 hours and 48 hours of 1.35, 2.11, 1.31 and 3.53 compared to 1.87, 2.99, 1.46 
and 5.07 for adenosylmethionine) over the 48 hour assay, indicating that it is a 
fragment of adenosylmethionine. 
Thymidine diphosphate is significantly altered after five hours in eflornithine, 
but doesn‟t show a large change in levels (just a 30 % increase). Thymine and 
thymidine were seen to show an opposite trend in sub IC50 levels of eflornithine, 
but were not seen to be altered at this drug level.  
There were many more metabolites changing over the 48 hours. There were 45 
significantly changing metabolites (t-test on 0 and 48 hour time point, 
significance taken as p<0.05) (Table 4-3). 113 
 
M/Z  RT  Formula 
Isomer
s  name 
Fold 
change 
p-
value 
324.1055  14.8  C12H20O10  4  Fructose 1,2':2,3'-dianhydride  0.36  0.000 
130.1107  13.3  C6H14N2O  2  Acetylputrescine  0.21  0.001 
146.0691  17.5  C5H10N2O3  6  Glutamine  0.64  0.003 
155.0347  19.9  C3H10NO4P  3  Aminopropan-2-ol O-phosphate  0.31  0.005 
482.1712  17.5  C18H26N8O6S  1  Cys-Ser-His-His  0.32  0.005 
309.1687  10.9  C15H23N3O4  2  Pro-Pro-Pro  0.44  0.006 
176.0681  7.5  C7H12O5  7  Propylmalate  9.67  0.007 
147.0529  9.0  C5H9NO4  14  hydroxyisopropyloxamate  0.40  0.009 
117.0790  15.9  C5H11NO2  16  Betaine  0.22  0.010 
250.0904  15.8  C18H28N8O7S  1  Asn-Cys-Gln-His  0.17  0.012 
129.0902  21.1  C5H11N3O  3  piperazine-2-carboxamide  0.42  0.012 
89.0476  15.6  C3H7NO2  9  beta-Alanine  0.53  0.013 
157.0349  15.7  C10H20O7P2  6  [PR] Geranyl pyrophosphte  0.46  0.014 
466.1002  15.7  C17H19N6O8P  1  Adenylanthranilate  0.33  0.014 
174.1117  21.1  C6H14N4O2  2  Arginine  0.42  0.014 
165.0790  10.1  C9H11NO2  7  Phenylalanine  0.35  0.016 
133.0198  14.3  C4H7NO2S  1  Thiazolidine-4-carboxylate  0.23  0.016 
358.0840  17.5  C14H18N2O7S  1  Miraxanthin-I  0.62  0.016 
100.0160  7.1  C4H4O3  1  2-oxobut-3-enanoate  0.65  0.018 
347.0630  20.3  C10H14N5O7P  7  3'-AMP  0.35  0.018 
174.1003  11.0  C7H14N2O3  5  Ethylglutamine  0.46  0.018 
257.1029  20.7  C8H20NO6P  1  sn-glycero-3-Phosphocholine  0.31  0.022 
405.1381  16.1  C15H23N3O10  1  Glu-Glu-Glu  0.35  0.024 
147.0354  12.1  C5H9NO2S  1  Thiomorpholine 3-carboxylate  0.24  0.024 
150.0526  15.4  C5H10O5  37  Xylulose  0.63  0.024 
132.0535  17.9  C4H8N2O3  6  Asparagine  0.28  0.025 
180.0632  15.5  C6H12O6  57  Glucose  0.61  0.025 
259.0455  23.3  C6H14NO8P  8  Glucosamine 6-phosphate  0.25  0.026 
131.0583  16.5  C5H9NO3  14  Glutamate 5-semialdehyde  0.40  0.028 
250.0702  8.1  C20H28N4O7S2  1  Glu-Phe-Cys-Cys  0.25  0.028 
805.5621  7.6  C46H80NO8P  28  Phosphocholine (16:0/22:6)  0.50  0.030 
147.0531  15.9  C5H9NO4  14  Glutamate  0.40  0.031 
260.1371  10.5  C11H20N2O5  4  Glu-Leu  0.59  0.033 
154.0376  12.0  C6H6N2O3  2  Imidazol-5-yl-pyruvate  0.39  0.034 
268.9702  16.1  C12H17BrN2O13P2  1  uridine-5'-diphosphate 
bromoacetol 
0.16  0.035 
565.4470  10.0  C30H64NO6P  4  Phosphocholine (10:2/12:2)  2.43  0.037 
793.5615  7.7  C45H80NO8P  28  Phosphocholine (15:0/22:5)  0.44  0.037 
136.0370  13.6  C4H8O5  3  Fatty acid trihydroxy (4:0)  0.32  0.037 
244.0693  12.0  C9H12N2O6  2  Pseudouridine  0.37  0.037 
246.1215  11.9  C10H18N2O5  6  Glu-Val  0.62  0.039 
137.0477  5.9  C7H7NO2  13  Anthranilate  2.61  0.039 
285.3032  6.1  C18H39NO  1  deoxy-sphinganine  2.94  0.041 
96.0209  15.5  C5H4O2  3  Furfural  0.57  0.043 
324.0356  23.2  C9H13N2O9P  4  Pseudouridine 5'-phosphate  0.16  0.043 
755.5471  7.7  C42H78NO8P  17  Phosphocholine (16:0/18:3)  0.38  0.045 
Table 4-3. Metabolites significantly changed after 48 hours in 500 µM eflornithine. 
Significance was calculated in IDEOM using the Student‟s paired t-test. Peptides are shaded 114 
 
blue and lipids yellow. „M/Z‟ relates to the detected mass charge ratio (peak height) 
corrected for positive or negative ionisation. Fold change relates to the ratio of the 48 hour 
sample intensity compared to 0 hour intensity. 
 
The fact that the majority of metabolites decrease at the 48 hour time point 
suggests that the cell membrane has been compromised. The cells were 
observed under the light microscope and appeared more convoluted than 
healthy cells, but were clearly still alive and moving. Bacchi et al. reported 
double nuclei and two undulating membranes in eflornithine treated cells 
(Bacchi et al., 1983). The cells were fixed and Giemsa stained (Fig 4-8), but no 
differences in the cell architecture were obvious. The processing of the cells 
involves cooling them to 0 ºC in a dry ice–ethanol bath and two centrifugation 
steps (See methods section 2.2.1 of this thesis). These weakened cells are 
therefore potentially more leaky than cells that have not been compromised for 
so long in the drug. This is evident in the large amount of blue colouration at 48 
hours in the heat map (Fig 4-9), relating to a decrease in the majority of 
metabolites. 
Figure 4-8. Cells at 48 hours with (+) and without (-) 500 µM eflornithine treatment. 100 x 
magnification under oil immersion. 
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Figure 4-9. Heat map of cells in 500 µM eflornithine. Blue represents a decrease in 
metabolite intensity, red an increase and yellow represents unchanged levels. Metabolites 
are classified down the left hand side. Red arrows highlight metabolites that consistently 
increase, blue highlights those consistently decreased over the time course. 
 
There are only two metabolites that significantly increase at the 48 hour time 
point. Propylmalate (the only isomers in our database, methylhydroxyglutarate 
and validone, have RT errors of 7.6 % and 47.7 % respectively, compared to 1.4 % 
for propylmalate) (Fig 4-10). Increases steadily over the 48 hours in eflornithine 
and anthranilate stays relatively stable and then increases at the 48 hour time 
point (Fig 4-11). An unsaturated phosphocholine and deoxy-sphinganine also 
increase, whereas saturated phosphocholines decrease. The unsaturation of 
lipids means that hydrogen atoms are being lost from the carbon chains. This 
may be due to attack by reactive oxygen species, which would remove a 
hydrogen atom from the chain. The increase in deoxysphinganine may be a 
reflection of the degradation of sphingophospholipds, key structural components 116 
 
of the membrane (Serricchio and Butikofer, 2011).  Free lipids generally 
decrease after 24 hours. This may indicate that the trypanosomes are using 
these free lipids in an attempt to maintain their cell membranes. 
 
Figure 4-10. Propylmalate levels increase in eflornithine. Error bars shown standard error of 
the mean from three replicates.  
 
Propylmalate has a retention time of 7.5 minutes, similar to the retention times 
of many of the phosphocholines, which are decreasing over the 48 hours. 
Propylmalate could therefore be a breakdown product of these lipids. 
 
Figure 4-11. Anthranilate levels increase after 48 hours in eflornithine. Error bars show 
standard error of the mean from three replicates. 117 
 
 
Anthranilate is a precursor to tryptophan biosynthesis (or a breakdown product 
in its degradation) and can be degraded in the tricarboxylic acid cycle in many 
organisms (Choi et al., 2011). It has many stereoisomers, but anthranilate is the 
most likely based on the retention time and genes present in T. brucei. 
Anthanilate is interestingly also thought to be a precursor in quinolone (a 
kynurenine) quorum signalling in Pseudomonas aeroginosa. Kynurenines have 
also been shown to modulate the host immune response, reducing inflammatory 
responses (De Ravin et al., 2010), although some kynurenines (but not 
anthranilate) were shown to be antimicrobial (Narui et al., 2009). The decrease 
in adenylanthranilate concurrent with the increase in anthanilate suggests that 
anthranilate is being released from the base, perhaps in order to form more ATP 
for energy. Why anthranilate should be conjugated to adenine is unclear. 
Kynurenines can also be converted to nicotinamide through conjugation to a 
ribonucleotide. It is possible therefore that adenylanthranilate may be related to 
nicotinamide synthesis. Nicotinamidase has been annotated in the T. vivax 
(TvY486_0901400) and T. b. gambiense (Tbg972.9.2100) genomes, but its 
syntenic partner (Tb427tmp.160.2600) is not annotated in the T. b. brucei 
genome (despite 100 % similarity at the amino acid level to the T. b. gambiense 
gene). Nicotinamide (m/z: 123.0553, RT: 7.9 minutes) and ribosylnicotinamide 
(m/z: 255.0973, RT: 14.0 minutes) are detected in the data set, but are not 
significantly altered until the decrease, with the majority of metabolites, at 48 
hours. 
An adenine-anthranilate conjugate has not been reported previously in the 
literature. More analysis of the role of anthranilate in eflornithine-treated cells 
would be useful, perhaps with the use of isotopically labelled tryptophan. 
Interestingly, eflornithine levels in the cells did not increase significantly over 
the 48 hours although this is probably due to high levels of residual eflornithine 
from the medium masking any uptake.  
Some metabolites were seen to increase, but not significantly due to the large 
levels of variation see in the biological data. Sedoheptulose (m/z: 210.0738, RT: 
14.9 minutes), sedoheptulose phosphate (m/z: 290.0400, RT: 25.4 minutes) and 118 
 
the water loss in-source fragment of sedoheptulose phosphate (m/z: 272.0296, 
RT: 25.4 minutes) showed the same trend (Fig 4-12).  
 
Figure 4-12. Sedoheptulose (top graph), sedoheptulose phosphate (middle graph) and the 
fragment of sedoheptulose phosphate increase with 500 µM eflornithine. X-axes show time 
in hours, Y-axes relative intensity (peak height). Error bars show standard error of the mean 
from three replicates. 119 
 
Sedoheptulose phosphate is a seven carbon sugar of the pentose phosphate 
pathway formed, along with glyceraldehyde 3-phosphate, from ribose-5-
phosphate and xylulose-5-phosphate through transketolase (Tb927.8.6170) 
action. Transketolase has, however, been shown not to have activity in 
bloodstream-form trypanosomes (Stoffel et al., 2011).That being said, 
sedoheptulose 7-phosphate was evident in procyclic trypanosomes knocked out 
for transketolase, albeit at reduced levels, indicating an alternative source of 
the metabolite in these cells. Xyulose and ribose 5-phosphate levels are not 
altered over the time course to 48 hours, further suggesting an alternative 
source of sedoheptulose phosphate. The increase in sedoheptulose may also be 
indicative of stumpy formation if this is the mode of killing by eflornithine as 
was suggested by Alan Bitonti (Bitonti et al., (1986). 
 Sedoheptulose phosphate can also be formed through transaldolase 
(Tb927.8.5600) from erythrose 4-phosphate and fructose 6-phosphate but it is 
unclear why the trypanosomes would do this in response to eflornithine 
exposure. Moreover, this reaction requires a supply of erythrose 4-phosphate, 
usually produced by the absent transketolase. Trypanosomes might, therefore, 
have another, as yet unidentified, source of erythrose 4-phosphate (erythrose 4-
phosphate is not detected in this dataset, but erythrose (m/z: 119.0349, RT: 9.4 
minutes) is (Appendix 8-4)). Of note also is that aldolase can fuse sugar 
phosphates to yield longer chain bisphosphates that could then be cleaved with a 
bisphosphatase. For example, erythrose 4-phosphate and dihydroxyacetone 
phosphate would yield sedoheptulose 1,7-bisphosphate that could then yield 
sedoheptulose 7-phosphate by sedoheptulose 1,7-bisphosphatase 
(Tb427.02.5800) (Clasquin et al., 2011). 
To ensure that the metabolites seen as altered from eflornithine treatment are 
specific to eflornithine or if they are implicated in a more generalised drug 
response. Another trypanocide, nifurtimox, was also analysed by metabolomics. 120 
 
4.2.2 Nifurtimox and eflornithine synergy 
The IC50 of nifurtimox was found to be 4 µM in bloodstream form T. b. brucei by 
alamar blue assay (Fig 4-13). Nifurtimox given orally (15 mg/kg) gives a 
maximum serum concentration of 2.6 µM (Gonzalez-Martin et al., 1992) and it 
appears to be concentrated in the CSF of mice from 6 µM in perfused serum to 
12 µM in the CSF (Jeganathan et al., 2011) indicating that nifurtimox would be 
more useful for stage two HAT where parasites have invaded the brain. 
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Figure 4-13. The IC50 value of nifurtimox in bloodstream form T. b. brucei is 4 µM. N = 4, 
error bars depict standard error of the mean. 
 
As eflornithine use in the field is increasingly being superceded by a nifurtimox-
eflornithine combination therapy, we wanted to see how the two drugs interact 
in trypanosomes.  
Alamar blue assays were used to ascertain whether the two drugs were 
synergistic in vitro. 
Interestingly, isobologram analyses (Fig 4-14) revealed that nifurtimox and 
eflornithine are not synergistic to one another‟s activity in vitro.  121 
 
 
 
Figure 4-14.  Isobologram analysis shows that nifurtimox and eflornithine (DFMO) are 
antagonistic in vitro (top graph). DB75 (bottom left) was additive, but NA42 (bottom middle) 
and NA134 (bottom right) were midly antagonistic. Y-axes show the nifurtimox 
concentration in µM. X-axes show the combination drug used in µM (DB75) or nM (NA42 and 
NA134). Black points show the IC50 of the drugs in isolation. White points show the drug 
combination IC50s. N = at least 3. 
 
The average fractional inhibitory concentration (FIC) is used as a measure of 
interaction between two drugs and is a sum of the IC50 of the drug acting in 
combination divided by the IC50 of the drug acting alone. An FIC of 1.5 was 
recorded for eflornithine and nifurtimox (n = 3), where a value ≥1.4 is taken as 
antagonistic (Snyder et al., 2007). This was interesting given the theory that 
eflornithine would deplete cellular trypanothione thus rendering the cells more 
susceptible to oxidative stress induced by nifurtimox. The fact that eflornithine 
is trypanostatic, rather than trypanocidal may explain why the two drugs are 122 
 
antagonistic in vitro i.e. if nifurtimox requires dividing cells to exert its effects 
then eflornithine combination would be counteractive. It would be interesting to 
measure nitroreductase activity in eflornithine-treated cells to ascertain 
whether it is down-regulated or not. Isobologram analyses with other 
trypanostatic drugs (adenosine analogues NA42 and NA134 (Rodenko et al., 
2007)) found antagonism with the adenosine analogue NA42 (FIC: 1.4) and with 
NA134 (FIC: 1.6), but not with DB75 (FIC: 1.1) suggesting that the antagonism 
may be due to the static nature of eflornithine‟s mode of action, although other 
factors may also be involved. 
4.2.3 Nifurtimox mode of action 
To ascertain the nifurtimox concentrations suitable for a sub IC50 and a 
nifurtimox to death study, growth curves were conducted in various 
concentrations of nifurtimox (Fig 4-15). 
 
Figure 4-15. Growth curves of wildtype T. b. brucei in nifurtimox. Cells in 6 µM nifurtimox fail 
to survive after 55 hours. Cells cultured in 60 µM nifurtimox start to die at 5 hours (data not 
shown). 
 
A level of 1.5 µM was chosen for the sub IC50 metabolome measurements as this 
was shown to be non lethal over 48 hours. 60 µM was used for toxicity 
experiments, but as the cells died at between 5 and 8 hours time points of 0, 1, 123 
 
2 and five hours were taken. All metabolomics experiments were performed at 
least in triplicate. 
4.2.3.1  Sub IC50 metabolome 
After data reduction through the mzMatch and IDEOM softwares, 594 
reproducible metabolites were identified. Polyamine pathway metabolites were 
largely unchanged in cells challenged with 1.5 µM nifurtimox (Fig 4-16). This 
data adds support to the specific changes seen with DFMO treatment. Thiol 
levels within the cells also remained largely unchanged (Table 4-4), although 
some fluctuations were seen. Ovothiol (unconfirmed identification, due to an 
absence of an ovothiol standard) levels increased the most, but the increase was 
not statistically significant (p-value 0.079 from t-test). 124 
 
 
 
Figure 4-16. Polyamine metabolite changes in 1.5 µM nifurtimox. X-axes indicate the time in 
hours since drug addition. Y-axes indicate the relative intensity (area under the curve) of 
each metabolite. ND: not detected. Methionine (M+H: 150.0581, RT: 12.4 minutes), S-
adenosylmethionine (M+H: 399.1444, RT: 26.7 minutes), methylthioadenosine (M+H: 
298.0968, RT: 9.1 minutes), arginine (M+H: 175.1190, RT: 23.8 minutes), ornithine (M+H: 
133.0971, RT: 24.0 minutes), acetylornithine (M+H: 175.1077, RT: 15.1 minutes), putrescine 
(M+H: 89.1072, RT: 29.6 minutes), spermidine (M+H: 146.1652, RT: 41.9 minutes), glutathione 
(M+H: 308.0910, RT: 19.6 minutes) and trypanothione disulphide (M+H: 722.2960, RT: 24.7 
minutes).  * indicates a p-value less than 0.05 in a Student‟s paired t-test to the 0 time point, 
** indicates a p-value less than 0.001. N = 3. 
 
Thiol  Time point 
0  1  24  48 
Methylthiobutanoate  1.00  0.81  0.60  0.86 
Methylthioribose1phosphate  1.00  1.58  1.25  1.38 
Homocysteinethiolactone  1.00  0.84  1.39  0.72 
Cysteine  1.00  0.54  1.28  0.99 
Ovothiol A  1.00  2.40  1.77  1.13 
Table 4-4. Thiol levels in nifurtimox treated cells. Numbers show ratios (area under curve) 
compared to time 0. Methylthiobutanoate (M+H: 147.0122, RT: 6.0 minutes), 
methylthioribulose 1-phosphate (M+H: 259.0048, RT: 9.7 minutes), homocysteinethiolactone 
(M+H: 118.0320, RT: 13.25 minutes), cysteine (M+H: 122.0270, RT: 14.5 minutes) and ovothiol 
A (M+H: 202.0642, RT: 20.33 minutes). N = 3. 
 125 
 
Metabolites found to be significantly altered (p<0.05 comparing 0 and 48 hour 
time points) in the T. b. brucei metabolome after challenge with nifurtimox are 
listed in Table 4-5. 
M/Z  RT  Formula  Isomers  Name 
Fold 
change 
P-
value 
78.0139  8.4  C2H6OS  3  Mercaptoethanol  470  0.005 
243.1219  15.5  C10H17N3O4  2  Ala-Gly-Pro  0.48  0.006 
219.0855  19.7  C7H13N3O5  3  Gly-Gly-Ser  0.69  0.006 
168.0899  7.5  C8H12N2O2  3  Cyclo(deltaAla-L-Val)  0.74  0.007 
309.1323  15.3  C14H19N3O5  3  Ala-Gly-Tyr  0.81  0.007 
243.1218  15.2  C10H17N3O4  2  Gln-Pro  0.38  0.008 
446.2373  9.2  C19H34N4O8  8  Asp-Leu-Leu-Ser  0.65  0.009 
222.0564  5.5  C8H14O5S  1  Methylthio propylmalate  0.64  0.013 
204.1110  15.2  C8H16N2O4  5  Val-Ser   0.57  0.020 
289.1638  12.9  C12H23N3O5  5  Leu-Ala-Ser  0.72  0.022 
281.2718  5.5  C18H35NO  1  Fatty acid (18:1)  1.35  0.023 
523.1906  13.5  C22H29N5O10  2  Asp-Phe-Asp-Gln  0.62  0.024 
358.1850  17.0  C15H26N4O6  3  Ala-Thr-Ala-Pro  0.75  0.031 
129.5949  24.2  C12H25N3O3  2  Leu-Lys  0.79  0.033 
254.1379  24.0  C11H18N4O3  2  Val-His  0.66  0.033 
310.1165  14.4  C14H18N2O6  2  Glu-Tyr  0.81  0.033 
181.0740  13.2  C9H11NO3  5  Threo phenylserine  0.83  0.033 
252.0857  16.7  C10H12N4O4  2  Ribosylpurine  1.47  0.037 
188.1526  24.7  C9H20N2O2  2  N6,N6,N6-Trimethyl lysine  0.77  0.038 
197.0798  15.1  C8H11N3O3  3  acetylhistidine  0.59  0.040 
276.0959  16.3  C10H16N2O7  2  Glu-Glu  2.04  0.041 
331.2106  10.9  C15H29N3O5  5  Leu-Leu-Ser  0.79  0.041 
174.1118  23.8  C6H14N4O2  1  Arginine  0.84  0.042 
231.1217  15.3  C9H17N3O4  3  Val-Asn  0.51  0.043 
229.1061  16.7  C9H15N3O4  2  Asn-Pro  2.05  0.044 
131.0946  11.6  C6H13NO2  9  Leucine  0.88  0.045 
Table 4-5. Metabolites significantly altered after treatment with sub IC50 levels of nifurtimox. 
Peptides are shaded blue and lipids yellow. „M/Z‟ relates to the detected mass charge ratio 
(peak height) corrected for positive or negative ionisation. Fold change relates to the ratio 
of the 48 hour sample intensity compared to 0 hour intensity. P-values were calculated 
using a Student‟s t-test. 
 
The metabolite with the smallest p-value was labelled as mercaptoethanol, but 
as mercaptoethanol is a stereoisomer of DMSO (dimethyl sulfoxide) and DMSO is 
used to dissolve the nifurtimox then the more likely metabolite is DMSO (even 
though the RT error for DMSO is 27.3 % from the calculated RT while for 
mercaptoethanol the RT error is 6.4 %). 126 
 
Propylmalate was seen to increase in eflornithine toxicity studies, but 
methylthio propylmalate, a thiol derivative of propylmalate, is seen to decrease 
upon nifurtimox challenge. Methylthio propylmalate is not thought to be 
involved in any naturally occurring pathways (from KEGG). Propylmalate in the 
eflornithine study appeared to be a lipid fragment, methylthio propylmalate 
could equally be a lipid fragment (it elutes at the same time as a group of fatty 
acids and sphingolipids), although the thiol is not present in any of these lipids.  
Ribosylpurine (32.4 % error form calculated RT (the deoxyinosine isomer has a RT 
error of 45.6 %)) was seen to increase 47 % after 48 hours in 1.5 µM nifurtimox. 
When the whole time course is taken into consideration however, the relatively 
minor increase is not very convincing (Fig 4-17). 
 
Figure 4-17. Ribosylpurine increases slightly after treatment with sub IC50 levels of 
nifurtimox. Error bars show standard error of the mean over three biological replicates. 
 
All the peptides, amino acids and amino acid derivatives that had significant 
changes were decreased after 48 hours in nifurtimox except for the asparagine-
proline and glutamate-glutamate dipeptides. The Asp-Pro peak is, however, in a 
very noisy region and it is likely that the processing software removed the peak 
for the 0 hour time points due to the large amount of noise. This dipeptide is 
therefore not significantly altered over the time course. The glutamate 
dipeptide only doubled after 48 hours after having fluctuated at the one and 24 127 
 
hour time points. The inconsistent increases in this metabolite‟s levels are 
probably just due to biological variation. 
The decreases in peptides may indicate a reduced uptake of peptides from the 
medium or a reduction in the breakdown of proteins, indicating that the cells 
are entering a more senescent state. However, the heat map (Fig 4-18) of 
metabolite levels shows a clear correlation between the one and 48 hour time 
points. In this assay, the one and 48 hour time points were extracted together as 
were the 0 and 24 hour time points. This trend indicates the paramount 
importance of extracting all metabolite samples on the same day at the same 
time and under the same conditions. 
Overall, not many metabolites were altered after nifurtimox challenge as shown 
in the heat map although a lot of the map is blue, depicting a decrease. This 
may mean that the 0 hour samples have a greater concentration of metabolites 
in them due to experimental error.  128 
 
 
 
Figure 4-18. Heat map of metabolites altered after nifurtimox challenge at sub IC50. Blue 
represents a decrease in metabolite intensity, red an increase and yellow represents 
unchanged levels. Metabolites are classified down the left hand side. The red arrows 
highlight metabolites that consistently increase, blue highlights those consistently 
decreased over the time course. 
 
Arginine phosphate levels have previously been shown to increase  in T. cruzi 
treated with 10 µM nifurtimox (Miranda et al. 2006), but in these samples the 
relative intensity remains stable (data not shown). 
Analysis of nifurtimox levels in the cells showed that the drug levels decrease 
between 24 and 48 hours (Fig 4-19).  129 
 
 
Figure 4-19. Nifurtimox levels in cells treated for 48 hours. Nifurtimox (M+H 288.0648, RT: 
5.5 minutes) decreases between the 24 and the 48 hour time points. N = 3. Error bars show 
standard error of the mean.  
 
Shane Wilkinson at the Queen Mary University of London showed that nifurtimox 
is reduced by type I nitroreductases to form a reactive open chain nitrile (Hall et 
al., 2011). This decrease in the nifurtimox levels may therefore be due to 
nifurtimox‟s metabolism to this open chain nitrile. A targeted search for the 
nitrile metabolite revealed no peaks for the mass in positive mode (M+H: 
256.0750), negative mode (M-H: 254.0606), positive mode with a sodium adduct 
(M+NaH: 278.0575) or negative mode with a sodium adduct (M-H+Na: 276.0431). 
Wilkinson‟s group postulated that the open chain nitrile may act as a Michael 
acceptor, attacking any carbon next to a ketone as a way of binding to 
macromolecules such as DNA and proteins. As the nitrile would be expected to 
be extremely reactive, it is unlikely that we would see it as a free metabolite 
and we therefore searched the data for any metabolite mass with an additional 
256.0750 atomic mass units (the nitrile adduct).  
The nitrile could not be detected as an adduct attached to any metabolites in 
our dataset. The mass spectrometry platform used scans for metabolites in a 
mass range of 70 - 1, 400 atomic mass units. The vast majority of 
macromolecules are outwith this range and therefore would not be detected. A 
proteomics assay on treated cells may reveal the metabolite attached to 130 
 
proteins and larger peptides. A large number of peptides are detected in our 
datasets, however, none of these were discovered with a mass corresponding to 
their conjugation to the nitrile adduct. It is likely that the levels of the nitrile 
within the cells would be very low and this may be why no peaks could be 
detected. A higher dose of nifurtimox may reveal the presence of the nitrile.  
4.2.3.2  Nifurtimox toxicity 
A higher dose of eflornithine at 60 µM was used for toxicity experiments with 
samples collected after 0, 1, 2 and 5 hours in drug. After data reduction through 
the mzMatch and IDEOM softwares, 670 reproducible metabolites were identified 
(see included CD). Thirty metabolites showed a significant difference between 
the 0 and the 5 hour time point (Table 4-6). 
Over a third of the metabolites with significantly altered intensities were lipids, 
although the changes were not consistently up or down. The phosphocholines 
were all decreased over the time course, however, which may indicate that the 
cells are using these to increase synthesis of the other lipids. 
Purines (deoxyadenosine, AMP and GMP) are all increased whereas sugars and 
sugar phosphates (glucose 6-phosphate (two peaks probably representing 
different isomers as the retention times are different), succinate and 
deoxyribose (two peaks probably representing different isomers)) are decreased. 
The increase in purines and in uracil may be a result of RNA and DNA 
degradation as the nifurtimox active metabolite is thought to bind to 
macromolecules (Hall et al., 2011) and nucleic acid breakdown might be 
stimulated on modified DNA. Most of the peptides seen also increase, which may 
mean that nifurtimox also binds to proteins causing degradation. A targeted look 
for the nifurtimox metabolite (M+H: 258.0906) attached to macromolecules 
produced no hits with peptides, purines and pyrimidines. Since the Orbitrap only 
records masses up to 1,400, however, larger molecules with nifurtimox attached 
would not be detected. 
Formyldihydrofolate is likely to result from the spontaneous oxidation of 
formylfolate. Formyl tetrahydrofolate has been shown to be important in 131 
 
regulating purine levels in leishmania (Vickers et al., 2009). However, the 
identity of this metabolite is not certain and the IDEOM software highlighted this 
mass as possibly relating to the phosphocholines, as a fragment.  
M/Z  RT  Formula  Isomers  Name 
Fold 
change 
P-
value 
434.2432  4.8  C21H39O7P  3  Lipophosphatidic acid (0:0/18:2)  1.36  0.002 
112.0274  7.9  C4H4N2O2  1  Uracil  2.62  0.003 
260.0298  17.4  C6H13O9P  46  Glucose 6-phosphate  0.46  0.003 
862.5579  4.4  C45H83O13P  9  Phosphatidylinositol (18:0/18:0)  1.26  0.006 
250.0987  16.6  C9H18N2O4S  1  Met-Thr  2.52  0.009 
141.0192  19.7  C2H8NO4P  2  Ethanolamine phosphate  0.44  0.011 
507.3691  9.6  C26H54NO6P  6  Phophocholine (18:1)  0.66  0.012 
118.0268  6.6  C4H6O4  7  Succinate  0.75  0.013 
260.0297  18.1  C6H13O9P  46  D-Glucose 6-phosphate  0.55  0.013 
260.1373  15.2  C11H20N2O5  4  Glu-Leu  1.32  0.013 
134.0578  7.8  C5H10O4  6  Deoxyribose  0.42  0.014 
266.1267  15.2  C13H18N2O4  1  Phe-Thr  2.56  0.014 
273.2667  12.0  C16H35NO2  1  Hexadecasphinganine  0.60  0.019 
134.0579  7.6  C5H10O4  6  Deoxyribose  0.41  0.019 
479.3376  9.9  C24H50NO6P  5  Phosphocholine (16:1)  0.49  0.020 
213.044  22.6  C13H22N4O8S2  2  Asp-Cys-Cys-Ser  0.49  0.021 
251.1018  13.2  C10H13N5O3  4  Deoxyadenosine  4.11  0.021 
602.5274  4.4  C39H70O4  1  Glycerolipid (15:0/8:0)  1.22  0.023 
701.5364  5.9  C39H76NO7P  11 
Phosphoethanolamine 
(16:0/18:1) 
1.39  0.028 
617.4785  4.8  C34H68NO6P  1  sphingeninephosphate (16:0)  0.74  0.030 
471.1503  10.1  C20H21N7O7  1  10-Formyldihydrofolate  0.73  0.030 
465.322  10.1  C23H48NO6P  3  Phosphocholine (15:1)  0.43  0.033 
446.3393  5.0  C28H46O4  22  Dehydroteasterone  11.32  0.035 
699.5197  5.8  C39H74NO7P  6 
Phosphoethanolamine 
(16:1/18:1) 
1.40  0.040 
347.0631  17.8  C10H14N5O7P  7  AMP  3.61  0.041 
774.5416  4.3  C42H79O10P  9  Phosphoglycerol (18:1/18:1)  1.30  0.041 
188.1161  17.5  C8H16N2O3  7  Val-Ala  2.35  0.041 
363.0580  17.5  C10H14N5O8P  5  GMP  1.52  0.044 
801.5518  7.9  C43H80NO10P  1  Phosphoglycerol (17:0/20:4)  0.78  0.046 
166.0057  39.3  C8H14NO9S2  1  Glucocapparin  0.88  0.048 
Table 4-6. Significantly changing metabolites with 60 µM nifurtimox. Peptides are shaded 
blue and lipids yellow. „M/Z‟ relates to the detected mass charge ratio (peak height) 
corrected for positive or negative ionisation. Fold change relates to the ratio of the five hour 
sample intensity compared to 0 hour intensity. P-values were calculated using a Student‟s t-
test. 
 
Dehydroxyteasterone is a hormone and would not be present in trypanosomes. 
Its levels increase steadily over the time course and the mass is likely to relate 
to nifurtimox, especially as the retention time is very similar to nifurtimox (RT: 132 
 
5.4 minutes). However, the mass of dehydroxyteasterone (m/z 446.3393) minus 
the mass of the open chain nitrile (either saturated or unsaturated) or 
nifurtimox reveals no hits in the metabolite databases. The identity of this large, 
early eluting (and therefore non-polar) metabolite remains unknown for now, 
although fragmentation could be undertaken in the future to aid its 
identification. Metabolites of the polyamine pathway are not significantly 
altered over the nifurtimox time course (Fig 4-20) although there is a a slight 
increase in glutathione and decrease in trypanothione after 5 hours. Thiol levels 
are also not significantly altered (Table 4-7). The lack of changes in thiol and 
polyamine levels suggests that oxidative stress is not important in nifurtimox 
killing, although the redox state of the thiols was not measured so a definitive 
conclusion cannot be drawn. 
 
Figure 4-20. Polyamine metabolite changes in 60 µM nifurtimox. X-axes indicate the time in 
hours since drug addition. Y-axes indicate the relative intensity (area under the curve) of 
each metabolite. ND: not detected. Methionine (M+H: 150.0581, RT: 14.5 minutes), S-
adenosylmethionine (M+H: 399.1444, RT: 32.6 minutes), methylthioadenosine (M+H: 
298.0968, RT: 11.1 minutes), arginine (M+H: 175.1190, RT: 28.7 minutes), ornithine (M+H: 
133.0971, RT: 28.8 minutes), acetylornithine (M+H: 175.1077, RT: 18.0 minutes), spermidine 
(M+H: 146.1652, RT: 33.9 minutes), glutathione (M+H: 308.0910, RT: 16.7 minutes) and 
trypanothione disulphide (M+H: 722.2960, RT: 29.9 minutes). No metabolites showed 
significance at a p = 0.0.5 level in a t-test comparing levels to the 0 hour time point. N = 3. 133 
 
 
Thiol 
Time Point 
0  1  2  5 
methylthiobutanoate  1.00  0.91  0.91  0.83 
deoxymethylthioadenosine  1.00  0.77  1.16  1.03 
cysteine  1.00  1.08  0.88  1.17 
methionine  1.00  0.95  1.24  1.25 
glutathione  1.00  0.63  0.59  1.22 
trypanothione disulphide  1.00  0.74  0.55  0.55 
adenosylmethionine  1.00  1.32  1.26  1.30 
Table 4-7. Thiol levels in 60 µM nifurtimox treated cells. Numbers show ratios compared to 
time 0 (area under curve). Methylthiobutanoate (M+H: 147.0122, RT: 5.8 minutes), 
deoxymethylthioadenosine (M+H: 298.0968, RT: 11.1 minutes), cysteine (M+H: 122.0270, RT: 
16.7 minutes), methionine (M+H: 150.0581, RT: 14.45 minutes), glutathione (M+H: 308.0910, 
RT: 16.6 minutes), trypanothione disulphide (M+H: 722.2960, RT: 29.8 and 
adenosylmethionine (M+H: 399.1444, RT: 32.7 minutes. Ovothiol A could not be detected. N 
= 3. 
 
Reduction of nifurtimox to its reactive metabolite requires several steps (Fig 4-
21) (Hall et al., 2011). 
 
Figure 4-21. The reduction of nifurtimox (a nitrofuran) to its active compound, a saturated 
open chain nitrile. (From (Hall et al., 2011)) 
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A targeted search for the metabolites in the reduction of nifurtimox to its 
saturated open chain nitrile revealed just the start and end metabolites of the 
pathway, not the intermediates (Fig 4-22). This indicates that the reduction is 
rapid and intermediates in the pathway do not persist or persist at very low, 
undetectable levels. 
 
 
Figure 4-22. Nifurtimox reduction in T. b. brucei. Nifurtimox (M+H: 288.0648, RT: 5.4 minutes) 
is reduced, through a number of steps to an open chain nitrile (M+H: 258.0906, RT: 5.7 
minutes). Neither metabolite is detected at the 0 time point (where no drug is added). N = 3. 
 
The high levels of nifurtimox observed are probably related to exogenous 
nifurtimox levels, which are very high as cells are not washed after quenching, 
rather than internal nifurtimox. The saturated open chain nitrile levels 135 
 
decreased after an initial peak at one hour. This is interesting as it means that 
the pool of the active metabolite is not maintained during the nifurtimox time 
course, even though the levels of nifurtimox are high. Either uptake of 
nifurtimox must be reduced or the processing to the active metabolite is down 
regulated. The uptake mechanism of nifurtimox is unknown, but the current 
data are consistent with passive diffusion (Delespaux and De Koning, 2007). The 
Wilkinson group only recorded the saturated nitrile after 24 hours of drug 
exposure, whereas our assay shows its appearance after just one hour. This 
difference may be due to different experimental conditions as the Wilkinson 
group measured activity in purified nitroreductase (Hall et al., 2011), whereas 
whole cells were utilised for the study shown here. 
4.2.4 NECT metabolome 
The nifurtimox-eflornithine combination therapy is gaining momentum as a 
preferred treatment of late-stage T. b. gambiense HAT (Yun et al., 2010). 
Synergism of the two drugs has not be proven, however, either in vitro or in the 
field. 
As the nifurtimox-eflornithine combination therapy was shown to be antagonistic 
in our in vitro assay (as were other trypanostatic drugs in combination with 
nifurtimox (Fig 4-14)), we wanted to measure the metabolome of the 
combination therapy and compare it to the metabolomes of each drug in 
isolation. It was thought that the antagonism could be due to a decrease in 
nifurtimox reduction in non-dividing cells. The metabolome of NECT treated 
cells was therefore measured using drug levels that were toxic in the 
monotharapies (500 µM for eflornithine and 60 µM for nifurtimox) and the time 
points used in the nifurtimox toxicity assay (0, 1, 2 and 5 hours) (see included 
CD). A targeted look at nifurtimox reduction was conducted (Fig 4-23), but the 
reduction to the open chain nitrile was still achieved over the five hours. 136 
 
 
  
Figure 4-23. Nifurtimox reduction in T. b. brucei treated with a nifurtimox-eflornithine 
combination. Nifurtimox (M+H: 288.0648, RT: 5.4 minutes) is reduced, through a number of 
steps to an open chain nitrile (M+H: 258.0906, RT: 5.7 minutes). Neither metabolite is 
detected at the 0 time point (where no drug is added). N = 3. 
 
The polyamine pathway metabolites were also analysed in the combination 
therapy using a targeted approach (Fig 4-24). Ornithine levels at one hour and 
trypanothione levels at five hours and putrescine levels showed significant 
differences at a level of p = 0.05 and p = 0.01 in a t-test compared to the 0 hour 
time point. The level of ornithine is generally increased and spermidine and 
putrescine are generally decreased, indicating that eflornithine is still able to 
inhibit ODC in the combination therapy. 137 
 
 
Figure 4-24. Polyamine metabolite changes in NECT. X-axes indicate the time in hours since 
drug addition. Y-axes indicate the relative intensity (area under the curve) of each 
metabolite. ND: not detected. Methionine (M+H: 150.0581, RT: 14.5 minutes), S-
adenosylmethionine (M+H: 399.1444, RT: 32.7 minutes), methylthioadenosine (M+H: 
298.0968, RT: 11.1 minutes), arginine (M+H: 175.1190, RT: 28.7 minutes), ornithine (M+H: 
133.0971, RT: 28.8 minutes), acetylornithine (M+H: 175.1077, RT: 18.0 minutes), spermidine 
(M+H: 146.1652, RT: 33.7 minutes), glutathione (M+H: 308.0910, RT: 16.7 minutes) and 
trypanothione disulphide (M+H: 722.2960, RT: 30.0 minutes). * denotes significance at a p = 
0.05 level and ** denotes significance at a p = 0.01 level in a t-test comparing levels to the 0 
hour time point. N = 3. 
 
An untargeted analysis of the NECT metabolome revealed 36 significantly altered 
metabolites after five hours (p = 0.05) (Table 4-8). Interestingly, where 
ethanolamines were increased in the nifurtimox monotherapy, in the 
combination therapy the one ethanolamine with a significant alteration (at p = 
0.05) shows decreased intensity levels, as do the other lipids. AMP and uracil (in 
UMP) maintain their increase in intensity and the sugars maintain their decrease 
in intensity in line with the nifurtimox monotherapy.  138 
 
 
M/Z  RT  Formula  Isomers  Name  Ratio  p-
value 
135.0544  16.4  C5H5N5  1  Adenine  3.03  0.001 
715.5148  6.9  C39H74NO8P  11  Phosphoethanolamine (14:0/20:2)  0.72  0.002 
134.0579  7.8  C5H10O4  6  Deoxyribose  0.18  0.002 
134.0580  7.4  C5H10O4  6  (R)-2,3-Dihydroxy-3-
methylbutanoate 
0.18  0.002 
88.1001  36.1  C4H12N2  1  Putrescine  0.11  0.003 
71.0735  35.8  C4H9N  2  3-Buten-1-amine  0.18  0.005 
86.0368  14.8  C4H6O2  7  Diacetyl  1.67  0.006 
550.4962  5.1  C35H66O4  1  1-O-(1Z-Tetradecenyl)-2-(9Z-
octadecenoyl)-sn-glycerol 
0.51  0.006 
70.0531  18.2  C3H6N2  3  beta-Aminopropionitrile  1.29  0.007 
266.0903  7.4  C12H14N2O5  1  p-aminobenzoyl glutamate  2.73  0.008 
264.1045  34.3  C12H17N4OS  1  Thiamin  1.92  0.009 
132.0899  28.8  C5H12N2O2  3  L-Ornithine  2.97  0.009 
241.0926  6.5  C21H30N4O7S  4  Ala-Met-Phe-Asp  1.55  0.011 
237.9952  9.5  C12H8OCl2  6  2,6-Dichloro-4'-biphenylol  0.29  0.011 
130.1107  36.1  C6H14N2O  2  N-Acetylputrescine  1.69  0.012 
520.1613  23.7  C19H32N6O5S3  1  Cys-Met-Met-His  1.23  0.013 
148.0735  5.5  C6H12O4  14  (R)-2,3-Dihydroxy-3-
methylpentanoate 
1.58  0.013 
713.4997  5.8  C39H72NO8P  12  Phosphoethanolamine (16:0/18:3)  0.52  0.020 
338.0232  6.4  C8H8HgO2  1  mercuriphenyl acetate  0.56  0.021 
408.3751  5.1  C30H48  2  4,4'-Diapophytoene  1.36  0.027 
314.0590  5.5  C10H19O7PS  1  Malaoxon  1.29  0.030 
118.0268  6.6  C4H6O4  7  Succinate  0.49  0.030 
112.0274  7.9  C4H4N2O2  1  Uracil  1.93  0.031 
446.3394  5.1  C28H46O4  22  3-Dehydroteasterone  7.26  0.033 
188.1160  17.9  C8H16N2O3  7  Glycyl-leucine  1.79  0.033 
191.0616  6.0  C7H13NO3S  1  N-Acetylmethionine  0.47  0.033 
331.5544  20.3  C21H28N7O14P2  1  NAD+  1.15  0.034 
185.9928  20.9  C3H7O7P  2  2-Phospho-D-glycerate  0.44  0.035 
192.1011  17.0  C17H28N4O6  1  Ala-Thr-Pro-Pro  0.68  0.037 
324.0358  14.3  C9H13N2O9P  4  3'-UMP  1.89  0.040 
130.1107  36.4  C6H14N2O  2  N-Acetylputrescine  1.52  0.042 
347.0631  17.8  C10H14N5O7P  7  AMP  3.00  0.043 
386.3555  5.2  C27H46O  14  [ST] cholest-7-en-3beta-ol  0.62  0.044 
390.2271  5.2  C20H30N4O4  1  Lys-Phe-Pro  1.68  0.044 
200.0300  6.5  C12H8OS  1  dibenzothiophene-5-oxide  1.38  0.044 
202.1428  26.6  C8H18N4O2  3  NG,NG-Dimethyl-L-arginine  1.56  0.047 
Table 4-8. Significantly changing metabolites with NECT. Peptides are shaded blue and 
lipids yellow. „M/Z‟ relates to the detected mass charge ratio (peak height) corrected for 
positive or negative ionisation. Fold change relates to the ratio of the five hour sample 
intensity compared to 0 hour intensity.  
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The combination therapy showed the same changes as were present in each of 
the monotherapies alone. This indicates that both of the drugs are able to exert 
their individual effects, but means that the basis for the antagonism shown is 
still unknown. It is also of value in offering additional independent corroboration 
of changes seen in monotherapy. 
There are also many metabolites with unknown identities. Dehydroteasterone is 
again present and shows the same upward trend as in the nifurtimox toxicity 
experiment. Other metabolites that have been identified here (such as 
mercuriphenyl acetate) are unlikely to be present in trypanosomes and therefore 
probably relate to other metabolites not in the regularly-used databases. These 
unusual metabolites will require further investigation. 
A comparison of selected metabolites from the three toxic dose drug treatments 
was conducted (Table 4-9). Some metabolites show an additive effect when in 
combination (succinate, peptides, deoxyribose, spermidine, sedoheptulose 
phosphate and putrescine) as might be expected in a combination therapy. Some 
of the metabolites show opposite trends in eflornithine and nifurtimox (glucose 
6-phosphate, dehydroteasterone, formyldihydrofolate, acetylornithine and AMP), 
meaning that the combination therapy shows a more moderate change. This is 
also true of the increase in ornithine levels, which is lessened in the combination 
therapy as compared to the eflornithine monotherapy. It is possible that a 
reduced impact on these metabolite levels may be responsible for the lack of 
synergy in the combination therapy.  140 
 
 
   Ratio 1:5 hours 
Name  Eflornithine  Nifurtimox  NECT 
Peptides (average)  1.22  1.07  1.61 
Lipids (average)  1.17  1.04  0.97 
Succinate  0.77  0.75  0.49 
Uracil  1.08  2.62  1.93 
D-Glucose 6-phosphate 
(average) 
1.25  0.51  0.72 
Deoxyribose  0.76  0.42  0.18 
3-Dehydroteasterone  0.76  11.32  7.26 
10-Formyldihydrofolate  1.59  0.73  0.85 
Acetylputrescine  0.37  0.97  1.61 
Cystathionine  2.75  1.09  1.13 
Methylthioadenosine  2.23  1.11  2.06 
Acetylornithine  3.03  0.93  1.25 
Ornithine  4.21  1.11  2.97 
Spermidine  0.82  0.87  0.45 
AMP  0.82  3.61  3 
Sedoheptulose  1.49  Not found  1.35 
GMP  1.24  1.52  1.25 
Sedoheptulose phosphate  2.14  1.82  6.17 
Putrescine  0.13  0.94  0.11 
Table 4-9. A comparison of metabolite levels in the three drug treatments. The ratio is the 
metabolite intensity at 5 hours compared to the intensity at the 0 hour time point. Blue 
shading indicates a decrease in metabolite levels, red and increase and yellow shading 
indicates that levels are not altered. 141 
 
4.3 Discussion 
At low levels of drug (sub IC50) specific changes to the metabolome can be 
detected as was evidenced with eflornithine. The data reveal only very localised 
changes in the sub IC50 experiments, which is surprising considering the number 
of metabolites that are detected. It is clear with eflornithine that the specific 
changes are not disseminated through the metabolome revealing a degree of 
robustness within the metabolic network. A recovery was also noted between 48 
and 72 hours further demonstrating that trypanosomes are able to react to 
changes within the polyamine pathway and regulate the expression or kinetics of 
the enzymes. Acetylated ornithine and putrescine were detected, with 
acetylornithine correlating particularly well with ornithine levels. This 
metabolite has an unknown function within trypanosomes and is investigated 
further in chapter five. This proof of principle reveals the power of 
metabolomics for predicting the MOA of compounds with a metabolic (enzyme 
inhibition) mode of action. 
Changes to nifurtimox-treated cells (sub IC50 and at toxic doses) did not involve 
alterations to the polyamine pathway metabolites or thiols. It is unfortunate 
that the oxidation state of the metabolites cannot be measured on the platform 
used. Dr. Dong Hyun-Kim at the University of Glasgow is optimising a method to 
detect the oxidation state of all the thiols within the trypanosome. In this 
method reduced thiols are derivatised with bromobimane which, when 
conjugated to a thiol, fluoresces. The fluorescence, when read after samples 
have been separated by mass on a HPLC column, can inform the user as to the 
oxidation state of each thiol within a cell extract (Dr. Dong Hyun-Kim, personal 
communication and Petrotchenko et al. 2011). 
No robust, linear, significant changes were detected with sub IC50 levels of 
nifurtimox. Any significant changes at 48 hours were likely due to the processing 
method as there was a correlation between time points that were processed on 
the same day. This is a clear demonstration of the paramount importance of 
standardising protocols as much as possible and quenching all metabolic samples 
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The lack of changes to the nifurtimox sub IC50 metabolome could serve to 
demonstrate that nifurtimox does not act metabolically. The reactive open chain 
nitrile, predicted to be the active compound of nifurtimox after processing with 
type I nitroreductases (Hall et al., 2011), could not be detected either alone or 
as an adduct to other metabolites, although the levels of nifurtimox were seen 
to be reduced between 24 and 48 hours. Higher doses of nifurtimox did not 
detect any of the intermediates of nifurtimox processing, but the open chain 
nitrile was detected after one hour. Levels of this active metabolite decreased, 
however, after the initial peak at one hour, suggesting that the processing of 
nifurtimox is somehow compromised or that the active metabolite is used more 
rapidly at later time points. 
4.3.1 Eflornithine MOA 
Eflornithine inhibited ODC relatively quickly with levels of ornithine and 
putrescine demonstrably altered after just five hours in drug. The drug was seen 
to be trypanostatic for 48 hours, before killing the parasites after compromising 
the membrane of the cell. It has been suggested that the irreversible 
transformation to non-dividing forms produces parasites that have a limited life 
span (Fairlamb and Cerami, 1992). Whether cells eventually die through 
apoptosis or through another form of lysis remains unexplained. 
One interesting observation from the eflornithine toxicity experiment is that 
levels of trypanothione are not greatly reduced. The levels fall by approximately 
50 %, similar to the decrease of 66 % seen by Fairlamb et al. (1987). It may be 
that this decrease is sufficient to exert the cytostatic effects of the drug or it 
may be that the reduction in levels of spermidine are more important. 
Spermidine is an essential polyamine known to modulate DNA stability, 
transcription, translation and apoptosis (Igarashi and Kashiwagi, 2010), but 
rescue experiments where spermidine is given exogenously to ODC knock down 
cells were unsuccessful (Xiao et al., 2009).  
Exogenous spermidine increases the life span of yeast, nematodes, flies and 
human immune cells in culture (Eisenberg et al., 2009). The mechanism for this 
death delay is not known, but was suggested that it may involve remodelling of 
chromatin and upregulation of autophagy, increasing resistance to oxidative 143 
 
stress (Eisenberg et al., 2009). In human lymphocytes it has been shown that 60 
% of total spermidine is ionically bound to RNA (Igarashi and Kashiwagi, 2010), 
which demonstrates its importance in these immune cells.  
When spermidine levels in T. cruzi are reduced, lipid peroxidation was shown to 
be increased and the effects could not be rescued by trypanothione.  Spermine 
was observed to be more effective at lipid peroxidation rescue (Hernandez et 
al., 2006), but T. b. brucei are not capable of producing spermine (they do not 
contain a spermine synthase) and levels are very low or undetectable (Bacchi et 
al., 1983;Fairlamb et al., 1987). There is also no evidence seen of an increase in 
lipid peroxidation from our T. b. brucei data. 
Spermidine conjugated to glutathione has been found to increase as cells move 
into stationary phase of the growth cycle, but it is unclear whether this is a 
trigger for cytostasis or not (Shim and Fairlamb, 1988). Glutathionylspermidine 
was not detected in our assays, but if more spermidine is present then it may be 
that more glutathionylspermidine is being produced as the cells become 
stationary either exerting the effects of eflornithine or because of the effects of 
eflornithine. However, Fairlamb et al. found no increase in 
glutathionylspermidine over 48 hours (levels remain at approximately 0.25 
nmol/10
8 cells) despite the approximate three fold reduction in spermidine 
(Fairlamb et al., 1987). 
Free lipids decreased after 24 hours and the cells became more permeable after 
48 hours. The decrease in lipids at 24 hours may indicate an attempt to maintain 
the integrity of the membrane. 
An increase in sedoheptulose and sedoheptulose phosphate was an interesting 
observation in eflornithine-treated cells, especially as the transketolase required 
to produce the four or five carbon sugars required for the synthesis of seven 
carbon sugars is not present in bloodstream forms of the parasite (Stoffel et al., 
2011). It could be that eflornithine treated cells are differentiating into stumpy 
forms and transketolase is being expressed. Quantitative PCR analysis of 
transketolase expression would be useful to investigate this hypothesis. An 
alternative source of erythrose 4-phosphate is evident, however, as this four 
carbon sugar can be detected within bloodstream form cells and in procyclic 144 
 
cells with the transketolase gene knocked out (Michael Barrett, unpublished). A 
possible alternative route could be through phosphoketolase (Ingram-Smith et 
al., 2005), although this enzyme is usually bacterial and no orthologues could be 
found in the trypanosome gene databases. This phosphoketolase would convert 
fructose 6-phosphate to phosphoacetate and erythrose 4-phosphate. The 
Bringaud group at the Centre National de Recherche Scientifique, Bordeaux, 
have noted a high rate of conversion of glucose to acetate, in support of this 
hypothesis (Frédéric Bringaud, personal communication).  
It is unclear whether the increases in sedoheptulose and sedoheptulose 
phosphate are a specific response to eflornithine treatment or whether they are 
a general reaction in dying cells. An assay with toxic doses of nifurtimox did not 
reveal changes in sedoheptulose or sedoheptulose phosphate. This may mean 
that the two drugs have different mechanisms of killing. 
4.3.2 Nifurtimox toxicity 
Toxic doses of nifurtimox revealed alterations to lipids (both increases and 
decreases), sugars (decreases in sugars and sugar phosphates) and uracil and 
purines (increases). More work will need to be done do ascertain why these 
metabolites‟ levels are altered with nifurtimox treatment. One way to 
investigate whether there has been an effect on glycolysis, the TCA cycle and 
the pentose phosphate pathway could be to provide exogenous ribose, succinate 
or sugar phosphates to the cells to see if the effects of nifurtimox can be 
lessened in an alamar blue assay. The decrease in deoxyribose could also be 
linked to DNA synthesis or breakdown, although there is a negative correlation 
between the DNA bases and deoxyribose. 
4.3.3 NECT 
The nifurtimox-eflornithine combination therapy, which was previously assumed 
to be synergistic, was shown to be mildly antagonistic in vitro although a 
metabolomic analysis revealed that both of the drugs were able to exert their 
effects in the combination therapy and nifurtimox was still reduced to its active 
form. The combination therapy has not, as yet, revealed any antagonism in the 
field, although its use has been limited so far. A synergistic effect in vivo may 145 
 
not be evident in vitro if nifurtimox increases eflornithine entry into the brain 
allowing more of the drug to reach the late-stage trypanosomes. Studies have 
shown that very little eflornithine actually enters the brain on its own (CSF 
levels are recorded at 68.9 µM during the normal monotherapy treatment regime 
(Milord et al., 1993)), or in combination with nifurtimox in mice (10 - 40 nM 
using an artificial plasma perfusion with 1 µM eflornithine (Sanderson et al., 
2008)). It is however possible that nifurtimox could allow more entry of 
eflornithine across the blood-brain barrier in humans.  
Another reason why the drug combination is not synergistic in vitro may be that 
downstream effects of nifurtimox may only be possible in dividing cells so when 
growth arrest is induced by eflornithine, nifurtimox‟s efficiency is reduced. This 
hypothesis was confounded with the antagonism seen with the other 
trypanostatic compounds NA42 and NA134, adenosine analogues developed by 
Boris Rodenko (Rodenko et al., 2007). Metabolomic studies of NECT, however, 
revealed no major differences in nifurtimox reduction or the metabolome when 
compared the drugs tested in isolation. 
The power of using metabolomics to elucidate the mode of action of a drug is 
very clear; assays can be untargeted and can reveal the action of the drug at a 
range of doses and time points. The sensitivity of the assays is, however, a 
double-edged sword. The number of metabolites detected will inevitably lead to 
some metabolites showing significant alterations by chance rather than due to 
biological significance, if the number of replicates is not adequate. Care must 
also be taken to verify the identity of all mass identifications as there are many 
artefacts, isomers and fragments in the datasets, even after very stringent 
processing through the mzMatch and IDEOM softwares. 
The confidence of identification can be increased through the use of heavy label 
tracking. Cells can be cultured in medium containing heavy atoms in the form of 
a starter metabolite and this can be tracked through the cell in a resting state 
and after perturbation with a drug. In the case of eflornithine, heavy nitrogen 
could be tracked through the polyamine pathway from a starting metabolite of 
arginine in the growth medium. Rates of nitrogen incorporation could then be 
measured and compared with and without drug. If a build up of ornithine is toxic 
to the cells and they therefore have to produce acetylornithine to store the 146 
 
ornithine then this incorporation would be observed. This technique has been 
tested before in E. coli  and was shown to be very effective in tracking heavy 
ammonia through the folate pathway after treatment with trimethoprim (Kwon 
et al., 2008).  
As metabolomics technologies and data processing softwares become more 
advanced, the utility of a metabolomics experiment to provide a read out of the 
perturbations in a cell system are likely to become more and more obvious to 
biologists. The relative ease and cost of sample preparation in comparison to 
proteomics, transcriptomics and genomics methods will be an attraction to 
many, but a great deal of skill and care is still required in the analysis of 
metabolic data. 
The advantages of metabolomics in the prediction of a mode of action of a drug 
should be obvious to anyone working in the pharmaceutical industry, but the low 
cost and ease of these assays will allow any lab scientist with access to a high 
resolution mass spectrometer to produce a list of metabolites altered in 
perturbation of a system. 147 
 
  5. Ornithine Biosynthesis in T. b. brucei 
5.1 Introduction 
The unexpected discovery of N-acetylornithine in trypanosomes during 
eflornithine mode of action studies (section 4.2.1.2) prompted the further 
investigation of the polyamine pathway to ascertain whether a new pathway 
may contribute to the production of ornithine. 
Ornithine is a basic amino acid closely related in structure and charge to 
arginine and lysine (Fig 5-1). It is the second metabolite in the polyamine 
pathway where it loses a carboxyl group through the action of ornithine 
decarboxylase to become putrescine, which is in turn converted to spermidine 
and conjugated to two molecules of glutathione to form trypanothione, the 
trypanosome‟s main thiol (Fairlamb and Cerami, 1992). A thiol pool is imperative 
to all cells to react with damaging free radicals and protect them from oxidative 
stress. Blocking the polyamine pathway with eflornithine (an inhibitor of 
ornithine decarboxylase) in trypanosomes results in a cessation of the cell cycle 
and ultimately cell death.  
 
Figure 5-1. Lysine, ornithine and arginine (l-r). These basic amino acids are structurally 
related with a carboxyl group at one end and multiple amines at the other. Ornithine can be 
produced from arginine by the cleavage of a CN2H4 fragment, classically by the enzyme 
arginase. 
 
The polyamine pathway in eukaryotes commences upon the uptake or synthesis 
of arginine. Arginine uptake has been shown to occur in L. donovani and in T. 
cruzi. In L. donovani the rate of uptake has been reported to occur via LdAAP3 
(Km 1.9 µM, Vmax 16.9 pmol/min/10
6 cells) (Shaked-Mishan et al., 2006) and in T. 148 
 
cruzi via TcAAAP411 (Km 30 µM) (Carrillo et al., 2010). These rates are relatively 
low (c.f. a Vmax of 1, 300 pmol/min/10
6 cells for high-rate glucose transport 
(Barrett et al., 1998) or 6.4 pmol/min/10
6 cells for the low-rate transport of 
adenosine (Carter and Fairlamb, 1993), but the rate of arginine uptake and the 
fate of arginine within the African trypanosome has yet to be fully investigated.  
Arginine is classically converted to ornithine by arginase, an enzyme of the urea 
cycle (Fig 5-2).  
 
Figure 5-2.The urea cycle. Enzymes in red are NAGS: N-acetylglutamate synthetase, CPS: 
carbamoyl phosphate synthase, OTC: ornithine transcarbamoylase, AS: argininosuccinate 
synthetase and AL: argininosuccinate lyase. Adapted from Brusilow and Horwich (1995). 
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Vertebrates generally have two arginase enzymes (Arg I and Arg II, whereas 
microorganisms more often encode just one arginase (NCBI protein database). 
The branch at the top of the urea cycle (Fig 5-2) provides carbamoyl phosphate 
to produce citrulline from ornithine. If ornithine transcarbamoylase can operate 
in the reverse direction, then this may be an alternative source of ornithine, 
either from the uptake of citrulline or aspartate or indeed from arginine.  
N-acetylornithine appears to correlate extremely closely with changes in 
ornithine levels after addition of eflornithine (see chapter 4). N-acetylation of 
ornithine as a sample preparation artefact is possible. However, it is clear that 
the acetylation is not an artefact of the ionisation process in these experiments 
for two reasons. One; acetylornithine and ornithine have different retention 
times and therefore any acetylation artefact must occur before entry into the 
column, which is unlikely as all enzymes are inactivated by the solvent. And two; 
when ornithine alone (or labelled ornithine in trypanosome growth medium) is 
added to the column, acetylornithine is not produced meaning a spontaneous 
non-enzymatic conversion is unlikely (data not shown). Furthermore, inspection 
of the T. brucei genome revealed the presence of a putative N-acetylornithine 
deacetylase (ArgE, Tb927.8.1910) predicted by sequence similarity to the 
Leishmania acetylornithine deacetylase-like genes LbrM.07.0280, LinJ.07.0430, 
LmjF.07.0270 and LmxM.07.0270. It is also syntenic with T. b. gambiense and T. 
congolense putative acetylornithine deacetylase genes. A putative aminoacylase 
(Tb927.1.3000) on TriTrypDB may also be able to acetylate ornithine, as has 
been seen in the B. stearothermophilus enzyme (which matches Tb927.1.3000 in 
a BLAST search with a score of p = 5.6e-61) (Sakanyan et al., 1993). 
N-acetylornithine is not a metabolite that has been observed in trypanosomes 
before. Indeed it has been predicted that only bacteria use N-acetylornithine in 
the conversion of glutamate to ornithine (Albrecht and Vogel 1964) (Fig 5-3). 
Although more recent data does predict a role of N-acetylglutamate synthase 
(NAGS) in mammals (a difference being that NAGS is inhibited in microbes and 
plants by arginine but stimulated in mammals (Caldovic et al., 2010)). However, 
trypanosomes are not predicted to have any of the enzymes for the glutamate to 
ornithine pathway (aside from the putative acetylornithine deacetylase) 
annotated in the genome and simple BLAST searches of the bacterial protein 
sequences do not draw any hits (data not shown).  150 
 
 
Figure 5-3. Ornithine biosynthesis from glutamate in Escherichia coli. The plasma 
membrane is represented by double line, metabolites are in boxes, enzymes are in italics. 
From Albrecht and Vogel (1964). 
 
An enhanced understanding of the polyamine pathway may allow other 
synergistic compounds to be designed relieving the pressure on nifurtimox-
eflornithine combination therapy (which has been shown not to be synergistic in 
vitro, so may not be the best combination to use in the field (see section 4.2.2 
of this thesis)). The use of more combination therapies and more choice of drugs 
in general will reduce the risk of resistance occurring. 
Arginase, the first enzyme in the classical ornithine synthesis pathway, has been 
studied in myriad organisms including Helicobacter pylori (Zhang et al., 2011), 
Staphyococcus saprophyticus (Deutch, 2011), mammals (Cederbaum et al., 2004) 
and fish (Joerink et al., 2006;Srivastava and Ratha, 2010) but its role within 
trypanosomes is unknown. Arginase activity within the host has been shown to 151 
 
be increased in the blood of mice upon trypanosome infection (Duleu et al., 
2004), but not in brain (Amrouni et al., 2011).  
Arginase has also been studied extensively in Leishmania species. It appears to 
be essential in L. mexicana  promastigotes (Riley et al., 2011), but not in L. 
mexicana amastigotes or L. major amastigotes (Gaur et al., 2007;Muleme et al., 
2009). Furthermore, the recombinant protein has been expressed, purified and 
characterised biochemically (da Silva et al., 2002;da Silva et al., 2008). In L. 
mexiana and L. braziliensis, the arginase gene is located on chromosome 34 
while in L. major and L. infantum it is on chromosome 35, which is the 
equivalent genomic position. The gene is missing in the syntenic region of T. 
brucei. Also within the arginase family of proteins are agmatinases and 
formiminoglutamases. There is an agmatinase-like gene predicted on 
chromosome 23 of the Leishmania species, and this does have a syntenic partner 
in T. brucei with the putative arginase at Tb927.8.2020 (also labelled as 
agmatinase in some databases, but as arginase in the T. brucei databases until 
2010). Fomiminoglutamases hydrolyse N-formimidoyl-L-glutamate to L-glutamate 
and formamide and are not well researched in comparison to arginases and 
agmatinases. 
5.2 Heavy isotope labelling 
The non-targeted nature of global metabolomics can often reveal unexpected 
metabolites and pathways that are not predicted to be present from the genome 
of an organism. This is especially true in parasites as many more of the pathways 
are likely to result from salvaged precursors (Fairlamb, 1989). 
The natural isotope pattern of metabolites is useful in the assignment of 
empirical formulae as the isotope ratio is unique to each element (Fig 5-4), but 
it can also be useful to track metabolites through a pathway. When done 
quantitatively and as a function of time this technique is known as fluxomics 
(Niittylae et al., 2009). 152 
 
 
Figure 5-4. Isotope abundance patterns of guanamine (Miura et al., 2010). Peaks related to 
the parent metabolite (C17H28N10O4) are detected approximately one atomic mass unit from 
the parent ion relating to the 
13C and the 
15N
 isotope. The 
13C and 
15N isotope labels can only 
be differentiated in high resolution instruments. 
 
The McConville group in Melbourne, Australia, recently used 
13C labelled 
metabolites to interrogate central carbon metabolism in L. mexicana (Saunders 
et al., 2011). They were able to track glucose, aspartate and alanine though 
glycolysis, the pentose phosphate pathway and the tricarboxylic acid cycle using 
NMR and GC-MS (Saunders et al., 2011). These experiments provided a lot of 
information on the use of these pathways and gave indications as to the rates of 
these pathways; experiments that, without metabolomic techniques, would have 
taken a great deal more time and effort. In T. b. brucei, more focussed studies 153 
 
using 
13C proline revealed differences in glucose metabolism depending on the 
carbon source used in procyclic forms (Coustou et al., 2008). 
In trypanosomes, Van Weelden et al. (2005) tracked radio-labelled glucose, 
glycerol, proline and threonine using HPLC to analyse catabolic and anabolic 
functions of the TCA cycle after growing procyclic trypanosomes in glucose-rich 
and glucose-deprived media. They found that the TCA cycle does not always 
operate as a cycle and instead distinct branches of the cycle provide separate 
anabolic and catabolic reactions. For example, in the presence or absence of 
glucose, proline is transported into the mitochondrion where it is broken down 
to ketoglutarate and ultimately succinate. The succinate is not further 
catabolised to fumarate, but is instead expelled from the cell (van Weelden et 
al., 2005). Anabolic processes also occur from this “cycle”. In glycerol and 
glucose-deprived medium the cells reduced succinate excretion and instead used 
the succinate to produce malate through fumarate. This malate was then 
thought to be used in the cytosol for production of phosphoenolpyruvate to 
provide energy for the cell. The formation of citrate from oxalacetate and 
pyruvate forms another branch of the cycle. The citrate is then used for the 
formation of acetyl-coA for fatty acid biosynthesis. The oxalacetate must, 
however, be formed through malate dehydrogenase (van Weelden et al., 2005) 
meaning the malate branch of the cycle is not isolated from the other parts of 
the cycle. 
To analyse ornithine biosynthesis,
15N may be a more useful isotope label than 
13C 
as nitrogen is a less common element than carbon. This means that the natural 
isotope abundance will be lower compared to carbon, making the spectra easier 
to interpret. For tracking ornithine and subsequent polyamine synthesis it is also 
more beneficial to have the amine group labelled for following its fate through 
the polyamine pathway.  
In this chapter I address the question: “how do trypanosomes obtain ornithine?”. 
If ornithine can be produced via the deacetylation of N-acetylornithine then is N-
acetylornithine part of an alternative route for ornithine production in 
trypanosomes? If this is the case, then what would be the role of arginase, a 
gene for which Tb927.8.2020 was annotated in the TriTrypDB as recently as 154 
 
autumn 2010? The biosynthesis of ornithine is investigated using biochemical, 
bioinformatic and metabolomic techniques. 
5.3 Results 
In order to assess the contribution of arginase to the production of ornithine, 
Tb927.8.2020 (annotated as arginase in trypanosome gene databases until 
autumn 2010) was analysed at the sequence and biochemical levels. 
5.3.1 Arginine uptake in bloodstream form T. b. brucei 
In most eukaryotes arginine serves as a precursor to ornithine. We therefore 
measured the rate of uptake of this amino acid into trypanosomes. Arginine 
uptake in T. b. brucei appeared to show a biphasic uptake pattern suggesting 
that there were two transporters responsible for arginine transport; one low 
affinity and one high affinity. The low affinity transporter was analysed over a 
substrate range of 125 to 2,000 µM and the high affinity transporter over a 
substrate range of 1.25 to 80 µM arginine.  The low affinity transporter gave an 
average apparent Km of 1,169 ± 300 µM and a Vmax of 91.6 ± 62.5 
pmol/minute/10
6 cells. The high affinity transporter gave an apparent Km of 26 ± 
1.9 µM and Vmax of 5.98 ± 2.78 pmol/minute/10
6 cells (Fig 5-5). Values are mean 
± standard error of the mean. 155 
 
 
Figure 5-5. The uptake of arginine appears to use two transporters. A, Uptake via the high 
affinity transporter. B, Uptake via the low affinity transporter. Representative of two 
experiments for the low affinity and three experiments for the high affinity transporter. Error 
bars show standard error of the mean. 
 
Both transporters show a higher Km value than the L. donovani transporter (Km 
1.9 µM (Shaked-Mishan et al., 2006)), but the high affinity transporter shows a 156 
 
similar Km to the measured constant in T. cruzi (30 µM (Carrillo et al., 2010)). 
The higher Km would be expected as human blood serum levels range from 63 - 
218 µM. 
5.3.2 The trypanosome “arginase” 
5.3.2.1  Arginase inhibitors do not work in T. b. brucei 
Ornithine is classically created through the hydrolysis of arginine by arginase 
(EC: 3.5.3.1). If trypanosomes used this route, arginase inhibitors would be 
useful against HAT as they would be expected to synergise with eflornithine. 
Arginase inhibitors (2S-amino- 6-boronohexanoic acid, methyl 2S-amino- 6-
boronohexanoic acid and 2S-amino- 6-boronohexanoic acid) were tested for 
activity against bloodstream-form trypanosomes. These compounds, which have 
shown activity against mammalian arginase (Christianson, 2005), did not kill 
trypanosomes in concentrations up to 100 µM (Kate Beckham, unpublished data). 
It may be that the concentrations of these inhibitors used were not high enough 
as another arginase inhibitor, N-hydroxy-nor-L-arginine, is used at 500 µM to 
inhibit macrophage arginase (Duleu et al., 2004). However, purified 
Tb927.8.2020 (from heterologous expression in E.coli) enzyme produced no 
detectable arginase activity through mass spectrometry analysis of trypanosome 
growth medium with and without enzyme (Kate Beckham, unpublished data).  
5.3.2.2  The T. b. brucei  “arginase” gene is divergent from other conserved 
arginases 
The gene in T.b. brucei 927 was labelled as an arginase by sequence homology 
and synteny with a putative leishmania arginase is Tb927.8.2020 in TritrypDB. 
This gene has since been re-named as an agmatinase-like gene in some, but not 
all, of the databases as it is syntenic with an agmatinase-like gene in leishmania. 
The characterised L. mexicana arginase (LmxM.34.1480) (Riley et al., 2011) is 
syntenic with L. major, L. braziliensis and L. infantum arginases, but is missing 
in T. brucei. The T. b. gambiense (Tbg972.8.1660), T. congolense 
(TcIL3000.8.2050) and T. vivax (TvY480.0801520) genes are still annotated as 
putative arginases. 157 
 
Arginase amino acid sequences were compared between a range of species 
(Appendix 8-5) and a phylogenetic tree was produced using a neighbour-joining 
algorithm bootstrapped 1000 times (Fig 5-6). From the sequences included in the 
tree, the closest neighbours of Tb927.8.2020 were the L. mexicana agmatinase-
like protein, which has not had its agmatinase activity confirmed, and the 
bacterium, D. radiodurans, agmatinase (a confirmed agmatinase (Ahn et al., 
2004)), but with the largest branch size in the tree with a distance of 2.227 
(average substitutions per site) between the two genes, they are not close 
relatives.  158 
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Work by Perozich et al. (1998) analysed the catalytic and structural residues in a 
range of amino acid sequences from the arginase family of proteins, which 
includes agmatinases and formiminoglutamases. Thirty one sequences were 
compared and the highly conserved residues were identified. These residues 
showed very little divergence (over 80 % conserved over the 31 family members) 
between family members and different species (Perozich et al., 1998). The 
arginase alignment was compared to T. b. brucei at the sequence level. Many of 
the residues found to be structurally or functionally important by Perozich et al. 
were found to be missing in T. brucei (Table 5-1).  160 
 
 
Conserved 
residue 
(human 
arginase 1 
position) 
Residue in 
Tb927.8.20
20 
Residue in 
LmxM.23.0070 
(agmatinase-
like) 
Residue in 
LmxM34.1480 
(arginase) 
Function of residue in protein 
Ser230  Ser222  Ser223  Ser241  Indirect metal binding 
Asp274  Asp265  Asp266  Asp285  Indirect metal binding 
His228  * Phe220  *Phe221  Met239*  Indirect metal binding 
Pro14  * Asp18  Pro13  Pro21  Important for structural bends 
Pro28  Pro25  Pro25  Pro35  Important for structural bends 
Pro144  Pro160  Pro161  Pro157  Important for structural bends 
Pro238  Pro230  Pro231  Pro249  Important for structural bends 
Pro280  Pro271  Pro272  Pro291  Important for structural bends 
Gly23  * -  *-  Gly30  Start of first α-helix 
Gly142  * -  *-  Gly155  Important for structural bends 
Gly178  Gly177  Gly178  Gly189  Hold metal ligands in place 
Gly245  * Asp237  *Gln238  Gly256  Important for structural bends 
Gly250  Gly242  Gly243  Gly261  Important for structural bends 
His141  * -  *-  His154  Catalytic function 
Asp100  Asp123  Asp124  Asp113  Structural 
His101  * Gly124  *Gly125  His114  Metal-ligand 
Asp234  * Ser226  Asp227  Asp245  Metal ligand 
Glu256  * Asp248  *Asp249  Glu267  Subunit interaction 
Arg255  Arg247  Arg248  Arg266  Structural 
Ala243  Ala235  Ala236  Ala232  Structural 
Arg180  Arg179  Arg180  Arg191  Hold metal ligands in place 
Thr292  *Gly295  *Ser296  Thr303  Structural 
Table 5-1. Highly conserved residues across the arginase family. Strictly conserved 
residues are shaded (from Perozich et al., (1998)). Equivalent T. b. brucei residues predicted 
from an alignment in CLC workbench. * denotes a change from the conserved human 
residue. Tb927.8.2020 and LmxM.23.0700 show 225/332 Identity, Tb927.8.2020 and human 
arginase I show 58/332. Human arginase and L. mexicana arginase show 204/332 identity. 
 161 
 
Of the four most highly conserved residues within the arginase family, three 
were altered or missing in Tb927.8.2020. Gly23 in the H. sapiens arginase begins 
the first α-helix in all the arginases compared in Perozich‟s study (1998) and is 
strictly conserved, but is absent in the T. b. brucei sequence.  
His141 is present in all members of the arginase family apart from two 
formiminoglutamases. Mutations to this residue (Cavalli et al., 1994;Vockley et 
al., 1996) have shown that it probably serves a catalytic function. This is further 
supported by its side chain‟s close proximity to the water molecule which 
bridges two manganese atoms (discovered through site-directed mutagenesis). 
This residue is therefore thought to be a proton shuttle during the catalysis of 
arginine (Kanyo et al., 1996; Perozich et al., 1998). This residue is completely 
absent in the T. b. brucei sequence and the L. mexicana agmatinase-like 
sequence, but is replaced with a tryptophan in the D. radiodurans sequence. It is 
therefore unlikely that Tb927.8.2020 would be able to catalyse arginine 
metabolism in the same way as other arginases. 
The side chain of Glu256 falls just 2.9 Ångströms away from the Arg255 of a 
different subunit and is therefore thought to be integral in interactions between 
arginase‟s multiple (rat and human arginases are homotrimers (Perozich et al., 
1998;Di Costanzo et al., 2005)) subunit interactions. The T. b. brucei enzyme 
has substituted Glu256 for Asp248. As aspartate has a shorter side chain than 
glutamate this may mean that the subunits cannot complex together properly, 
but without a crystal structure of Tb927.8.2020, this cannot be tested. 
Arg180 holds his101 and Asp234 in place for metal binding as well as helping to 
maintain the overall structure of the enzyme (Perozich et al., 1998) and is 
conserved in the T. b. brucei enzyme. 
Studies on the substrate specificity of arginase have found that hydrogen 
bonding between Thr135 and Asn130 are both essential to allow arginine binding 
in the active site. Agmatine binds 11 fold less well at this site. Site-directed 
mutagenesis of Asn130 to Asp130 reduces the binding affinity of arginine nine 
fold, while producing no effect on agmatine binding (Carvajal et al., 1999; 
Alarcon et al., 2006) . Tb927.8.2020 and LmxM.23.0070 (the leishmania 
agmatinase-like protein) both lack Thr135. A confirmed agmatinase from D. 162 
 
radiodurans (an extremophilic bacterium (Ahn et al., 2004)) does, however, 
have a threonine in this position. Tb927.8.2020 has a serine at position 130 and 
LmxM.23.0070 has a glutamate, while the D. radiodurans agmatinase is missing 
this residue altogether providing further evidence that the predicted enzymes 
are not able to bind arginine. 
The main difference found between human arginase and the D. radiodurans 
agmatinase appears to be in loops four and five flanking the active site (Shishova 
et al., 2009). Residues from loops four and five in the D. radiodurans agmatinase 
(Asn153,Tthr155, Gly183, Asp187 and Ala190) do not, however, match the loops 
in the leishmania agmatinase-like sequence (-, -, Cys181, Ser183 and Asp186) or 
Tb927.8.2020 (-, -, Gln180, Ser182 and Asp185). 
Tb927.8.2020 has many residues in common with the L. mexicana agmatinase-
like protein sequence, which are different to the conserved arginase family 
residues and from the D. radiodurans agmatinase. This would suggest that 
trypanosome and leishmania genes do not code for arginases or agmatinases. No 
structural or activity research on formiminoglutaminases could be found in the 
literature so confirmed amino acid sequences could not be obtained and aligned 
with Tb927.8.2020. The function of this putative enzyme remains unknown. It 
would be interesting to knock out the gene to see if a function can be ascribed 
to it. The protein could also be heterologously expressed and characterised using 
metabolomic approaches. 
5.3.2.3  T. b. brucei has negligible arginase activity 
The overwhelming sequence data evidence suggests that TB927.8.2020 is not an 
arginase, or indeed a member of the greater arginase family, which includes 
agmatinase and formininoglutaminase. It does not, however, prove that there is 
an absence of arginase activity in bloodstream form T. b. brucei. To quantify 
arginase activity within the bloodstream form trypanosome a commercial 
arginase assay kit was used comparing the amount of urea produced over two 
hours in a cell extract. T. b. brucei extracts were compared to L. mexicana and 
published rat and human extracts. Results are summarised in table 5-2.  
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Species  Arginase activity (Units/L) 
T. brucei brucei  0.128 ± 0.206 
L. mexicana  19.704 ± 0.841 
R. norvegicus plasma 
(from literature in assay kit) 
322 
H. sapiens plasma 
(from literature in assay kit) 
0.88 
Table 5-2 Arginase activities of T. b. brucei and L. mexicana. A unit is defined as 1 µmole of 
arginine converted to ornithine and urea per minute at pH 9.5 and 37ºC. N = 3. Results show 
mean ± S.E.M (n = 3).  
 
T. b. brucei has very low arginase activity in bloodstream forms. It has been 
shown that some parasites upregulate arginase activity upon infection of a 
mammalian host in order to diminish arginine pools, decreasing the ability of 
nitric oxide synthase to produce toxic nitric oxide (an alternative product of 
arginine metabolism) from arginine (e.g. Salmonella (Lahiri et al., 2008), L. 
mexicana (Gaur et al., 2007), L. major (Iniesta et al., 2005), Helicobacter pylori 
(Gobert et al., 2001) and hepatitis C (Cao et al., 2009)). Upregulation of 
arginase to increase conversion of host arginine to ornithine has also been 
observed in P. falciparum-infected red blood cells (Olszewski et al., 2009). 
These adaptations protect pathogens from toxic nitric oxide and increase the 
amount of ornithine available to make polyamines, further protecting them from 
oxidative stress. This  does not seem to be the case in trypanosomes, however, 
because inducible nitric oxide synthase knock outs in mice have no effect on T. 
cruzi infections (Cummings and Tarleton, 2004) and arginase activity does not 
even seem to be present in T. b. brucei. Duleu et al.(2004) have shown that 
mice are more susceptible to trypanosome infection if arginase I and II 
expression by macrophages is increased, the increase in expression appearing to 
be induced by the trypanosomes (Duleu et al., 2004). The arginase activity was 
shown to result in a reduction in nitric oxide production, probably through the 
diversion of arginine away from nitric oxide synthase (Duleu et al., 2004), but 
would also result in more ornithine for uptake by the trypanosome. 164 
 
Foetal calf serum used in the lab is heat inactivated at 55 ºC for half an hour, 
but it has been shown that bovine arginase only loses half its activity at 77 ºC 
over 10 minutes (Rossi et al., 1983). The arginase activity detected in 
trypanosomes is very low and there could potentially be arginase activity carried 
over from the foetal calf serum (FCS) that the cells are grown in. Arginase assays 
on heat-inactivated (-0.204 units/L (a negative value is likely due to variation 
around a level of 0, rather than a decrease in urea)) and non heat-inactivated 
FCS (0.469 units/L) (one unit is defined as 1 µmole of arginine converted to 
ornithine and urea per minute at pH 9.5 and 37 ºC) revealed similar low levels of 
activity to the T. b. brucei cells, which are likely to be negligible variance 
around zero activity.  
Another test was used to ascertain whether there is arginase activity in the 
medium or not. Isotopically labelled arginine (four 
15N labels) was added to HMI-
9 with 10 % FCS (heat inactivated) and to FCS (heat inactivated) alone and left 
for two hours (Fig 5-7). Cells washed four times in CBSS were also tested for one 
hour. 
 
Figure 5-7. Heavy ornithine production from heavy arginine in medium. FCS: foetal calf 
serum, medium is the trypanosome growth medium (HMI-9 + 10 % FCS), Values show the 
percentage of label (2 labels, M+H: 135.0988, RT: 25.7 minutes) compared to non-labelled 
ornithine (M+H: 133.1047, RT: 25.7 minutes). N = 3. Error bars show the standard error of the 
mean. 
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Labelled ornithine was detected in the washed cell sample and in the HMI-9 + 
FCS sample albeit at very low levels, but not in the FCS alone. There should be 
no enzymatic activity in the HMI-9 so it must be the FCS that is causing the 
conversion, but why there is no conversion in the FCS alone is unclear. It is 
possible that there are cofactors required for arginase activity that are available 
in the medium, but not in the FCS. Manganese is known to be required for 
arginase activity and is an essential component of the arginase activity kit. It is 
also possible that arginase inhibitors present in the serum are diluted out in the 
whole medium, allowing previously blocked activity to recommence. 
Labelled ornithine was detected in the cell samples that had been washed 
thoroughly (three replicates) (Fig 5-7), confirming that cells are able to convert 
arginine to ornithine, although without producing urea, which would have been 
detected in the assay kit. 
5.3.3 The production of Ornithine 
In the absence of arginase, there may be many routes biochemically able to 
produce ornithine. Some species of bacteria are able to convert glutamate to 
ornithine via acetylglutamate and acetylornithine (Fig 5-3) (Albrecht and Vogel, 
1964). The only enzyme of this pathway found in trypanosomes, acetylornithine 
deacetylase (Tb927.8.1910) was successfully knocked out indicating that it is not 
essential in normal bloodstream form in vitro growth conditions (Eduard 
Kerkhoven, unpublished data). The recombinant protein was expressed in E. 
coli, purified and was shown to have significant deacetylase activity on several 
amino acids (Eduard Kerkhoven, Darren Creek and Felicity Lumb, unpublished 
data) but it remains to be seen whether N-acetylornithine, ornithine or 
polyamine levels are altered in the knock out line.  
Heavy isotope distribution patterns were used with several amino acid 
precursors to determine the possible route(s) of ornithine biosynthesis. Data was 
collected in positive and negative ionisation modes, but polyamine relative 
levels were acquired from positive mode data as the amine groups are more 
readily ionised in positive mode. An untargeted approach using the IDEOM 
software was used to search for labelled metabolites (see section 2.2.3.1), 166 
 
followed by a more quantitave analysis of the relative intensities of the 
metabolites using Thermo QuanBrowser. 
5.3.3.1  Glutamate distribution 
To assess whether glutamate might serve as a precursor of ornithine via the 
bacterial-like pathway (Fig 5-3) in T. b. brucei, 
15N labelled glutamate was 
added to bloodstream form cells in CBSS buffer and the isotope distribution was 
analysed after two hours. Glutamate was not taken into the cells to any 
appreciable level (data not shown) over the time frame (two hours) and the 
conditions (in CBSS at room temperature) used so no isotope distribution was 
observable. This could indicate a lack of glutamate transport, although 
glutamate transport in T. b. brucei has been measured in the past at a relatively 
low Km of 158 µM and a Vmax of 36 pmol/minute/10
6 cells (Hasne, 2000) (which is 
between the values of the two arginine transporters measured here).  
The uptake of glutamate in L. mexicana was also seen to be very low in nutrient-
rich conditions with more glutamate produced (from glucose, aspartate and 
alanine) through the TCA cycle than taken up (Saunders et al., 2011). Abrogation 
of the TCA cycle using sodium fluoroacetate, resulting in growth arrest, is 
rescued by exogenous glutamate underlining the importance of glutamate to 
normal cell growth in these parasites (Saunders et al., 2011). It is thought that 
the glutamate transporter is expressed at low levels during periods of nutritional 
abundance to prevent leakage of intracellular glutamate, but that this 
transporter can be upregulated when required. 
Trypanosome intracellular glutamate pools may also be replenished through 
synthesis from other amino acids (and possibly glucose if the Saunders data is 
corroborated) rather than through uptake. 
5.3.3.2  Glutamine distribution 
Glutamate can be produced via the removal of an amine group from glutamine 
by glutamine synthetase (EC 6.3.1.2) or glutaminase (EC 3.5.1.2 or 3.5.1.38). To 
test this theory, 
15N-labelled glutamine was applied to bloodstream form cells. 
The isotope distribution is shown in figure 5-8. 167 
 
 
Figure 5-8. The isotope distribution of glutamine in ornithine biosynthesis. Metabolites are 
shown in boxes, enzymes in italics. Bar charts show the relative intensity (area under the 
curve (divided by 10
7)) of 
14N (red) and 
15N (blue) metabolites. ND: not detected, NL: not 
labelled. Glutamine is detected at M+H: 147.0764 (
14N) or 148.0734 (
15N), RT: 15.7 minutes. 
Glutamate is detected at M+H: 148.0604 (
14N), 149.0575 (
15N), RT: 14.6 minutes. N-
acetylglutamate semialdehyde: M+H: 190.0710, RT: 5.5 minutes, acetylornithine: M+H: 
175.1077, RT: 14.5 minutes, ornithine: M+H: 133.0972, RT: 22.9 minutes. N = 3. 
 
Glutamate was labelled after two hours at 5 % of the 
14N isotope level. As the 
15N 
natural isotope abundance is 1 % and no labelled glutamate was detected in the 
control (HMI-9 plus FCS without cells) samples (data not shown), then this 
represents a significant amount of label and shows glutamine is taken into 
trypanosomes and converted to glutamate.  
Human glutaminase is thought to exist in two isoforms, termed the kidney and 
liver glutaminases (Erdmann et al., 2009). In most mammals kidney glutaminase 
is known to be localised to the mitochondrion while liver glutaminase was shown 
to be localised to the nuclei of rat and monkey brains (Olalla et al., 2002). A 
simple search for glutaminase in TriTrypdb reveals no annotated trypanosome 
gene and a BLAST search with rat glutaminase produces no trypanosome hits. A 
BLAST search with Ferrimonas balearica DSM 9799 glutaminase gives a very high 
p-value of 0.993 with a T. b. brucei gene termed “kinetoplastid-specific dual 
specificity phosphatase, putative” (Tb427.10.10670). It is very unlikely that this 
protein would have any glutamine deaminase function.  168 
 
If glutaminase were present and were also located in the mitochondrion of T. b. 
brucei, separating the glutamate from other polyamine pathway enzymes (in L. 
major, trypanothione synthetase is located in the cytosol (Oza et al., 2005) and 
the trypanothione peroxidise system in T. brucei has been shown to be cytosolic 
(Tetaud et al., 2001) although the location of all the enzymes in T. brucei have 
yet to be determined), then further conversion to ornithine may be prevented. 
This would only be true, however, if glutamate were to be retained within an 
organelle, which is unlikely as it in required in many cellular processes including 
protein synthesis. 
Glutamine synthetases are ubiquitous and are found in all domains of life with 
three isoforms distinguishable by length (360, 450 and 730 amino acids) and 
many organisms having multiple isoforms (van Rooyen et al., 2011). A putative 
glutamine amidotransferase is annotated in TriTrypdb at Tb927.7.2100. 
Amidotransferases usually add an NH2 group to an acceptor (rather than 
removing the NH3 from glutamine) but it is possible that they could work in the 
reverse direction and remove an amide if thermodynamically favourable (Keq > 
800 (Benzinger and Hems, 1956)). Tb927.7.2100 appears to be expressed in 
bloodstream and insect stages of the T. brucei life cycle (from TriTrypDB) but 
exhibits no loss of fitness when knocked down (Alsford et al., 2011). 
Other members of the pathway in figure 5-3 including acetylglutamate and N-
acetyl-glutamyl phosphate could not be detected with the mass spectrometry 
platform used. This may be due to low levels in the trypanosome, poor ionisation 
or poor stability, or they may be absent. N-acetyl-glutamate semialdehyde, 
acetylornithine and ornithine were unlabelled after two hours, which is probably 
due to the non-existence of the pathway, although the conditions of the 
experiment (cells in CBSS at room temperature for two hours) might also 
influence this. In all, the fact that the orthologues of the key enzymes are 
absent, as are the key intermediates added to the fact that 
15N-glutamine does 
not distribute to ornithine suggests that this pathway is unlikely in T. b. brucei. 
5.3.3.3  Proline distribution 
Another route to produce glutamate commences with the uptake of proline. 
Proline dehydrogenase (Tb927.7.210) converts L-proline to L-1-pyrroline 5-169 
 
carboxylate, which is then oxidised by pyrroline 5-carboxylate dehydrogenase 
(putative at Tb927.10.3210). This also occurs within the mitochondrion (Coustou 
et al., 2008), so if glutamate is not further metabolised into the polyamine 
pathway then this would support the theory that glutamate is isolated from the 
polyamine pathway enzymes. 
The 
15N amine distribution from proline was analysed in bloodstream form 
trypanosomes to detect conversions to glutamate and ascertain whether proline-
derived glutamate can be converted further to ornithine (Fig 5-9). Procyclic form 
trypanosomes were also studied for comparative purposes.  
 
Figure 5-9. The isotope distribution of proline in ornithine biosynthesis. Metabolites are 
shown in boxes, enzymes in italics. Bar charts show the relative intensity (area under the 
curve (divided by 10
7)) of 
14N (red) and 
15N (blue) metabolites. ND: not detected, NL: not 
labelled. Proline is detected at M+H: 116.0706 (
14N) or 117.0676 (
15N), RT: 16.6 minutes. 
Glutamate is detected at M+H: 148.0604 (
14N), 149.0575 (
15N), RT: 17.9 minutes. 
Acetylornithine is at M+H: 175.1077, RT: 17.9 minutes and ornithine is at M+H: 133.0972, RT: 
27.5 minutes. N = 3 
 
In bloodstream form trypanosomes the 
15N label from proline was detected in 
glutamate, but at only 3.1 % of the 
14N label after two hours. This represents a 
slight increase from 1.9 % at 0 hours and 
15N glutamate is not detected in the 
CBSS buffer. The fact that heavy glutamate is only detected at 0.17 % in samples 
where no label was added indicates that the 1.9 % seen may be due to a very 
fast uptake of proline and conversion to glutamate at the “0 hour” time point. 170 
 
The first stage in the processing of the 0 hour time point involves a cooled 
centrifugation step (method 2.2.1) that should stop enzyme activity, but 
samples do not cool immediately in the centrifuge and are still in contact with 
the medium including heavy substrate so some enzymatic activity may still be 
taking place. However, since levels of heavy glutamate after two hours are still 
not very high, a rapid conversion seems unlikely and the high background at the 
0 time point remains unexplained. 
Levels of unlabelled glutamate in the two hour samples are increased. This may 
indicate a back-conversion of glutamate from another metabolite or from 
protein and may explain why the percentage of 
15N label is relatively low. The 
increase in glutamate is mirrored in many amino acids (methionine, ornithine, 
arginine, leucine/isoleucine, valine, tyrosine and glutamine) but not all 
(phenylalanine, tryptophan, histidine and lysine do not change and alanine, 
serine, asparagine and threonine show a decreasing trend). If the increase in 
glutamate were due to an increase in protein degradation then you would expect 
all amino acids to display a similar trend, but this is not the case so the increase 
is more likely due to a metabolic change. The decreases in amino acids are 
probably due to a decrease in uptake from medium, as CBSS has no amino acid 
additives. 
Saunders et al. recently showed that the TCA cycle is used to sustain levels of 
glutamate within L. mexicana promastigotes (the insect stages). Glucose, 
aspartate and alanine were all converted to glutamate under normal culture 
conditions and inhibition of mitochondrial aconitase (required to convert citrate 
to ketoglutarate) caused a depletion in glutamate that lead to growth arrest 
that was rescued with exogenous glutamate (Sauders ét al., 2011). It may be 
that when trypanosomes are kept in glutamate-free medium (CBSS) for too long 
then they too need to produce more glutamate through the TCA cycle and 
through glutamine and proline. The uptake of glutamate in bloodstream form 
trypanosomes does not appear to be very efficient (see section 1.3.3.1) so levels 
may have to be maintained through anabolic or catabolic processes within the 
trypanosome. 
The IDEOM software also detected the heavy label in alanine (M+H: 90.0549 
(
14N), 91.0519 (
15N), RT: 18.0 minutes) at 28 % of the unlabelled after two hours. 171 
 
Alanine could be an artefact caused by the fragmentation of proline or 
glutamate. If this were the case then the retention time of alanine (18.0 
minutes) would match the retention time of proline (16.6 minutes) or glutamate 
(17.9 minutes). As the retention times of glutamate and alanine are very similar, 
it cannot be determined whether the alanine is a fragment of glutamate or if it 
occurs enzymatically, but as the percentage of incorporation is higher than that 
for glutamate it can be assumed that the alanine peaks are not fragments. It has 
been shown that glutamate donates a nitrogen to pyruvate to produce alanine 
through L-alanine aminotransferase (Tb927.1.3950) (Fig 5-10) in procyclic 
trypanosomes, but this mechanism is not thought to exist in bloodstream forms 
of the parasite (Coustou et al., 2008). Derek Nolan‟s lab in Dublin, Ireland found 
that alanine aminotransferase knockouts could not be created in bloodstream-
forms, although high levels of RNA knock down resulted in no growth phenotype 
(Spitznagel et al., 2009), which indicates that alanine aminotransferase is 
important to bloodstream form trypanosomes, but very low levels are sufficient 
to maintain metabolic activity. 
 
Figure 5-10. The amine group from proline can be tracked to glutamate, aspartate and 
alanine in bloodstream cells. 1: Pyrroline dehydrogenase and Pyrroline carboxylate 
dehydrogenase, 2: TCA cycle to pyruvate and alanine aminotransferase, 3: aspartate 
aminotransferase. Percentages show the incorporation of heavy label as a percentage of 
unlabelled amino acid after two hours in heavy proline. 172 
 
Other data from our laboratory shows that 
13C-labelled glucose produces high 
levels of alanine in bloodstream form trypanosomes (Jana Anderson, University 
of Glasgow) as did early NMR experiments by Neil Mackenzie (Mackenzie et al., 
1983). This suggests that the endpoint of bloodstream form glycolysis may not 
always be pyruvate as has previously been thought (Opperdoes and Borst, 
1977;Bakker et al., 1997;Bringaud et al., 2006). 
Glutamine was also found to be labelled after two hours of 
15N-proline exposure 
in bloodstream form parasites, but at levels of incorporation at only 1.3 % of 
unlabelled, the levels were not significantly higher than the expected natural 
isotope abundance of 1 %. Aspartate (M+H: 134.0447 (
14N), 135.0417 (
15N), RT: 
18.63 minutes) was heavily labelled at 78 % of unlabelled after two hours. 
Oxaloacetate can be transaminated from any donor amino acid by L-aspartate 
aminotransferase (Tb927.10.3660) to form aspartate. If oxaloacetate is 
generated from glutamate then ketoglutarate would be formed that could feed 
into the TCA cycle producing energy or other metabolites. This may be the case 
in procyclic forms, where aspartate was labelled at 118 % of unlabelled, but in 
bloodstream forms the TCA cycle is not thought to be active (Durieux et al., 
1991). Recent evidence, however, indicates that many of the enzymes of the 
TCA cycle are active, at least in cultured bloodstream forms (Jana Anderson, 
unpublished data), hence it is possible that the cycle is operative in cultured 
forms of the bloodstream-form parasite. Ketoglutarate (not detectable with our 
mass spectrometry method due to its high acidity) is a metabolite that is 
involved in many reactions, but usually as an end product, so the reasons for its 
hypothesised production increase in bloodstream forms is unclear.  
In procyclic forms of the parasite the same experimental setup resulted in 
greater incorporation of the label into glutamate (75 % of unlabelled), which 
could be tracked further into glutathione (17 %) and trypanothione disulphide 
(10 %). Glutamine was also labelled at 4.7 % and alanine had a greater 
incorporation than bloodstream forms at 81 %. Procyclic forms of the parasite 
have been shown to use proline as a carbon source when glucose is not available, 
reflective of the nutrient situation in the tsetse midgut (Coustou et al., 2008). 
The proline is converted to glutamate and further to ketoglutarate (Coustou et 
al., 2008), which enters the tricarboxylic acid cycle. This may provide energy for 
the cell or may be part of a reduced cycle providing, for example, citrate to be 173 
 
converted to acetate for lipid synthesis (van Weelden et al., 2005). The greater 
incorporation of label into glutamate is likely to be due to this different energy 
source requirement in procyclic trypanosomes and the increased glutamate was 
able to disseminate its amine group down the polyamine pathway into 
glutathione and trypanothione.  Unfortunately, incorporation into the 
tricarboxylic acid cycle cannot be tracked as the heavy nitrogen is lost on 
aspartate during the formation ketoglutarate.  
The proline to glutamate pathway is in the mitochondrion of procyclic form 
trypanosomes. From this data it is clear that compartmentalisation of this 
pathway does not hinder further progress to trypanothione in insect stages. 
Glutamate was labelled in both stages of the parasite, but the label was not 
incorporated into ornithine in either stage. This does not disprove the existence 
of a glutamate to ornithine pathway in trypanosomes, but shows that it was not 
active in the conditions used and makes it less likely that acetylornithine is 
produced in this way. 
5.3.3.4  Lysine distribution 
Gaston et al. (2011) showed recently that lysine can be used to produce 
methylornithine through PylB, which may in turn become demethylated to 
become ornithine in the pyrrolysine pathway (Fig 5-11). 
15N-lysine was therefore 
assessed for its potential contribution to the polyamine pathway with a 
conceivable route through methylornithine in T. brucei. 174 
 
 
 
Figure 5-11. Lysine can be converted to methylornithine via PylB in Methanosarcina spp. 
SAM: S-adenosyl methionine, used in the conversion of lysine to methylornithine. From 
(Gaston et al., 2011).  
 
The heavy label was not found to be passed on to any of the polyamine 
metabolites during the two hour assay, nor was it passed on to any other 
metabolite detected by IDEOM. As methylornithine has the same mass as lysine 
(it is a stereoisomer) and a very similar predicted retention time on the HILIC 
column (a retention factor of 2.5 compared to 2.4 for lysine (from the Sequant 
retention time predictor at www.sequant.com/prediction)), it was not possible 
to ascertain whether heavy methylornithine had been obtained. A retention time 
more specific for the University of Glasgow metabolomic platform could be 
obtained by running a standard for methylornithine through the apparatus, but 
as it is likely that this would be difficult to separate from lysine and ornithine 
was not labelled in this experiment this avenue was not pursued. 
A search for genes annotated with pyrrolysine or PylB in kinetoplastids revealed 
no hits and a BLAST search with the Methanosarcina barkeri PylB protein 
sequence (GenBank accession: AAL40868.1) produced just one hit of a 
probability of 0.73 with a T. vivax hypothetical gene (TvY486_0044100). A BLAST 
search of the T. vivax hypothetical gene on the NCBI database produced no 
significant hits. It appears that this route of ornithine production does not exist 
in T. b. brucei. 175 
 
5.3.3.5  Ornithine distribution 
No labelling of ornithine from glutamate, glutamine, proline or lysine was found. 
If the acetylornithine deacetylase enzyme works reversibly, then another 
possible means to seek the source of ornithine involves adding labelled ornithine 
to cells to allow the pathway involved in its production to be identified. 
Ornithine labelled with two heavy nitrogens was added to cells and was found to 
be taken up into the trypanosomes and converted to acetylornithine (Fig 5-12).  
 
 
Figure 5-12. The isotope distribution of ornithine. Metabolites are shown in boxes, enzymes 
in italics. Bar charts show the relative intensity (area under the curve (divided by 10
6)) of 
14N 
(red),
 15N (green) and 2*
15N (blue) metabolites. ND: not detected, NL: not labelled. Ornithine 
is detected at M+H: 133.0972, (
14N), 134.0942 (
15N), or 135.0912 (2*
15N), RT: 22.8 minutes. 
Acetylornithine is detected at M+H: 175.1077 (
14N), 176.1048 (
15N), or 177.1018 (2*
15N), RT: 
14.4 minutes. Spermidine is detected at M+H: 146.1652, (
14N), 147.1622 (
15N), or 148.1592 
(2*
15N), RT: 37.7 minutes. Spermidine was not detected with 3*
15N. Glutathione is detected at 
M+H: 308.0911, RT: 13.4 minutes and trypanothione disulphide at M+H: 722.2960, RT: 23.5 
minutes. N = 3. 
 
The acetylornithine was labelled at 287 % of unlabelled after two hours. This is a 
very significant back-conversion when compared to 0.7 % at 0 hours, which is 
interesting as acetylornithine deacetylase was thought to favour the 
deacetylation direction, with a Keq for amino acids usually in the range of 3 – 33 
(NIST database (Goldberg et al., 2004)), meaning you would need around 3 - 33 176 
 
fold more ornithine to reverse the direction of the reaction. However, there may 
be other acetylases and acetyltransferases yet to be annotated within the T. b. 
brucei genome and clearly ornithine is being acetylated at a high rate in these 
experimental conditions. The relative levels of ornithine and acetylornithine 
support a Keq of around 100 (ornithine is detected at approximately 100 times 
the intensity of acetylornithine, data not shown) if there is no 
compartmentalisation of the two metabolites.  
Acetylornithine has the same mass as the glycine-valine dipeptide, prolinyl-
glycine and ethyl-glutamine (175.1077 (
14N) or 177.1018 (2*
15N)), but the 
retention times are different at 14.4 minutes for acetylornithine, a calculated 11 
minutes for the dipeptide and prolinyl-glycine and 12 minutes for ethyl-
glutamine (using RT calculator, developed by Darren Creek, University of 
Glasgow). Further confirmation that the detected mass relates to 
acetylornithine and not its isomers comes from a targeted analysis of the valine, 
proline, glutamine and glycine amino acids separately, which revealed no 
15N 
incorporations making it highly unlikely that the amino acid derivatives were 
labelled and confirming that the mass detected was acetylornithine.   
It is interesting that the total levels of both ornithine and acetylornithine 
increase over the two hours in CBSS. It may be that the cells are stressed in this 
buffer solution and are therefore taking in increased ornithine for the production 
of trypanothione, although thiol production using the heavy metabolites is not 
observed in the two hour time frame. 
No metabolite further back along the glutamate to ornithine pathway (Fig 5-3) 
was labelled. This may be because this pathway is not in use or because the 
conditions and length of time used in the assay were not conducive to their 
labelling, but the most likely reason is that this pathway is absent in 
bloodstream form trypanosomes. 
Arginine was detected as its natural isotope, but a heavy isotope (of one, two or 
four labelled nitrogens) was not detected.  
Chapter 3 of this thesis showed that ornithine is transported into bloodstream 
form trypanosomes. Whether this transport would be sufficient to provide all the 177 
 
amines for the polyamine pathway is unclear although a metabolic model of the 
polyamine pathway, developed by Dr. Xu Gu, University of Glasgow, suggests 
that it would be (Dr. X u Gu, personal communication). Ornithine was quantified 
in HMI-9 + FCS by spiking a range of concentrations of 2*
15N ornithine into HMI-9 
for mass spectrometry. The absolute concentration of ornithine in HMI-9 + FCS 
could then be ascertained using a calibration curve for the known concentrations 
of the heavy isotope. Ornithine in HMI-9 + FCS was found to be at 77 µM from 
this method (Fig 5-13). Published levels of ornithine in human adult blood are 
54-100 µM (HMDB) and in CSF the levels are around 5 µM (HMDB). 
 
Figure 5-13. Ornithine quantification in medium. Ornithine levels (M+H : 133.0972, RT: 22.2 
minutes) in HMI-9 + 10 % FCS were quantified using a calibration curve of 2*
15N ornithine 
(M+H : 135.0912,  RT: 22.2 minutes) spiked into HMI-9 + FCS over a range of concentrations. 
Ornithine levels were found to be at 77 µM. 
 
The level of ornithine in blood is similar to the reported arginine concentration 
of 70 µM found within trypanosomes (Smith et al., 2009). It seems possible 
therefore that sufficient ornithine could be transported into the trypanosome 
directly, bypassing the need for an arginase enzyme.  178 
 
Ornithine uptake into bloodstream form trypanosomes was measured with an 
estimated Vmax (the curve was not adequately level for an accurate 
measurement) of 40 pmol/min/10
6 cells and a Km of approximately 300 µM (Fig 
5-14).  
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Figure 5-14. Ornithine uptake in bloodstream form T. b. brucei. One of two repeats is shown. 
Levels shown are for 10
7 cells. 
 
The Km of a transporter is usually similar to the concentration of the substrate in 
the natural medium, allowing maximum efficiency of uptake, so this Km is very 
high when compared to the measured level of ornithine in blood and in HMI-9 + 
FCS and may not be very accurate. The measurement of ornithine uptake may be 
complicated if there are several transporters contributing to the total uptake 
rate. This would explain why the uptake curve was not saturated in increasing 
ornithine concentrations. More analysis of ornithine uptake is required. 
A longer-term analysis of ornithine amine incorporation would allow an 
assessment of how much ornithine contributes to the overall production of 
glutathionylspermidine and trypanothione. Ornithine is found in the serum used 
to produce the trypanosome growth medium. An attempt was made to create 
ornithine-free medium using ornithine transcarbamoylase (6 units per 500 ml 
medium) and 700 µM carbamoyl phosphate. Ornithine transcarbamoylase adds a 179 
 
carbamoyl group to ornithine to create citrulline and is thought to greatly favour 
the citrulline direction thermodynamically (Reichard and Reichard, 1958). 2*
15N- 
ornithine was then added to the medium with cells and the incorporation was 
analysed over four hours. Interestingly, heavy putrescine could not be detected 
in the cells over the four hour time course, but heavy spermidine (M+H: 
148.1593, RT: 42.0 minutes) increased steadily (Fig 5-15). This suggests that 
putrescine is a transient metabolite in these cells and the flux favours storage of 
spermidine.   
 
Figure 5-15. Spermidine is labelled from ornithine over four hours. Results are shown as a 
percentage of labelling. This study was performed just once so error bars are not available. 
 
The Bacchi et al. and Fairlamb et al. studies measured levels of putrescine and 
spermidine. The Bacchi study found natural levels of putrescine at an average of 
6.95 ± 2.22 nmol per mg protein (average of four ± s.e.m), four times lower than 
the spermidine levels (Bacchi et al., 1983). The Fairlamb study found levels of 
putrescine to be around three times lower than spermidine (Fairlamb et al., 
1987). This supports the theory that putrescine is not stored, but is instead 
rapidly converted to spermidine, although some labelled putrescine would still 
be expected. This assay for longer term incorporation in rich medium will need 
to be repeated, possibly over a longer period. 
Heavy trypanothione (with two heavy nitrogen labels M+H: 724.2901) was 
detected at 1.7 % of the 
14N isotope after one hour and 1.8 % after two hours. 180 
 
The heavy label was however, undetectable after four hours in heavy ornithine. 
As the heavy spermidine levels were high after four hours, the lack of heavy 
trypanothione is interesting. The cells were not under stress as they were 
growing in normal growth medium so were perhaps not producing any new 
trypanothione, but why the levels of heavy trypanothione already made should 
decrease is unclear. The trypanothione must have been metabolised, either back 
to spermidine or through some, as yet unidentified, pathway. From the mode of 
action studies with toxic doses of eflornithine in the previous chapter (section 
4.2.1.3) it was seen that trypanothione levels are not depleted significantly as 
the cells are dying whereas spermidine levels are. It was therefore thought that 
decreases in spermidine may be more important in eflornithine trypanocidal 
action than trypanothione. Maintaining high levels of spermidine in these 
experiments may therefore be attained by catalysis of the less important 
trypanothione. Glutathione levels in this assay decrease to approximately 30 % of 
the 0 hour level after four hours, in contradiction to this hypothesis, although 
the glutathione may also be catalysed to produce other metabolites, such as 
cysteine. 
5.3.3.6  Arginine distribution 
Since it seems that arginine can produce ornithine within the trypanosomes, in 
spite of an apparent absence of arginase, a more detailed analysis of the fate of 
arginine was performed. The role of arginine within the trypanosome was 
investigated using arginine labelled with four heavy nitrogen atoms (Fig 5-16). 
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Figure 5-16. The isotope distribution of arginine. Metabolites are shown in boxes, enzymes 
in italics. Bar charts show the relative intensity (area under the curve (divided by 10
6)) of 
14N 
(red), 
15N (purple), 2*
15N (blue) and 4*
15N (green) metabolites. ND: not detected, NL: not 
labelled. Arginine is detected at M+H: 175.1190 (
14N), 176.1160 (
15N), 177.1131 (2*
15N), 
179.1073 (4*
15N), RT: 22.1 minutes. Ornithine is detected at M+H: 133.0972, (
14N), 134.0942 
(
15N), or 135.0912 (2*
15N), RT: 22.8 minutes. Acetylornithine is detected at M+H: 175.1077 
(
14N), 176.1048 (
15N), or 177.1018 (2*
15N), RT: 14.3 minutes. Spermidine: M+H: 146.1654, RT: 
37.9 minutes, glutathione: M+H: 308.0911, RT: 13.4 minutes, trypanothione disulphide: M+H: 
722.2960, RT: 23.6 minutes. N = 3 
 
Arginine was converted to ornithine (10 % of unlabelled) and further into 
acetylornithine (0.7 %) (confirmation was obtained that the potential isomer 
constituents for acetylornithine (glycine and valine) were not labelled (see 
section 5.3.3.5)). As there is no arginase activity within the trypanosome it is 
unclear how this conversion could take place. It is possible that there is an as 
yet unknown mechanism to convert arginine to ornithine without creating urea 
(urea would have been detected in the arginase activity kit).  
A targeted analysis of the urea cycle intermediates was undertaken to ascertain 
whether this cycle could be working in reverse to produce ornithine from 
arginine via argininosuccinate and citrulline. 
14N peaks for citrulline were of very 182 
 
low intensities (an average 14, 000 (area under the curve) where one would 
normally consider anything with an intensity below 10, 000 as noise), so labelled 
peaks would not have been expected.  Argininosuccinate could not be detected 
on our mass spectrometry platform, although it would be thought to be detected 
in either positive or negative ionisation mode, so its levels must be below the 
limit of detection or not present at all. The absence of detectable 
argininosuccinate and the lack of label detected in citrulline mean that it cannot 
be determined whether the ornithine produced was a result of the urea cycle 
(Fig 5-2) working in reverse or through some other mechanism. 
The IDEOM software detected labelling in 4*
15N CDP ethanolamine (M+H: 
449.0423, RT: 22.2 minutes), 4*
15N arginine phosphate (M+H: 257.0586, RT: 21.3 
minutes), 3*
15N imidazole ethanamine (M+H: 115.0778, RT: 22.2 minutes) and 
3*
15N piperazine carboxamide (M+H: 133.0883, RT: 22.2 minutes) as well as the 
ornithine and acetylornithine already discussed. The retention times of the 
masses labelled as imidazole ethanamine and piperazine carboxamide are similar 
to that of arginine (22.1 minutes) making it likely that they are fragments, 
adducts or other artefacts of the very abundant arginine peak. CDP 
ethanolamine, also has a similar retention time to arginine, but does not appear 
to be a fragment or be a related to arginine through an adduct multimer of a 
fragment. CDP ethanolamine may therefore be labelled with four heavy amide 
groups from arginine, although its synthesis from arginine is not obvious. The 
mass for the labelled CDP-ethanolamine if around 10 times higher than the mass 
of unlabelled CDP-ethanolamine, which is unlikely to occur naturally as arginine 
would have to be catabolised to small amine-containing compounds to 
reconstitute to CDP-ethanolamine. This mass is therefore thought not to be 
labelled CDP-ethanolamine, but is unexplained.  
Arginine phosphate has a retention time that differs by nearly one minute from 
arginine meaning that this is probably a real peak and arginine has been 
phosphorylated in these cells. There are three arginine kinase genes present in 
T. b. brucei (Tb.09.160.4560, Tb.09.160.4570 and Tb.09.160.4590), which are 
syntenic with a proven arginine kinase in T. cruzi (Pereira et al., 2003). 
A longer term assay in HMI-9 showed that ornithine is only produced from heavy 
arginine at very low levels over four hours (Fig 5-17), and heavy acetylornithine 183 
 
was not produced at all. The retention times of ornithine and arginine are very 
similar in this assay (RT: 25.2 minutes for arginine, 25.7 for ornithine) meaning 
that the heavy ornithine seen could also be a fragment of arginine. This suggests 
that ornithine and acetylornithine are only made from the catalysis of arginine 
during stress conditions (e.g. in CBSS, where ornithine is lacking). Citrulline 
levels were much higher in this analysis, and 
15N citrulline was detected at 0.3 % 
of light, although this was constant over all time points suggesting that the 
levels detected were merely the natural isotope. 
 
Figure 5-17. Ornithine is produced from heavy arginine over four hours, but only at very low 
levels. N = 1. 
 
Of the enzymes in the urea cycle, only Tb927.8.2020 (proven not to be an 
arginase) and a putative aspartate carbamoyltransferase (Tb427.05.3820) could 
be found with text searches. A BLAST search with this carbamoyltransferase 
protein sequence confirmed that it held a high degree of similarity with 
carbamoyltransferases from many other organisms. The argininosuccinate lyase 
or synthase could not be found in TriTrypDB from BLAST searches with gene 
orthologues from a range of other organisms. Arginine deiminase is predicted to 
be able to convert arginine to citrulline directly releasing ammonia instead of 
the urea released in the production of ornithine (detected in the arginase assay). 
This bypasses the need for argininosuccinate lyase and argininosuccinate 
synthase (Morada et al., 2011). A T. congolense gene in TriTrypDB is an 
orthologue of a group of bacterial glutamine deiminases (81 % identity with a 184 
 
Pseudomonas gene), but a match in T. b. brucei could not be found. A BLAST 
search with a Helicobacter mustelae deiminase produced a tenuous match with 
Tb427tmp.211.1070, a hypothetical protein, but with a p value of just 0.996, it 
is not a good match. 
Apart from in the case of arginine deiminase, citrulline is only known to be made 
from ornithine-containing compounds (acetylornithine can be converted to 
acetylcitrulline and then deacetylated, or succinylornithine can be converted to 
succinylcitrulline and desuccinated). Uptake of citrulline in trypanosomes cannot 
be ruled out, indeed a protein predicted to transport ornithine and citrulline 
exists in mammals termed ORNT1 (Tonazzi and Indiveri, 2011;Camacho et al., 
2006), although BLAST searches in kinetoplasta revealed no orthologues. 185 
 
5.4 Discussion 
Bloodstream form T. b. brucei take in ornithine.  This ornithine uptake would be 
unnecessary if the arginase enzyme were functioning. The lower rate of arginine 
uptake compared to Leishmania, which have relatively high levels of arginase 
activity, suggests that T. brucei require less arginine than other 
trypanosomatids. 
Ornithine was found to be present in the bloodstream form T. brucei growth 
medium at a level of 77 µM. It was thought that there may be arginase activity in 
the foetal calf serum used to prepare the trypanosome growth medium, which 
would produce the ornithine. The arginase assay and use of heavy arginine failed 
to substantiate this claim, as FCS alone was not seen to produce ornithine from 
arginine, although growth medium with 10 % FCS was able to produce a small 
amount. This may be due to cofactors in the growth medium or to the dilution of 
inhibitors in the FCS.  
Levels in human serum are similar to the 77 µM seen in the medium, but in 
cerebrospinal fluid are significantly less at around 5 µM (HMDB). The levels in 
tsetse haemolymph have not been measured. The metabolism of trypanosomes 
in CSF or in haemolymph is not well understood, although it is known that in the 
haemolymph (procyclic forms) trypanosomes rely much more on amino acid 
metabolism than glucose for energy (Coustou et al., 2008). 
In summary of the amino acid label distributions, glutamate and lysine were 
either not taken into the cell or were not converted to any other amine-
containing metabolites. The amine group from glutamine was incorporated into 
glutamate only. Proline was converted to glutamate, alanine, aspartate and 
glutamine in bloodstream-forms and further to glutathione and trypanothione 
disulphide in procyclic-forms. Ornithine was found to only label acetylornithine 
when in CBSS for two hours, but in HMI-9, spermidine and trypanothione 
disulphide were found to be labelled. Arginine labelled ornithine and 
acetylornithine when in CBSS, where ornithine is absent, but not when in 
ornithine-rich HMI-9, and arginine phosphate. Glutamate is not thought to be 
converted to ornithine and it seems likely that ornithine can be both taken up 186 
 
through transport and synthesised from arginine. We can hypothesise from the 
evidence presented here that ornithine uptake is sufficient for polyamine 
synthesis in normal growth conditions but when no ornithine is present it can be 
synthesised from arginine. 
An interesting hypothesis for the reason that T. b. brucei do not encode an 
arginase within their genome is put forward by Canepa et al. (2011). Vertebrates 
use creatine phosphate as the main phosphagen for energy storage. T. brucei, 
Leishmania and T. cruzi parasites do not encode a creatine kinase (TriTrypDB), 
however, and are thought to use arginine phosphate instead as a stored source 
of energy. Arginine kinase would compete directly with arginase for arginine and 
it was suggested that trypanosomes and other arginase-lacking organisms 
evolved other ways to produce ornithine in order to create high levels of 
arginine phosphate for stored energy. T. brucei encodes at least three arginine 
kinases (Tb09.160.4560 (not essential (Alsford et al., 2011)), Tb09.160.4570 and 
Tb09.160.4590) and T. cruzi has one annotated (Tc00.1047053507241.30) and 
several putative arginine kinases, but leishmania do not have any annotated. The 
fact that leishmania possess an arginase, but no arginine kinase and neither of 
the trypanosomes have an arginase, but do have arginine kinases supports this 
arginine competition hypothesis. It should be noted that arginine phosphate has 
been observed in leishmania, although whether this phosphorylation occurs 
through arginine kinase or through an unspecific phosphatase is not verified 
(Malcolm McConville, personal communication). Further evidence for the 
hypothesis comes from studies in our lab that show arginine phosphate 
increasing upon introduction of the oxidative stress inducer, methylene blue 
(Dong-Hyun Kim, unpublished data).  
The absence of arginase in African trypanosomes is clear, but heavy arginine was 
still seen to be converted to ornithine although the way that this conversion 
takes place is unclear. The shortest routes from arginine to ornithine are through 
the urea cycle, requiring the cycle to operate in the opposite direction to 
normal or through arginine deiminase. The other intermediates in the urea cycle 
could not be detected, however, or were detected at very low levels, so proof of 
this theory could not be obtained. A different mass spectrometry platform (such 
as using a pHILIC column for the chromatography, which has been shown to 
provide better separation for succinate (Dr. Gavin Blackburn, University of 187 
 
Strathclyde)) may allow better detection of arginosuccinate and citrulline to 
analyse incorporations from heavy arginine. Although if the problem is one of 
low abundance then simply using more cells may help. 
5.4.1 A role for acetylornithine 
Acetylornithine is produced from ornithine at detectable levels within a two 
hour time span, but the mechanism for this conversion is unclear. It was 
hypothesised that acetylornithine was produced from glutamate as a 
consequence of T. b. brucei’s lack of arginase activity. This hypothesis could not 
be proven in the time scale and conditions used and the pathway is unlikely to 
be present in bloodstream form trypanosomes.  
Ornithine is transported into cells and converted to acetylornithine rapidly, 
reaching a labelled level three times that of unlabelled after two hours in CBSS 
with heavy ornithine. The reasons for this conversion are unclear. In 
Mycobacterium tuberculosis it was shown that acetylornithine deacetylase 
reversibly transfers the acetyl group of acetylornithine to glutamate as part of 
arginine biosynthesis (Sankaranarayanan et al., 2010), but this pathway is 
thought to be confined to bacterial species and metabolites further along the 
pathway from acetylornithine were not observed in T. b. brucei. There may be 
other enzymes capable of the acetylation of ornithine that have yet to be 
verified in the T. brucei genome. 
If arginine to ornithine conversion were not possible, and uptake was the only 
source of ornithine, then it might be advantageous to store some ornithine as 
acetylornithine for use when blood levels are lower. However, arginine was 
observed to produce ornithine when exogenous ornithine was lacking through an 
alternative route to the classical arginase pathway. This route may be the urea 
cycle working in reverse, but could not be determined as levels of citrulline are 
too low for accurate measurement and argininosuccinate cannot be analysed on 
the mass spectrometry platform used. Furthermore, argininosuccinate lyase and 
synthase (or arginine deiminase) gene sequences could not be found within the 
T. brucei genome. The lack of gene sequences homologous to identified genes 
does not rule out their existence, however, especially in the case of arginine 
deiminase, where very few genes have been characterised. 188 
 
The data appears to show that stress, either through eflornithine (section 4.2.1) 
or through nutritional deprivation (e.g. in CBSS) increases the production of 
acetylornithine. It has been shown in human cells that acetylation of polyamines 
occurs more in cancerous cells compared to healthy cells (Kingsnorth and 
Wallace, 1985) and these acetylated polyamines (spermidine and spermine) are 
involved in the generation of reactive oxygen species leading to apoptosis 
(Wallace et al., 2003). The enzymes required for this free radical production 
include an acetyltransferase and a polyamine oxidase. A polyamine oxidase 
could not be found in trypanosomes through BLAST searches with known 
polyamine oxidases, however, so the apoptosis mechanism may not be present in 
trypanosomes. 
5.4.2 The use of heavy labelling to interrogate pathways 
The advantages of using heavy labelling to interrogate pathways are clear. The 
mzMatch and IDEOM softwares were very useful for producing untargeted 
analyses of each experiment. They did not, however, always identify all of the 
metabolites that were labelled in each experiment. This is probably due to the 
rigorous filters built into the softwares that aim only to report those peaks with 
a high reproducibility, which may not always be appropriate for smaller scale 
biological experiments where creating a lot of power by increasing numbers of 
replicates isn‟t always possible or cost effective. A targeted approach was 
therefore also used to look for metabolites that were missed by the automated 
programmes. This is much more time consuming and requires a prior hypothesis 
to determine which metabolites to seek. More labelled metabolites were 
reported using a targeted approach. 
Levels of labelled metabolites were often relatively low in these experiments, 
which is probably reflective of the conditions used. The leishmania 
13C labelling 
experiments performed by Saunders et al. (2011) were undertaken in a 
completely defined medium, which included amino acids, vitamins, heme, 
bovine serum albumin (BSA) and fatty acids (bound to the BSA). This more 
complete medium is likely to contain many more cofactors and essential 
nutrients for efficient labelling. Labelling in the leishmania experiments was also 
conducted for two days prior to quenching, allowing an equilibrium of labelled 189 
 
to non-labelled atoms to be reached providing more detailed information on 
which metabolites are taken up from medium and which are produced through 
anabolic and catabolic reactions within the parasite. The van Weelden 
experiments were also conducted in rich medium replacing metabolites under 
test with heavy isotopes (van Weelden et al., 2005). The labelling in the 
experiments described in this chapter was mainly conducted in CBSS buffer 
solution at room temperature. This is sufficient to keep bloodstream form cells 
alive for up to eight hours, but the cells may not be metabolising as they 
normally would and may lack essential precursors and cofactors. The creation of 
drop out medium is quite time-consuming, however, and adaptation to the 
medium may be required by the parasites as was seen in the van Weelden 
experiments (van Weelden et al., 2005). A minimal defined medium for 
bloodstream form trypanosomes has not been created before, but is a priority 
for future metabolomics experiments. The relative ease of conducting 
experiments in CBSS and the lack of necessity of an adaptation stage means that 
parasites can be assayed with their metabolic machinery in a natural state. The 
medium also contains much fewer contaminating metabolites so cells do not 
require a washing step, which can be stressful to the cells and cause reactionary 
metabolism. Both protocols are therefore useful and complementary for 
measuring short term and longer term incorporations. 
One of the major disadvantages of mass spectrometry over nuclear magnetic 
resonance is that it is not quantitative. Here, we have shown that metabolites 
can be quantified using a calibration curve of the heavy isotope (Fig 5-13). A 
replete labelled metabolome could be created by growing a culture of cells on a 
labelled carbon source for several generations until every carbon in the 
metabolome were labelled as has be done previously by Kiefer et al. with M. 
Extorquens (2008). This metabolite mixture, could have each metabolite 
quantified and be used to spike into samples with unknown metabolite levels for 
quantification. This is an aim for the metabolomics community in the near future 
and is being validated in our laboratory by Dr. Dong-Hyun Kim. 190 
 
  6. Final Conclusions 
The main findings of this thesis are: 
  Eflornithine resistance is rapidly selected in the laboratory (chapter 3). 
  In vitro resistance to eflornithine is due to the loss of TbAAT6, an amino 
acid transporter able to transport eflornithine into bloodstream form 
trypanosomes (chapter 3). 
  Metabolomic methods to predict the mode of action of drugs against T. 
brucei work in untargeted analyses (chapter 4). 
  Acetylornithine is produced in large quantities from ornithine and levels 
correlate highly with ornithine when the polyamine pathway is perturbed 
(chapter 4 and 5). 
  Ornithine is not produced from arginine under normal growth conditions, 
but is when cells are in buffer solution lacking nutrients (chapter 5). 
  Tb927.8.2020, previously annotated as arginase, is not an arginase 
(chapter 5). 
  Sedoheptulose, sedoheptulose phosphate and erythrose phosphate are 
present in in vitro grown bloodstream form T. b. brucei, suggesting some 
aldolase or transketolase action or possibly a novel phosphoketolase 
(chapter 4). 
  Nifurtimox-eflornithine combination therapy is not synergistic in vitro as 
has been shown in isobologram and metabolomic analyses (chapter 4). 
Studies into the mode of drug action and resistance in trypanosomes are of 
paramount importance if we are to achieve the aim of bringing this treatable 
disease under control. The drugs in use against HAT are insufficient due to lack 
of efficacy against late stage disease (pentamidine and suramin), unacceptable 
toxicity (melarsoprol) and emerging resistance (eflornithine and melarsoprol). 191 
 
The latest therapy for use against HAT is the drug combination NECT. The uptake 
of this new therapy has been much more rapid than the uptake of eflornithine 
alone was in the 1990s, mainly due to the reduced quantities required and 
therefore the reduction in transportation costs. 
The emergence of resistance to eflornithine is of real concern and may thwart 
the use of the new combination therapy as nifurtimox monotherapy is ineffective 
at the dose used in the combination therapy. Tests for resistance in the field 
would therefore be extremely useful for assigning treatment regimes to 
patients.  
We present here a substantial body of evidence that an amino acid transporter, 
TbAAT6, is lost in eflornithine resistance in vitro and can be responsible for 
resistance when knocked down by RNAi. The natural substrate for this 
transporter is not known, but as the transporter is not essential in bloodstream 
forms of the parasite it is expected that the natural substrate would have 
multiple modes of entry to the cell or is able to be synthesised de novo by the 
parasite. It would be interesting to find out the natural substrate of TbAAT6. It 
is possible that this transporter is not essential in the artificial growth medium 
used in the laboratory, but in a different environment (e.g. in vivo) may have 
increased importance, although the fact that the resistance phenotype was 
retained in mice would contradict this argument. A different resistance 
mechanism may occur in the field. A cell line selected for eflornithine resistance 
was created by Frank Jennings (University of Glasgow) by passage through 
eflornithine treated mice. It will be interesting to test this cell line for the 
absence of TbAAT6.  
In the field the loss of TbAAT6 may have more detrimental effects on the 
parasite than it would in an in vitro environment. The human-infective strains 
may have different nutrient requirements or human blood may have a different 
nutrient availability than mouse blood that prevents the loss of TbAAT6. The 
monomorphic strains in the laboratory are also not passed through the tsetse fly 
vector so if TbAAT6 is essential for growth in the tsetse midgut or survival in the 
tsetse salivary glands, for example, then the resistance phenotype would not be 
passed on in the field. Studies on the essentiality of TbAAT6 in procyclic form 
trypanosomes were inconclusive. A TbAAT6 RNAi line showed no growth 192 
 
phenotype when induced, but levels of gene knockdown were not measured. 
Another RNAi line for TbAAT6 created by David Horn‟s laboratory in London did 
reveal a lethal phenotype in a large scale RNAi assay (Baker et al., 2010), but on 
further, more targeted analyses, the knock down was found not to be essential 
in procyclic forms (David Horn, personal communication). It is of note that 
recent evidence suggests a role for TbAAT6 in proline uptake (Doris Rentsch, 
personal communication), which would be likely to have a negative effect, if 
lost, in procyclic forms of the parasite given their dependence on proline as an 
energy source. Growth curves for the procyclic TbAAT6 RNAi line should 
therefore be attempted in SDM80 medium, which lacks glucose, allowing proline 
to be used as an energy source. 
Attempts to assess the status of TbAAT6 in field isolates of eflornithine 
refractory parasites in blood samples were unsuccessful. The levels of 
parasitaemia in these samples were known to be very low. Methods of 
concentrating parasites for PCR in the field have been developed (Buscher et al. 
2009) as have more sensitive PCR methods (Ahmed et al., 2011) so it will be a 
priority in the field to optimise the protocols for testing the TbAAT6 status. 
Determining the mode of action of new active compounds against HAT is also 
going to be important for licensing, prediction of toxicity and the prediction of 
synergism with other compounds. Here we show a method for determining the 
mode of action of trypanocides using a metabolic approach. Eflornithine was 
used as a proof of principle with sub IC50 doses causing very localised changes to 
the metabolic network and higher doses causing many more changes as the cells 
are dying from the drug. The fact that the analysis was untargeted, but still 
picked out the metabolites that would be most expected to changes with 
eflornithine addition is very promising. 
For our studies of eflornithine toxicity it appears that spermidine levels may be 
more important than trypanothione in the mode of action of the drug. This is 
supported by the fact that spermidine levels are much more greatly affected 
than levels of trypanothione as the cells are dying (Fig 4-6) and that heavy 
trypanothione is converted back to spermidine in cells grown in HMI-9 (Fig 5-15). 
In similar experiments, administering eflornithine in drinking water to 
dehydrated rats, trypanothione levels were found to decrease (66% (Fairlamb et 193 
 
al., 1987) and in vitro studies saw levels reduced to 40 % of untreated. In fact, 
our experiments did see a 40 % reduction in trypanothione disulphide after 48 
hours, but as the cells were losing their integrity at this point and the majority 
of metabolite levels are reduced, the reduction was not seen to be significant. 
As the other three studies only looked at a small range of metabolites, with no 
non-polyamine controls, it cannot be concluded whether their studies also 
suffered from a loss of cell wall integrity. The Phillips study saw a depletion in 
all metabolite levels tested apart from decarboxylated S-adenosylmethionine 
after three days at sub-IC50 levels (Xiao et al., 2009). In our studies, it is not 
thought that the membrane has been damaged at this drug level, but we do 
begin to see a recovery of treated cells at 72 hours (when the Phillips metabolite 
levels are recorded).  
After 24 hours in drug, trypanothione disulphide levels are only reduced to 75 % 
of the normal levels (Fig 4-6), whereas spermidine has suffered a much more 
profound loss to 33 % of normal growth levels. Phillips noted that adding 
exogenous spermidine rescued tryps that had knocked down ODC expression 
(Xiao et al., 2009), but it is unclear whether this spermidine was used to 
produce more trypanothione or not. It would be interesting to attempt an add 
back of trypanothione to treated cells, but whether this thiol would be taken 
into the cell is unknown and it may simply result in the back-conversion to 
spermidine. Trypanothione synthase has been shown to be essential (Wyllie et 
al., 2009) and pharmacological inhibition of trypanothione reductase has been 
shown to be very effective (Olin-Sandoval et al., 2010) but while trypanothione 
is essential to the cell, depleted levels of the thiol may not be the reason that 
trypanosomes die from eflornithine. 
Similar analyses with nifurtimox were more complex. It is unknown how 
nifurtimox kills trypanosomes, but it was thought to induce oxidative stress, 
which might have explained why it was thought to be synergistic with 
eflornithine as trypanosomes with reduced polyamines would be less able to 
detoxify reactive oxygen intermediates (Michael Barrett, personal 
communication). However, our studies have shown that the two drugs are not 
synergistic in vitro and that nifurtimox does not significantly affect any of the 
polyamines or other thiols in sub IC50 or toxicity assays. The apparent lack of 
synergy may be seen if nifurtimox is only effective on dividing cells and 194 
 
eflornithine treatment causes trypanosomes to enter a static, non-dividing state. 
A type I nitroreductase has been shown to be important in the processing of the 
nifurtimox pro-drug to its active compound (Hall et al., 2011). This enzyme is 
NADH dependent and may only be active in growing cells, however our data 
shows that nifurtimox is still reduced to its active form in the combination 
therapy. Studies with other trypanostatic drugs show a similar antagonism, 
although this antagonism is not as pronounced as with eflornithine. The reasons 
for the reduced action in combination may be more complex than a requirement 
for growing cells in nifurtimox action. 
Acetylornithine and acetylputrescine were seen to highly correlate with 
ornithine and putrescine in the eflornithine mode of action studies. It was 
hypothesised that acetylornithine may be involved in the production of ornithine 
through a bacterial pathway commencing on the uptake of glutamate. This 
pathway could have been required to produce ornithine for polyamine synthesis 
as arginase activity is not seen in T. b. brucei. Glutamate was not seen to be 
transported into trypanosomes in our metabolite tracking assays, however, and 
glutamate produced from glutamine or proline was not traceable to ornithine in 
bloodstream forms. Uptake of ornithine was detected and may be sufficient to 
produce all of the ornithine required for the production of polyamines (with 
acetylornithine as a possible storage metabolite). Arginine to ornithine 
conversion was detected, even though no arginase activity can be detected in 
trypanosomes and the gene previously thought to encode an arginase was shown 
not to have many of the arginase catalytic residues. The mechanism for this 
conversion has not been discovered through metabolite tracking. Possible 
mechanisms include the urea cycle working in reverse to convert arginine to 
ornithine via argininosuccinate and citrulline or through arginine deiminase 
conversion of arginine to citrulline and to ornithine. It would be useful to 
investigate these theories further using heavy citrulline, longer-term assays and 
metabolomic platforms that can assay argininosuccinate levels. 
Arginase is thought to be important in many parasitic organisms to divert 
arginine away from host nitric oxide synthases reducing the amount of toxic 
nitric oxide in the parasite‟s environment. Trypanosomes lacking arginase may 
therefore be vulnerable to nitric oxide when grown inside their vertebrate host. 
A high level of conversion of arginine to arginine phosphate in T. b. brucei, seen 195 
 
in arginine tracking experiments, may therefore be used to divert arginine from 
nitric oxide synthase. 
There are three arginine kinases in trypanosomes, which appear to have been 
acquired through horizontal gene transfer from arthropod vectors. Vertebrates 
lack arginine kinases (Hoffman and Ellington, 2011), possibly because they are in 
direct competition with high rates of arginase activity. Vertebrates therefore use 
creatine phosphate as a phosphagen store, where T. brucei uses arginine 
phosphate. 
In T. cruzi, it was shown that over expression of arginine kinase improved their 
capability to deal with oxidative stress (Pereira et al., 2003) and H2O2 treatment 
results in a time-dependent increase in arginine kinase expression (Miranda et 
al., 2006). A knockout of one arginine kinase in T. b. brucei produced no growth 
phenotype. Attempts are being made in our laboratory to knockout all three 
arginine kinases in T. b. brucei. 
These results together suggest that the trypanosomatids lack an arginase as they 
use arginine phosphate as a phosphagen store to deal with oxidative stress and 
high rates of arginine kinase activity are not compatible with high arginase 
activity. 
The untargeted nature of metabolomics can reveal many interesting leads in a 
large dataset. Acetylornithine was one such metabolite that had an unexpected 
presence in the trypanosome data and was investigated further. Other 
metabolites that were thought not to be present in bloodstream form parasites 
were sedoheptulose and sedoheptulose phosphate, which will require further 
investigations. Malate is also consistently seen in bloodstream form data in this 
laboratory. As the TCA cycle is not thought to be operative in bloodstream 
stages, malate was an unexpected discovery. Studies that looked at the absence 
of a TCA cycle in bloodstream stages used parasites grown in animals rather than 
in vitro (Ryley, 1956; Grant and Fulton, 1957; Ryley, 1962) so it may be that a 
difference in culture conditions (e.g. more amino acids in the medium) induces a 
metabolic shift in these parasites. Alternatively, these metabolites may be 
evidence that there is some mitochondrial energy generation after all. More 
analyses, using heavy labelled glucose are being undertaken in our laboratory. 196 
 
More analysis of nifurtimox‟s mode of action is also warrented. Our analyses 
reveal no changes in polyamine or thiol levels, although significant changes in 
sugar, sugar phosphate and DNA base levels are observed. 
Automatic processing methods failed to highlight metabolites that had small, but 
robust changes across the drug perturbation time courses. Groups of related 
metabolites (such as sedoheptulose and sedoheptulose phosphate) were also not 
highlighted as being significant in the automated processing. A group at INRA-
ENVT, Toulouse, are using metabolic network modelling to map metabolic 
changes, helping to highlight areas of the network that are changed, rather than 
looking at individual metabolite levels (Jourdan et al., 2010), which may help to 
highlight small changes that occur in a group of related metabolites. 
The uses of metabolomic studies are not limited to the description of drug mode 
of action, but can be used to ascribe metabolic phenotypes to any kind of 
cellular perturbation such as gene knockouts to ascribe gene function, effects of 
nutrient starvation and describing resistance mechanisms as was used in the 
comparison of wildtype and eflornithine resistant trypanosomes in this thesis 
(section 3.2.2). Combining these metabolomics approaches with heavy isotope 
labelling of metabolites will provide extra power to the data, aiding in the 
identification of metabolites and as a measure of the rate of flux through 
pathways.  
6.1 Future work 
An assessment of the status of TbAAT6 in eflornithine treatment areas will be 
important to determine whether loss of TbAAT6 confers resistance to 
eflornithine in T. b. gambiense in a field setting.  
The role of acetylornithine in T. brucei has not been determined. As there are 
several potential enzymes capable of the acetylation of ornithine, knocking each 
one out and tracking heavy labelled ornithine through the pathway would be 
time consuming. If acetylornithine has a role in providing ornithine when 
exogenous levels are reduced and before the arginine production commences 
then studying levels as cells adapt to ornithine depleted medium would be 
useful. Depletion of ornithine in medium using ornithine carbamoyl transferase 197 
 
was not successful in this thesis, but may work after some optimisation. 
Otherwise a defined medium could be created. 
The mechanism by which arginine is converted to ornithine is yet to be verified. 
Using higher numbers of cells to analyse whether 
15N isotope labels from arginine 
are transferred to citrulline or argininosuccinate will be informative. A more 
detailed search for the enzymes of the urea cycle or the arginine deiminase may 
also reveal the way by which arginine can form ornithine in the absence of 
arginase. 
Further analysis of nifurtimox MOA will be a priority for the future as will be 
further analysis of nifurtimox and eflornithine action in combination. This will be 
imperative to advise on the implementation of the combination therapy in the 
field, which is being taken up at a much faster rate than eflornithine was as a 
monotherapy. 
It would be interesting to determine how the oxidation states of thiols within 
the drug treated trypanosomes are altered during treatment. Methods to 
measure the oxidation state of the thiols are available and are being optimised 
for use in our metabolomic platform (Dong Hyun-Kim, University of Glasgow), 
but methods are complicated and involve the rapid derivitisation of the oxidised 
and reduced thiols to prevent further changes when cells are lysed. These 
methods will be particularly useful in further studies into nifurtimox‟s mode of 
action to ascertain why the drug is antagonistic with eflornithine.  198 
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  8. Appendix 
8.1  A comparison of wildtype and DFMOR1 metabolite levels 
Putative metabolite  Formula  m/z  Polarity  RT (minutes) 
DFMOR1 vs 
WT 
P 
value 
WT 
intensity 
WT sd 
DFMOR1 
insensity 
DFMOR
1 sd 
5'-Methylthioadenosine  C11H15N5O3S  298.0971  +  8.1  1.3  0.34  524  162  697  220 
glutathionylspermidine  C17H34N6O5S  435.2378  +  32.25  0.8  0.61  7  5  6  2 
L-Ornithine  C5H12N2O2  133.0978  +  21.98  0.5  0.47  76  70  39  25 
N-acetylglutamate semialdehyde  C7H11NO4  174.0754  +  10.07  1.0  0.98  801  71  805  199 
N-Acetylornithine  C7H14N2O3  175.1077  +  14.16  0.9  0.81  123  78  111  29 
Putrescine  C4H12N2  89.10727  +  29.82  0.9  0.50  399  32  361  76 
S-Adenosyl-L-methionine  C15H22N6O5S  399.1455  +  25.13  1.1  0.90  12  4  12  8 
Spermidine  C7H19N3  146.1653  +  41.61  1.1  0.86  1301  330  1361  437 
Trypanothione disulfide  C27H47N9O10S2  722.295  +  23.15  1.0  0.97  87  17  88  35 
3-Methyl-2-oxobutanoic acid  C5H8O3  115.0401  -  6.07  1.0  0.94  1172  542  1218  817 
4-Aminobutanoate  C4H9NO2  102.0561  -  14.03  1.2  0.63  372  128  442  192 
4-Trimethylammoniobutanoate  C7H15NO2  146.1176  +  9.21  1.0  0.92  102  24  104  26 
8-Methoxykynurenate  C11H9NO4  218.0459  -  10.01  0.9  0.60  21  3  18  7 
Adenine  C5H5N5  136.0617  +  11.72  1.0  0.96  2423  1242  2378  1110 
Anthranilate  C7H7NO2  138.0554  +  14  0.2  0.01  322  41  70  2 
Benzoate  C7H6O2  123.0443  +  6.48  1.3  0.26  11  2  15  4 
Carnitine  C7H15NO3  162.1124  +  13.54  1.2  0.58  1111  477  1318  337 
Choline phosphate  C5H14NO4P  184.0734  +  19.66  1.4  0.29  1572  344  2270  861 
CMP-N-trimethyl-2- C14H26N4O10P2  473.1199  +  20.1  1.1  0.54  47  12  52  5 230 
 
aminoethylphosphonate 
D-Glucosamine 6-phosphate  C6H14NO8P  258.0382  -  15.84  1.7  0.09  23  2  38  9 
Glutathione  C10H17N3O6S  308.0908  +  13.19  1.2  0.79  6  3  7  1 
Imidazole-4-acetaldehyde  C5H6N2O  111.0552  +  16.5  1.4  0.21  19  4  27  8 
L-Arginine phosphate  C6H15N4O5P  255.0852  +  19.77  1.2  0.75  177  93  204  104 
L-Cystathionine  C7H14N2O4S  223.0748  +  18.72  1.1  0.40  105  14  118  20 
N4-Acetylaminobutanal  C6H11NO2  130.0867  +  11.21  0.9  0.27  82  7  75  7 
N-acetyl-D-glucosamine-6-
phosphate 
C8H16NO9P  324.0462  +  14.99  1.3  0.49  26  7  33  15 
O-Acetylcarnitine  C9H17NO4  204.1227  +  11.11  1.2  0.54  160  20  190  69 
Phenylpyruvate  C9H8O3  163.0401  -  5.52  0.9  0.42  1527  186  1331  315 
trans-4-Hydroxy-L-proline  C5H9NO3  132.066  +  14.23  0.8  0.24  147  31  110  34 
(R)-Lactate  C3H6O3  89.02428  -  6.67  1.2  0.53  110  15  127  37 
(S)-Malate  C4H6O5  133.0141  -  8.43  1.2  0.67  232  112  277  129 
2-Oxoglutarate  C5H6O5  145.0142  -  8.57  1.4  0.61  624  447  885  664 
citrate  C6H8O7  191.0197  -  9.4  1.0  0.69  54  3  53  5 
D-glucose-6-phosphate  C6H13O9P  283.0183  +  17.54  1.1  0.48  28  7  31  1 
D-Ribose  C5H10O5  149.0455  -  9.99  1.2  0.56  113  18  132  48 
D-Xylulose 5-phosphate  C5H11O8P  229.0121  -  15.68  0.6  0.56  32  30  20  9 
Fumarate  C4H4O4  115.0037  -  8.36  1.1  0.79  56  30  63  31 
Glycerol  C3H8O3  93.05456  +  9.67  1.1  0.59  1347  182  1478  329 
L-Arabinono-1-5-lactone  C5H8O5  149.0446  +  7.4  0.9  0.83  53  15  50  16 
L-Gulonate  C6H12O7  195.0508  -  9.99  1.2  0.64  43  4  51  23 
Succinate  C4H6O4  117.0193  -  6.67  1.4  0.35  1376  776  1935  399 
sucrose  C12H22O11  341.1085  -  13.69  0.9  0.30  87  10  78  10 
NAD+  C21H27N7O14P2  686.0977  +  16.48  1.1  0.64  10  2  11  3 
(R)-3-Hydroxybutanoate  C4H8O3  103.0401  -  7.35  0.8  0.39  97  34  75  16 
Acetoacetate  C4H6O3  101.0244  -  8.57  1.4  0.62  391  273  545  411 231 
 
sn-glycero-3-Phosphocholine  C8H20NO6P  280.0924  +  17.4  1.2  0.31  8225  1659  10195  2371 
sn-glycero-3-Phosphoethanolamine  C5H14NO6P  238.0453  +  15.69  3.0  0.26  184  24  559  420 
sn-Glycerol 3-phosphate  C3H9O6P  171.0063  -  15.3  1.1  0.39  16855  2616  18707  2078 
Choline  C5H13NO  104.1069  +  14.33  1.5  0.44  21503  9814  31658  17553 
D-glucose  C6H12O6  203.0524  +  12.98  1.2  0.61  434  209  517  148 
Folate  C19H19N7O6  442.1476  +  9.05  1.1  0.77  218  28  229  53 
Hypoxanthine  C5H4N4O  137.0463  +  9.05  1.2  0.38  56986  5515  65670  13145 
Nicotinamide  C6H6N2O  123.0556  +  8.03  1.1  0.61  1418  191  1575  426 
Orthophosphate  H3O4P  98.9845  +  15.25  1.3  0.71  81  33  101  80 
Pantothenate  C9H17NO5  220.118  +  6.64  1.3  0.35  854  70  1146  423 
Phenol Red  C19H14O5S  355.0635  +  5.72  1.0  0.88  3344  749  3490  1407 
Pyridoxal  C8H9NO3  168.0651  +  11.72  1.2  0.58  551  95  647  244 
Pyruvate  C3H4O3  87.0087  -  7.56  1.0  0.90  7542  979  7795  3000 
riboflavin  C17H20N4O6  377.1453  +  7.55  1.0  0.99  69  22  70  27 
Thiamine  C12H16N4OS  265.1117  +  23.08  1.4  0.63  1859  992  2539  1950 
Thymidine  C10H14N2O5  241.0829  -  7.09  0.9  0.82  149  111  127  111 
Glycine  C2H5NO2  76.03952  +  15.32  1.2  0.70  1438  1010  1697  180 
L-Alanine  C3H7NO2  90.05495  +  14.23  1.2  0.64  70091  8050  85201  48225 
L-Arginine  C6H14N4O2  175.119  +  21.27  1.1  0.66  15235  1185  16992  5865 
L-Asparagine  C4H8N2O3  133.0612  +  15.62  1.3  0.79  655  783  824  682 
L-Aspartate  C4H7NO4  134.0454  +  14.54  1.5  0.35  400  82  586  268 
L-Cysteine  C3H7NO2S  122.0273  +  13.77  1.0  0.90  70  14  73  32 
L-Cystine  C6H12N2O4S2  241.0309  +  18.83  1.3  0.67  204  41  259  186 
L-Glutamate  C5H9NO4  148.0604  +  14.07  1.6  0.47  12005  4459  19255  14178 
L-Glutamine  C5H10N2O3  147.0769  +  15.13  1.2  0.32  45949  9107  54379  8961 
L-Histidine  C6H9N3O2  156.0769  +  20.4  1.1  0.62  6667  939  7592  2696 
L-isoleucine  C6H13NO2  132.1023  +  10.63  1.1  0.16  61077  5032  67409  3399 232 
 
L-Leucine  C6H13NO2  132.1023  +  11.01  1.1  0.13  62113  3927  69326  5241 
L-Lysine  C6H14N2O2  147.1132  +  21.54  1.2  0.41  15797  871  18169  3981 
L-Methionine  C5H11NO2S  150.0577  +  11.51  1.1  0.16  16088  927  17713  1297 
L-Phenylalanine  C9H11NO2  166.0855  +  10.12  1.3  0.41  23713  10449  30500  6702 
L-Proline  C5H9NO2  116.0707  +  13.77  0.9  0.71  20439  1913  18966  5750 
L-Serine  C3H7NO3  106.0503  +  15.13  1.3  0.58  1978  944  2574  1399 
L-Threonine  C4H9NO3  120.0655  +  14.44  1.2  0.53  21012  1797  24219  7361 
L-Tryptophan  C11H12N2O2  205.0969  +  10.56  1.2  0.22  6121  147  7119  994 
L-Tyrosine  C9H11NO3  182.0812  +  12.21  1.0  0.30  26322  918  25564  556 
L-Valine  C5H11NO2  118.0865  +  12.4  1.1  0.13  49695  1108  56337  4685 
Nicotinate  C6H5NO2  124.0398  +  7.38  1.2  0.74  284  150  338  211 
N-Ribosylnicotinamide  C11H14N2O5  255.0971  +  14.44  0.6  0.44  22  9  12  18 
ubiquinone-8  C49H74O4  727.5696  +  7.68  0.9  0.69  13  4  12  1 
3',5'-Cyclic AMP  C10H12N5O6P  330.0601  +  15.94  0.8  0.26  28  7  22  5 
Adenosine  C10H13N5O4  268.1035  +  10.32  0.7  0.39  84  41  56  26 
AMP  C10H14N5O7P  348.0712  +  15.3  1.7  0.62  174  97  301  377 
dTMP  C10H15N2O8P  321.0492  -  12.15  1.0  0.96  23  14  24  18 
Guanine  C5H5N5O  152.0565  +  11.9  0.7  0.01  494  34  345  36 
IMP  C10H13N4O8P  347.0394  -  14.99  1.1  0.76  29  5  34  20 
UMP  C9H13N2O9P  323.0279  -  14.61  1.0  0.92  74  26  71  35 
Uracil  C4H4N2O2  113.0347  +  7.62  1.2  0.64  389  96  474  262 
Uridine  C9H12N2O6  243.0621  -  10.6  1.0  0.86  65  15  63  17 
Xanthine  C5H4N4O2  153.0407  +  8.54  1.2  0.64  1741  95  1998  825 
Appendix 8-1. Putative metabolite identification based on accurate mass match in KEGG (tbr) and/or trypanocyc databases. Common fragments, adducts and false 
identifications have been removed from putative identification list based on retention time and reproducibility. Results were obtained using a boiling ethanol extraction 
method. Data analysed by Dr. Darren Creek. 233 
 
8.2  ODC sequences 234 
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Appendix 8-2. Wildtype and DFMOR1 ornithine decarboxylase gene sequences. Alignments were performed in CLC workbench 236 
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8.4  Eflornithine toxicity metabolomics 
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32 
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69  C5H10  1  butylene  5  0  Metacyc  0 
1.
00 
1.
18 
1.
30 
1.1
5 
0.8
2  1 
0.634
125 
0.427
277 
0.575
067 
0.704
181 
71.0735
5159 
8.48
18 
C4H9N  2  3-Buten-1-amine  5  0  KEGG  C12244 
1.
00 
0.
98 
1.
18 
1.1
0 
0.7
0 
1 
0.863
118 
0.202
028 
0.693
717 
0.078
595 
75.0684
074 
13.5
59 
C3H9NO  6  1-Aminopropan-2-ol  7  0  KEGG  C05771 
1.
00 
0.
97 
0.
80 
0.9
4 
0.6
0 
1 
0.826
97 
0.393
381 
0.744
036 
0.103
096 
84.0686
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21.2
05  C8H16N4  1  &alpha; -allenylagmatine  7  0  Metacyc  0 
1.
00 
1.
23 
1.
54 
1.0
6 
0.6
5  1 
0.696
64 
0.345
428 
0.924
549 
0.513
892 
85.0526
942 
7.43
84 
C4H7NO  2  Acetone cyanohydrin  8  0  KEGG_Metacyc  C02659 
1.
00 
0.
92 
0.
95 
1.0
2 
0.5
2 
1 
0.761
345 
0.859
046 
0.955
599 
0.123
493 
89.0840
235 
12.8
73 
C4H11NO  1  N-dimethylethanolamine  5  0  Metacyc  0 
1.
00 
1.
12 
1.
30 
1.0
3 
0.6
7 
1 
0.550
2 
0.428
372 
0.880
447 
0.181
951 
91.0349
4999 
7.14
82  C6H15O4P  2  Diisopropyl phosphate  7  0  KEGG_Metacyc  C03113 
1.
00 
1.
17 
0.
99 
1.0
1 
0.7
5  1 
0.560
627 
0.983
28 
0.980
567 
0.551
029 
96.0209
418 
15.4
88 
C5H4O2  3  Furfural  5  0  KEGG_Metacyc  C14279 
1.
00 
1.
39 
1.
47 
1.0
1 
0.5
7 
1 
0.249
909 
0.038
424 
0.941
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0.042
535 
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4747 
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78 
C5H4O2  3  Furfural  7  0  KEGG_Metacyc  C14279 
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1.0
5 
1.2
0 
1 
0.027
024 
0.188
952 
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66 
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719 
100.016
0082 
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15 
C4H4O3  1  2-oxobut-3-enanoate  7  0  Metacyc  0 
1.
00 
1.
16 
1.
01 
0.7
1 
0.6
5 
1 
0.493
586 
0.971
938 
0.055
007 
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564 250 
 
101.047
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C4H7NO2  5 
L-Azetidine 2-carboxylic 
acid 
5  0  KEGG_Metacyc  C08267 
1.
00 
1.
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2.
11 
1.3
1 
3.5
3 
1 
0.285
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03 
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179 
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C4H7NO2  5  Diacetylmonoxime  5  0  KEGG  C07509  1.
00 
0.
95 
1.
19 
0.9
1 
0.5
8 
1  0.761
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28  C4H6O3  8  4-Hydroxycrotonicacid  7  0  HMDB  0 
1.
00 
0.
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0.
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0.9
0 
0.4
5  1 
0.705
855 
0.628
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06 
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13.9
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C5H10N2O  2  L-proline amide  5  0  Metacyc  0 
1.
00 
1.
05 
1.
61 
1.4
6 
0.7
7 
1 
0.808
707 
0.028
996 
0.322
668 
0.556
492 
118.026
516 
6.81
09 
C4H6O4  7  Methyl oxalate  7  0  KEGG  C10900  1.
00 
1.
18 
1.
07 
0.4
8 
0.7
5 
1  0.726
021 
0.886
789 
0.178
561 
0.442
272 
118.078
3489 
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11  C9H10  1  alpha-Methylstyrene  5  0  KEGG  C14395 
1.
00 
1.
33 
0.
92 
0.7
9 
0.8
1  1 
0.134
649 
0.625
079 
0.285
45 
0.331
549 
120.042
1038 
12.4
69 
C4H8O4  9  D-Erythrulose  5  0  KEGG_Metacyc  C02022 
1.
00 
0.
85 
0.
92 
0.8
8 
0.5
0 
1 
0.113
431 
0.482
462 
0.468
8 
0.128
689 
120.093
9521 
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43 
C9H12  6  1,2,4-Trimethylbenzene  5  0  KEGG_Metacyc  C14533  1.
00 
0.
91 
1.
07 
0.6
6 
1.3
2 
1  0.839
451 
0.913
894 
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85  C5H11N3O  3 
(S)-piperazine-2-
carboxamide  5  0  Metacyc  0 
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00 
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09 
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1 
0.4
2  1 
0.674
482 
0.834
381 
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0.012
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13.6
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C5H8O4  16  Deoxyribonolactone  5  0 
KEGG_Metacyc_H
MDB 
C02674 
1.
00 
0.
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0.
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1.0
4 
0.4
4 
1 
0.954
34 
0.603
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489 
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133.019
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14.3
27 
C4H7NO2S  1  L-thiazolidine-4-
carboxylate 
7  0  Metacyc  0  1.
00 
0.
88 
0.
93 
0.7
4 
0.2
3 
1  0.537
497 
0.705
901 
0.208
635 
0.015
844 
133.073
9415 
11.5
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C5H11NO3  4  N-hydroxyvaline  7  0  Metacyc  0 
1.
00 
1.
31 
2.
54 
1.3
3 
1.5
5 
1 
0.233
449 
0.035
914 
0.166
323 
0.432
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136.038
5148 
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23 
C5H4N4O  3  allopurinol  7  0  KEGG_Metacyc  D00224 
1.
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4 
0.5
3 
1 
0.837
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C7H13NO2  2  Stachydrine  5  0 
KEGG_Metacyc_H
MDB 
C10172 
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C4H5ClN4  1  4-chloro-2,6-
diaminopyrimidine 
5  0  Metacyc  0  1.
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17  C9H7NO  7  1(2H)-Isoquinolinone  5  0  KEGG_Metacyc  C06324 
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0.835
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C9H7NO  7  3-Methyleneoxindole  7  0  KEGG_Metacyc  C02796 
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C5H9NO2S  1  Thiomorpholine 3-
carboxylate 
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41  C5H9NO4  14 
N-hydroxy-N-
isopropyloxamate  5  0  Metacyc  0 
1.
00 
1.
42 
1.
21 
1.2
0 
0.4
0  1 
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934 
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0.009
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37 
C5H10O3S  1 
2-hydroxy-4-
methylthiobutanoate 
7  0  Metacyc  0 
1.
00 
0.
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0.8
9 
2.9
8 
1 
0.480
743 
0.389
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0.832
972 
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154.002
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C3H7O5P  3  Hydroxyacetone 
phosphate 
7  0  KEGG_Metacyc  C03505  1.
00 
1.
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0.
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0.7
1 
0.3
2 
1  0.952
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0.462
427 
0.595
93 
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35  C6H11NO2S  1  allylcysteine  5  0  KEGG_Metacyc  C16759 
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00 
0.
77 
0.
82 
0.7
3 
0.2
3  1 
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C7H15NO3  2  (S)-Carnitine  5  0  KEGG_Metacyc  C15025 
1.
00 
1.
24 
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0.9
9 
0.3
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1 
0.510
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7 
C6H13NO4  9  D-Fucosamine  5  0  KEGG  C15478  1.
00 
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0.7
8 
0.3
5 
1  0.641
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0.350
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34 
C6H7N5O  5  3-Methylguanine  5  0  KEGG_HMDB  C02230 
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C8H14NO9S
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1  Glucocapparin  7  0  KEGG  C08404 
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C6H14O5  2  L-rhamnitol  7  0  Metacyc  0 
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C7H14N2O3  5  N5-Ethyl-L-glutamine  7  0  KEGG_Metacyc  C01047  1.
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C9H9NO3  6  N-Acetylanthranilate  5  0  KEGG_Metacyc  C06332 
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00 
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717 
0.694
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99  C5H11NO4S  1  DL-Methionine sulfone  5  0  Metacyc  0 
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00 
1.
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5  1 
0.821
95 
0.735
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551 
181.980
0701 
5.13
17 
C15H12O2Cl
4 
1  Tetrachlorobisphenol A  7  0  KEGG  C14528 
1.
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1.
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1.
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1.0
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1.0
7 
1 
0.989
512 
0.830
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0.849
885 
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336 
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C9H21N3O  2  N1-Acetylspermidine  7  0  KEGG_Metacyc_H
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96 
0.106
486 
0.088
82 
0.695
554 
188.079
3979 
9.42
7 
C7H12N2O4  2  N-Acetylglutamine  5  0  HMDB  0 
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00 
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092 
0.817
796 
0.130
376 
0.055
708 
192.063
1344 
8.20
21 
C7H12O6  6 
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pentahydroxycyclohexan
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5  0  KEGG_Metacyc  C01295  1.
00 
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1  0.209
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C7H12O6  6  Valiolone  5  0  KEGG  C12113 
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00 
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0.335
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C7H17NO5  1  N-methyl glucamine  9  0  IntStd  0  1.
00 
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0.9
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0 
1  0.938
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C8H11N3O3  3 
Methyl5-(but-3-en-1-
yl)amino-1,3,4-
oxadiazole-2-carboxylate 
7  0  KEGG  C12245 
1.
00 
1.
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0.
88 
1.2
3 
0.5
5 
1 
0.240
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0.574
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007 
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88  C8H11N3O3  3  N-Acetyl-L-histidine  7  0  KEGG_Metacyc  C02997 
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6 
0.5
7  1 
0.915
6 
0.869
136 
0.701
264 
0.218
669 
202.143
0106 
19.1
15 
C8H18N4O2  3 
NG,NG-Dimethyl-L-
arginine 
7  0 
KEGG_Metacyc_H
MDB 
C03626 
1.
00 
0.
99 
1.
04 
1.1
7 
0.6
0 
1 
0.970
384 
0.849
317 
0.488
578 
0.204
041 
203.058
007 
5.72
89 
C11H9NO3  2  Anibine  7  0  KEGG  C10127  1.
00 
1.
58 
1.
54 
0.8
5 
0.8
8 
1  0.112
729 
0.278
827 
0.529
757 
0.705
786 
203.079
2501 
14.1
25  C8H13NO5  2  2-acetamidoglucal  5  0  Metacyc  0 
1.
00 
0.
97 
1.
32 
0.9
6 
0.5
4  1 
0.857
593 
0.462
333 
0.846
084 
0.224
221 
204.110
9014 
20.6
3 
C8H16N2O4  5 
N5-(L-1-Carboxyethyl)-L-
ornithine 
7  0  KEGG_Metacyc  C04210 
1.
00 
0.
65 
1.
97 
7.0
2 
22.
59 
1 
0.455
385 
0.146
532 
0.015
804 
0.424
95 
210.073
691 
13.3
82 
C7H14O7  4  alpha-D-
Mannoheptulopyranose 
7  0  KEGG  C08236  1.
00 
1.
21 
1.
73 
2.6
9 
2.9
4 
1  0.402
414 
0.120
416 
0.072
898 
0.170
693 
212.008
2638 
22.9
63  C5H9O7P  3  phosphinomethylmalate  5  0  Metacyc  0 
1.
00 
0.
62 
1.
21 
0.6
2 
0.9
4  1 
0.195
1 
0.417
103 
0.194
008 
0.897
457 
217.077
3166 
5.96
64 
C9H15NO3S  2  captopril  7  0  KEGG_Metacyc  D00251 
1.
00 
0.
82 
0.
92 
1.0
8 
0.9
5 
1 
0.794
072 
0.913
315 
0.911
074 
0.960
537 
222.056
2995 
5.23
18 
C8H14O5S  2 
2-(3'-
methylthio)propylmalate 
5  0  KEGG_Metacyc  C17214 
1.
00 
3.
07 
2.
00 
2.4
6 
0.6
0 
1 
   
0.122
493 
0.549
402 
224.089
8741 
10.1
87  C9H12N4O3  1  Temurin  7  0  HMDB  0 
1.
00 
0.
81 
0.
83 
0.9
1 
0.7
8  1 
0.571
894 
0.622
054 
0.790
006 
0.778
894 254 
 
228.110
9936 
14.1
43 
C10H16N2O
4 
2  (S)-ATPA  5  0  KEGG  C13733 
1.
00 
1.
01 
1.
03 
1.1
4 
0.4
0 
1 
0.965
28 
0.936
1 
0.596
403 
0.099
543 
232.219
1697 
5.16
11 
C17H28  1  sterone-ring  5  0  Metacyc  0  1.
00 
1.
16 
1.
70 
0.9
4 
1.4
9 
1  0.776
274 
0.336
746 
0.918
379 
0.347
875 
240.045
1467 
19.7
12  C21H20O13  1  Gossypin  7  0  KEGG  C10051 
1.
00 
1.
16 
1.
50 
19.
86 
1.0
4  1 
0.435
738 
0.078
762 
0.414
398 
0.877
012 
242.018
9623 
26.8  C6H11O8P  2 
D-myo-Inositol 1,2-cyclic 
phosphate 
7  0 
KEGG_Metacyc_H
MDB 
C04299 
1.
00 
1.
07 
1.
26 
0.8
7 
0.4
2 
1 
0.831
9 
0.609
951 
0.648
083 
0.165
457 
242.019
1874 
25.4
31 
C6H11O8P  2  6-deoxy-5-ketofructose-
1-phosphate 
7  0  Metacyc  0  1.
00 
0.
82 
1.
30 
1.1
2 
0.5
5 
1  0.484
251 
0.454
783 
0.661
309 
0.294
726 
245.162
6781 
6.55
12  C12H23NO4  4 
N-(octanoyl)-L-
homoserine  7  0  Metacyc  0 
1.
00 
0.
88 
1.
23 
1.1
5 
0.9
9  1 
0.339
888 
0.245
787 
0.359
44 
0.983
487 
246.050
1309 
22.4
2 
C6H15O8P  3  Glycerophosphoglycerol  7  0  KEGG_Metacyc  C03274 
1.
00 
0.
72 
0.
93 
0.7
4 
0.3
1 
1 
0.095
295 
0.681
431 
0.122
287 
0.048
86 
246.085
3381 
10.0
99 
C9H14N2O6  2  5-6-Dihydrouridine  7  0  HMDB  0  1.
00 
0.
78 
0.
83 
0.6
7 
0.6
0 
1  0.547
296 
0.621
991 
0.344
185 
0.331
265 
249.086
1147 
8.05
32 
C10H19NO2
S2  2  S-Acetyldihydrolipoamide  8  0 
KEGG_Metacyc_H
MDB  C01136 
1.
00 
0.
76 
0.
91 
0.8
8 
0.4
6  1 
0.457
662 
0.781
359 
0.811
644 
0.159
75 
266.090
1539 
7.61
91 
C12H14N2O
5 
1 
p-aminobenzoyl 
glutamate 
5  0  Metacyc  0 
1.
00 
0.
72 
1.
02 
1.2
5 
0.6
9 
1 
0.491
135 
0.926
909 
0.565
528 
0.225
241 
267.056
5166 
7.51
7 
C12H13NO4
S 
1  Oxycarboxin  7  0  KEGG  C10956  1.
00 
0.
77 
1.
83 
1.3
6 
0.6
9 
1  0.548
217 
0.375
004 
0.562
419 
0.479
889 
267.095
2714 
12.4
85 
C9H17NO8  2  Miserotoxin  5  0  KEGG  C08507 
1.
00 
0.
81 
0.
94 
0.9
2 
0.5
0 
1 
0.173
37 
0.675
569 
0.667
518 
0.159
403 
268.079
2831 
14.0
53 
C9H16O9  4 
2-keto-3-deoxy-D-
glycero-D-galacto-
nononate 
5  0  Metacyc  0  1.
00 
1.
00 
1.
08 
1.0
1 
0.8
2 
1  0.992
963 
0.871
904 
0.979
457 
0.689
147 255 
 
268.079
3033 
14.7
88 
C9H16O9  4 
2(alpha-D-Mannosyl)-D-
glycerate 
6  0  KEGG_Metacyc  C11544 
1.
00 
1.
00 
1.
11 
1.0
0 
0.6
2 
1 
0.994
406 
0.716
864 
0.997
135 
0.398
454 
268.970
2295 
16.1
02 
C12H17BrN
2O13P2 
1  uridine-5'-diphosphate 
bromoacetol 
7  0  Metacyc  0  1.
00 
1.
00 
0.
75 
0.9
0 
0.1
6 
1  0.999
23 
0.438
637 
0.692
949 
0.035
191 
272.029
5876 
25.3
62 
C7H13O9P  2 
&alpha;-(2,6-anhydro-3-
deoxy-D-arabino-
heptulopyranosid)onate 
7-phosphate 
7  0  Metacyc  0 
1.
00 
1.
25 
1.
93 
4.0
8 
5.3
8 
1 
0.438
776 
0.266
953 
0.069
677 
0.123
66 
272.083
6695 
5.24
06 
C19H12O2  2  7,8-benzoflavone  5  0  Metacyc  0 
1.
00 
1.
11 
1.
45 
0.6
8 
1.5
2 
1 
0.786
178 
0.411
591 
0.401
488 
0.556
827 
272.235
0553 
5.19
62  C16H32O3  18  16-hydroxypalmitate  7  0  Metacyc_HMDB  0 
1.
00 
1.
08 
0.
83 
1.5
2 
0.9
2  1 
0.845
672 
0.563
368 
0.278
421 
0.827
833 
274.156
9707 
5.04
38 
C17H22O3  3  Podocarpic acid  5  0  KEGG  C09171 
1.
00 
1.
15 
0.
78 
1.4
3 
1.9
3 
1 
0.851
108 
0.262
879 
0.697
879 
0.414
72 
288.095
7234 
7.62
54 
C13H21O3P
S 
1  Iprobenfos  7  0  KEGG  C15230 
1.
00 
1.
01 
0.
90 
0.9
5 
0.7
4 
1 
0.974
588 
0.640
808 
0.853
734 
0.682
603 
291.095
3494 
12.1
43  C11H17NO8  3 
2,7-Anhydro-alpha-N-
acetylneuraminic acid  7  0  KEGG_Metacyc  C04521 
1.
00 
0.
91 
0.
84 
0.7
0 
0.4
5  1 
0.861
851 
0.774
676 
0.555
202 
0.320
306 
292.167
3902 
5.11
2 
C17H24O4  2  Trichodermin  5  0  KEGG  C09741 
1.
00 
0.
91 
0.
78 
0.9
5 
1.3
2 
1 
0.886
94 
0.391
762 
0.917
248 
0.451
433 
299.061
4812 
8.12
9 
C16H13NO3
S 
2 
8-Anilino-1-naphthalene 
sulfonic acid 
5  0  KEGG  C11326 
1.
00 
0.
49 
0.
64 
0.8
0 
0.6
7 
1 
0.030
176 
0.187
11 
0.407
955 
0.238
073 
309.105
8359 
12.4
56  C11H19NO9  5 
&alpha;-N-
acetylneuraminate  5  0  Metacyc  0 
1.
00 
0.
97 
1.
16 
1.0
3 
0.5
7  1 
0.919
092 
0.649
903 
0.918
093 
0.361
247 
311.121
4921 
12.4
56 
C12H17N5O
5 
2 
N2-N2-
Dimethylguanosine 
5  0  HMDB  0 
1.
00 
0.
64 
0.
69 
0.9
4 
0.6
3 
1 
0.104
246 
0.139
832 
0.842
791 
0.343
049 
311.132
7388 
13.3
52 
C19H18FNO
2 
1  Citalopram alcohol  5  0  KEGG  C16611 
1.
00 
0.
96 
0.
83 
0.9
9 
0.3
6 
1 
0.879
765 
0.455
813 
0.980
641 
0.060
325 256 
 
316.092
259 
6.47
16 
C18H17FO2
S 
1  SC-57666  5  0  KEGG  C11706 
1.
00 
0.
70 
0.
83 
0.9
1 
0.5
7 
1 
0.548
289 
0.729
952 
0.828
583 
0.354
924 
324.105
4532 
14.8
05 
C12H20O10  4  D-Fructofuranose 
1,2':2,3'-dianhydride 
5  0  KEGG  C04420  1.
00 
1.
02 
0.
88 
1.1
0 
0.3
6 
1  0.909
756 
0.580
213 
0.633
003 
0.000
346 
324.105
4813 
14.0
93  C12H20O10  4 
Bis-D-fructose 2',1:2,1'-
dianhydride  5  0  KEGG_Metacyc  C04333 
1.
00 
1.
03 
1.
12 
1.0
0 
0.5
1  1 
0.937
195 
0.820
381 
0.991
211 
0.211
181 
327.277
2009 
7.54
33 
C19H37NO3  1  Margaroylglycine  5  0  HMDB  0 
1.
00 
0.
78 
1.
37 
1.0
4 
0.7
4 
1 
0.167
797 
0.145
388 
0.800
963 
0.118
838 
335.132
6531 
18.8
87 
C12H21N3O
8 
3  N4-(Acetyl-beta-D-
glucosaminyl)asparagine 
5  0  KEGG_Metacyc_H
MDB 
C04540  1.
00 
0.
80 
1.
21 
1.6
1 
0.7
8 
1  0.081
372 
0.169
107 
0.002
777 
0.447
288 
336.266
403 
7.95
83 
C21H36O3  3 
5beta-Pregnane-
3alpha,17alpha,20alpha-
triol 
7  0  KEGG  C14680 
1.
00 
1.
07 
1.
62 
1.1
8 
1.8
4 
1 
0.763
623 
0.179
987 
0.338
032 
0.109
107 
340.142
8826 
5.47
97 
C19H20N2O
4  1 
N2,N5-Dibenzoyl-L-
ornithine  7  0  KEGG_Metacyc  C03712 
1.
00 
1.
24 
1.
98 
1.3
4 
1.1
7  1 
0.356
911 
0.186
239 
0.411
856 
0.483
927 
343.094
9409 
7.82
68 
C20H13N3O
3 
1  violacein  5  0  Metacyc  0 
1.
00 
0.
97 
1.
80 
1.4
8 
1.9
9 
1 
0.881
258 
0.120
773 
0.155
153 
0.109
857 
348.046
8978 
23.8
91 
C10H13N4O
8P 
3  dXMP  7  0  Metacyc  0  1.
00 
0.
36 
0.
56 
0.8
1 
0.3
5 
1  0.002
082 
0.061
747 
0.529
548 
0.060
089 
358.083
9662 
17.5
05 
C14H18N2O
7S  1  Miraxanthin-I  5  0  KEGG  C08554 
1.
00 
1.
09 
1.
00 
1.0
0 
0.6
2  1 
0.453
113 
0.976
269 
0.977
162 
0.016
392 
371.133
04 
8.12
4 
C34H46O18  1  Acanthoside D  7  0  KEGG  C10543 
1.
00 
1.
21 
1.
18 
1.5
9 
0.4
8 
1 
0.659
224 
0.802
41 
0.235
051 
0.274
651 
395.303
3943 
5.96
64  C23H41NO4  1 
9,12-
Hexadecadienoylcarnitin
e 
7  0  HMDB  0 
1.
00 
1.
43 
1.
16 
1.2
7 
1.7
8  1 
0.354
919 
0.508
258 
0.340
272 
0.341
842 
402.163
7112 
12.6
29 
C18H22N6O
5 
1 
7,8-H2pterin-6-ylmethyl-
l-(4-aminophenyl)-1-
deoxy-D-ribitol 
7  0  Metacyc  0 
1.
00 
1.
10 
0.
98 
0.8
1 
0.7
3 
1 
0.787
686 
0.949
644 
0.590
995 
0.454
863 257 
 
411.135
7015 
15.2
2 
C19H25NO7
S 
1 
13E-Tetranor-16-
carboxy-LTE4 
5  0  HMDB  0 
1.
00 
1.
06 
0.
91 
0.7
8 
0.4
7 
1 
0.903
296 
0.743
925 
0.457
07 
0.140
551 
416.232
5259 
7.55
3 
C21H37O6P  1  CPA(18:2(9Z,12Z)/0:0)  7  0  HMDB  0  1.
00 
0.
51 
3.
20 
0.5
1 
1.0
7 
1  0.074
709 
0.010
547   
0.940
876 
418.018
8999 
17.4
61 
C10H16N2O
12P2  2 
P1-uridyl-P2-methyl 
diphosphate  5  0  Metacyc  0 
1.
00 
0.
99 
1.
01 
0.9
9 
0.6
1  1 
0.629
177 
0.880
008 
0.658
014 
0.328
14 
464.054
4052 
11.2
1 
C16H20N2O
10S2 
1 
4-hydroxy-3-
indolylmethyl-
glucosinolate 
5  0  Metacyc  0  1.
00 
0.
85 
0.
84 
0.8
9 
0.7
9 
1  0.532
47 
0.532
23 
0.610
693 
0.380
933 
466.100
2404 
15.6
85 
C17H19N6O
8P 
1  N-Adenylylanthranilate  5  0  KEGG_Metacyc  C03293 
1.
00 
1.
03 
1.
35 
0.8
9 
0.3
3 
1 
0.741
864 
0.420
408 
0.369
789 
0.014
152 
519.332
2938 
6.25
74 
C26H50NO7
P  3 
1-
Linoleoylglycerophospho
choline 
7  0  KEGG_Metacyc  C04100 
1.
00 
1.
27 
1.
34 
1.0
1 
0.5
2  1 
0.580
698 
0.177
902 
0.977
935 
0.373
137 
521.348
4407 
10.1
77 
C26H52NO7
P  11 
1-
Oleoylglycerophosphoch
oline 
5  0  KEGG_Metacyc  C03916 
1.
00 
0.
99 
1.
03 
1.2
3 
0.2
5  1 
0.973
847 
0.938
79 
0.557
075 
0.095
175 
522.890
6005 
16.5
55 
C10H12Mo
N5O8PS2 
1  molybdenum cofactor  5  0  Metacyc  0 
1.
00 
0.
96 
0.
92 
0.9
1 
0.7
2 
1 
0.550
021 
0.188
187 
0.067
217 
0.292
406 
541.060
0152 
22.1
14 
C15H21N5O
13P2  1  Cyclic ADP-ribose  5  0  KEGG  C13050 
1.
00 
1.
08 
1.
24 
1.1
6 
1.2
3  1 
0.203
417 
0.217
81 
0.210
45 
0.686
69 
713.239
339 
20.7
5 
C30H35N9O
12 
1 
pteroyl-&gamma;-
glutamyl-&gamma;-
glutamylglutamate 
7  0  Metacyc  0  1.
00 
1.
17 
1.
32 
0.8
3 
0.6
3 
1  0.452
253 
0.181
148 
0.235
773 
0.141
124 
798.445
2476 
5.27
64 
C38H72O13
P2 
1 
Phosphatidylglycerophos
phate (dihexadec-9-
enoyl, n-C16:1) 
7  0  Metacyc_HMDB  0 
1.
00 
1.
11 
1.
14 
0.7
4 
0.8
1 
1 
0.897
605 
0.867
915 
0.714
944 
0.836
52 
826.247
3785 
20.5
13 
C39H42N2O
18 
1  Pradimicin C  5  0  KEGG  C06786 
1.
00 
1.
57 
1.
38 
1.6
9 
2.2
8 
1 
0.150
219 
0.254
315 
0.097
476 
0.051
756 
839.567
8431 
8.03
63 
C46H82NO1
0P 
1  1-22:1-2-18:3-
phosphatidylserine 
5  0  Metacyc  0  1.
00 
1.
09 
1.
06 
0.4
6 
0.8
7 
1  0.786
995 
0.878
824 
0.128
706 
0.733
625 258 
 
858.526
4227 
9.19
64 
C45H79O13
P 
15 
1-18:2-2-18:2-
phosphatidylinositol 
5  0  Metacyc  0 
1.
00 
1.
19 
1.
42 
0.6
3 
0.9
5 
1 
0.717
098 
0.479
097 
0.350
537 
0.887
444 
882.526
0657 
8.73
56 
C55H70N4O
6 
1  geranylgeranyl-
bacteriopheophytin 
7  0  Metacyc  0  1.
00 
1.
07 
1.
20 
0.7
7 
0.7
1 
1  0.831
809 
0.562
132 
0.442
091 
0.450
74 
75.0317
2565 
17.8
56 
C2H5NO2  3  Glycine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00037 
1.
00 
0.
92 
1.
04 
0.9
7 
1.7
8 
1 
0.728
559 
0.805
247 
0.863
682 
0.571
137 
75.0320
5583 
17.6
35 
C2H5NO2  3  Glycine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00037  1.
00 
1.
10 
1.
12 
0.9
6 
1.6
8 
1  0.513
584 
0.482
724 
0.764
805 
0.573
817 
83.0734
4968 
12.7
77 
C5H9N  4  Piperideine  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C06181 
1.
00 
1.
06 
1.
17 
0.9
9 
1.0
3 
1 
0.100
421 
0.508
76 
0.793
944 
0.778
39 
87.0319
6475 
21.8
1 
C3H5NO2  3  2-Aminoacrylate  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02218 
1.
00 
0.
96 
0.
98 
1.2
0 
0.8
3 
1 
0.771
13 
0.864
32 
0.307
104 
0.332
35 
101.047
6288 
12.4
84 
C4H7NO2  5 
1-Aminocyclopropane-1-
carboxylate 
6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C01234 
1.
00 
0.
86 
0.
88 
0.9
2 
0.4
6 
1 
0.418
718 
0.540
624 
0.697
378 
0.071
123 
101.047
6699 
13.4
44 
C4H7NO2  5 
1-Aminocyclopropane-1-
carboxylate 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C01234 
1.
00 
1.
24 
2.
10 
1.0
4 
1.1
7 
1 
0.331
532 
0.109
984 
0.766
067 
0.662
039 
103.063
268 
10.1
5 
C4H9NO2  14  L-3-Amino-isobutanoate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C03284 
1.
00 
1.
02 
1.
20 
1.0
4 
0.9
6 
1 
0.898
317 
0.129
69 
0.711
772 
0.697
356 
103.063
3214 
13.8
71  C4H9NO2  14  N,N-Dimethylglycine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB  C01026 
1.
00 
1.
08 
1.
21 
0.8
8 
0.4
7  1 
0.703
783 
0.192
087 
0.493
241 
0.072
584 259 
 
103.099
7349 
12.6
98 
C5H13NO  1  Choline  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00114 
1.
00 
0.
75 
0.
78 
0.8
6 
0.4
2 
1 
0.423
809 
0.440
833 
0.634
004 
0.110
935 
105.042
6156 
17.8
4  C3H7NO3  3  L-Serine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00065 
1.
00 
0.
98 
1.
08 
0.8
8 
0.3
9  1 
0.935
052 
0.709
764 
0.484
327 
0.064
556 
113.047
7073 
17.2
52 
C5H7NO2  6 
(S)-1-Pyrroline-5-
carboxylate 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C03912 
1.
00 
1.
00 
0.
95 
0.9
3 
0.4
5 
1 
0.987
897 
0.690
287 
0.644
385 
0.132
085 
113.058
9894 
11.8
99 
C4H7N3O  1  Creatinine  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00791 
1.
00 
1.
01 
1.
14 
1.0
2 
0.4
8 
1 
0.931
868 
0.648
881 
0.913
262 
0.150
689 
115.063
3425 
15.2
22 
C5H9NO2  4  L-Proline  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00148  1.
00 
1.
16 
1.
05 
0.8
5 
0.6
2 
1  0.615
34 
0.755
397 
0.284
958 
0.093
756 
116.047
2565 
7.96
19 
C5H8O3  9 
3-Methyl-2-oxobutanoic 
acid 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C00141 
1.
00 
1.
15 
1.
03 
0.7
5 
0.4
8 
1 
0.628
032 
0.899
828 
0.419
158 
0.189
707 
116.047
397 
7.60
2 
C5H8O3  9  3-Methyl-2-oxobutanoic 
acid 
6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C00141  1.
00 
1.
09 
0.
93 
1.3
1 
0.8
9 
1  0.886
66 
0.857
419 
0.498
617 
0.816
796 
117.079
0085 
15.9
28 
C5H11NO2  16  Betaine  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00719 
1.
00 
1.
12 
1.
26 
0.8
2 
0.2
2 
1 
0.549
914 
0.240
908 
0.403
854 
0.009
846 
117.079
0202 
12.5
09 
C5H11NO2  16  L-Valine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00183  1.
00 
1.
03 
1.
21 
0.9
9 
0.5
7 
1  0.673
486 
0.433
641 
0.942
341 
0.221
488 260 
 
119.058
3313 
16.4
98 
C4H9NO3  11  L-Threonine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00188 
1.
00 
0.
93 
1.
03 
0.7
1 
0.5
7 
1 
0.793
861 
0.883
601 
0.228
408 
0.259
15 
121.019
5631 
21.6
84  C3H7NO2S  2  L-Cysteine  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00097 
1.
00 
1.
17 
0.
87 
1.2
5 
0.4
3  1 
0.739
041 
0.814
585 
0.663
012 
0.318
521 
121.019
6705 
15.4
28 
C3H7NO2S  2  L-Cysteine  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00097 
1.
00 
0.
56 
0.
68 
0.5
4 
0.2
7 
1 
0.390
879 
0.513
755 
0.372
122 
0.211
01 
122.036
6543 
5.62
79 
C7H6O2  6  Benzoate  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00180 
1.
00 
0.
88 
0.
77 
0.6
4 
1.6
7 
1 
0.883
535 
0.772
934 
0.645
854 
0.541
623 
125.998
4717 
18.7
49 
C2H6O4S  1  2-
Hydroxyethanesulfonate 
7 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C05123  1.
00 
0.
60 
0.
86 
1.1
8 
0.6
9 
1  0.490
883 
0.570
867 
0.211
502 
  
125.998
4832 
21.1
55 
C2H6O4S  1 
2-
Hydroxyethanesulfonate 
7 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C05123 
1.
00 
1.
08 
1.
22 
0.9
5 
0.7
8 
1 
0.818
237 
0.373
37 
0.822
578 
0.625
561 
128.058
6255 
14.0
1 
C5H8N2O2  3  gamma-Amino-gamma-
cyanobutanoate 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Lipidmaps   C05715  1.
00 
0.
95 
1.
09 
0.8
9 
0.4
6 
1  0.847
378 
0.757
941 
0.715
952 
0.133
653 
129.042
4814 
8.21
11 
C5H7NO3  6 
L-1-Pyrroline-3-hydroxy-
5-carboxylate 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C04281 
1.
00 
1.
02 
0.
93 
0.9
5 
0.4
8 
1 
0.960
096 
0.847
451 
0.888
024 
0.219
807 
129.079
0666 
13.7
32 
C6H11NO2  9  L-Pipecolate  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00408  1.
00 
1.
12 
1.
23 
1.1
1 
0.6
5 
1  0.258
548 
0.141
509 
0.517
607 
0.166
833 261 
 
129.079
1039 
9.10
32 
C6H11NO2  9  N4-Acetylaminobutanal  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C05936 
1.
00 
1.
10 
1.
48 
0.9
7 
0.7
5 
1 
0.673
857 
0.140
946 
0.883
434 
0.264
08 
130.062
8575 
6.33
15  C6H10O3  17 
(S)-3-Methyl-2-
oxopentanoic acid  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB   C00671 
1.
00 
1.
15 
0.
98 
0.7
2 
0.3
5  1 
0.729
051 
0.924
02 
0.261
046 
0.065
725 
130.110
7031 
13.2
57 
C6H14N2O  2  N-Acetylputrescine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02714 
1.
00 
0.
86 
0.
37 
0.1
4 
0.2
1 
1 
0.273
961 
0.017
161 
0.002
133 
0.001
308 
131.058
3101 
16.5
34 
C5H9NO3  14 
L-Glutamate 5-
semialdehyde 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01165 
1.
00 
1.
17 
1.
23 
0.9
6 
0.4
0 
1 
0.505
968 
0.345
37 
0.821
22 
0.027
61 
131.069
5572 
13.2
98 
C4H9N3O2  2  Creatine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00300  1.
00 
1.
00 
1.
14 
0.9
0 
0.3
9 
1  0.983
499 
0.355
984 
0.587
822 
0.068
262 
132.053
5468 
17.8
78 
C4H8N2O3  6  L-Asparagine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00152 
1.
00 
1.
01 
1.
07 
0.8
1 
0.2
8 
1 
0.979
556 
0.776
941 
0.295
019 
0.024
518 
132.089
6542 
21.0
84 
C5H12N2O2  6  D-Ornithine  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00515  1.
00 
0.
73 
0.
93 
0.8
5 
0.5
3 
1  0.502
443 
0.844
566 
0.719
465 
0.303
021 
132.089
964 
21.8
94 
C5H12N2O2  6  L-Ornithine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00077 
1.
00 
1.
56 
4.
21 
4.8
0 
1.5
8 
1 
0.393
104 
0.150
035 
0.009
421 
0.623
776 
133.037
4959 
18.5
65 
C4H7NO4  4  D-Aspartate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00402  1.
00 
0.
96 
1.
02 
1.0
0 
2.2
2 
1  0.788
111 
0.850
485 
0.961
434 
0.531
397 262 
 
133.037
5688 
17.5
18 
C4H7NO4  4  L-Aspartate  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00402 
1.
00 
1.
17 
1.
06 
1.1
0 
2.1
3 
1 
0.069
805 
0.429
623 
0.411
483 
0.496
793 
140.058
4644 
11.2
75  C6H8N2O2  7 
Methylimidazoleacetic 
acid  6 
Amino 
Acid 
Metabolis
m 
KEGG_HMDB  C05828 
1.
00 
1.
20 
1.
21 
1.1
5 
0.3
9  1 
0.332
059 
0.486
773 
0.686
206 
0.068
149 
144.126
2145 
21.7
06 
C7H16N2O  2 
1-(3-aminopropyl)-4-
aminobutanal 
6 
Amino 
Acid 
Metabolis
m 
Metacyc_HMDB  0 
1.
00 
1.
18 
1.
04 
1.1
5 
0.3
0 
1 
0.496
112 
0.917
541 
0.676
099 
0.073
657 
145.037
247 
7.86
56 
C5H7NO4  2  2-Oxoglutaramate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00940 
1.
00 
1.
50 
0.
53 
0.9
0 
0.0
0     
#DIV/
0! 
#DIV/
0! 
  
145.073
74 
13.7
29 
C6H11NO3  9  6-Amino-2-oxohexanoate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C03239  1.
00 
1.
43 
1.
22 
1.1
0 
1.4
9 
1  0.604
845 
0.696
194 
0.812
255 
0.609
259 
145.074
0399 
12.0
44 
C6H11NO3  9 
[FA oxo,amino(6:0)] 3-
oxo-5S-amino-hexanoic 
acid 
6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C03656 
1.
00 
0.
99 
1.
02 
0.9
0 
0.7
0 
1 
0.969
547 
0.933
875 
0.518
418 
0.147
29 
145.110
2213 
7.91
07 
C7H15NO2  6  3-Dehydroxycarnitine  3 
Amino 
Acid 
Metabolis
m 
KEGG_HMDB  C05543  1.
00 
1.
04 
0.
99 
1.1
4 
0.6
5 
1  0.914
17 
0.984
112 
0.446
792 
0.118
267 
145.157
9035 
32.4
07 
C7H19N3  1  Spermidine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00315 
1.
00 
1.
06 
0.
82 
0.3
4 
0.3
8 
1 
0.716
374 
0.337
029 
0.017
641 
0.049
361 
146.069
1481 
17.4
89 
C5H10N2O3  6  D-Glutamine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00819  1.
00 
1.
12 
1.
07 
0.9
6 
0.6
4 
1  0.488
214 
0.343
581 
0.752
088 
0.002
548 263 
 
146.105
4877 
21.4
93 
C6H14N2O2  7  L-Lysine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00047 
1.
00 
1.
09 
0.
98 
1.1
0 
0.4
3 
1 
0.578
487 
0.920
193 
0.627
38 
0.095
112 
147.053
1062 
15.9
41  C5H9NO4  14  L-Glutamate  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00025 
1.
00 
0.
93 
1.
01 
0.7
8 
0.4
0  1 
0.418
064 
0.966
706 
0.104
566 
0.030
941 
148.019
3168 
7.81
34 
C5H8O3S  1 
[FA oxo,methyl(4:0)] 2-
oxo-4-methylthio-
butanoic acid 
6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C01180 
1.
00 
1.
14 
1.
14 
0.6
9 
0.8
9 
1 
0.687
029 
0.697
973 
0.400
782 
0.731
432 
149.047
6693 
7.98
34 
C8H7NO2  8  5,6-Dihydroxyindole  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C05578 
1.
00 
0.
92 
1.
14 
1.7
6 
0.8
9 
1 
0.778
45 
0.662
968 
0.119
811 
0.591
67 
149.051
0691 
11.9  C5H11NO2S  5  L-Methionine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00073  1.
00 
1.
05 
1.
12 
0.9
9 
0.5
2 
1  0.476
176 
0.411
14 
0.866
686 
0.141
857 
152.047
0606 
6.10
79 
C8H8O3  25 
3,4-
Dihydroxyphenylacetalde
hyde 
6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C04043 
1.
00 
1.
11 
0.
88 
1.1
4 
2.0
9 
1 
0.812
576 
0.752
266 
0.701
506 
0.469
963 
154.037
5511 
11.9
65 
C6H6N2O3  2  Imidazol-5-yl-pyruvate  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C03277  1.
00 
1.
06 
0.
99 
0.9
6 
0.3
9 
1  0.723
318 
0.953
544 
0.797
123 
0.033
767 
155.069
543 
20.6
97 
C6H9N3O2  4  L-Histidine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00135 
1.
00 
1.
11 
1.
07 
0.9
7 
0.4
8 
1 
0.257
022 
0.410
611 
0.706
034 
0.104
644 
160.121
0176 
20.9
4 
C7H16N2O2  6  N6-Methyl-L-lysine  7 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02728  1.
00 
1.
00 
1.
34 
1.0
1 
0.9
6 
1  0.988
582 
0.336
039 
0.968
468 
0.923
941 264 
 
161.068
6934 
14.3
48 
C6H11NO4  10  O-Acetyl-L-homoserine  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C01077 
1.
00 
1.
03 
1.
01 
1.0
4 
0.5
2 
1 
0.814
99 
0.958
733 
0.854
818 
0.092
445 
163.066
601 
8.25
84  C6H13NO2S  6  S-Methyl-L-methionine  8 
Amino 
acid 
Metabolis
m 
KEGG_Metacyc  C03172 
1.
00 
1.
07 
1.
66 
1.2
1 
0.8
5  1 
0.733
321 
0.029
809 
0.353
113 
0.471
972 
164.047
1121 
6.44
12 
C9H8O3  13  4-Coumarate  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00811 
1.
00 
1.
09 
0.
87 
1.0
6 
0.8
0 
1 
0.831
667 
0.759
457 
0.890
527 
0.724
838 
164.047
1262 
6.94
35 
C9H8O3  13  enol-Phenylpyruvate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02763 
1.
00 
0.
91 
1.
03 
1.1
8 
0.8
0 
1 
0.839
787 
0.946
885 
0.687
004 
0.730
882 
164.047
1304 
5.58
91 
C9H8O3  13  Phenylpyruvate  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00166  1.
00 
1.
12 
1.
29 
0.7
0 
1.0
0 
1  0.843
296 
0.666
209 
0.528
899 
0.996
263 
164.047
1512 
7.58
99 
C9H8O3  13 
trans-3-
Hydroxycinnamate 
8 
Amino 
Acid 
Metabolis
m 
KEGG_HMDB  C12621 
1.
00 
0.
80 
1.
56 
1.7
1 
0.3
8 
1 
0.606
727 
0.457
337 
0.403
003 
0.205
673 
165.079
0108 
10.0
69 
C9H11NO2  7  D-Phenylalanine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C02265  1.
00 
1.
03 
0.
98 
0.9
7 
0.3
5 
1  0.872
975 
0.865
766 
0.839
619 
0.015
531 
166.062
6351 
5.80
31 
C9H10O3  17 
3-(3-Hydroxy-phenyl)-
propanoic acid 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C11457 
1.
00 
0.
81 
0.
72 
0.8
0 
0.9
5 
1 
0.369
038 
0.283
511 
0.355
058 
0.926
631 
169.085
0364 
20.8
52 
C7H11N3O2  4  N(pi)-Methyl-L-histidine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01152  1.
00 
0.
94 
0.
60 
0.8
4 
0.0
9 
1  0.924
619 
0.511
853 
0.797
319 
0.213
838 265 
 
173.068
743 
11.0
09 
C7H11NO4  6 
N-Acetyl-L-glutamate 5-
semialdehyde 
6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01250 
1.
00 
1.
00 
1.
11 
0.9
0 
0.6
6 
1 
0.988
681 
0.486
682 
0.350
343 
0.157
045 
174.052
4488 
7.60
97  C7H10O5  6 
(2S)-2-Isopropyl-3-
oxosuccinate  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB  C04236 
1.
00 
0.
32 
0.
58 
1.3
3 
0.4
3  1 
0.040
502 
0.128
011 
0.415
464 
0.070
865 
174.052
6751 
10.6
08 
C7H10O5  6  Shikimate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00493 
1.
00 
0.
53 
0.
49 
0.8
2 
0.4
0 
1 
0.331
466 
0.178
213 
0.573
091 
0.130
723 
174.100
3737 
16.1
56 
C7H14N2O3  5  N-Acetylornithine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00437 
1.
00 
2.
19 
3.
03 
4.8
4 
2.2
7 
1 
0.050
287 
0.036
044 
0.000
599 
0.353
974 
174.111
7071 
21.0
93 
C6H14N4O2  2  L-Arginine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00062  1.
00 
1.
00 
0.
93 
0.8
1 
0.4
2 
1  0.978
096 
0.629
636 
0.139
127 
0.014
21 
175.095
6056 
18.0
68 
C6H13N3O3  3  L-Citrulline  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00327 
1.
00 
1.
05 
1.
12 
0.9
2 
0.3
9 
1 
0.611
893 
0.525
29 
0.555
833 
0.318
392 
176.068
0727 
7.51
59 
C7H12O5  7  (2S)-2-Isopropylmalate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02504  1.
00 
2.
07 
2.
75 
4.3
6 
9.6
7 
1  0.389
894 
0.325
621 
0.025
701 
0.007
046 
179.057
9641 
5.95
17 
C9H9NO3  6  Hippurate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01586 
1.
00 
1.
05 
0.
91 
0.9
1 
0.9
6 
1 
0.846
502 
0.712
376 
0.711
14 
0.958
745 
180.041
9742 
6.06
32 
C9H8O4  11  trans-2,3-
Dihydroxycinnamate 
6 
Amino 
Acid 
Metabolis
m 
KEGG  C12623  1.
00 
0.
71 
1.
20 
0.8
2 
0.6
8 
1  0.362
642 
0.677
076 
0.536
76 
0.535
507 266 
 
180.042
3144 
10.6
43 
C9H8O4  11 
2-Hydroxy-3-(4-
hydroxyphenyl)propenoa
te 
8 
Amino 
Acid 
Metabolis
m 
KEGG_HMDB  C05350 
1.
00 
0.
62 
0.
55 
0.5
5 
1.5
4 
1 
0.668
55 
0.610
232 
0.593
708 
0.555
856 
181.073
9738 
12.7
49  C9H11NO3  11  L-Tyrosine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00082 
1.
00 
1.
07 
1.
07 
1.0
5 
0.4
9  1 
0.394
449 
0.683
319 
0.668
347 
0.138
856 
187.084
4247 
10.7
08 
C8H13NO4  6 
6-Acetamido-2-
oxohexanoate 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C05548 
1.
00 
0.
93 
1.
10 
2.2
1 
3.3
9 
1 
0.874
843 
0.834
677 
0.157
029 
0.112
062 
188.116
1357 
14.7
79 
C8H16N2O3  7  N6-Acetyl-L-lysine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02727 
1.
00 
1.
17 
2.
11 
1.9
1 
19.
78 
1 
0.554
791 
0.118
024 
0.042
217 
0.336
475 
188.127
4009 
20.6
3 
C7H16N4O2  5  Homoarginine  5 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01924  1.
00 
1.
19 
1.
14 
0.8
4 
0.6
1 
1  0.323
985 
0.673
497 
0.499
883 
0.075
273 
188.152
4946 
22.2
75 
C9H20N2O2  2 
N6,N6,N6-Trimethyl-L-
lysine 
10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C03793 
1.
00 
1.
08 
1.
43 
1.2
1 
8.3
4 
1 
0.808
23 
0.265
05 
0.609
872 
0.360
921 
189.082
353 
7.86
88 
C8H15NO2S  1  Prenyl-L-cysteine  7 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C06751  1.
00 
0.
78 
0.
78 
0.7
7 
0.1
5 
1  0.491
333 
0.485
315 
0.452
297 
0.062
444 
190.047
5227 
8.12
75 
C7H10O6  4 
[FA hydroxy(7:1/2:0)] 
2,4-dihydroxy-2-
heptenedioc acid 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Lipidmaps   C06201 
1.
00 
1.
27 
0.
87 
1.1
8 
0.4
8 
1 
0.366
933 
0.535
371 
0.456
501 
0.075
715 
192.063
06 
12.7
47 
C7H12O6  6  Quinate  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00296  1.
00 
0.
88 
0.
94 
0.8
2 
0.4
2 
1  0.780
997 
0.873
083 
0.639
04 
0.218
927 267 
 
193.073
6536 
5.87
15 
C10H11NO3  10  Phenylacetylglycine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C05598 
1.
00 
1.
27 
0.
98 
0.8
4 
1.3
8 
1 
0.320
475 
0.932
9 
0.547
261 
0.563
921 
195.089
4833 
8.51
01  C10H13NO3  6  L-Tyrosine methyl ester  7 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C03404 
1.
00 
0.
96 
1.
38 
1.1
2 
0.8
5  1 
0.620
961 
0.060
782 
0.424
846 
0.440
221 
197.018
1051 
14.1
93 
C5H11NO3S
2 
1 
CysteineMercaptoethano
l disulfide 
7 
Amino 
Acid 
Metabolis
m 
Medium   0 
1.
00 
1.
07 
1.
13 
1.1
3 
0.6
8 
1 
0.700
256 
0.675
796 
0.566
739 
0.152
318 
200.976
1462 
24.3
78 
C3H7NO5S2  1  S-Sulfo-L-cysteine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C05824 
1.
00 
0.
91 
0.
83 
0.7
1 
0.4
3 
1 
0.827
853 
0.681
248 
0.487
495 
0.231
808 
203.058
1144 
7.61
21 
C11H9NO3  2  Indolepyruvate  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C00331  1.
00 
0.
62 
0.
91 
1.0
5 
0.3
0 
1  0.447
513 
0.854
227 
0.928
806 
0.225
847 
203.079
4057 
12.4
56 
C8H13NO5  2 
N2-Acetyl-L-
aminoadipate 
6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C12986 
1.
00 
1.
12 
1.
57 
0.9
0 
0.5
5 
1 
0.673
39 
0.238
647 
0.710
8 
0.168
527 
204.089
9275 
10.4
1 
C11H12N2O
2 
6  D-Tryptophan  7 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00525  1.
00 
0.
98 
1.
06 
1.0
2 
0.4
2 
1  0.864
306 
0.768
238 
0.905
333 
0.052
053 
206.042
3822 
7.69
52 
C7H10O7  5 
2-Hydroxybutane-1,2,4-
tricarboxylate 
6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01251 
1.
00 
1.
20 
1.
85 
2.0
9 
0.1
6 
1 
0.866
643 
0.629
404 
0.558
543 
  
216.110
9603 
13.2
8 
C9H16N2O4  3 
gamma-Glutamyl-
gamma-
aminobutyraldehyde 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C15700  1.
00 
1.
61 
1.
33 
1.0
4 
1.1
8 
1  0.038
96 
0.157
765 
0.860
753 
0.625
814 268 
 
218.105
458 
7.95
77 
C12H14N2O
2 
7  N-Acetylserotonin  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00978 
1.
00 
1.
06 
1.
57 
1.2
3 
0.4
9 
1 
0.904
648 
0.671
344 
0.601
624 
0.280
945 
219.110
7345 
7.45
68  C9H17NO5  1  Pantothenate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00864 
1.
00 
1.
00 
0.
75 
2.1
1 
0.3
0  1 
0.994
799 
0.518
881 
0.134
886 
0.138
208 
222.067
408 
21.2
08 
C7H14N2O4
S 
4  L-Cystathionine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02291 
1.
00 
1.
27 
2.
75 
1.3
5 
6.7
2 
1 
0.487
528 
0.011
421 
0.364 
0.407
904 
226.106
3409 
21.1
42 
C9H14N4O3  3  Carnosine  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00386 
1.
00 
0.
99 
1.
38 
1.0
1 
0.5
0 
1 
0.971
237 
0.191
404 
0.970
322 
0.168
008 
240.023
8094 
21.6
64 
C6H12N2O4
S2 
2  L-Cystine  10 
Amino 
Acid 
Metabolis
m 
medium_KEGG_M
etacyc_HMDB 
C00491  1.
00 
1.
08 
1.
02 
1.3
3 
0.6
2 
1  0.800
953 
0.955
404 
0.359
051 
0.439
05 
243.085
432 
14.9
65 
C9H13N3O5  4 
gamma-Glutamyl-beta-
cyanoalanine 
6 
Amino 
Acid 
Metabolis
m 
KEGG  C05711 
1.
00 
0.
91 
1.
05 
0.9
5 
0.6
3 
1 
0.612
643 
0.891
162 
0.785
25 
0.114
165 
254.077
895 
22.8
39 
C6H15N4O5
P 
1  L-Arginine phosphate  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C05945  1.
00 
0.
94 
0.
63 
0.5
0 
1.1
6 
1  0.913
484 
0.479
458 
0.343
202 
0.894
794 
259.045
5123 
23.2
53 
C6H14NO8P  8 
D-Glucosamine 6-
phosphate 
10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00352 
1.
00 
0.
83 
0.
82 
0.7
2 
0.2
5 
1 
0.113
599 
0.130
355 
0.043
784 
0.025
682 
283.045
6131 
23.5
27 
C8H14NO8P  2  N2-Acetyl-L-aminoadipyl-
delta-phosphate 
8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C12987  1.
00 
0.
82 
1.
01 
0.8
5 
0.5
7 
1  0.454
564 
0.969
616 
0.475
604 
0.279
756 269 
 
297.089
6303 
7.82
81 
C11H15N5O
3S 
2  5'-Methylthioadenosine  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00170 
1.
00 
1.
04 
2.
23 
1.5
8 
1.9
0 
1 
0.904
05 
0.013
431 
0.119
082 
0.259
158 
301.055
9498 
23.5
29  C8H16NO9P  9 
N-Acetyl-D-glucosamine 
6-phosphate  6 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00357 
1.
00 
0.
82 
1.
14 
0.9
2 
0.6
2  1 
0.465
479 
0.593
864 
0.714
984 
0.387
613 
307.083
6059 
15.3
35 
C10H17N3O
6S 
3  Glutathione  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00051 
1.
00 
0.
31 
0.
81 
0.3
4 
6.5
2 
1 
0.387
548 
0.769
227 
0.401
926 
0.529
393 
360.644
2388 
22.7
25 
C27H47N9O
10S2 
1  Trypanothione disulfide  10 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc  C03170 
1.
00 
1.
04 
1.
12 
0.7
7 
1.0
5 
1 
0.894
586 
0.693
922 
0.301
565 
0.953
291 
398.137
0824 
22.7
31 
C15H23N6O
5S 
1  S-Adenosyl-L-methionine  8 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00019  1.
00 
1.
87 
2.
99 
1.4
6 
5.0
7 
1  0.331
569 
0.223
152 
0.385
124 
0.421
883 
426.087
9557 
20.7
08 
C13H22N4O
8S2 
2  S-glutathionyl-L-cysteine  7 
Amino 
Acid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C05526 
1.
00 
1.
29 
1.
32 
1.1
8 
0.2
9 
1 
0.497
399 
0.590
517 
0.621
429 
0.050
185 
430.066
111 
17.9
6 
C11H20N4O
10P2 
1  CMP-2-
aminoethylphosphonate 
6 
Amino 
Acid 
Metabolis
m 
KEGG  C05673  1.
00 
0.
97 
1.
09 
0.6
2 
0.3
1 
1  0.943
886 
0.835
436 
0.311
651 
  
529.086
3367 
15.9
56 
C16H25N3O
13P2 
1 
dTDP-3-amino-2,3,6-
trideoxy-D-threo-
hexopyranos-4-ulose 
5 
Biosynthe
sis of 
Polyketid
es and 
Nonribos
omal 
Peptides  
KEGG  C12318 
1.
00 
0.
74 
0.
65 
0.5
0 
0.2
9 
1 
0.243
204 
0.214
394 
0.062
201 
  
564.039
9605 
14.9
2 
C15H22N2O
17P2 
1  UDP-3-ketoglucose  5 
Biosynthe
sis of 
Polyketid
KEGG_Metacyc  C12210  1.
00 
1.
08 
1.
04 
1.0
5 
0.5
3 
1  0.416
67 
0.743
61 
0.705
659 
0.290
59 270 
 
es and 
Nonribos
omal 
Peptides  
564.040
2487 
15.4
08 
C15H22N2O
17P2 
1  UDP-3-ketoglucose  5 
Biosynthe
sis of 
Polyketid
es and 
Nonribos
omal 
Peptides  
KEGG_Metacyc  C12210 
1.
00 
0.
97 
1.
03 
1.0
9 
0.6
2 
1 
0.875
516 
0.957
549 
0.522
122 
0.327
214 
139.099
6766 
10.8
43 
C8H13NO  2  Tropinone  6 
Biosynthe
sis of 
Secondar
y 
Metabolit
es  
KEGG_Metacyc  C00783 
1.
00 
1.
34 
1.
25 
1.2
0 
0.9
7 
1 
0.047
208 
0.203
686 
0.279
248 
0.670
853 
180.042
0271 
9.12
34 
C9H8O4  11 
3,4-Dihydroxy-trans-
cinnamate 
6 
Biosynthe
sis of 
Secondar
y 
Metabolit
es  
KEGG_Metacyc_H
MDB 
C01197 
1.
00 
0.
96 
0.
95 
0.9
7 
0.4
6 
1 
0.908
333 
0.888
079 
0.940
345 
0.202
371 
240.147
2942 
11.1
46 
C12H20N2O
3  2  Slaframine  7 
Biosynthe
sis of 
Secondar
y 
Metabolit
es  
KEGG  C06185 
1.
00 
1.
10 
1.
25 
0.7
9 
0.6
0  1 
0.696
642 
0.273
718 
0.238
733 
0.283
451 
575.057
6022 
20.7
81 
C15H24N5O
13P3 
1 
Isopentenyladenosine-5'-
triphosphate 
6 
Biosynthe
sis of 
Secondar
y 
Metabolit
es  
KEGG_Metacyc  C16424 
1.
00 
0.
47 
0.
86 
0.9
5 
0.9
4 
1 
0.152
864 
0.359
58 
0.209
909 
0.745
236 
74.0364
8069 
7.06
82 
C3H6O2  7  Propanoate  8 
Carbohyd
rate 
Metabolis
KEGG_Metacyc_Li
pidmaps_HMDB  
C00163 
1.
00 
1.
18 
0.
91 
1.1
7 
0.6
8 
1 
0.574
293 
0.802
096 
0.838
495 
0.096
531 271 
 
m 
88.0161
65 
10.3
13 
C3H4O3  3  3-Oxopropanoate  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00222  1.
00 
0.
99 
1.
08 
1.0
6 
1.0
3 
1  0.965
495 
0.803
114 
0.833
497 
0.935
977 
88.0523
716 
7.95
48 
C4H8O2  7  Butanoic acid  6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C00246 
1.
00 
1.
21 
1.
02 
0.7
2 
0.5
2 
1 
0.497
407 
0.933
254 
0.366
743 
0.213
932 
92.0472
785 
10.4
14 
C3H8O3  1  Glycerol  10 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00116 
1.
00 
0.
75 
0.
88 
0.7
3 
0.7
4 
1 
0.680
472 
0.863
503 
0.646
627 
0.719
116 
104.010
9036 
9.37
72 
C3H4O4  3 
2-Hydroxy-3-
oxopropanoate 
6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01146 
1.
00 
1.
11 
0.
62 
0.9
1 
0.3
9 
1 
0.870
5 
0.189
446 
0.838
831 
0.087
102 
106.026
6802 
10.3
82 
C3H6O4  2  D-Glycerate  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00258 
1.
00 
1.
18 
1.
33 
1.2
4 
0.8
9 
1 
0.587
828 
0.450
149 
0.282
779 
0.830
782 
116.010
8466 
10.9
33 
C4H4O4  3  Maleic acid  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01384 
1.
00 
0.
63 
0.
81 
0.8
2 
0.1
5 
1 
0.714
458 
0.867
897 
0.861
676 
0.421
888 
118.026
5153 
7.48
39  C4H6O4  7  Succinate  10 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB   C00042 
1.
00 
1.
03 
0.
77 
1.9
7 
0.3
6  1 
0.959
651 
0.665
279 
0.087
222 
0.197
364 
120.042
0987 
13.8
09 
C4H8O4  9  L-Erythrulose  7 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02045 
1.
00 
1.
07 
0.
90 
1.0
4 
0.4
8 
1 
0.612
066 
0.556
272 
0.832
325 
0.104
175 
120.042
1255 
9.43
49 
C4H8O4  9  D-Erythrose  9 
Carbohyd
rate 
Metabolis
KEGG_Metacyc_H
MDB 
C01796 
1.
00 
1.
00 
0.
75 
1.4
2 
1.1
0 
1 
0.997
714 
0.476
617 
0.332
107 
0.891
675 272 
 
m 
120.042
1298 
8.86
75 
C4H8O4  9  D-Threose  5 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc  C06463  1.
00 
1.
07 
0.
83 
1.2
8 
0.9
4 
1  0.798
028 
0.589
664 
0.538
208 
0.834
814 
130.026
5697 
9.51
23 
C5H6O4  7  Mesaconate  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01732 
1.
00 
0.
76 
0.
58 
0.8
5 
0.6
3 
1 
0.424
308 
0.107
07 
0.535
247 
0.240
829 
132.042
0728 
11.3
53 
C5H8O4  16  2-Acetolactate  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00900 
1.
00 
1.
08 
1.
15 
0.7
7 
0.6
0 
1 
0.796
353 
0.484
058 
0.127
733 
0.277
135 
134.021
3676 
12.3
88 
C4H6O5  4  (R)-Malate  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc  C00497 
1.
00 
1.
97 
1.
47 
2.4
9 
0.3
3 
1 
0.498
521 
0.679
002 
0.380
15 
0.371
731 
134.021
4013 
9.90
32 
C4H6O5  4  (S)-Malate  10 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00149 
1.
00 
1.
60 
1.
62 
1.8
8 
0.5
1 
1 
0.419
621 
0.595
632 
0.244
588 
0.461
454 
136.037
0266 
13.6
39 
C4H8O5  3 
[FA trihydroxy(4:0)] 
2,3,4-trihydroxy-butanoic 
acid 
8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C01620 
1.
00 
1.
05 
0.
90 
1.0
6 
0.3
2 
1 
0.790
082 
0.601
415 
0.805
403 
0.036
713 
146.021
2658 
13.1
15  C5H6O5  7  Methyloxaloacetate  7 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc  C06030 
1.
00 
0.
98 
0.
82 
0.5
0 
0.1
6  1 
0.939
88 
0.704
203 
0.178
823 
0.064
036 
148.036
9113 
9.77
92 
C5H8O5  18 
2-Dehydro-3-deoxy-L-
arabinonate 
8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc  C00684 
1.
00 
0.
38 
0.
52 
0.4
9 
2.4
1 
1 
0.096
491 
0.171
806 
0.139
775 
0.551
199 
148.036
9496 
8.09
77 
C5H8O5  18  D-Xylonolactone  8 
Carbohyd
rate 
Metabolis
KEGG_Metacyc_H
MDB 
C02266 
1.
00 
0.
54 
0.
61 
0.7
6 
0.9
1 
1 
0.061
374 
0.140
676 
0.262
961 
0.866
824 273 
 
m 
150.052
442 
13.2
05 
C5H10O5  37  L-Xylulose  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00312  1.
00 
1.
13 
0.
92 
1.0
9 
0.7
6 
1  0.470
123 
0.715
802 
0.646
082 
0.400
656 
150.052
5174 
15.6
67 
C5H10O5  37  L-Arabinose  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00259 
1.
00 
0.
83 
0.
80 
1.2
2 
0.7
0 
1 
0.656
69 
0.522
875 
0.676
399 
0.360
859 
150.052
5998 
15.4
2 
C5H10O5  37  D-Xylulose  6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00310 
1.
00 
1.
09 
0.
96 
1.0
7 
0.6
3 
1 
0.322
362 
0.465
6 
0.324
536 
0.024
474 
152.068
1534 
13.4
13 
C5H12O5  4  Xylitol  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00379 
1.
00 
1.
01 
0.
93 
1.0
5 
0.4
7 
1 
0.930
375 
0.625
606 
0.730
117 
0.104
144 
167.981
9679 
29.3
99 
C3H5O6P  3  Phosphoenolpyruvate  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00074 
1.
00 
1.
18 
1.
11 
1.0
9 
2.7
4 
1 
0.625
719 
0.719
187 
0.732
78 
0.479
932 
169.997
7043 
24.6
77 
C3H7O6P  7  Glycerone phosphate  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00111 
1.
00 
0.
83 
1.
04 
0.8
2 
0.3
6 
1 
0.612
688 
0.911
873 
0.569
776 
0.117
206 
178.047
5097 
10.0
53  C6H10O6  26 
2-Dehydro-3-deoxy-D-
gluconate  6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00204 
1.
00 
0.
95 
1.
00 
1.0
4 
2.4
4  1 
0.949
319 
0.997
503 
0.961
234 
0.338
665 
178.047
6917 
10.3
25 
C6H10O6  26  D-Glucono-1,5-lactone  6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00198 
1.
00 
0.
89 
1.
04 
1.2
1 
2.3
2 
1 
0.872
413 
0.948
015 
0.710
531 
0.369
213 
179.079
2696 
19.0
69 
C6H13NO5  10  D-Glucosamine  8 
Carbohyd
rate 
Metabolis
KEGG_Metacyc_H
MDB 
C00329 
1.
00 
0.
99 
1.
01 
0.9
0 
1.4
2 
1 
0.950
768 
0.980
767 
0.603
699 
0.699
567 274 
 
m 
180.063
1853 
15.4
66 
C6H12O6  57  D-Glucose  10 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00221  1.
00 
1.
00 
0.
97 
1.0
5 
0.6
1 
1  0.942
574 
0.612
766 
0.542
489 
0.024
934 
182.078
7896 
14.5
91 
C6H14O6  6  D-Sorbitol  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00794 
1.
00 
1.
04 
0.
98 
1.0
3 
0.4
6 
1 
0.772
558 
0.908
746 
0.852
507 
0.119
168 
185.992
6006 
29.5
26 
C3H7O7P  3  3-Phospho-D-glycerate  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00197 
1.
00 
1.
00 
1.
14 
0.9
2 
1.7
9 
1 
0.993
341 
0.651
246 
0.740
094 
0.577
487 
192.026
8113 
20.2
65 
C6H8O7  12 
5-Dehydro-4-deoxy-D-
glucarate 
8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc  C00679 
1.
00 
0.
97 
1.
16 
1.2
3 
0.5
2 
1 
0.932
152 
0.707
587 
0.662
417 
0.301
227 
194.042
9735 
10.3
33 
C6H10O7  16  3-Dehydro-L-gulonate  6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00618 
1.
00 
0.
86 
1.
06 
0.9
3 
1.2
5 
1 
0.787
566 
0.920
771 
0.873
887 
0.657
679 
196.057
9592 
19.2
94 
C6H12O7  11  D-Mannonate  6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc  C00514 
1.
00 
1.
56 
1.
53 
1.4
5 
1.5
9 
1 
0.576
385 
0.530
027 
0.652
202 
0.698
064 
196.057
9617 
21.5
26  C6H12O7  11  L-Gulonate  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00800 
1.
00 
1.
57 
1.
38 
1.4
1 
0.4
7  1 
0.590
794 
0.618
699 
0.669
073 
0.463
276 
196.058
024 
16.0
28 
C6H12O7  11  D-Gluconic acid  10 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00257 
1.
00 
1.
77 
2.
07 
0.9
2 
0.4
6 
1 
0.432
663 
0.050
011 
0.891
259 
0.169
167 
196.058
0602 
11.4
94 
C6H12O7  11  D-Galactonate  6 
Carbohyd
rate 
Metabolis
KEGG_Metacyc  C00880 
1.
00 
0.
98 
1.
03 
0.8
7 
0.3
8 
1 
0.922
061 
0.870
138 
0.261
785 
0.056
091 275 
 
m 
196.058
1737 
11.0
44 
C6H12O7  11  D-Altronate  6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc  C00817  1.
00 
1.
02 
1.
08 
0.9
5 
0.6
8 
1  0.877
826 
0.677
95 
0.695
991 
0.193
462 
200.008
2395 
26.6
09 
C4H9O7P  4  Erythrulose 1-phosphate  5 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc  C03394 
1.
00 
0.
89 
1.
34 
1.1
7 
0.6
1 
1 
0.663
347 
0.431
433 
0.553
328 
0.306
144 
221.089
9117 
12.4
58 
C8H15NO6  7 
N-Acetyl-D-
mannosamine 
6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00645 
1.
00 
1.
18 
1.
21 
1.1
8 
0.5
7 
1 
0.363
694 
0.571
467 
0.455
676 
0.135
775 
230.018
7896 
24.9  C5H11O8P  16  D-Ribose 5-phosphate  10 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00117 
1.
00 
1.
30 
0.
98 
0.8
5 
0.1
5 
1 
0.625
922 
0.966
402 
0.665
774 
0.103
503 
230.019
1227 
24.6
63 
C5H11O8P  16  D-Ribose 5-phosphate  10 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00117 
1.
00 
1.
22 
0.
95 
0.7
0 
0.1
5 
1 
0.752
766 
0.925
627 
0.483
998 
0.134
018 
260.029
4049 
25.2
55 
C6H13O9P  46  D-Fructose 6-phosphate  10 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00085 
1.
00 
0.
85 
1.
23 
1.0
4 
0.5
2 
1 
0.535
691 
0.510
014 
0.848
026 
0.190
325 
260.029
4061 
25.7
23  C6H13O9P  46  D-Glucose 6-phosphate  10 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00092 
1.
00 
0.
86 
1.
25 
1.1
8 
0.5
5  1 
0.618
308 
0.523
993 
0.553
05 
0.233
539 
260.029
4387 
26.5
77 
C6H13O9P  46  D-Mannose 1-phosphate  6 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00636 
1.
00 
0.
87 
1.
17 
1.1
3 
0.5
6 
1 
0.625
255 
0.623
085 
0.655
989 
0.224
182 
290.040
0955 
25.3
77 
C7H15O10P  6 
D-Sedoheptulose 7-
phosphate 
8 
Carbohyd
rate 
Metabolis
KEGG_Metacyc  C05382 
1.
00 
1.
36 
2.
14 
5.0
4 
6.0
1 
1 
0.240
439 
0.306
621 
0.064
381 
0.135
491 276 
 
m 
566.053
8362 
1.66
92 
C15H24N2O
17P2 
3  UDP-glucose  8 
Carbohyd
rate 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00029  1.
00 
1.
51 
0.
86 
0.4
3 
1.4
2 
1  0.509
128 
0.575
176 
0.390
809 
0.168
314 
75.0684
0155 
10.7
06 
C3H9NO  6  Trimethylamine N-oxide  7 
Energy 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01104 
1.
00 
1.
20 
1.
18 
1.0
2 
0.5
2 
1 
0.552
274 
0.657
178 
0.948
813 
0.250
581 
97.9767
3489 
23.0
63 
H3O4P  1  Orthophosphate  10 
Energy 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00009 
1.
00 
0.
95 
0.
96 
0.9
3 
1.4
2 
1 
0.652
783 
0.730
895 
0.542
838 
0.644
291 
97.9769
2148 
23.9
74 
H3O4P  1  Orthophosphate  8 
Energy 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00009 
1.
00 
0.
75 
0.
98 
0.9
7 
0.6
0 
1 
0.155
198 
0.918
629 
0.671
1 
0.139
972 
210.073
8113 
14.8
83 
C7H14O7  4  Sedoheptulose  7 
Energy 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02076 
1.
00 
1.
14 
1.
49 
2.4
3 
2.1
5 
1 
0.368
03 
0.242
563 
0.135
181 
0.334
786 
331.554
5142 
22.1
16 
C21H28N7O
14P2 
1  NAD+  10 
Energy 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00003 
1.
00 
1.
03 
1.
12 
1.1
2 
1.2
6 
1 
0.701
147 
0.140
105 
0.407
09 
0.622
005 
371.537
434 
35.0
09 
C21H29N7O
17P3 
1  NADP+  8 
Energy 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00006 
1.
00 
1.
60 
1.
48 
0.9
5 
0.8
8 
1 
0.230
438 
0.362
686 
0.805
544 
0.464
516 
238.068
8926 
10.9
91  C8H14O8  1 
3-Deoxy-D-manno-
octulosonate  8 
Glycan 
Biosynthe
sis and 
Metabolis
m 
KEGG_Metacyc  C01187 
1.
00 
0.
90 
1.
01 
0.8
1 
0.8
6  1 
0.763
222 
0.988
527 
0.557
47 
0.687
47 
104.047
2933 
6.61
01 
C4H8O3  13  (R)-3-Hydroxybutanoate  6 
Lipid 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C01089 
1.
00 
0.
95 
0.
90 
1.0
5 
0.8
0 
1 
0.822
558 
0.438
856 
0.841
109 
0.157
643 
125.014
4842 
17.1
01 
C2H7NO3S  1  Taurine  8 
Lipid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00245 
1.
00 
1.
07 
1.
11 
0.8
2 
3.4
9 
1 
0.674
996 
0.501
873 
0.318
364 
0.497
409 277 
 
145.110
1564 
10.8
16 
C7H15NO2  6  Acetylcholine  8 
Lipid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01996  1.
00 
1.
23 
1.
13 
1.2
0 
0.4
1 
1  0.698
204 
0.761
688 
0.691
09 
0.196
857 
155.034
77 
16.0
32 
C3H10NO4P  3  N-Methylethanolamine 
phosphate 
8 
Lipid 
Metabolis
m 
KEGG_Metacyc  C01210  1.
00 
1.
02 
1.
15 
1.0
2 
0.5
6 
1  0.699
451 
0.382
032 
0.832
323 
0.126
413 
157.034
9275 
15.7
4 
C10H20O7P
2 
6  [PR] Geranyl 
pyrophosphate 
8 
Lipid 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C00341  1.
00 
1.
02 
1.
08 
0.9
8 
0.4
6 
1  0.761
551 
0.561
866 
0.847
465 
0.013
938 
169.050
2829 
20.5
32 
C4H12NO4P  1 
Phosphodimethylethanol
amine 
6 
Lipid 
Metabolis
m 
KEGG_Metacyc  C13482 
1.
00 
0.
72 
0.
89 
0.7
3 
0.4
7 
1 
0.266
43 
0.661
699 
0.271
459 
0.098
246 
172.013
379 
24.0
73 
C3H9O6P  3  sn-Glycerol 3-phosphate  10 
Lipid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00093  1.
00 
0.
72 
0.
96 
0.8
9 
0.4
1 
1  0.123
612 
0.836
163 
0.221
332 
0.105
165 
183.066
1188 
23.1
52 
C5H14NO4P  1  Choline phosphate  10 
Lipid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00588  1.
00 
0.
68 
1.
20 
1.0
5 
0.5
2 
1  0.405
32 
0.644
749 
0.894
764 
0.186
811 
215.055
6647 
18.6
88 
C5H14NO6P  1 
sn-glycero-3-
Phosphoethanolamine 
8 
Lipid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01233 
1.
00 
0.
80 
1.
13 
1.0
2 
0.8
6 
1 
0.494
138 
0.554
227 
0.938
379 
0.790
859 
244.053
6445 
24.7
3 
C14H26N4O
11P2 
1  CDP-choline  8 
Lipid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00307 
1.
00 
1.
98 
2.
07 
1.4
6 
1.0
3 
1 
0.025
47 
0.062
135 
0.256
781 
0.942
611 
254.224
439 
5.18
59 
C16H30O2  19  (9Z)-Hexadecenoic acid  8 
Lipid 
Metabolis
m 
KEGG_Lipidmaps_
HMDB 
C08362 
1.
00 
1.
25 
0.
67 
1.1
5 
1.2
6 
1 
0.349
256   
0.558
452 
0.652
708 
257.102
9335 
20.6
9 
C8H20NO6P  1 
sn-glycero-3-
Phosphocholine 
10 
Lipid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00670 
1.
00 
0.
89 
0.
81 
1.1
0 
0.3
1 
1 
0.630
889 
0.249
187 
0.718
823 
0.022
042 
400.334
0084 
5.18
1 
C27H44O2  35 
7alpha-Hydroxycholest-
4-en-3-one 
8 
Lipid 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C05455 
1.
00 
1.
03 
0.
84 
1.1
4 
0.6
0 
1 
0.961
055 
0.763
038 
0.831
479 
0.462
567 
449.314
0325 
5.60
96 
C26H43NO5  6  Glycodeoxycholate  7 
Lipid 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C05464 
1.
00 
1.
17 
1.
15 
0.9
7 
0.7
3 
1 
0.439
951 
0.585
418 
0.874
929 
0.233
325 278 
 
472.112
3978 
24.1
69 
C14H27N4O
10P2 
1  CMP-N-trimethyl-2-
aminoethylphosphonate 
5 
Lipid 
Metabolis
m 
KEGG  C05674  1.
00 
0.
95 
1.
23 
0.9
6 
0.7
3 
1  0.785
325 
0.581
692 
0.711
936 
0.308
727 
102.067
9991 
6.23
1 
C5H10O2  5  Pentanoate  5 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C00803  1.
00 
1.
77 
1.
37 
0.8
5 
0.5
7 
1  0.300
613 
0.406
168 
0.362
641 
0.476
977 
102.068
014 
6.52
89 
C5H10O2  5  3-Methylbutanoic acid  5 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C08262  1.
00 
0.
65 
0.
76 
0.6
7 
0.5
6 
1  0.265
576 
0.371
014 
0.263
94 
0.170
685 
116.083
7259 
5.36
02 
C6H12O2  16  Hexanoic acid  5 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C01585 
1.
00 
0.
74 
1.
09 
0.7
7 
0.8
5 
1 
0.337
825 
0.324
316 
0.366
897 
0.584
676 
118.062
9005 
6.12
19 
C5H10O3  12  5-Hydroxypentanoate  7 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps  
C02804  1.
00 
0.
88 
0.
82 
1.0
3 
0.8
9 
1  0.671
799 
0.512
058 
0.902
602 
0.790
339 
132.042
0156 
6.38
02 
C5H8O4  16  Glutarate  6 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C00489  1.
00 
0.
88 
0.
87 
1.0
9 
0.8
5 
1  0.722
758 
0.655
646 
0.779
17 
0.609
837 
146.057
3895 
6.22
33 
C6H10O4  16  Adipate  8 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C06104 
1.
00 
0.
85 
0.
71 
0.9
6 
0.5
0 
1 
0.710
116 
0.455
931 
0.915
329 
0.247
86 
148.073
3023 
7.62
08 
C6H12O4  14 
[FA methyl,hydroxy(5:0)] 
3R-methyl-3,5-dihydroxy-
pentanoic acid 
8 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C00418 
1.
00 
1.
19 
1.
08 
0.9
1 
2.3
2 
1 
0.720
434 
0.827
222 
0.794
914 
0.503
826 
160.073
0941 
5.85
48 
C7H12O4  4 
[FA (7:0/2:0)] 
Heptanedioic acid 
8 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C02656 
1.
00 
1.
06 
0.
96 
1.0
5 
0.9
5 
1 
0.794
477 
0.805
116 
0.820
758 
0.925
327 
174.088
7057 
5.63
92 
C8H14O4  3  Suberic acid  7 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C08278 
1.
00 
1.
03 
0.
82 
1.0
8 
0.7
2 
1 
0.923
18 
0.432
479 
0.888
289 
0.248
245 
202.120
2786 
5.46
19 
C10H18O4  2 
[FA (10:0/2:0)] 
Decanedioic acid 
7 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C08277 
1.
00 
1.
08 
0.
86 
0.8
4 
0.5
3 
1 
0.843
558 
0.588
361 
0.698
207 
0.139
939 
216.172
6041 
5.26
52 
C12H24O3  11 
12-Hydroxydodecanoic 
acid 
5 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps_HMDB  
C08317 
1.
00 
3.
75 
1.
08 
2.9
1 
0.4
0 
1 
0.514
836 
0.934
236 
0.082
992 
0.297
678 279 
 
217.131
4263 
8.41
32 
C10H19NO4  1  O-Propanoylcarnitine  7 
Lipids: 
Fatty 
Acyls 
KEGG_Lipidmaps_
HMDB 
C03017  1.
00 
0.
89 
0.
99 
1.0
7 
0.6
5 
1  0.642
312 
0.974
457 
0.813
81 
0.209
235 
222.089
0082 
5.33
93 
C12H14O4  8 
[FA (12:4/2:0)] 
2E,4E,8E,10E-
Dodecatetraenedioic acid 
7 
Lipids: 
Fatty 
Acyls 
Lipidmaps   0  1.
00 
0.
97 
0.
75 
0.9
6 
0.5
2 
1  0.943
756 
0.439
224 
0.873
993 
0.177
28 
231.147
0116 
8.00
76 
C11H21NO4  3  O-Butanoylcarnitine  7 
Lipids: 
Fatty 
Acyls 
KEGG_Lipidmaps_
HMDB 
C02862  1.
00 
1.
01 
1.
25 
1.0
3 
1.1
3 
1  0.977
337 
0.624
623 
0.905
247 
0.714
038 
281.271
819 
7.54
36 
C18H35NO  1 
[FA (18:1)] 9Z-
octadecenamide 
7 
Lipids: 
Fatty 
Acyls 
Metacyc_Lipidmap
s_HMDB 
0 
1.
00 
0.
87 
1.
42 
1.1
4 
0.8
6 
1 
0.255
47 
0.186
435 
0.284
17 
0.228
666 
290.188
2148 
5.18
27 
C18H26O3  6 
[FA hydroxy(18:1/2:0)] 8-
hydroxy-13Z-octadecene-
9,11-diynoic acid 
7 
Lipids: 
Fatty 
Acyls 
Lipidmaps   0  1.
00 
1.
12 
1.
17 
1.4
5 
4.2
5 
1  0.811
139 
0.778
915 
0.430
677 
0.568
66 
298.250
8203 
5.15
76 
C18H34O3  46  2-Oxooctadecanoic acid  5 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps  
C00869  1.
00 
1.
36 
1.
01 
0.8
5 
0.9
5 
1  0.316
023 
0.967
658 
0.269
272 
0.850
494 
300.266
2744 
5.16
67 
C18H36O3  27 
[FA hydroxy(18:0)] 2S-
hydroxy-octadecanoic 
acid 
5 
Lipids: 
Fatty 
Acyls 
KEGG_Metacyc_Li
pidmaps  
C03045 
1.
00 
1.
08 
0.
87 
1.4
2 
0.8
4 
1 
0.829
99 
0.564
035 
0.211
043 
0.583
054 
316.261
3015 
5.24
54 
C18H36O4  19 
[FA hydroxy(18:0)] 9,10-
dihydroxy-octadecanoic 
acid 
5 
Lipids: 
Fatty 
Acyls 
Metacyc_Lipidmap
s 
0 
1.
00 
1.
57 
0.
82 
1.0
9 
0.8
2 
1 
0.563
171 
0.568
678 
0.762
721 
0.578
084 
342.313
3048 
5.19
73 
C21H42O3  6 
[FA hydroxy(21:0)] 21-
hydroxy-heneicosanoic 
acid 
5 
Lipids: 
Fatty 
Acyls 
Lipidmaps   0 
1.
00 
0.
81 
1.
22 
1.1
8 
0.5
7 
1 
0.593
139 
0.530
038 
0.569
233 
0.239
135 
354.276
7186 
5.05
84 
C21H38O4  5 
[FA methoxy,trihydrox] 
1-methoxy-9S,11R,15S-
trihydroxy-5Z,13E-
prostadiene 
5 
Lipids: 
Fatty 
Acyls 
Lipidmaps   0 
1.
00 
0.
73 
1.
74 
0.7
1 
1.0
6 
1 
0.300
106 
0.159
238 
0.384
484 
0.919
149 
370.308
1784 
5.05
35 
C22H42O4  3  2-monooleoylglycerol  7 
Lipids: 
Glycerolip
ids 
Metacyc_HMDB  0 
1.
00 
1.
14 
1.
70 
2.1
8 
0.7
4 
1 
0.772
698 
0.209
961 
0.288
736 
0.626
306 
465.321
6509 
6.09
62 
C23H48NO6
P  3 
[PE (18:1)] 1-(9Z-
octadecenyl)-sn-glycero-
3-phosphoethanolamine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
76 
0.
96 
1.2
7 
0.5
5  1 
0.600
366 
0.920
622 
0.496
126 
0.279
504 280 
 
465.321
6902 
7.62
59 
C23H48NO6
P 
3 
[PC (15:1)] 1-(1Z-
pentadecenyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
72 
0.
94 
1.0
4 
0.2
2 
1 
0.573
511 
0.887
913 
0.925
319 
0.154
969 
465.321
7736 
10.4
39 
C23H48NO6
P  3 
[PE (18:1)] 1-(1Z-
octadecenyl)-sn-glycero-
3-phosphoethanolamine 
3 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
1.
17 
1.
04 
0.7
9 
0.5
8  1 
0.677
678 
0.923
524 
0.613
402 
0.406
451 
477.285
2667 
6.10
53 
C23H44NO7
P 
2  LysoPE(0:0/18:2(9Z,12Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
HMDB  0 
1.
00 
1.
43 
1.
21 
1.5
3 
1.1
6 
1 
0.412
269 
0.523
133 
0.278
695 
0.549
135 
479.337
4523 
10.2
63 
C24H50NO6
P 
5 
[PC (16:1)] 1-(1Z-
hexadecenyl)-sn-glycero-
3-phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C04230 
1.
00 
1.
15 
1.
16 
0.8
6 
0.4
7 
1 
0.769
615 
0.809
992 
0.749
306 
0.302
416 
493.316
589 
10.4
53 
C24H48NO7
P 
3 
[PC (16:0)] 1-(9Z-
hexadecenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Metacyc_Lipidmap
s 
0  1.
00 
1.
25 
1.
28 
0.9
3 
0.1
4 
1  0.666
642 
0.553
686 
0.872
34 
0.092
238 
493.352
9031 
6.10
38 
C25H52NO6
P 
1 
[PC (17:1)] 1-(1Z-
heptadecenyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
86 
1.
02 
1.0
0 
0.9
6 
1 
0.403
11 
0.721
001 
0.986
906 
0.937
058 
493.352
9632 
10.1
44 
C25H52NO6
P 
1 
[PC (17:1)] 1-(1Z-
heptadecenyl)-sn-
glycero-3-
phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps  0  1.
00 
0.
86 
1.
28 
0.9
5 
0.5
2 
1  0.739
594 
0.632
647 
0.882
471 
0.234
662 
495.332
2661 
10.3
52 
C24H50NO7
P 
5 
[PC (16:0)] 1-
hexadecanoyl-sn-glycero-
3-phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C04230 
1.
00 
1.
14 
0.
97 
1.8
2 
0.2
5 
1 
0.848
007 
0.953
46 
0.298
474 
0.160
232 
507.368
5676 
6.19
38 
C26H54NO6
P 
6 
[PC (18:1)] 3-(9E-
octadecenyl)-sn-glycero-
1-phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0  1.
00 
0.
62 
0.
92 
1.1
3 
0.4
2 
1  0.207
21 
0.810
358 
0.737
753 
0.111
192 281 
 
507.368
7814 
9.90
09 
C26H54NO6
P 
6 
[PC (18:1)] 1-(11Z-
octadecenyl)-sn-glycero-
3-phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
98 
1.
33 
1.0
7 
0.8
5 
1 
0.960
415 
0.483
594 
0.825
822 
0.703
256 
509.347
7356 
10.2
16 
C25H52NO7
P  8  LysoPC(17:0)  7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C04230 
1.
00 
0.
97 
0.
91 
1.3
9 
0.3
3  1 
0.961
503 
0.898
331 
0.483
528 
0.159
313 
509.384
499 
10.3
98 
C26H56NO6
P 
8  LysoPC(O-18:0)  7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C04317 
1.
00 
0.
82 
0.
88 
1.1
7 
0.8
0 
1 
0.588
623 
0.689
805 
0.603
072 
0.535
622 
519.332
3177 
10.2
55 
C26H50NO7
P 
3 
[PC (18:2)] 1-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C04230 
1.
00 
1.
32 
1.
09 
1.4
2 
0.1
5 
1 
0.547
197 
0.787
519 
0.398
24 
0.084
64 
521.348
2982 
6.23
06 
C26H52NO7
P 
11  LysoPC(18:1(9Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C04230  1.
00 
0.
90 
1.
06 
1.0
9 
0.3
0 
1  0.744
423 
0.881
478 
0.752
691 
0.059
741 
523.363
6768 
6.21
62 
C26H54NO7
P 
9  LysoPC(18:0)  7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C04230 
1.
00 
0.
90 
1.
39 
1.1
9 
0.4
0 
1 
0.812
268 
0.726
56 
0.627
07 
  
523.363
7702 
10.0
87 
C26H54NO7
P 
9 
[PC (18:0)] 1-
octadecanoyl-sn-glycero-
3-phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Metacyc_Lipidmap
s 
0  1.
00 
0.
86 
0.
72 
1.4
6 
0.4
1 
1  0.784
217 
0.558
458 
0.415
952 
0.241
11 
535.399
9381 
9.76
09 
C28H58NO6
P 
1 
[PC (18:2)] 1-octadecyl-2-
(1E-ethenyl)-sn-glycero-
3-phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
93 
1.
72 
1.0
9 
0.7
9 
1 
0.686
49 
0.261
438 
0.644
806 
0.534
804 
537.415
7468 
10.1
84 
C28H60NO6
P 
7 
[PC (10:2/10:2)] 1-decyl-
2-decyl-sn-glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0  1.
00 
0.
99 
1.
10 
1.0
8 
0.8
1 
1  0.935
816 
0.579
824 
0.631
981 
0.704
313 282 
 
565.447
0169 
9.97
38 
C30H64NO6
P 
4 
[PC (10:2/12:2)] 1-decyl-
2-dodecyl-sn-glycero-3-
phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
99 
1.
43 
0.9
3 
2.4
3 
1 
0.979
025 
0.535
447 
0.869
882 
0.036
569 
567.332
2247 
6.18
98 
C30H50NO7
P 
2 
[PC (22:6)] 1-
(4E,7E,10E,13E,16E,19E-
docosahexaenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0  1.
00 
1.
07 
1.
08 
0.8
6 
0.3
8 
1  0.916
177 
0.845
337 
0.664
122 
0.143
354 
567.332
4132 
9.96
1 
C30H50NO7
P  2 
[PC (22:6)] 1-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C04230 
1.
00 
1.
45 
1.
10 
1.0
3 
0.3
3  1 
0.493
973 
0.760
02 
0.939
83 
0.138
942 
569.348
1185 
6.18 
C30H52NO7
P 
2 
LysoPC(22:5(7Z,10Z,13Z,1
6Z,19Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C04230 
1.
00 
1.
24 
1.
20 
1.0
1 
0.4
2 
1 
0.623
234 
0.512
841 
0.972
748 
0.098
071 
569.348
3693 
9.86
45 
C30H52NO7
P 
2  LysoPC(22:5(4Z,7Z,10Z,13
Z,16Z)) 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C04230  1.
00 
1.
29 
1.
15 
1.0
4 
0.3
7 
1  0.535
227 
0.666
664 
0.916
813 
0.132
337 
571.363
6937 
6.17
22 
C30H54NO7
P 
1 
LysoPC(22:4(7Z,10Z,13Z,1
6Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C04230 
1.
00 
1.
18 
1.
18 
0.9
5 
0.8
6 
1 
0.617
234 
0.577
612 
0.852
763 
  
571.364
0486 
9.83
54 
C30H54NO7
P 
1 
LysoPC(22:4(7Z,10Z,13Z,1
6Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C04230 
1.
00 
1.
30 
1.
60 
1.1
0 
0.4
0 
1 
0.393
849 
0.207
352 
0.779
071 
0.056
892 
675.520
9773 
5.84
44 
C37H74NO7
P 
4  PE(14:0/P-18:0)  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
33 
1.
72 
0.3
0 
0.7
1 
1 
0.370
07     
0.305
268 
687.520
892 
5.83
51 
C38H74NO7
P  7  PC(14:1(9Z)/P-16:0)  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157 
1.
00 
1.
03 
1.
28 
0.4
2 
0.9
7  1 
0.939
691 
0.709
228 
0.058
409 
0.917
188 283 
 
699.520
3472 
5.75
49 
C39H74NO7
P 
6  PE(16:1(9Z)/P-18:1(11Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
29 
1.
88 
0.5
8 
2.0
8 
1 
0.708
382 
0.484
298 
0.468
22 
0.160
306 
701.536
4684 
5.78
45 
C39H76NO7
P  11  PE(16:0/P-18:1(11Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
04 
1.
37 
0.3
0 
1.2
7  1 
0.960
761 
0.705
32 
0.294
341 
0.698
427 
713.500
2379 
5.79
68 
C39H72NO8
P 
12 
[PE (16:0/18:3)] 1-
hexadecanoyl-2-
(9Z,12Z,15Z-
octadecatrienoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C00350 
1.
00 
1.
50 
1.
13 
0.6
6 
0.6
4 
1 
0.348
561 
0.696
256 
0.322
782 
0.341
303 
713.536
1507 
5.74
32 
C40H76NO7
P 
5  PC(14:1(9Z)/P-18:1(11Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157 
1.
00 
1.
29 
1.
98 
0.3
7 
1.9
4 
1 
0.716
966 
0.479
839 
0.311
083 
0.245
059 
715.515
5781 
5.79
44 
C39H74NO8
P 
11 
[PE (16:0/18:2)] 1-
hexadecanoyl-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C00350 
1.
00 
1.
25 
1.
06 
0.5
4 
0.6
8 
1 
0.764
748 
0.932
047 
0.455
335 
0.577
775 
715.551
7449 
5.88
53 
C40H78NO7
P 
12  PC(14:0/P-18:1(11Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157  1.
00 
1.
08 
1.
41 
0.4
7 
1.3
2 
1  0.903
997 
0.658
292 
0.368
857 
0.640
894 
717.531
5514 
5.81
66 
C39H76NO8
P 
17 
[PE (16:0/18:1)] 1-
Hexadecanoyl-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphoethanolamine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C13877 
1.
00 
1.
21 
0.
76 
0.2
6 
0.4
9 
1 
0.783
825 
0.694
345 
0.245
936 
0.377
113 
717.531
7166 
7.76
45 
C39H76NO8
P 
17 
[PE (16:0/18:1)] 1-
hexadecanoyl-2-(11Z-
octadecenoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds 
KEGG_Lipidmaps_
HMDB 
C00350 
1.
00 
1.
38 
1.
42 
0.7
5 
0.1
3 
1 
0.440
851 
0.440
664 
0.589
252 
  284 
 
725.536
0304 
5.72
3 
C41H76NO7
P 
13 
PE(18:2(9Z,12Z)/P-
18:1(11Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
36 
1.
74 
0.5
0 
1.6
5 
1 
0.663
139 
0.490
034 
0.411
5 
0.353
989 
727.551
4799 
5.75
1 
C41H78NO7
P  12 
PE(18:1(11Z)/P-
18:1(11Z))  7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
50 
1.
84 
0.3
5 
2.1
2  1 
0.545
492 
0.464
748 
0.284
731 
0.121
592 
727.551
843 
7.62
7 
C41H78NO7
P 
12  PE(18:1(11Z)/P-18:1(9Z))  7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
2.
68 
1.
12 
2.8
0 
1.2
3 
1 
0.433
895 
0.653
015 
0.003
583 
0.601
04 
729.531
4783 
7.78
51 
C40H76NO8
P 
14 
[PC (14:0/18:2)] 1-
tetradecanoyl-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
19 
1.
36 
0.6
2 
0.4
1 
1 
0.786
365 
0.641
939 
0.516
704 
0.362
79 
729.567
2056 
5.90
3 
C41H80NO7
P  14 
[PE (18:1/18:1)] 1-(1Z-
octadecenyl)-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps_HMDB   0 
1.
00 
1.
28 
1.
08 
0.6
3 
2.2
2  1 
0.639
784 
0.911
817 
0.534
774 
0.107
102 
729.567
5597 
7.64
23 
C41H80NO7
P 
14  PC(15:0/P-18:1(11Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157 
1.
00 
2.
22 
0.
78 
1.9
9 
1.1
3 
1 
0.490
959 
0.659
934 
0.135
642 
0.866
352 
731.547
2838 
7.76
77 
C40H78NO8
P 
14 
[PC (14:0/18:1)] 1-
tetradecanoyl-2-(11Z-
octadecenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
02 
1.
32 
0.5
9 
0.3
4 
1 
0.957
35 
0.554
693 
0.364
091 
0.194
978 
731.547
4698 
6.14
62 
C40H78NO8
P 
14 
[PC (14:0/18:1)] 1-
tetradecanoyl-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
0.
95 
1.
11 
0.6
0 
0.3
7 
1 
0.907
574 
0.814
34 
0.296
596 
  285 
 
733.562
7549 
7.78
16 
C40H80NO8
P 
24 
[PC (16:0/16:0)] 1-
hexadecanoyl-2-
hexadecanoyl-sn-glycero-
3-phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C00157 
1.
00 
0.
84 
0.
86 
1.0
0 
0.8
9 
1 
0.795
191 
0.811
438 
0.995
203 
0.882
181 
739.514
5629 
5.75
14 
C41H74NO8
P 
24 
[PE (16:0/20:4)] 1-
hexadecanoyl-2-
(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-
glycero-3-
phosphoethanolamine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00350 
1.
00 
1.
15 
1.
23 
0.8
8 
1.3
1 
1 
0.801
922 
0.709
74 
0.812
394 
0.529
654 
741.530
292 
5.75
56 
C41H76NO8
P 
20 
[PE (18:1/18:2)] 1-(9Z-
octadecenoyl)-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C00350 
1.
00 
1.
16 
1.
10 
0.5
8 
1.3
2 
1 
0.822
046 
0.892
727 
0.445
088 
0.674
388 
741.567
093 
6.13
32 
C42H80NO7
P 
10  PC(16:1(9Z)/P-18:1(11Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157  1.
00 
1.
00 
1.
20 
0.9
2 
1.6
7 
1  0.996
647 
0.755
854 
0.884
887 
0.295
038 
741.567
5547 
7.67
99 
C42H80NO7
P  10 
[PC (16:1/18:2)] 1-(1Z-
hexadecenyl)-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps_HMDB   0 
1.
00 
0.
99 
1.
36 
1.4
3 
1.4
5  1 
0.977
539 
0.344
776 
0.271
805 
0.335
114 
741.567
7049 
5.80
71 
C42H80NO7
P 
10 
[PC (16:1/18:2)] 1-(1Z-
hexadecenyl)-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps_HMDB   0 
1.
00 
1.
47 
1.
14 
0.6
1 
2.2
7 
1 
0.400
313 
0.835
76 
0.477
934 
0.083
2 
743.545
9829 
5.77
73 
C41H78NO8
P 
18 
[PE (18:0/18:2)] 1-
octadecanoyl-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C00350 
1.
00 
1.
04 
1.
06 
0.3
0 
1.5
5 
1 
0.950
691 
0.921
158 
0.157
188 
0.343
87 
743.583
105 
6.14
61 
C42H82NO7
P 
14 
[PC (16:2/18:2)] 1-
hexadecyl-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps_HMDB   0 
1.
00 
0.
90 
0.
89 
0.6
4 
0.8
4 
1 
0.886
692 
0.865
994 
0.558
777 
0.783
958 286 
 
phosphocholine 
743.583
1677 
7.74
86 
C42H82NO7
P 
14 
1-Hexadecanoyl-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphonocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps   C13876  1.
00 
1.
02 
1.
28 
1.0
2 
0.8
9 
1  0.972
995 
0.639
141 
0.974
498 
0.836
425 
748.504
0202 
7.38
16 
C43H73O8P  1 
[GP (18:0/22:6)] 1-
octadecanoyl-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-phosphate 
7 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
63 
1.
31 
0.3
8 
0.3
9 
1 
0.277
702 
0.352
688   
0.135
095 
753.566
5513 
5.69
86 
C43H80NO7
P 
9 
PE(20:2(11Z,14Z)/P-
18:1(11Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
52 
2.
00 
0.2
0 
1.6
3 
1 
0.569
283 
0.439
318 
0.233
636 
0.402
815 
753.567
0452 
7.69
06 
C43H80NO7
P  9 
PE(20:2(11Z,14Z)/P-
18:1(9Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
0.
96 
1.
29 
1.4
0 
1.4
4  1 
0.802
771 
0.455
939 
0.106
835 
0.516
945 
755.546
9348 
6.13
02 
C42H78NO8
P  17 
[PC (16:0/18:3)] 1-
hexadecanoyl-2-
(6Z,9Z,12Z-
octadecatrienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00157 
1.
00 
1.
12 
1.
34 
0.5
5 
0.3
5  1 
0.766
54 
0.416
217 
0.171
392 
0.083
896 
755.547
0789 
7.72
69 
C42H78NO8
P 
17 
[PC (16:0/18:3)] 1-
hexadecanoyl-2-
(9Z,12Z,15Z-
octadecatrienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C00157  1.
00 
1.
11 
1.
58 
0.6
5 
0.3
8 
1  0.583
187 
0.058
521 
0.133
192 
0.044
706 
755.582
3832 
6.09
67 
C43H82NO7
P 
8  PE(20:1(11Z)/P-18:1(9Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350  1.
00 
1.
06 
1.
32 
0.7
8 
2.2
0 
1  0.930
856 
0.727
41 
0.723
094 
0.148
369 287 
 
755.582
7978 
7.65
37 
C43H82NO7
P 
8 
PE(20:1(11Z)/P-
18:1(11Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
00 
1.
42 
1.5
2 
1.5
2 
1 
0.999
265 
0.450
754 
0.294
476 
0.468
988 
757.562
4392 
6.13
89 
C42H80NO8
P 
34 
[PC (16:1/18:1)] 1-(9Z-
hexadecenoyl)-2-(11Z-
octadecenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157  1.
00 
0.
94 
0.
96 
0.7
6 
0.4
9 
1  0.898
856 
0.922
833 
0.545
51 
0.228
386 
757.562
6985 
7.72
31 
C42H80NO8
P  34 
[PC (16:0/18:2)] 1-
hexadecanoyl-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB   C00157 
1.
00 
0.
89 
1.
16 
0.9
5 
0.4
3  1 
0.762
903 
0.640
092 
0.870
276 
0.156
968 
759.577
8148 
7.73
09 
C42H82NO8
P  20 
[PC (16:0/18:1)] 1-
hexadecanoyl-2-(11Z-
octadecenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00157 
1.
00 
0.
89 
1.
02 
0.7
3 
0.3
9  1 
0.773
688 
0.958
933 
0.510
667 
0.193
13 
759.578
2113 
6.17
09 
C42H82NO8
P  20 
[PC (16:0/18:1)] 1-
hexadecanoyl-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB   C13875 
1.
00 
0.
91 
0.
95 
0.4
7 
0.5
5  1 
0.896
864 
0.941
919 
0.388
608 
0.438
446 
763.515
7444 
5.67
8 
C43H74NO8
P  24 
[PE (16:0/22:6)] 1-
hexadecanoyl-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-
phosphoethanolamine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00350 
1.
00 
1.
08 
0.
68 
0.9
4 
0.6
0  1 
0.850
875 
0.392
047 
0.866
401 
0.321
093 
767.546
1738 
5.82
08 
C43H78NO8
P 
31 
[PE (18:0/20:4)] 1-
octadecanoyl-2-
(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00350 
1.
00 
1.
31 
1.
17 
0.5
4 
1.0
0 
1 
0.491
79 
0.723
73 
0.153
695 
0.995
17 288 
 
769.563
118 
7.70
96 
C43H80NO8
P 
21  PC(15:0/20:3(5Z,8Z,11Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157 
1.
00 
0.
99 
1.
38 
0.6
5 
0.7
3 
1 
0.910
785 
0.054
118 
0.040
403 
0.687
211 
769.598
3398 
6.15
04 
C44H84NO7
P  15  PC(18:1(11Z)/P-18:1(9Z))  7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157 
1.
00 
1.
05 
1.
27 
0.4
7 
1.8
2  1 
0.949
527 
0.756
409 
0.407
539 
0.410
319 
769.598
6 
7.65
03 
C44H84NO7
P 
15 
PC(18:1(11Z)/P-
18:1(11Z)) 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157 
1.
00 
1.
02 
1.
29 
1.1
4 
1.4
2 
1 
0.955
436 
0.574
094 
0.664
324 
0.565
256 
771.577
2102 
5.80
94 
C43H82NO8
P 
24 
[PE (18:0/20:2)] 1-
octadecanoyl-2-(11Z,14Z-
eicosadienoyl)-sn-
glycero-3-
phosphoethanolamine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00350 
1.
00 
2.
02 
1.
63 
0.5
0 
1.0
0 
1 
0.148
647 
0.465
494 
0.311
206 
0.996
248 
771.613
8384 
7.70
95 
C44H86NO7
P  12 
[PC (18:1/18:0)] 1-(1Z-
octadecenyl)-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps_HMDB   0 
1.
00 
0.
97 
1.
08 
0.8
5 
1.1
2  1 
0.945
912 
0.869
413 
0.751
288 
0.839
541 
774.538
9351 
7.91
09 
C42H79O10
P 
9 
[PG (18:1/18:1)] 1,2-di-
(9Z-octadecenoyl)-sn-
glycero-3-phospho-(1'-
sn-glycerol) 
7 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
74 
1.
07 
0.5
5 
1.4
8 
1 
0.468
637 
0.867
148 
0.244
466 
0.649
225 
781.562
0179 
7.68
8 
C44H80NO8
P 
39 
[PC (16:0/20:4)] 1-
hexadecanoyl-2-
(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
0.
97 
1.
20 
1.0
0 
0.7
3 
1 
0.817
366 
0.220
329 
0.984
67 
0.207
645 
783.577
2752 
7.69
17 
C44H82NO8
P 
21 
PC(18:2(9Z,12Z)/18:1(9Z)
) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_H
MDB 
C00157 
1.
00 
0.
85 
1.
13 
0.8
8 
0.7
6 
1 
0.474
838 
0.494
027 
0.539
758 
0.532
552 289 
 
783.577
4551 
6.13
51 
C44H82NO8
P 
21 
[PC (18:1/18:2)] 1-(9Z-
octadecenoyl)-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
0.
91 
1.
01 
0.6
5 
0.7
5 
1 
0.850
849 
0.988
675 
0.413
735 
0.552
948 
785.592
8932 
7.70
08 
C44H84NO8
P 
54 
[PC (18:1/18:1)] 1-(9Z-
octadecenoyl)-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C00157 
1.
00 
0.
96 
1.
14 
0.8
5 
0.7
3 
1 
0.929
112 
0.781
592 
0.732
145 
0.554
814 
785.593
2399 
6.13
55 
C44H84NO8
P 
54 
[PC (18:0/18:2)] 1-
octadecanoyl-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C00157 
1.
00 
1.
02 
1.
10 
0.4
6 
0.9
1 
1 
0.979
424 
0.875
217 
0.327
513 
0.858
334 
787.515
6451 
5.64
46 
C45H74NO8
P 
21  PE(18:2(9Z,12Z)/22:6(4Z,
7Z,10Z,13Z,16Z,19Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350  1.
00 
1.
15 
0.
89 
0.8
5 
1.1
7 
1  0.712
987 
0.733
206 
0.681
455 
0.641
059 
787.535
3795 
7.96
3 
C42H78NO1
0P 
8 
[PS (18:1/18:1)] 1,2-di-
(9E-octadecenoyl)-sn-
glycero-3-phosphoserine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
1.
04 
1.
21 
0.6
6 
1.1
1 
1 
0.927
984 
0.608
757 
0.338
85 
0.814
101 
787.607
6899 
7.69
87 
C44H86NO8
P 
24 
[PC (18:0/18:1)] 1-
octadecanoyl-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Metacyc_Li
pidmaps_HMDB  
C00157 
1.
00 
0.
91 
0.
91 
0.6
5 
0.5
4 
1 
0.869
616 
0.862
159 
0.491
487 
0.382
077 
789.530
6927 
5.66
22 
C45H76NO8
P  22 
PE(18:1(11Z)/22:6(4Z,7Z,
10Z,13Z,16Z,19Z))  7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
44 
1.
37 
0.7
5 
1.5
2  1 
0.568
791 
0.634
063 
0.647
855 
0.474
564 
791.546
5577 
6.11
42 
C45H78NO8
P  26 
[PE (18:0/22:6)] 1-
octadecanoyl-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00350 
1.
00 
1.
23 
1.
35 
0.8
2 
0.5
6  1 
0.586
506 
0.468
371 
0.583
133 
0.206
393 290 
 
791.547
0351 
5.65
48 
C45H78NO8
P  26 
[PE (18:0/22:6)] 1-
octadecanoyl-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00350 
1.
00 
1.
09 
0.
80 
0.4
1 
1.1
8  1 
0.884
08 
0.718
262 
0.285
534 
0.712
298 
793.561
4833 
7.65
22 
C45H80NO8
P 
28 
PC(15:0/22:5(4Z,7Z,10Z,1
3Z,16Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157 
1.
00 
1.
04 
1.
16 
0.8
4 
0.4
4 
1 
0.821
481 
0.405
645 
0.380
95 
0.036
705 
793.561
8883 
6.09
82 
C45H80NO8
P 
28  PC(15:0/22:5(7Z,10Z,13Z,
16Z,19Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157  1.
00 
1.
16 
0.
86 
0.7
3 
0.6
0 
1  0.750
605 
0.728
62 
0.446
467 
0.274
447 
797.593
5941 
7.67
83 
C45H84NO8
P 
17 
PE(18:1(11Z)/22:2(13Z,16
Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
0.
90 
1.
20 
0.8
0 
1.1
7 
1 
0.711
596 
0.524
229 
0.468
711 
0.848
996 
797.629
7207 
7.66
43 
C46H88NO7
P 
10  PC(20:1(11Z)/P-
18:1(11Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157  1.
00 
1.
33 
1.
60 
1.1
5 
1.8
2 
1  0.602
643 
0.505
019 
0.742
061 
0.533
525 
799.610
4246 
6.18
02 
C45H86NO8
P  15 
[PE (20:0/20:2)] 1-
eicosanoyl-2-(11Z,14Z-
eicosadienoyl)-sn-
glycero-3-
phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00350 
1.
00 
1.
11 
1.
20 
0.3
1 
0.9
5  1 
0.696
203 
0.433
156 
0.129
43 
0.869
434 
801.552
5226 
7.75
68 
C43H80NO1
0P 
1 
[PG (17:0/20:4)] 1-
heptadecanoyl-2-
(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-
glycero-3-phospho-(1'-
rac-glycerol) (ammonium 
salt) 
7 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0  1.
00 
1.
08 
1.
25 
0.6
2 
0.5
0 
1  0.070
697 
0.027
378 
0.020
636 
0.055
414 
801.624
5715 
7.69
28 
C45H88NO8
P 
19 
[PE (18:0/22:1)] 1-
octadecanoyl-2-(13Z-
docosenoyl)-sn-glycero-
3-phosphoethanolamine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00350 
1.
00 
1.
25 
0.
86 
0.7
1 
0.7
8 
1 
0.657
909 
0.856
602 
0.565
605 
0.676
703 291 
 
803.568
0786 
6.15
9 
C43H82NO1
0P 
1 
[GP (18:0/18:0)] 1-
octadecanoyl-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphothreonine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
87 
1.
07 
1.1
1 
0.8
0 
1 
0.385
174 
0.615
054 
0.590
78 
0.657
258 
803.568
4448 
7.75
55 
C43H82NO1
0P 
1 
[GP (18:0/18:0)] 1-
octadecanoyl-2-(9Z-
octadecenoyl)-sn-
glycero-3-
phosphothreonine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0 
1.
00 
0.
91 
0.
97 
1.0
1 
0.8
2 
1 
0.690
276 
0.877
444 
0.982
788 
0.751
993 
805.562
1313 
7.63
98 
C46H80NO8
P 
28 
[PC (16:0/22:6)] 1-
hexadecanoyl-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
0.
92 
1.
03 
0.8
9 
0.5
0 
1 
0.581
613 
0.868
064 
0.440
649 
0.030
138 
805.562
1346 
6.12
3 
C46H80NO8
P 
28 
[PC (18:1/20:5)] 1-(11Z-
octadecenoyl)-2-
(5Z,8Z,11Z,14Z,17Z-
eicosapentaenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157  1.
00 
1.
05 
1.
11 
0.7
1 
0.5
1 
1  0.903
259 
0.794
51 
0.400
416 
0.195
195 
807.577
1868 
6.12
91 
C46H82NO8
P 
29 
[PC (18:1/20:4)] 1-(9Z-
octadecenoyl)-2-
(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
10 
1.
13 
0.6
5 
0.6
4 
1 
0.845
765 
0.812
25 
0.411
222 
0.371
823 
809.593
1745 
7.64
55 
C46H84NO8
P 
24 
[PC (18:1/20:3)] 1-(9Z-
octadecenoyl)-2-
(5Z,8Z,11Z-
eicosatrienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
0.
92 
1.
04 
0.7
1 
0.6
4 
1 
0.752
437 
0.900
05 
0.261
797 
0.176
487 
811.608
4608 
7.66
06 
C46H86NO8
P 
21 
PC(16:1(9Z)/22:2(13Z,16Z
)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157 
1.
00 
0.
96 
1.
05 
0.7
8 
0.8
4 
1 
0.911
881 
0.900
815 
0.553
565 
0.723
795 292 
 
811.608
6081 
6.16
21 
C46H86NO8
P  21 
[PC (18:0/20:3)] 1-
octadecanoyl-2-
(5Z,8Z,11Z-
eicosatrienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00157 
1.
00 
0.
66 
0.
74 
0.1
6 
0.6
5  1 
0.362
051 
0.537
272 
0.029
037 
0.055
887 
813.623
6261 
6.16
39 
C46H88NO8
P  22 
[PC (20:0/18:2)] 1-
eicosanoyl-2-(9Z,12Z-
octadecadienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00157 
1.
00 
1.
15 
1.
27 
0.3
3 
1.2
7  1 
0.851
722 
0.743
514 
0.299
773 
0.656
75 
813.623
8693 
7.67
58 
C46H88NO8
P 
22 
[PC (18:0/20:2)] 1-
octadecanoyl-2-(11Z,14Z-
eicosadienoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
0.
99 
1.
21 
0.7
6 
1.1
1 
1 
0.988
869 
0.705
848 
0.596
053 
0.877
891 
817.562
3998 
6.11
7 
C47H80NO8
P 
12 
PE(20:2(11Z,14Z)/22:5(4Z
,7Z,10Z,13Z,16Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
06 
1.
52 
0.5
6 
0.9
0 
1 
0.894
429 
0.405
242 
0.272
75 
0.866
411 
817.562
9361 
7.63
35 
C47H80NO8
P 
12  PE(20:1(11Z)/22:6(4Z,7Z,
10Z,13Z,16Z,19Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350  1.
00 
1.
00 
1.
30 
0.7
4 
0.9
8 
1  0.987
809 
0.228
806 
0.133
782 
0.975
831 
819.577
7787 
6.12
1 
C47H82NO8
P 
15 
PE(20:1(11Z)/22:5(4Z,7Z,
10Z,13Z,16Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
13 
1.
32 
0.6
5 
0.7
6 
1 
0.819
66 
0.597
713 
0.396
41 
0.555
106 
819.577
794 
7.62
96 
C47H82NO8
P  15 
PE(20:0/22:6(4Z,7Z,10Z,1
3Z,16Z,19Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
03 
1.
17 
0.9
0 
0.7
3  1 
0.894
373 
0.586
094 
0.609
43 
0.311
394 
821.593
6674 
6.13
27 
C47H84NO8
P 
20 
PE(20:0/22:5(4Z,7Z,10Z,1
3Z,16Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
13 
1.
24 
0.5
7 
0.9
2 
1 
0.832
256 
0.702
451 
0.374
317 
0.852
766 293 
 
821.593
7868 
7.63
86 
C47H84NO8
P 
20 
PE(18:4(6Z,9Z,12Z,15Z)/2
4:1(15Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
1.
03 
1.
20 
0.8
3 
0.7
8 
1 
0.927
436 
0.521
721 
0.468
128 
0.396
021 
823.608
9854 
6.14
77 
C47H86NO8
P  18 
PE(18:3(9Z,12Z,15Z)/24:1
(15Z))  5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
0.
75 
0.
87 
0.2
8 
0.6
7  1 
0.536
765 
0.787
266 
0.018
18 
0.047
736 
823.609
1114 
7.64
25 
C47H86NO8
P 
18 
PE(18:3(6Z,9Z,12Z)/24:1(
15Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350 
1.
00 
0.
96 
1.
29 
0.7
0 
0.9
4 
1 
0.898
371 
0.604
715 
0.371
708 
0.858
008 
824.556
7665 
7.83
64 
C46H81O10
P 
4 
PG(18:0/22:5(4Z,7Z,10Z,1
3Z,16Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
HMDB  0 
1.
00 
0.
98 
1.
18 
0.5
6 
0.7
3 
1 
0.923
732 
0.586
958 
0.044
782 
0.188
144 
825.625
0504 
7.65
26 
C47H88NO8
P 
14  PE(18:2(9Z,12Z)/24:1(15Z
)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00350  1.
00 
1.
03 
1.
09 
0.7
1 
0.8
7 
1  0.950
851 
0.875
649 
0.525
363 
0.774
593 
826.572
2826 
8.12
9 
C46H83O10
P 
1 
PG(18:0/22:4(7Z,10Z,13Z,
16Z)) 
7 
Lipids: 
Glyceroph
ospholipi
ds  
HMDB  0 
1.
00 
0.
92 
0.
94 
0.5
7 
0.6
3 
1 
0.847
17 
0.857
894 
0.265
525 
0.329
287 
829.562
1996 
6.11
45 
C48H80NO8
P 
23 
[PC (20:4/20:4)] 1,2-di-
(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-
glycero-3-
phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
22 
1.
45 
0.7
5 
1.2
3 
1 
0.598
449 
0.359
911 
0.335
958 
0.699
79 
829.562
2726 
7.62
38 
C48H80NO8
P 
23 
[PC (18:2/22:6)] 1-
(9Z,12Z-
octadecadienoyl)-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
04 
1.
27 
0.9
6 
1.2
3 
1 
0.780
988 
0.136
654 
0.786
201 
0.725
826 294 
 
831.576
914 
6.11
58 
C48H82NO8
P 
22 
[PC (18:2/22:5)] 1-
(9Z,12Z-
octadecadienoyl)-2-
(4Z,7Z,10Z,13Z,16Z-
docosapentaenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157  1.
00 
1.
15 
1.
36 
0.6
6 
1.3
0 
1  0.760
635 
0.520
099 
0.358
007 
0.675
493 
831.577
2574 
7.63
28 
C48H82NO8
P 
22 
[PC (18:1/22:6)] 1-(11Z-
octadecenoyl)-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-
phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
05 
1.
27 
0.9
3 
1.4
4 
1 
0.786
466 
0.219
671 
0.631
616 
0.630
805 
833.592
7117 
6.13
1 
C48H84NO8
P  27 
[PC (18:0/22:6)] 1-
octadecanoyl-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-
phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00157 
1.
00 
1.
21 
1.
23 
0.5
3 
1.0
1  1 
0.755
522 
0.725
611 
0.341
681 
0.979
593 
833.593
0546 
7.62
67 
C48H84NO8
P 
27 
[PC (18:1/22:5)] 1-(11Z-
octadecenoyl)-2-
(7Z,10Z,13Z,16Z,19Z-
docosapentaenoyl)-sn-
glycero-3-
phosphocholine 
7 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
07 
1.
12 
0.7
9 
0.6
5 
1 
0.853
945 
0.749
5 
0.535
889 
0.345
962 
835.535
331 
7.84
58 
C46H78NO1
0P 
3 
[PS (18:0/22:6)] 1-
octadecanoyl-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-phosphoserine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C02737 
1.
00 
1.
15 
1.
28 
0.7
0 
0.7
9 
1 
0.492
597 
0.158
616 
0.087
624 
0.260
598 
835.608
0038 
6.13
01 
C48H86NO8
P 
25 
[PC (18:0/22:5)] 1-
octadecanoyl-2-
(7Z,10Z,13Z,16Z,19Z-
docosapentaenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
09 
1.
13 
0.4
3 
1.0
2 
1 
0.896
14 
0.855
093 
0.312
739 
0.973
234 295 
 
835.608
2683 
7.63
45 
C48H86NO8
P  25 
[PC (18:0/22:5)] 1-
octadecanoyl-2-
(4Z,7Z,10Z,13Z,16Z-
docosapentaenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB  C00157 
1.
00 
1.
04 
1.
07 
0.7
6 
0.9
4  1 
0.930
741 
0.888
946 
0.543
644 
0.880
558 
837.623
9962 
6.17
06 
C48H88NO8
P 
21 
[PC (20:0/20:4)] 1-
eicosanoyl-2-
(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157  1.
00 
1.
14 
1.
25 
0.3
0 
1.0
7 
1  0.858
029 
0.767
441 
0.302
187 
0.907
407 
837.624
0239 
7.64
91 
C48H88NO8
P 
21 
[PC (18:0/22:4)] 1-
octadecanoyl-2-
(7Z,10Z,13Z,16Z-
docosatetraenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
10 
1.
13 
0.6
8 
0.6
0 
1 
0.838
631 
0.829
396 
0.476
108 
0.424
405 
877.562
1317 
6.09
49 
C52H80NO8
P 
3 
[PC (22:6/22:6)] 1,2-di-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-sn-
glycero-3-
phosphocholine 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_Lipidmaps_
HMDB 
C00157 
1.
00 
1.
20 
1.
27 
0.7
0 
2.7
7 
1 
0.732
186 
0.620
688 
0.516
455 
0.535
142 
881.613
2153 
6.18
85 
C49H88NO1
0P 
1 
[PG (21:0/22:6)] 1-
heneicosanoyl-2-
(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexenoyl)-sn-
glycero-3-phospho-(1'-
rac-glycerol) (ammonium 
salt) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
Lipidmaps   0  1.
00 
1.
04 
1.
16 
0.7
2 
1.5
2 
1  0.931
054 
0.675
44 
0.502
549 
0.149
317 
883.608
7013 
6.12
18 
C52H86NO8
P 
4 
PC(22:4(7Z,10Z,13Z,16Z)/
22:5(4Z,7Z,10Z,13Z,16Z)) 
5 
Lipids: 
Glyceroph
ospholipi
ds  
KEGG_HMDB  C00157 
1.
00 
1.
14 
1.
36 
0.5
9 
1.3
2 
1 
0.829
798 
0.629
346 
0.396
243 
0.760
524 
108.094
0069 
5.20
49 
C16H24  1 
[PR] (+)-3-longipinen-5-
one 
7 
Lipids: 
Prenols 
Lipidmaps   0 
1.
00 
1.
23 
1.
06 
0.9
3 
1.2
1 
1 
0.566
798 
0.873
482 
0.841
704 
0.511
761 296 
 
196.146
3336 
5.23
9 
C12H20O2  29 
(1S,2R,4S)-(-)-Bornyl 
acetate 
7 
Lipids: 
Prenols 
KEGG_Lipidmaps   C09837 
1.
00 
0.
87 
0.
67 
0.6
0 
0.5
8 
1 
0.630
136 
0.269
884 
0.211
474 
0.194
959 
273.266
7452 
6.13
37  C16H35NO2  1  Hexadecasphinganine  5 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps   C13915 
1.
00 
1.
04 
1.
07 
1.0
1 
1.4
2  1 
0.849
402 
0.720
756 
0.958
164 
0.602
833 
285.303
1582 
6.09
15  C18H39NO  1  [SP] 1-deoxy-sphinganine  5 
Lipids: 
Sphingoli
pids 
Lipidmaps   0 
1.
00 
0.
98 
1.
74 
1.4
8 
2.9
4  1 
0.964
108 
0.208
829 
0.319
99 
0.041
406 
327.313
7025 
5.21
69  C20H41NO2  1 
N,N-Dimethylsphing-4-
enine  5 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps_
HMDB  C13914 
1.
00 
0.
97 
1.
27 
0.9
3 
0.5
5  1 
0.939
246 
0.480
712 
0.860
795 
0.276
907 
466.353
3642 
8.69
46 
C23H51N2O
5P  1  LysoSM(d18:0)  5 
Lipids: 
Sphingoli
pids 
HMDB  0 
1.
00 
0.
70 
0.
45 
0.4
6 
0.3
9  1 
0.374
959 
0.116
284 
0.146
18 
0.091
024 
565.542
922 
5.11
17 
C36H71NO3  6 
[SP (18:0)] N-
(octadecanoyl)-sphing-4-
enine 
7 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps_
HMDB 
C00195 
1.
00 
1.
21 
1.
61 
0.2
6 
1.8
6 
1 
0.813
06 
0.558
692 
0.306
779 
0.454
401 
646.505
1085 
9.27
29 
C35H71N2O
6P  1  SM(d18:1/12:0)  5 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps_
HMDB  C00550 
1.
00 
0.
88 
1.
15 
0.9
6 
0.7
1  1 
0.638
027 
0.737
973 
0.912
734 
0.411
66 
674.535
8709 
6.13
44 
C37H75N2O
6P 
1  SM(d18:1/14:0)  5 
Lipids: 
Sphingoli
pids 
Lipidmaps_HMDB   0 
1.
00 
0.
88 
1.
15 
1.3
1 
1.8
8 
1 
0.737
828 
0.638
836 
0.471
483 
0.393
834 
674.536
2864 
9.08
64 
C37H75N2O
6P 
1  SM(d18:1/14:0)  5 
Lipids: 
Sphingoli
pids 
Lipidmaps_HMDB   0 
1.
00 
1.
28 
1.
80 
1.1
3 
1.1
0 
1 
0.604
264 
0.306
289 
0.766
62 
0.798
047 
688.551
637 
6.17
17 
C38H77N2O
6P 
1 
[SP (18:0/14:0)] N-
(octadecanoyl)-
tetradecasphing-4-enine-
1-phosphoethanolamine 
5 
Lipids: 
Sphingoli
pids 
Lipidmaps   0  1.
00 
0.
62 
1.
16 
1.2
6 
0.5
2 
1  0.137
811 
0.300
635 
0.500
178 
0.202
401 
688.551
9419 
9.00
55 
C38H77N2O
6P 
1 
[SP (18:0/14:0)] N-
(octadecanoyl)-
tetradecasphing-4-enine-
1-phosphoethanolamine 
5 
Lipids: 
Sphingoli
pids 
Lipidmaps   0 
1.
00 
1.
04 
1.
58 
1.1
1 
0.8
1 
1 
0.896
115 
0.193
826 
0.769
063 
0.682
416 
702.567
3227 
6.22
29 
C39H79N2O
6P  1 
[SP (16:0)] N-
(hexadecanoyl)-sphing-4-
enine-1-phosphocholine 
7 
Lipids: 
Sphingoli
pids 
Lipidmaps_HMDB   0 
1.
00 
0.
64 
1.
15 
1.1
0 
0.7
4  1 
0.141
846 
0.195
523 
0.788
57 
0.569
393 297 
 
702.567
3348 
8.90
39 
C39H79N2O
6P 
1 
[SP (16:0)] N-
(hexadecanoyl)-sphing-4-
enine-1-phosphocholine 
7 
Lipids: 
Sphingoli
pids 
Lipidmaps_HMDB   0  1.
00 
1.
01 
1.
40 
0.9
8 
0.7
6 
1  0.977
947 
0.263
724 
0.949
142 
0.593
028 
728.582
4781 
8.76
9 
C41H81N2O
6P 
2  SM(d18:1/18:1(9Z))  7 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps_
HMDB 
C00550  1.
00 
1.
06 
1.
57 
1.0
3 
0.9
3 
1  0.725
195 
0.075
851 
0.876
028 
0.867
658 
730.597
9114 
8.72
55 
C41H83N2O
6P 
3  SM(d18:0/18:1(9Z))  5 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps_
HMDB 
C00550  1.
00 
1.
15 
1.
36 
0.7
8 
0.8
3 
1  0.720
658 
0.284
709 
0.467
348 
0.648
411 
732.613
3871 
8.57
28 
C41H85N2O
6P 
1  SM(d18:0/18:0)  7 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps_
HMDB 
C00550 
1.
00 
0.
81 
0.
49 
0.3
9 
1.1
1 
1 
0.776
135 
0.452
434 
0.384
256 
0.922
986 
758.630
1035 
8.61
52 
C43H87N2O
6P 
1  SM(d18:1/20:0)  5 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps_
HMDB 
C00550  1.
00 
1.
22 
1.
14 
0.7
9 
0.9
8 
1  0.782
705 
0.849
421 
0.731
327 
0.975
048 
784.645
5725 
8.50
52 
C45H89N2O
6P 
2  SM(d18:1/22:1(13Z))  5 
Lipids: 
Sphingoli
pids 
KEGG_HMDB  C00550  1.
00 
1.
11 
1.
07 
0.8
4 
0.9
5 
1  0.864
394 
0.919
622 
0.778
093 
0.942
433 
786.661
6711 
8.50
48 
C45H91N2O
6P 
2  SM(d18:1/22:0)  5 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps_
HMDB 
C00550 
1.
00 
1.
08 
1.
03 
0.5
7 
0.8
3 
1 
0.923
486 
0.964
724 
0.529
099 
0.817
757 
798.661
1029 
8.46
29 
C46H92N2O
6P 
1  SM(d17:1/24:1(15Z))  5 
Lipids: 
Sphingoli
pids 
HMDB  0 
1.
00 
1.
17 
1.
13 
0.7
9 
0.8
9 
1 
0.823
555 
0.854
677 
0.723
083 
0.869
017 
812.676
9741 
8.42
74 
C47H93N2O
6P 
1  SM(d18:1/24:1(15Z))  7 
Lipids: 
Sphingoli
pids 
KEGG_Lipidmaps_
HMDB 
C00550 
1.
00 
1.
15 
1.
09 
0.6
7 
0.8
0 
1 
0.849
782 
0.911
941 
0.620
412 
0.776
907 
368.344
3024 
5.15
89 
C27H44  1 
[ST] (5Z,7E)-9,10-seco-
5,7,10(19)-cholestatriene 
7 
Lipids: 
Sterol 
lipids 
Lipidmaps   0 
1.
00 
1.
30 
1.
29 
0.8
6 
1.3
3 
1 
0.692
935 
0.741
141 
0.840
797 
0.673
698 
384.339
2208 
5.18
79 
C27H44O  28 
[ST (2:0)] 5alpha-
cholesta-8,24-dien-
3beta-ol 
6 
Lipids: 
Sterol 
lipids 
KEGG_Metacyc_Li
pidmaps_HMDB  
C05437 
1.
00 
0.
94 
0.
92 
1.2
9 
0.8
2 
1 
0.916
389 
0.885
031 
0.662
696 
0.736
544 
390.276
8445 
5.05
25 
C24H38O4  58 
[ST hydrox] 
3alpha,12alpha-
Dihydroxy-5beta-chol-6-
en-24-oic Acid 
7 
Lipids: 
Sterol 
lipids 
KEGG_Lipidmaps   C11637 
1.
00 
1.
09 
1.
45 
1.0
3 
0.6
5 
1 
0.826
918 
0.334
062 
0.917
248 
0.485
35 298 
 
404.292
3391 
5.04
79 
C25H40O4  7 
[ST (3:0)] (5Z,7E)-(1S,3R)-
21-nor-20-oxa-9,10-seco-
5,7,10(19)-
cholestatriene-1,3,25-
triol 
5 
Lipids: 
Sterol 
lipids 
Lipidmaps   0 
1.
00 
1.
40 
1.
11 
1.8
3 
2.4
4 
1 
0.696
477 
0.785
949 
0.571
527 
0.326
636 
414.312
8727 
5.21
14 
C27H42O3  28 
[ST hydroxy(3:0)] (5Z,7E)-
(1S,3R)-1,3-dihydroxy-
9,10-seco-5,7,10(19)-
cholestatrien-22-one 
5 
Lipids: 
Sterol 
lipids 
Lipidmaps   0 
1.
00 
1.
48 
1.
17 
1.7
9 
0.9
9 
1 
0.403
153 
0.670
183 
0.523
081 
0.967
955 
416.328
5414 
5.20
17 
C27H44O3  46 
[ST (3:0)] (5Z,7E)-(1S,3R)-
9,10-seco-5,7,10(19)-
cholestatriene-1,3,25-
triol 
8 
Lipids: 
Sterol 
lipids 
KEGG_Metacyc_Li
pidmaps_HMDB  
C01673 
1.
00 
1.
32 
1.
04 
1.8
6 
0.8
8 
1 
0.420
647 
0.915
635 
0.468
743 
0.775
665 
418.307
9675 
5.03
76 
C26H42O4  10 
[ST (3:0)] (5Z,7E)-
(1S,3R,24R)-22-oxa-9,10-
seco-5,7,10(19)-
cholestatriene-1,3,24-
triol 
7 
Lipids: 
Sterol 
lipids 
Lipidmaps   0 
1.
00 
1.
18 
0.
89 
1.6
2 
2.1
2 
1 
0.838
353 
0.719
171 
0.608
504 
0.373
909 
432.323
5594 
5.18
41 
C27H44O4  34 
[ST (2:0)] (7E)-(1S,3R,6R)-
6,19-epidioxy-9,10-seco-
5(10),7-cholestadiene-
1,3-diol 
5 
Lipids: 
Sterol 
lipids 
Lipidmaps   0  1.
00 
1.
41 
0.
75 
0.5
4 
1.8
1 
1  0.694
04 
0.363
143 
0.143
875 
0.417
335 
448.318
4682 
5.61
06 
C27H44O5  16 
[ST (3:0)] 25R-spirostan-
2beta,3beta,6beta-triol 
5 
Lipids: 
Sterol 
lipids 
Lipidmaps   0 
1.
00 
1.
15 
1.
48 
1.0
3 
0.8
3 
1 
0.689
673 
0.515
652 
0.927
604 
0.525
328 
455.339
3228 
5.42
83 
C29H45NO3  1 
[ST oxo(3:0/3:0)] (5Z,7E)-
(1S,3R)-24-oxo-25-aza-
26,27-propano-9,10-
seco-5,7,10(19)-
cholestatriene-1,3,25-
triol 
5 
Lipids: 
Sterol 
lipids 
Lipidmaps   0 
1.
00 
0.
91 
1.
19 
1.0
4 
0.7
2 
1 
0.788
775 
0.612
158 
0.897
366 
0.485
314 
238.098
8237 
20.2
88 
C8H18N2O4
S 
1  HEPES  10 
Medium 
Compone
nt  
Medium   0 
1.
00 
1.
01 
0.
99 
1.0
2 
0.8
7 
1 
0.902
829 
0.784
221 
0.785
915 
0.062
12 
520.076
1276 
15.0
3 
C26H20N2O
6S2  
1 
Bathocuproine disulfonic 
acid 
8 
Medium 
Compone
nt  
Medium   0 
1.
00 
1.
11 
1.
37 
1.0
7 
0.7
5 
1 
0.201
233 
0.370
336 
0.629
608 
0.557
408 299 
 
191.025
1479 
18.6
57 
C6H9NO4S  1  a Cysteine adduct  7 
Medium 
Contamin
ant 
Medium   0  1.
00 
0.
93 
1.
06 
0.9
0 
0.5
6 
1  0.409
385 
0.642
42 
0.343
734 
0.254
755 
191.025
1625 
17.2
15 
C6H9NO4S  1  a Cysteine adduct  7 
Medium 
Contamin
ant 
Medium   0  1.
00 
1.
03 
1.
09 
0.9
8 
0.4
5 
1  0.815
559 
0.681
75 
0.894
28 
0.218
385 
191.025
2322 
8.22
98 
C6H9NO4S  1  a Cysteine adduct  5 
Medium 
Contamin
ant 
Medium   0  1.
00 
0.
99 
1.
05 
0.9
7 
0.5
5 
1  0.978
991 
0.907
612 
0.914
612 
0.226
976 
122.048
1067 
7.91
46 
C6H6N2O  4  Nicotinamide  8 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc_H
MDB 
C00153 
1.
00 
1.
02 
1.
05 
1.2
2 
0.4
4 
1 
0.928
648 
0.774
75 
0.454
056 
0.101
924 
128.047
4045 
5.11
81 
C6H8O3  9 
Dihydro-4,4-dimethyl-
2,3-Furandione 
5 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc  C01125 
1.
00 
1.
12 
1.
29 
1.6
7 
0.7
4 
1 
0.764
765 
0.395
916 
0.281
939 
0.438
285 
141.975
7141 
17.5
03 
C2H6O3S2  1 
2-
Mercaptoethanesulfonat
e 
6 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc_H
MDB 
C03576 
1.
00 
1.
03 
0.
90 
0.8
9 
0.2
6 
1 
0.918
274 
0.770
687 
0.728
327 
  
155.034
6523 
19.8
67 
C3H10NO4P  3 
D-1-Aminopropan-2-ol O-
phosphate 
8 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc  C04122 
1.
00 
0.
94 
1.
22 
0.7
4 
0.3
1 
1 
0.796
825 
0.537
879 
0.063
328 
0.005
312 
167.058
0877 
10.0
85 
C8H9NO3  9  Isopyridoxal  6 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc_H
MDB 
C06051 
1.
00 
1.
03 
1.
23 
1.1
9 
0.6
5 
1 
0.904
062 
0.502
629 
0.448
113 
0.408
786 
168.089
7983 
19.3
06  C8H12N2O2  3  Pyridoxamine  8 
Metabolis
m of 
Cofactors 
and 
KEGG_Metacyc_H
MDB  C00534 
1.
00 
1.
22 
1.
12 
1.5
8 
0.5
8  1 
0.546
171 
0.779
018 
0.199
03 
0.086
558 300 
 
Vitamins 
183.052
9467 
8.23
83 
C8H9NO4  6  4-Pyridoxate  6 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc_H
MDB 
C00847 
1.
00 
0.
91 
0.
91 
0.9
7 
0.7
4 
1 
0.821
682 
0.833
544 
0.945
528 
0.505
886 
195.075
6327 
8.85
78 
C7H9N5O2  1 
2-Amino-4-hydroxy-6-
hydroxymethyl-7,8-
dihydropteridine 
6 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc  C01300  1.
00 
0.
83 
1.
45 
1.5
5 
0.4
3 
1  0.543
407 
0.135
992 
0.255
557 
0.117
631 
223.006
7154 
17.5
43 
C6H10NO4P
S 
1  4-Methyl-5-(2-
phosphoethyl)-thiazole 
6 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc  C04327  1.
00 
1.
19 
1.
08 
1.1
5 
2.4
8 
1  0.095
276 
0.331
29 
0.239
635 
0.499
061 
254.090
0681 
13.9
48 
C11H14N2O
5  4  N-Ribosylnicotinamide  8 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc_H
MDB  C03150 
1.
00 
0.
83 
1.
40 
1.4
8 
0.7
6  1 
0.566
69 
0.216
125 
0.376
407 
0.629
551 
264.104
2247 
19.8
72 
C12H17N4O
S  1  Thiamin  10 
Metabolis
m of 
Cofactors 
and 
Vitamins 
medium_KEGG_M
etacyc_HMDB  C00378 
1.
00 
1.
02 
0.
77 
0.6
9 
0.3
3  1 
0.939
972 
0.355
604 
0.225
473 
0.052
958 
264.104
5454 
19.7
41 
C12H17N4O
S 
1  Thiamin  8 
Metabolis
m of 
Cofactors 
and 
Vitamins 
medium_KEGG_M
etacyc_HMDB 
C00378 
1.
00 
1.
05 
1.
04 
1.1
7 
0.4
9 
1 
0.671
857 
0.752
099 
0.437
424 
0.154
013 
376.138
1031 
7.96
81 
C17H20N4O
6 
2  Riboflavin  10 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc_H
MDB 
C00255 
1.
00 
0.
97 
0.
89 
1.0
7 
0.4
4 
1 
0.787
119 
0.334
485 
0.722
221 
0.081
276 301 
 
441.140
4546 
10.3
03 
C19H19N7O
6 
1  Folate  8 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_HMDB  C00504 
1.
00 
1.
06 
1.
02 
1.1
9 
0.4
0 
1 
0.756
492 
0.917
456 
0.455
498 
0.070
667 
471.150
1292 
10.3
98 
C20H21N7O
7 
1  10-Formyldihydrofolate  7 
Metabolis
m of 
Cofactors 
and 
Vitamins 
KEGG_Metacyc_H
MDB 
C03204 
1.
00 
1.
17 
1.
59 
1.2
1 
0.8
2 
1 
0.331
709 
0.421
11 
0.108
646 
0.542
921 
74.0001
3966 
10.1
09 
C2H2O3  1  Glyoxylate  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00048  1.
00 
1.
23 
1.
14 
1.4
3 
0.6
5 
1  0.597
592 
0.761
252 
0.301
234 
0.221
135 
84.0322
4442 
14.8
14 
C3H4N2O  1  Imidazolone  6 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C06195 
1.
00 
0.
98 
0.
89 
0.9
5 
0.7
7 
1 
0.909
689 
0.365
445 
0.707
191 
0.089
864 
84.0322
4778 
15.4
88 
C3H4N2O  1  Imidazolone  6 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C06195  1.
00 
1.
01 
0.
95 
0.9
6 
0.9
7 
1  0.929
718 
0.582
367 
0.673
313 
0.762
087 
84.0325
2349 
10.3
64 
C3H4N2O  1  Imidazolone  6 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C06195 
1.
00 
0.
89 
0.
91 
0.8
3 
0.7
7 
1 
0.009
737 
0.425
973 
0.187
615 
0.175
467 
89.0476
3509 
15.5
61 
C3H7NO2  9  beta-Alanine  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00099 
1.
00 
0.
99 
1.
15 
0.8
0 
0.5
3 
1 
0.946
506 
0.422
342 
0.130
722 
0.012
696 
89.0476
3627 
13.2
78 
C3H7NO2  9  beta-Alanine  6 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00099 
1.
00 
1.
00 
0.
94 
1.0
0 
0.4
6 
1 
0.990
476 
0.567
288 
0.994
248 
0.115
733 
112.027
3028 
9.51
26  C4H4N2O2  1  Uracil  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00106 
1.
00 
0.
99 
1.
08 
1.0
4 
0.4
9  1 
0.959
799 
0.758
996 
0.877
773 
0.052
427 302 
 
126.043
0264 
7.59
68 
C5H6N2O2  2  Thymine  10 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00178 
1.
00 
0.
94 
0.
89 
1.2
3 
0.4
9 
1 
0.913
696 
0.739
752 
0.540
945 
0.202
06 
133.048
4678 
16.3
47  C3H7N3O3  2  Ureidoglycine  6 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc  C02091 
1.
00 
1.
08 
0.
95 
0.8
6 
0.5
6  1 
0.748
898 
0.830
887 
0.560
623 
0.143
243 
135.054
4148 
10.9
21 
C5H5N5  1  Adenine  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00603 
1.
00 
1.
15 
1.
26 
1.3
2 
0.7
5 
1 
0.201
988 
0.055
837 
0.028
125 
0.443
164 
151.049
3461 
12.4
67 
C5H5N5O  3  Guanine  10 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00242 
1.
00 
3.
65 
3.
63 
1.6
7 
0.7
2 
1 
0.156
519 
0.233
42 
0.258
49 
0.244
605 
152.033
4286 
9.15
94 
C5H4N4O2  3  Xanthine  10 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00385  1.
00 
1.
18 
1.
05 
1.0
6 
0.4
1 
1  0.723
683 
0.920
256 
0.906
06 
0.253
857 
158.043
7032 
13.7
01 
C4H6N4O3  3  Allantoin  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01551 
1.
00 
1.
01 
0.
94 
1.0
7 
0.4
3 
1 
0.947
249 
0.641
236 
0.674
335 
0.077
91 
168.028
0669 
12.4
76 
C5H4N4O3  1  Urate  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00366  1.
00 
1.
00 
0.
93 
1.0
1 
0.7
3 
1  0.981
907 
0.633
505 
0.908
092 
0.115
301 
176.054
2085 
16.3
4 
C4H8N4O4  1  Allantoate  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00499 
1.
00 
1.
06 
0.
88 
0.8
9 
0.5
2 
1 
0.858
066 
0.725
38 
0.751
456 
0.240
152 
228.074
4783 
8.02
75 
C9H12N2O5  3  Deoxyuridine  10 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00526  1.
00 
1.
93 
1.
15 
1.4
9 
0.8
6 
1  0.059
71 
0.444
596 
0.011
423 
0.386
807 303 
 
242.090
3659 
7.60
84 
C10H14N2O
5 
1  Thymidine  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00214 
1.
00 
0.
97 
0.
79 
1.1
1 
0.7
5 
1 
0.960
158 
0.480
61 
0.798
81 
0.420
142 
244.069
2849 
9.53
56  C9H12N2O6  2  Uridine  10 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00299 
1.
00 
0.
94 
0.
77 
0.9
4 
0.4
5  1 
0.838
292 
0.369
17 
0.795
959 
0.106
599 
244.069
3086 
11.9
53 
C9H12N2O6  2  Pseudouridine  6 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C02067 
1.
00 
1.
04 
0.
98 
0.9
1 
0.3
7 
1 
0.800
699 
0.944
425 
0.591
022 
0.037
046 
267.096
8371 
10.2
76 
C10H13N5O
4 
3  Adenosine  10 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00212 
1.
00 
0.
96 
1.
35 
1.4
0 
0.7
9 
1 
0.838
499 
0.740
477 
0.152
291 
0.626
877 
283.091
6259 
12.7
24 
C10H13N5O
5 
5  Guanosine  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00387  1.
00 
1.
00 
1.
97 
1.4
5 
1.2
2 
1  0.993
849 
0.116
211 
0.195
186 
0.758
137 
284.075
5655 
9.68
82 
C10H12N4O
6 
1  Xanthosine  6 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01762 
1.
00 
0.
97 
0.
84 
0.7
2 
0.2
4 
1 
0.931
883 
0.572
347 
0.340
523 
0.079
248 
323.051
5791 
20.8
27 
C9H14N3O8
P 
3  CMP  10 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00055  1.
00 
1.
38 
1.
69 
1.7
2 
0.8
2 
1  0.271
32 
0.221
64 
0.094
714 
0.677
653 
324.035
5752 
23.2
34 
C9H13N2O9
P 
4 
Pseudouridine 5'-
phosphate 
8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01168 
1.
00 
0.
88 
0.
60 
0.7
0 
0.1
6 
1 
0.753
767 
0.180
125 
0.354
885 
0.042
953 
347.063
0043 
20.2
88 
C10H14N5O
7P 
7  3'-AMP  8 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01367  1.
00 
0.
82 
0.
82 
0.7
3 
0.3
5 
1  0.407
726 
0.416
337 
0.187
281 
0.017
907 304 
 
363.057
8831 
25.0
12 
C10H14N5O
8P 
5  GMP  10 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00144 
1.
00 
1.
10 
1.
24 
0.8
8 
0.3
1 
1 
0.679
213 
0.370
148 
0.618
016 
0.060
402 
402.022
7375 
19.7
06 
C10H16N2O
11P2  1  dTDP  6 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB  C00363 
1.
00 
1.
14 
1.
30 
1.1
3 
1.0
0  1 
0.120
858 
0.029
557 
0.563
848 
0.991
509 
404.003
1602 
17.8
49 
C9H14N2O1
2P2 
1  UDP  6 
Nucleotid
e 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00015 
1.
00 
1.
02 
1.
03 
0.8
7 
0.4
2 
1 
0.912
439 
0.861
15 
0.319
899 
0.056
278 
276.095
6701 
16.3
15 
C10H16N2O
7  2 
GammaGlutamylglutamic
acid  7  Peptide 
KEGG_Metacyc_H
MDB  C05282 
1.
00 
1.
04 
1.
20 
0.6
6 
0.9
8  1 
0.894
52 
0.572
819 
0.213
971 
0.981
992 
186.100
346 
11.2
25 
C8H14N2O3  1  Ala-Pro  5 
Peptide(di
-) 
Peptides   0 
1.
00 
1.
51 
1.
41 
0.8
7 
0.5
5 
1 
0.195
806 
0.226
72 
0.582
916 
0.179
423 
202.131
6852 
11.3
47 
C9H18N2O3  3  Ile-Ala  5  Peptide(di
-) 
Peptides   0  1.
00 
0.
99 
1.
03 
1.0
1 
0.6
7 
1  0.971
22 
0.942
436 
0.982
884 
0.314
791 
202.131
7357 
8.30
9  C9H18N2O3  3  Leu-Ala  7 
Peptide(di
-)  Peptides   0 
1.
00 
1.
07 
1.
40 
1.2
9 
0.9
3  1 
0.739
399 
0.041
519 
0.289
409 
0.758
664 
208.051
709 
21.8
35 
C6H12N2O4
S 
2  Cys-Ser  7 
Peptide(di
-) 
Peptides   0 
1.
00 
0.
88 
1.
39 
1.1
3 
2.9
3 
1 
0.664
835 
0.295
673 
0.637
626 
0.395
558 
212.116
0167 
11.2
35 
C10H16N2O
3 
2  Pro-Pro  7  Peptide(di
-) 
Peptides_HMDB   0  1.
00 
1.
86 
1.
38 
1.0
6 
0.7
9 
1  0.200
238 
0.296
376 
0.819
623 
0.596
443 
214.131
6781 
10.9
41 
C10H18N2O
3 
2  Val-Pro  7 
Peptide(di
-) 
Peptides   0 
1.
00 
0.
81 
0.
79 
1.3
1 
0.7
2 
1 
0.622
226 
0.541
553 
0.418
31 
0.499
951 
218.126
6012 
12.9
72 
C9H18N2O4  5  Leu-Ser  7 
Peptide(di
-) 
Peptides   0 
1.
00 
0.
88 
1.
13 
0.9
0 
0.4
9 
1 
0.150
255 
0.634
427 
0.598
11 
0.140
056 
228.147
309 
10.7
37 
C11H20N2O
3 
3  Leu-Pro  5  Peptide(di
-) 
Peptides_HMDB   0  1.
00 
1.
13 
0.
93 
1.1
9 
0.4
6 
1  0.658
527 
0.764
848 
0.578
327 
0.069
948 305 
 
228.147
5003 
8.92
37 
C11H20N2O
3 
3  Ile-Pro  7 
Peptide(di
-) 
Peptides   0 
1.
00 
1.
35 
1.
46 
1.0
9 
0.8
9 
1 
0.206
021 
0.177
638 
0.681
509 
0.747
674 
230.090
1547 
14.1
05 
C9H14N2O5  1  Aspartyl-L-proline  7  Peptide(di
-) 
Peptides_HMDB   0  1.
00 
2.
04 
1.
34 
1.1
6 
0.8
1 
1  0.135
636 
0.475
13 
0.611
86 
0.606
077 
230.163
0213 
8.05
2 
C11H22N2O
3  2  Leu-Val  7 
Peptide(di
-)  Peptides   0 
1.
00 
0.
94 
1.
28 
1.6
5 
0.5
9  1 
0.861
937 
0.550
159 
0.184
328 
0.202
293 
244.178
7291 
6.33
14 
C12H24N2O
3 
4  Leucyl-leucine  5 
Peptide(di
-) 
KEGG_Metacyc_Pe
ptides  
C11332 
1.
00 
0.
80 
1.
17 
1.1
6 
1.5
6 
1 
0.512
275 
0.511
263 
0.706
544 
0.110
43 
246.121
5074 
11.9
49 
C10H18N2O
5 
6  Glu-Val  5  Peptide(di
-) 
Peptides   0  1.
00 
1.
10 
1.
12 
0.9
6 
0.6
2 
1  0.325
16 
0.511
44 
0.653
679 
0.038
891 
260.137
1167 
10.5
27 
C11H20N2O
5  4  Glu-Leu  5 
Peptide(di
-)  Peptides   0 
1.
00 
1.
16 
1.
07 
0.9
2 
0.5
9  1 
0.232
26 
0.817
528 
0.660
23 
0.032
559 
270.095
0724 
17.6
16 
C10H14N4O
5 
2  Asp-His  7 
Peptide(di
-) 
Peptides   0 
1.
00 
1.
04 
1.
38 
1.6
2 
0.8
8 
1 
0.895
747 
0.206
214 
0.055
693 
0.873
669 
214.092
6562 
21.4
77 
C17H28N6O
5S 
4  Ala-Met-Ala-His  7  Peptide(t
etra-) 
Peptides   0  1.
00 
0.
06 
1.
32 
1.4
2 
2.3
6 
1  0.411
675 
0.844
701 
0.758
745 
0.404
109 
229.071
2954 
23.1
52 
C17H26N6O
5S2  1  Cys-Cys-Pro-His  7 
Peptide(t
etra-)  Peptides  0 
1.
00 
0.
65 
1.
25 
0.9
9 
0.9
5  1 
0.349
158 
0.599
034 
0.978
835 
0.871
682 
250.070
1552 
8.11
96 
C20H28N4O
7S2 
1  Glu-Phe-Cys-Cys  7 
Peptide(t
etra-) 
Peptides   0 
1.
00 
1.
13 
0.
82 
0.9
0 
0.2
5 
1 
0.740
95 
0.375
116 
0.575
893 
0.028
123 
250.090
3648 
15.8
36 
C18H28N8O
7S 
1  Asn-Cys-Gln-His  7  Peptide(t
etra-) 
Peptides   0  1.
00 
1.
03 
1.
16 
0.8
8 
0.1
7 
1  0.767
617 
0.415
247 
0.286
677 
0.011
6 
260.126
9204 
19.8
84 
C18H36N10
O6S 
1  Arg-Cys-Ser-Arg  7 
Peptide(t
etra-) 
Peptides   0 
1.
00 
0.
98 
0.
94 
0.7
7 
0.6
5 
1 
0.945
294 
0.846
993 
0.495
764 
0.330
074 
412.172
2046 
20.7
18 
C16H24N6O
7 
3  Ala-Ala-Asp-His  5 
Peptide(t
etra-) 
Peptides   0 
1.
00 
0.
98 
1.
26 
0.9
1 
0.3
4 
1 
0.958
184 
0.556
834 
0.858
185 
0.205
614 306 
 
416.164
5637 
17.5
76 
C15H24N6O
8 
1  His-Ser-Ser-Ser  5 
Peptide(t
etra-) 
Peptides   0 
1.
00 
1.
29 
1.
21 
1.9
5 
1.1
0 
1 
0.397
24 
0.569
481 
0.102
599 
  
431.214
0681 
20.9
34 
C16H29N7O
7 
4  Ala-Ala-Asp-Arg  7  Peptide(t
etra-) 
Peptides   0  1.
00 
0.
37 
0.
71 
0.6
5 
0.3
1 
1  0.322
501 
0.615
613 
0.583
266 
0.291
003 
433.194
0868 
20.6
82 
C15H27N7O
8  1  Arg-Asp-Gly-Ser  5 
Peptide(t
etra-)  Peptides   0 
1.
00 
0.
53 
0.
91 
0.7
9 
0.7
3  1 
0.024
581 
0.698
834 
0.300
406    
450.194
0981 
9.88
97 
C21H30N4O
5S 
2  Met-Phe-Gly-Pro  7 
Peptide(t
etra-) 
Peptides   0 
1.
00 
0.
98 
1.
01 
0.8
7 
1.0
7 
1 
0.871
353 
0.927
917 
0.439
903 
0.886
045 
482.171
155 
17.5
28 
C18H26N8O
6S 
1  Cys-Ser-His-His  5  Peptide(t
etra-) 
Peptides   0  1.
00 
1.
23 
1.
00 
0.9
2 
0.3
2 
1  0.481
325 
0.997
519 
0.773
922 
0.005
338 
532.197
9363 
8.24
97 
C25H32N4O
7S  2  Cys-Phe-Thr-Tyr  5 
Peptide(t
etra-)  Peptides   0 
1.
00 
0.
83 
0.
93 
1.5
4 
0.5
6  1 
0.844
049 
0.927
774 
0.469
488 
0.583
155 
568.242
6471 
19.6
96 
C23H36N8O
7S 
1  Arg-Cys-Gln-Tyr  5 
Peptide(t
etra-) 
Peptides   0 
1.
00 
1.
83 
4.
31 
4.0
3 
1.1
1 
1 
0.190
531 
0.017
326 
0.107
975 
0.890
422 
579.199
4675 
8.42
44 
C25H33N5O
9S 
1  Glu-Met-Trp-Asp  7  Peptide(t
etra-) 
Peptides   0  1.
00 
1.
31 
0.
92 
1.0
9 
0.3
2 
1  0.490
708 
0.406
286 
0.678
569 
0.134
74 
301.163
6552 
11.8
22 
C13H23N3O
5  2  Val-Pro-Ser  7 
Peptide(tr
i-)  Peptides   0 
1.
00 
1.
14 
1.
13 
0.4
4 
0.7
8  1 
0.670
645 
0.730
175 
0.135
728 
0.793
149 
309.168
6631 
10.9
47 
C15H23N3O
4 
2  Pro-Pro-Pro  5 
Peptide(tr
i-) 
Peptides   0 
1.
00 
1.
55 
1.
54 
0.9
8 
0.4
4 
1 
0.166
334 
0.217
411 
0.916
058 
0.006
307 
331.210
55 
8.14
28 
C15H29N3O
5 
5  Leu-Leu-Ser  7  Peptide(tr
i-) 
Peptides   0  1.
00 
0.
95 
1.
43 
2.2
7 
1.2
4 
1  0.947
634 
0.441
204 
0.012
118 
0.827
874 
341.135
1734 
20.7
1 
C13H19N5O
6 
2  Ala-Asp-His  5 
Peptide(tr
i-) 
Peptides   0 
1.
00 
0.
82 
0.
96 
0.9
1 
0.4
0 
1 
0.506
913 
0.890
469 
0.772
964 
0.101
887 
350.125
9654 
20.3
03 
C12H22N4O
6S 
5  Met-Asn-Ser  5 
Peptide(tr
i-) 
Peptides   0 
1.
00 
0.
89 
0.
91 
0.7
6 
0.7
9 
1 
0.201
67 
0.275
06 
0.078
293 
0.062
278 307 
 
405.138
0914 
16.1
4 
C15H23N3O
10 
1  Glu-Glu-Glu  5 
Peptide(tr
i-) 
Peptides   0 
1.
00 
1.
00 
1.
11 
0.8
6 
0.3
5 
1 
0.997
19 
0.508
482 
0.413
357 
0.023
866 
446.190
8701 
19.7
48 
C20H26N6O
6 
6  Gln-Tyr-His  5  Peptide(tr
i-) 
Peptides   0  1.
00 
1.
19 
1.
17 
1.4
2 
0.8
6 
1  0.508
57 
0.577
956 
0.234
049 
0.730
676 
450.157
0597 
8.71
05 
C20H26N4O
6S  1  Met-Trp-Asp  7 
Peptide(tr
i-)  Peptides   0 
1.
00 
1.
05 
1.
09 
1.0
7 
1.0
8  1 
0.882
027 
0.727
76 
0.814
741 
0.887
55 
464.173
2053 
9.87
3 
C21H28N4O
6S 
1  Glu-Met-Trp  7 
Peptide(tr
i-) 
Peptides   0 
1.
00 
0.
80 
0.
97 
0.6
0 
0.7
3 
1 
0.512
993 
0.926
736 
0.215
366 
0.434
902 
96.0211
1235 
14.8
18 
C5H4O2  3  Protoanemonin  1 
Xenobioti
cs 
Biodegrad
ation and 
Metabolis
m 
KEGG_Metacyc  C07090 
1.
00 
1.
02 
1.
28 
0.8
5 
0.6
3 
1 
0.937
177 
0.491
071 
0.585
869 
0.230
959 
131.094
7143 
10.5
36 
C6H13NO2  11  6-Aminohexanoate  5.5 
Xenobioti
cs 
Biodegrad
ation and 
Metabolis
m 
KEGG_Metacyc_Li
pidmaps_HMDB  
C02378 
1.
00 
1.
05 
1.
24 
1.0
3 
0.6
1 
1 
0.568
875 
0.470
451 
0.799
172 
0.282
599 
137.047
6939 
5.88
26 
C7H7NO2  13  Anthranilate  5.5 
Xenobioti
cs 
Biodegrad
ation and 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C00108  1.
00 
0.
98 
1.
04 
0.8
0 
2.6
1 
1  0.971
538 
0.946
001 
0.655
87 
0.038
904 
166.026
316 
7.42
58 
C8H6O4  7  Phthalate  5.5 
Xenobioti
cs 
Biodegrad
ation and 
Metabolis
m 
KEGG_Metacyc_H
MDB 
C01606 
1.
00 
1.
97 
0.
83 
3.2
8 
0.3
2 
1 
0.490
442 
0.811
112 
0.389
394 
0.323
253 
166.026
4344 
10.5
99 
C8H6O4  7  Terephthalate  4.5 
Xenobioti
cs 
Biodegrad
KEGG_Metacyc_H
MDB 
C06337 
1.
00 
1.
33 
1.
07 
2.8
6 
1.8
5 
1 
0.111
079 
0.599
994 
0.441
845 
0.389
476 308 
 
ation and 
Metabolis
m 
182.086
7405 
19.7
08 
C6H12F2N2
O2 
1  Eflornithine  9 
Xenobioti
cs Drugs 
etc 
KEGG_Metacyc  C07997  1.
00 
1.
26 
1.
98 
2.0
5 
1.0
4 
1  0.284
484 
0.033
984 
0.038
533 
0.883
377 
Appendix 8-3. The eflornithine toxicity metabolome.  309 
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Appendix 8-4. Arginase sequence alignment. 